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ABSTRACT  
Atrial fibrillation (AF) is a common health problem and a major risk factor for stroke in older 
people. As the world population is ageing, the increased prevalence of AF and AF-related 
stroke are growing public health concerns. There is marked heterogeneity amongst people aged 
over 65 years. Some of this may be captured by increasing chronological age. However, much 
of this variability is thought to be due to biological age or frailty, a state of vulnerability that 
can impact on the treatment and prognosis in older people with AF. The broad aim of this thesis 
was to investigate the impact of frailty on the pharmacological treatment and outcomes in older 
patients with AF. 
A dominant part of this thesis involved a prospective observational study in Australia about the 
impact of frailty on the pharmacological treatment, coagulation changes and outcomes in older 
inpatients with AF. In this study, a total of 302 inpatients aged ≥65 years with AF admitted to 
Royal North Shore Hospital, a tertiary referral teaching hospital in Sydney, Australia, was 
recruited. Of these, 134 patients participated in the sub-study on coagulation function. Chapters 
One, Two, Three are introduction, literature review and methods, respectively. Chapter Four 
describes the differences in clinical characteristics, pharmacological treatment and incidence 
of stroke and major bleeding over six months between the frail and the non-frail. Compared to 
the non-frail, frail participants were older, had more comorbidities and higher risk of strokes 
(as reflected by CHA2DS2-VASc score) but not haemorrhage (as reflected by HASBLED 
score). Upon discharge, 55.7% participants were prescribed anticoagulants (49.3% frail, 62.6% 
non-frail, p=0.02). Frail participants were less likely to be prescribed an anticoagulant and were 
more likely to receive digoxin upon discharge, although the impact of frailty on these 
prescriptions was reduced in multivariate analysis. Compared to previous studies in Australia, 
prescription of anticoagulants was higher in this study in older patients with AF, especially in 
the frail. A significant percentage of participants with AF received antiplatelets with no 
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evidence of ischemic heart disease, suggesting that antiplatelets may be used for stroke 
prevention in AF although current guidelines do not recommend aspirin for stroke prevention 
in AF unless patients refuse the use of any oral anticoagulant. After six months, overall 
incidence of ischemic stroke was 2.1% and, in patients taking anticoagulants, incidence of 
major/severe bleeding was 6.3%, with no significant difference between frailty groups. The 
findings from Chapter Five established that in older inpatients with AF, frailty was associated 
with prolonged length of stay and increased all-cause mortality but not re-admission during six 
months after discharge. The coexistence of frailty and delirium during hospitalisation 
significantly increased the risk of mortality.  
Chapter Six and Chapter Seven report the two pilot studies testing the hypotheses of altered 
platelet function, coagulation function and responses to antithrombotic drugs in frail patients. 
In Chapter Six, platelet aggregation studies were performed using Whole Blood Impedance 
Aggregometry. While there was no significant relationship between frailty and platelet 
aggregation in participants not taking any antiplatelet drugs, there was a reduced 
responsiveness to aspirin in the frail amongst those taking aspirin. The observed reduced 
platelet responsiveness to aspirin in the frail supports the current guidelines that do not 
recommend aspirin for stroke prevention in AF, and raises a question about the risk benefit 
ratio of aspirin prescription in older patients with AF, which is usually commoner in the frail, 
in whom prescribers may be more concerned about using anticoagulants. In Chapter Seven, the 
Overall Haemostatic Potential and Calibrated Automated Thrombogram were used to globally 
assess coagulation function. Compared to non-frail participants, frail participants had 
significantly reduced fibrin generation, which may reflect decreased acute phase response in 
the frail. There was no difference on coagulation profiles between the frail and the non-frail on 
warfarin, suggesting that frail warfarinised patients are not at higher risk of bleeding which is 
consistent with the clinical follow up findings in Chapter Four.  
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There have been few published studies about AF or frailty in developing countries; hence, this 
thesis also aimed to investigate the evidence about AF and frailty in developing countries with 
two systematic reviews and an observational study in Vietnam. Chapter Eight is a systematic 
review of epidemiology and management of AF in developing countries with a summary of 70 
studies of AF in these countries. The prevalence of AF in the community-based studies ranged 
from 0.03% to 1.3%, while the prevalence of AF in hospital-based studies varied from 0.7% to 
55.7%. The most common conditions associated with AF were hypertension and valvular heart 
disease. The prevalence of stroke in patients with AF ranged from 6.7% to 27%. The utilisation 
of anticoagulants was highly variable (2.7%-72.7%). There was a high prevalence of use of 
rate control therapies (55.3%-87.3%). Chapter Nine is a systematic review of frailty research 
in developing countries, with a total of 20 studies of frailty in these countries. The prevalence 
of frailty in community-dwelling older people ranged from 5.4% to 43.9%. The prevalence of 
frailty in hospitalised and institutionalised older people was from 32.3% to 49.3%. The 
prevalence of frailty in outpatient clinics was 27.8% to 71.3%. Fried frailty phenotype was the 
most commonly used definition of frailty in developing countries. Frailty was associated with 
increased mortality and comorbidities, decreased physical and cognitive function, and poor 
perceptions of health in these countries.  
In the reviews in Chapter Eight and Chapter Nine, there were no published studies of the 
pharmacological treatment of AF in older patients in Vietnam and no published studies related 
to frailty in Vietnam, a typical developing country with a rapidly ageing population. Chapter 
Ten presents a cross-sectional study of the prevalence of AF among older hospitalised patients 
in Vietnam and describes clinical characteristics and treatment of these patients. Of the 461 
older patients recruited at the National Geriatric Hospital in Hanoi, Vietnam, during seven 
months, the prevalence of AF was 3.9%, which is similar to that reported in other countries. 
Amongst patients with AF, the most common medical conditions were hypertension (72.2%), 
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followed by stroke (55.6%), heart failure (50.0%), type 2 diabetes (44.4%). The prevalence of 
frailty in patients with AF was 39%. Living alone (OR=10.2, 95% CI 1.5–70.1), having a habit 
of using vitamins at home as self-medication (OR=3.8, 95% CI 1.1–13.4), having heart failure 
(OR=31.3, 95% CI 9.6–101.8), and having type 2 diabetes (OR=3.5, 95% CI 1.2–10.7) were 
associated with the presence of AF on admission. All patients with AF had a high risk of stroke 
and 72.2% of them had a high risk of bleeding with anticoagulant medications. Only 22.2% 
were anticoagulated on admission and 22.2% upon discharge, with no difference between frail 
and non-frail patients. 
In conclusion, AF and frailty are growing public health concerns in developed countries as well 
as in the developing world. The studies in this thesis in Australia and Vietnam provide new 
evidence on the frequency, treatment and prognosis for patients with AF. Frailty was common 
in older patients with AF in both Australia and in Vietnam. In both countries there was evidence 
of sub-optimal use of anticoagulant medications: among frail people with AF in Australia and 
among all patients with AF in Vietnam. A large size, multi-centre prospective cohort study or 
pharmaco-epidemiological study using existing linked healthcare data looking at outcomes in 
frail and non-frail patients on anticoagulants is needed to derive accurate results about the 
impact of frailty on anticoagulation utilisation, efficacy and complications. Further clinical 
epidemiological research is needed on AF and frailty in developing countries such as Vietnam. 
Such research will become increasingly important as population ageing leads to rapidly 
increasing numbers of people with AF and/or frailty. The interaction between frailty and 
coagulation requires further laboratory investigation. More research is also needed to 
investigate the impact of frailty on responses to newer direct oral anticoagulants. 
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Chapter One  
Introduction 
Atrial fibrillation (AF) is a common health problem and a major risk factor for stroke in older 
people. As the world population is ageing, the increased prevalence of AF and AF-related stroke 
are growing public health concerns. This thesis is mainly concerned with AF, its associated 
medical conditions and its management in older patients, especially in frail older patients. This 
chapter gives a general introduction to the topic with more detailed literature reviews in Chapters 
Two, Eight and Nine. 
Atrial fibrillation is the most common sustained cardiac arrhythmia (Camm, Kirchhof et al. 
2010). In 2010, there were 33.5 million people with AF in the world, constituting around 0.5% of 
the total world population (Chugh, Roth et al. 2014). The prevalence of AF ranged from 0.1% in 
people younger than 55 years to 10% or more in people aged 80 years or older (Ball, Carrington 
et al. 2013). The incidence of AF also increases with age (Heeringa, van der Kuip et al. 2006). 
The global burden of AF has been rising due to the ageing of the world’s population (Rahman, 
Kwan et al. 2014). The rates of AF related hospitalisation have increased worldwide over the last 
decades (Friberg, Buch et al. 2003; Wellens and Smith Jr 2006; Keech, Punekar et al. 2012; 
Patel, Deshmukh et al. 2014). There are many risk factors that have been reported to predispose 
to AF, including old age, male sex, hypertension, heart failure, ischemic heart disease, valvular 
heart diseases, diabetes, and obesity. Other risk factors that have been reported include 
hyperthyroidism, alcohol abuse, smoking, and pulmonary disease (Camm, Kirchhof et al. 2010). 
People with AF have an increased risk of stroke. In patients with AF, abnormalities of atrial 
endothelium, decrease in flow velocities within the left atria and the left atrial appendage are 
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predisposing factors to the formation of thrombus in the heart, which then can follow the blood 
flow to the brain and cause embolic stroke (Camm, Kirchhof et al. 2010). Data from the 
Framingham study showed that AF is associated with a substantial mortality and morbidity and a 
5-fold increase in the risk of stroke and thromboembolism (Wolf, Abbott et al. 1991). The 
incidence of stroke in people with AF is approximately 5%, which is two to seven times higher 
than the average prevalence of stroke in the general population. (Fuster, Ryden et al. 2001). 
Strokes associated with AF tend to be more severe and result in greater disability, longer hospital 
stays and less discharges to patient’s own home (Goto, Bhatt et al. 2008).   
Treatment of AF includes assessment of thromboembolic risk and stroke prevention, applying 
appropriate rate-control or rhythm-control strategies, and management of associated diseases 
(Fuster, Ryden et al. 2001; Lip, Tse et al. 2012). Many studies have shown the benefits of 
antithrombotic therapies in stroke prevention in patients with AF (Connolly, Laupacis et al. 
1991; Fuster, Ryden et al. 2006; Parkash, Wee et al. 2007). Antithrombotic therapy in patients 
with AF has been shown to reduce the frequency, severity and mortality from stroke (Hylek, Go 
et al. 2003). Current guidelines recommend anticoagulant therapy to obtain an International 
Normalised Ratio (INR) of 2.0-3.0 in patients at high risk of stroke unless contraindicated 
(Camm, Kirchhof et al. 2010; Cairns, Connolly et al. 2011; Wann, Curtis et al. 2011).   
Older hospitalised patients are at increased risk of adverse outcomes and these outcomes can be 
predicted by many factors like advanced age, comorbidities, immobility, malnutrition, delirium, 
falls, polypharmacy and especially by a frailty status (Clegg, Young et al. 2013; De Buyser, 
Petrovic et al. 2014). As the population ages, the prevalence and clinical importance of frailty are 
increasing (Raphael, Cava et al. 1995; Clegg, Young et al. 2013). Frailty is a state of 
vulnerability that carries an increased risk of poor outcomes in older adults (Clegg, Young et al. 
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2013). Multiple physiological factors are thought to be involved in the development of frailty, 
including the cardiovascular systems and thrombotic pathways (Chaves, Semba et al. 2005; 
Kanapuru and Ershler 2009). A relationship between frailty and cardiovascular disease has been 
observed, in which frailty has strong relationships with ischemic heart disease, heart failure and 
AF (Polidoro, Stefanelli et al. 2013; Von Haehling, Anker et al. 2013). More generally, frailty 
has been found to be associated with increased adverse outcomes in older patients, especially in 
patients with cardiovascular diseases (Cacciatore, Abete et al. 2005; Lee, Buth et al. 2010; 
Ekerstad, Swahn et al. 2011; Singh, Rihal et al. 2011; Singh, Gallacher et al. 2012; Conroy and 
Dowsing 2013; Cacciatore, Della-morte et al. 2014; Le Maguet, Roquilly et al. 2014; Ambler, 
Brooks et al. 2015; Bo, Puma et al. 2015).  
The prevalence of chronic diseases, polypharmacy and adverse drug reactions all increase with 
ageing (Hilmer, Gnjidic et al. 2012). Changes in pharmacokinetics and pharmacodynamics with 
aging, frailty and multimorbidity also increase inter- and intra-individual variability (Hardy and 
Hilmer 2011; Hilmer, Gnjidic et al. 2012; Hubbard, O'Mahony et al. 2013). Clinically, studies 
have shown that anticoagulants are underutilised in older patients with AF, especially frail 
patients (Antani, Beyth et al. 1996; Mendelson and Aronow 1998; Waldo, Becker et al. 2005; 
Perera, Bajorek et al. 2009; Radholm, Ostgren et al. 2011; Corvol, Gulsvik et al. 2014). Some 
previous studies have shown that frail older patients with AF are significantly less likely to 
receive anticoagulants than non-frail and appear more vulnerable to adverse clinical outcomes, 
with and without antithrombotic therapy (Johnson C, Lim W et al. 2005; Hylek, Evans-Molina et 
al. 2007; Perera, Bajorek et al. 2009).   
In developing countries, AF is a growing public health problem in the context of the 
epidemiologic transition from communicable to non-communicable diseases (Gaziano, Bitton et 
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al. 2010; Sala, Stigliano et al. 2010; WHO. 2010; Nshisso, Reese et al. 2012; Wagner and Brath 
2012). In addition to the effect of AF on mortality and morbidity, AF puts a great economic 
burden on these countries. The estimated annual cost of AF in Russia, China, India, Brazil and 
Turkey was 5.7 billion, 2.5 billion, 1.25 billion, 412 million and 159 million (2010 local 
currencies), respectively (Rizzo, Mallow et al. 2012). Anticoagulant use and monitoring are 
major issues in these countries. The accessibility to the monitoring test for anticoagulants, the 
unreliability of the test results, the lack of compliance of patients and complementary medicine 
and dietary issues are substantial in developing countries (Aalbers 2011; Anakwue, Ocheni et al. 
2011; Bronzetti, Corzani et al. 2012).  
Vietnam is a typical developing country with a rapidly ageing population, with the percentage of 
people aged 60 or over increasing from 8.7% in 2009 to 26.1% in 2049 (Table 1.1) (Feigin, 
Lawes et al. 2009). One study found that nearly 40% of older people in the community in 
Vietnam had multimorbidity (Ha, Le et al. 2015). Cardiovascular disease is the leading cause of 
death in Vietnam (Hoang, Dao et al. 2006; Islam, Purnat et al. 2014; Nhung, Long et al. 2014). 
The evidence of prevalence of AF in the general population or in hospitalised patients in 
Vietnam is very limited: a study found that around 1.3% of patients hospitalised with a first acute 
myocardial infarction had AF (Nguyen, Nguyen et al. 2014) and another found AF prevalence of 
to 6.6% in patients hospitalised with a first stroke (Nguyen, Do et al. 2015). There have been no 
published studies on the utilisation of anticoagulants or antiarrhythmics in older inpatients with 
AF and frailty is still a new concept in Vietnam.  
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Table 1.1. Population ageing in Vietnam 
 
Source: Feigin, Lawes et al. 2009 
This thesis is mainly concerned with the impact of frailty on the pharmacological treatment of 
AF and outcomes in older patients with AF. It was hypothesised that frail older patients with AF 
are less likely to receive anticoagulation therapy and are more likely to have bleeding 
complications and other adverse outcomes with anticoagulants compared to the non-frail. In 
addition, the utilisation of antiarrhythmic medications would differ between frail and non-frail 
older patients with AF.  It was hypothesised that there are differences in measures of coagulation 
and platelet function with and without anticoagulant or antiplatelet treatments, between frail and 
non-frail older patients with AF, which may provide mechanisms for any observed differences in 
outcomes. This thesis comprises two observational studies: the Australian study and the Vietnam 
study. The Australian study is designed to investigate the impact of frailty on anticoagulant 
utilisation, coagulation function and outcomes in older Australian inpatients with AF. The aims 
of the Vietnam study are to investigate the prevalence of AF among older Vietnamese 
hospitalised patients and to describe clinical characteristics and treatment of these patients. In 
addition, this thesis also aims to review the evidence about AF and frailty in developing 
countries (Chapter Eight and Chapter Nine). 
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The Australian study 
The specific aims of this study were in frail and non-frail older inpatients with AF to: 
(1) Describe the clinical characteristics and the utilisation of anticoagulants and 
antiplatelet agents and to identify whether frailty is independently associated with 
prescription of these medications (Chapter Four) 
(2) Study the safety and efficacy of anticoagulants agents through the incidence of major 
bleeding and strokes over 6 months (Chapter Four)   
(3) Investigate the impact of frailty on outcomes, including prolonged length of stay, re-
admission and all-cause mortality 6 months after discharge (Chapter Five) 
The secondary aims of this study were to: 
(4) Describe the utilisation of antiarrhythmic medications and to identify whether frailty 
is independently associated with prescription of these medications (Chapter Four) 
(5) In a subgroup of the study population, investigate differences in measures of 
coagulation and platelet function between frail and non-frail older patients with AF 
(Chapter Six and Chapter Seven) 
The Vietnam study 
The specific aims of this study were to investigate the prevalence of AF in older Vietnamese 
inpatients, the risk factors for AF and pharmacological treatment of AF in these patients (Chapter 
Ten). 
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 Chapter Two 
Literature Review 
2.1. Atrial fibrillation 
2.1.1. Definition of atrial fibrillation 
Atrial fibrillation is defined as a cardiac arrhythmia with irregular distances between QRS 
complexes and no obvious P-waves seen on the surface electrocardiogram (Morady and Zipes 
2014)  (Figure 2.1). Clinically, AF is suspected in patients who have an irregular pulse or heart 
rate (Hanon, Assayag et al. 2013). 
2.1.2. Classification of atrial fibrillation 
There are several ways to classify AF, based on electrocardiogram features or clinical 
presentation. For many years, AF has been classified as paroxysmal or chronic. Recently, AF has 
been classified as paroxysmal, persistent, long-standing persistent and permanent AF. AF that 
terminates spontaneously within seven days of onset is called paroxysmal, while AF that is 
present continuously for more than seven days is called persistent. Long-standing persistent AF 
lasts more than twelve months and permanent AF is defined when the physician or the patient 
decides not to seek restoration and maintenance of sinus rhythm (Prystowsky, Padanilam et al. 
2015). In addition, AF can be classified as “valvular” AF, which involves rheumatic valvular 
diseases, or non-valvular AF (Camm, Kirchhof et al. 2010).  
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 Figure 2.1. Electrocardiogram of atrial fibrillation. Source: Morady and Zipes (2014)  
2.1.3. Epidemiology of atrial fibrillation 
Atrial fibrillation is a growing public health concern. It is the most common arrhythmia in 
clinical practice (Camm, Kirchhof et al. 2010). There was evidence of an increasing rate of AF-
related hospitalisations over time in all countries (Ball, Carrington et al. 2013). The global 
burden of AF has been increasing due to the ageing of the world population (Rahman, Kwan et 
al. 2014). There have been many studies in Western countries reporting the high prevalence of 
AF. Approximately 2.3 million American people are affected by AF (Valderrama, Dunbar et al. 
2005). The prevalence of AF in adults aged 18 years or older in North America, the UK, Iceland 
and Australia ranges from 0.5% to 4% (Chugh, Blackshear et al. 2001; Go, Hylek et al. 2001; 
Stewart, Hart et al. 2001; Sturm, Davis et al. 2002). In France, AF affects between 600,000 and 1 
million people, two-thirds of whom are aged above 75 years (Hanon, Assayag et al. 2013). 
Studies have showed that the prevalence and incidence of AF increase significantly with age 
(Heeringa, van der Kuip et al. 2006; Ball, Carrington et al. 2013).   
Data about the prevalence of AF in Australia is limited. The earliest report about the prevalence 
of AF was published in 1989 from Busselton, Western Australia (Lake, Cullen et al. 1989). The 
study was conducted from 1966-1981 with follow-up of subjects to 1983, the prevalence of AF 
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was 4.9% in people aged ≥ 60 years (4.2% in women, 5.6% in men) and AF was associated with 
increased mortality (Lake, Cullen et al. 1989). In a study in 2000, the prevalence of AF is 
reported to be around 4% (4.0% in women, 6.0% in men) in the people aged ≥ 30 years attending 
general practice across Australia (Sturm, Davis et al. 2002). According to a study of Ball et al in 
which the authors applied international AF prevalence statistics to Australian adult population 
data (people aged ≥ 55 years) to estimate population prevalence of AF in Australia, the estimated 
prevalence of AF is 5.4% in people aged ≥ 55 years (4.8% in women, 6.0% in men), which 
equals around 328 562 cases of AF in 2014 (Ball, Thompson et al. 2015). It is estimated that the 
prevalence of AF in older people will increase to 6.4% in 2034 (over 600 000 cases) (Ball, 
Thompson et al. 2015). It is predicted that between 2014 and 2034 the number of people with AF 
will double among older age groups (from 200 638 to 414 377 people with AF among those aged 
≥ 75 years) and will increase 2.5-fold among men aged ≥ 85 years (from 29 370 to 71 582) (Ball, 
Thompson et al. 2015). An analysis of national data in Australia reported an annual increase of 
7.9% in hospitalisations for AF (Wong, Brooks et al. 2012). 
In developing countries, AF is a growing public health problem in the context of the 
epidemiologic transition from communicable to non-communicable diseases (Gaziano, Bitton et 
al. 2010; Sala, Stigliano et al. 2010; WHO. 2010; Nshisso, Reese et al. 2012; Wagner and Brath 
2012). Estimates of the prevalence of AF in the community in developing countries have ranged 
from 0.03% to 1.25%, while the prevalence of AF in hospital-based studies has varied from 0.7% 
to 55.7% (Nguyen, Hilmer et al. 2013). (Please see Chapter Eight: A review of epidemiology and 
management of AF in developing countries.) 
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2.1.4. Mechanism of atrial fibrillation 
The current understanding of the mechanisms and pathogenesis of AF is incomplete. There are 
several mechanisms explaining AF and they are likely to co-exist at various time (Camm, 
Kirchhof et al. 2010; January, Wann et al. 2014). The first mechanism is structural remodeling of 
the atria. Any kind of structural heart disease may trigger a process of remodeling of the heart, 
including the atria and this will result in electrical abnormalities within the heart. The second 
mechanism concerns electrophysiology abnormalities that involve triggered activity and multi-
wavelet re-entry. In addition, AF has a familial component, especially if early onset. Data from 
the Framingham Heart Study showed that the risk of AF in the offspring increased if they have at 
least one parent with AF (Menezes, Lavie et al. 2013). There were many studies that have 
reported genetic mutations in people with AF and there are associations between AF and some 
inherited cardiac diseases such as hypertrophic cardio-myopathy (Camm, Kirchhof et al. 2010; 
January, Wann et al. 2014). 
2.1.5. Risk factors of atrial fibrillation and co-morbidities 
Cardiovascular risk factors, particularly hypertension, are also associated with the risk of AF 
(Hanon, Assayag et al. 2013). Other common risk factors include heart failure, diabetes, obesity, 
dyslipidemia, chronic pulmonary diseases, thyroid disorders, male gender, excessive alcohol 
consumption (Camm, Kirchhof et al. 2010). Besides those well-established risk factors for AF, 
other risk factors including excessive vitamin D intake, excessive niacin intake, excessive 
physical exertion and inflammation have been reported recently (Menezes, Lavie et al. 2013; 
Rahman, Kwan et al. 2014). 
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2.1.6. Complications of atrial fibrillation 
Besides its effect on cardiac function, AF increases the risk of stroke and embolism, 
hospitalisation and mortality and it leads to reduced quality of life (Camm, Kirchhof et al. 2010). 
Thromboembolism is the most serious and frequent complication of AF. In patients with AF, 
there is a hypercoagulable state with abnormal blood constituents (Watson, Shantsila et al. 2009). 
In addition, there are abnormalities of atrial endothelium like dilatation and denudation of the 
atria. Echocardiography in patients with AF shows a decrease in flow velocities within the left 
atria and the left atrial appendage (Watson, Shantsila et al. 2009; Camm, Kirchhof et al. 2010). 
All of these factors contribute to the formation of thrombus in the heart. Thrombus is located in 
the left atrial appendage in up to 90% cases and it can follow the blood flow to the brain to cause 
embolic stroke (Camm, Kirchhof et al. 2010). The incidence of stroke in people with AF is two 
to seven times higher than the average rate of stroke in the general population, depending on the 
presence of other stroke risk factors (Fuster, Ryden et al. 2001). According to the Global Burden 
of Ischemic and Hemorrhagic Stroke (the GBD 2013 study), in 2013 the age-adjusted prevalence 
of ischemic stroke was 0.3% and the age-adjusted incidence of ischemic stroke was 
approximately 0.1% per year (116 per 100000 people) (Feigin, Krishnamurthi et al. 2015). 
According to the Framingham study, the annual risk of stroke in patients with AF was 1.5% in 
those aged 50–59 years and 23.5% in those aged 80–89 years (Wolf, Abbott et al. 1991). Stroke 
in AF is usually severe and results in chronic disability or death (Camm, Kirchhof et al. 2010).  
2.1.7. Stroke risk and bleeding risk assessment  
In patients with non-valvular AF, the CHA2DS2-VASc score is recommended for assessment of 
stroke risk and oral anticoagulants are recommended for patients with high risk of stroke on this 
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scale (January, Wann et al. 2014). The individual components of the CHA2DS2-VASc score are 
presented in Table 2.1. The maximum score is nine. A CHA2DS2-VASc score of two or above 
indicates a “high risk” of stroke, a CHA2DS2-VASc score of one indicates “moderate risk” and a 
score of zero indicates “low risk” for stroke. 
A crucial consideration in patients treated with anticoagulants is the risk for bleeding. All 
patients should be assessed for bleeding risk before commencing anticoagulation therapy 
(Camm, Kirchhof et al. 2010). The HAS-BLED score reflects the risk of bleeding among 
patients with AF and on anticoagulants. The individual components of the HAS-BLED score are 
presented in Table 2.2. The maximum score is nine and a total score of three or above indicates a 
high risk of bleeding (Pisters, Lane et al. 2010). Caution and regular review of the patient with 
high risk is needed following the initiation of antithrombotic medication, as well as efforts to 
correct the potentially reversible risk factors for bleeding (Camm, Kirchhof et al. 2010). The 
HAS-BLED score itself should not be used to exclude patients from anticoagulation therapy but 
allows clinicians to make an informed assessment of bleeding risk and, more crucially, prompts 
them to think of the correctable risk factors for bleeding such as uncontrolled blood pressure, 
concomitant use of aspirin/non-steroidal anti-inflammatory drugs (NSAIDs), labile INRs 
(Camm, Lip et al. 2012). 
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Table 2.1. CHA2DS2-VASc score and stroke rate (Camm, Kirchhof et al. 2010; Lip, Frison et 
al. 2010) 
Individual components of the CHA2DS2-VASc score Points awarded 
Congestive heart failure 1 
Hypertension  1 
Age ≥ 75 2 
Diabetes mellitus  1 
Stroke/Transient Ischemic Attack/ Thrombo-embolism 2 
Vascular disease (Myocardial infarction, peripheral artery 
disease, aortic atherosclerosis) 
1 
Age 65-74 1 
Female gender 1 
Adjusted stroke rate according to CHA2DS2-VASc score (Lip, Frison et al. 
2010) 
CHA2DS2-VASc score Adjusted stroke 
rate (%/year) 
0 0% 
1 1.3% 
2 2.2% 
3 3.2% 
4 4.0% 
5 6.7% 
6 9.8% 
7 9.6% 
8 6.7% 
9 15.2% 
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Table 2.2. The HAS-BLED score 
Factors Points awarded 
Hypertension 1 
Abnormal renal function (serum creatinine 200μmol/L/ chronic dialysis/ 
renal transplantation)  
1 
Abnormal liver function (chronic hepatic disease as cirrhosis/ 
biochemical evidence of significant hepatic derangement, e.g. bilirubin >2x 
upper limit of normal, in association with AST/ALT/ALP >3x upper limit 
normal) 
1 
Stroke  1 
Bleeding (major bleeding history or predisposition to bleeding) 1 
Labile INRs 1 
Elderly (aged ≥65 years) 1 
Drug therapy (concomitant use of drugs, such as antiplatelet agents, non-
steroidal anti-inflammatory drugs) 
1 
Alcohol abuse (consuming 8 or more alcoholic drinks per week) 1 
INR: International Normalised Ratio; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; ALP: 
Alkaline Phosphatase 
 
 
2.1.8. Pharmacological treatment of atrial fibrillation 
Treatment of AF aims at stroke prevention with antithrombotic therapies, reducing symptoms 
with rate-control or rhythm-control strategies, and management of associated medical conditions 
(Camm, Kirchhof et al. 2010; January, Wann et al. 2014). (Figure 2.2) 
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 Figure 2.2. Overview of management of atrial fibrillation. Source: Prystowsky, Padanilam et 
al. (2015) 
The cornerstone in the treatment of AF is stroke prevention with antithrombotic therapy, 
including anticoagulants (such as vitamin K antagonists, newer oral anticoagulants) and 
antiplatelet agents (Camm, Kirchhof et al. 2010). Antithrombotic therapy in patients with AF has 
been shown to reduce the frequency, severity and mortality from stroke (Connolly, Laupacis et 
al. 1991; Hylek, Go et al. 2003; Fuster, Ryden et al. 2006; Parkash, Wee et al. 2007; January, 
Wann et al. 2014). Anticoagulants are more effective than antiplatelet agents at reducing stroke 
risk in patients with AF. Benefits of anticoagulation therapy for people aged over 75 who have 
AF were demonstrated by the BAFTA study (the Birmingham Atrial Fibrillation Treatment of 
the Aged Study) (Mant, Hobbs et al. 2007). In this randomised trial, 973 patients aged 75 years 
or over (mean age 81·5 years, SD 4·2) with AF were recruited from primary care and randomly 
assigned to warfarin (target international normalised ratio 2–3) or aspirin (75 mg per day), with 
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mean follow-up time of 2.7 years (SD 1.2). The yearly risk of strokes in people taking warfarin 
was 1.8% compared to 3.8% in people taking aspirin (p=0.003) and the annual risk of major 
bleeding was 1.4% in people taking warfarin versus 1.6% in those taking aspirin. Figure 2.3 
shows the approach to thromboprophylaxis in patients with AF. 
Antithrombotic therapies 
Vitamin K antagonists or the coumarins 
The coumarins or vitamin K antagonists (VKAs) have been the mainstay of oral anticoagulant 
therapy for more than 60 years, with warfarin being the most commonly used VKAs (Ansell, 
Hirsh et al. 2008). In some countries, especially developing countries, acenocoumarol is the only 
VKA available. Acenocoumarol has a shorter half-life (10 hours) compared to warfarin (36 
hours) (Barcellona, Vannini et al. 1998). VKAs themselves are cheap, but the concomitant 
expenses associated with VKA dose adjustment and monitoring is more than 100-fold higher 
than its price (Belousov, Yavelov et al. 2012). The utilisation of VKAs in clinical practice is 
challenging for the following reasons: narrow therapeutic window, considerable variability in 
dose response amongst patients due to genetic and other factors, interactions with drugs and diet, 
and maintenance of a therapeutic level of anticoagulation requires a good understanding of the 
pharmacokinetics and pharmacodynamics of warfarin and good patient communication (Ansell, 
Hirsh et al. 2008). Warfarin is fully absorbed by the gastrointestinal tract after oral 
administration with a peak concentration achieved within the first four hours (Rang, Dale et al. 
2003). Terminal half-life of warfarin after a single dose is approximately one week; however, the 
effective half-life ranges from 20 to 60 hours with a mean of 36 hours (Rang, Dale et al. 2003). 
Warfarin is metabolised in the liver and kidneys to inactive metabolites which are then excreted 
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in the urine and stool (Horton and Bushwick 1999; Hirsh, Dalen et al. 2001). Warfarin inhibits 
vitamin K-dependent clotting factors II (prothrombin), VII, IX, and X and naturally occurring 
endogenous anticoagulant proteins C and S (Figure 2.4) (Hirsh, Dalen et al. 2001). The 
anticoagulant activity of warfarin depends on the clearance of functional clotting factors from the 
systemic circulation once the drug is administered (Horton and Bushwick 1999; Hirsh, Dalen et 
al. 2001). Anticoagulation with VKAs requires careful monitoring with a blood test called the 
International Normalised Ratio (INR). The target INR should be 2.0 to 3.0, which provides the 
best balance between stroke prevention and bleeding complications (Camm, Kirchhof et al. 
2010). Interactions of warfarin are presented in Table 2.3. 
Table 2.3. Interactions of warfarin with drugs, food and dietary supplements 
 
Source: Ansell, Hirsh et al. (2008) 
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Figure 2.3. Approach to thromboprophylaxis in patients with atrial fibrillation.  
Source: Camm, Lip et al. (2012) 
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Newer oral anticoagulants (NOACs) 
A direct thrombin inhibitor (dabigatran), and factor Xa inhibitors (rivaroxaban, apixaban, 
edoxaban) have been approved by the US Food and Drug Administration for prevention of stroke 
in patients with AF (January, Wann et al. 2014; Mullard 2015). Randomised controlled trials 
have demonstrated that these new oral anticoagulants are superior or at least noninferior to 
warfarin in efficacy and safety (January, Wann et al. 2014). In the RE-LY study, dabigatran (150 
mg twice daily) was associated with a lower risk for stroke and systemic embolism and a similar 
rate of major hemorrhage compared to warfarin (Connolly, Ezekowitz et al. 2009). In the 
ROCKET-AF study, rivaroxaban (20 mg once daily) was noninferior to warfarin in preventing 
stroke, with a similar risk for major bleeding but lower rates of intracranial hemorrhage and fatal 
bleeding (Patel, Mahaffey et al. 2011). In the ARISTOTLE study, apixaban (5 mg twice daily) 
was superior to warfarin in prevention of stroke/systemic embolism and was associated with a 
lower risk for bleeding and lower mortality (Granger, Alexander et al. 2011). Recently, edoxaban 
has been approved by the US Food and Drug Administration for stroke prevention in patients 
with AF. Edoxaban (30 mg or 60 mg daily) was found to be non-inferior to dose-adjusted 
warfarin in reducing the rate of stroke and systemic embolism in patients with non-valvular AF 
in the ENGAGE AF-TIMI 48 trial, with a lower incidence of bleeding complications and 
cardiovascular deaths (Acharya and Deedwania 2015). 
These new oral anticoagulants have several advantages over VKAs such as being a fixed dosing 
regimen, no need for monitoring of a laboratory test such as the INR, fewer drug interactions, no 
food interactions, rapid onset of action that obviates the need for bridging therapy (January, 
Wann et al. 2014). However, compared to warfarin, they also have some disadvantages such as 
higher cost, more gastrointestinal side effects (in the case of dabigatran), twice-daily dosing (in 
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the case of dabigatran and apixaban), and absence of a laboratory test to verify compliance. 
Moreover, these agents cannot be used safely in patients with severe renal disease. Another 
limitation is that the effects of the newer anticoagulants may be difficult to reverse in 
patients with an overdose or hemorrhage (January, Wann et al. 2014). $ major disadvantage of 
NOACs has been the lack of specific antidotes IRU UHYHUVDO SULRU WR XUJHQW VXUJHU\ RU
LQ WKH HYHQW RI D VHYHUH KDHPRUUKDJH. Activated charcoal, hemodialysis, and activated 
Prothrombin Complex Concentrate have been considered as the nonspecific agents used in 
a OAC associated bleeding but with limited success (Tummala, Kavtaradze et al. 2016). The 
first NOAC antidote, idarucizumab – a humanised monoclonal antibody fragment that 
binds to dabigatran was given an accelerated approval by FDA on October 16, 2015  
(Miyares, Kuyumjian et al. 2016). Other antidotes for NOACs such as andexanet alfa and 
aripazine are currently being studied in clinical trials (Tummala, Kavtaradze et al. 2016). 
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 Figure 2.4. Coagulation cascade and sites of action of oral anticoagulants. Source: January, 
Wann et al. (2014) 
Antiplatelet agents 
Current guidelines no longer recommend aspirin for stroke prevention in AF unless patients 
refuse the use of any oral anticoagulants (VKAs or NOACs) (Camm, Lip et al. 2012; January, 
Wann et al. 2014). The evidence for stroke prevention with aspirin in AF is weak and, in fact, the 
risk of major bleeding or intracranial bleeding with aspirin is similar to that of oral 
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anticoagulants, especially in older people (Potpara and Lip 2015). In the BAFTA study, the 
annual incidence of major bleeding in patients aged above 85 years was 2.9% with VKAs and 
3.7% with aspirin (Mant, Hobbs et al. 2007). Moreover, in the ATRIA study, the annual 
incidence of intracerebral bleeding after the age of 80 years was similar in patients treated with 
VKAs (0.70%) and aspirin (0.69%) (Go, Hylek et al. 2001). 
Clopidogrel monotherapy is not indicated for stroke prevention in AF (Camm, Kirchhof et al. 
2010; January, Wann et al. 2014). The combination of aspirin 75 mg/day with clopidogrel 75 
mg/day was superior to aspirin alone for stroke prevention but with a higher bleeding risk and no 
positive effect on thromboembolic risk was observed in the subgroup of patients aged above 75 
years (Connolly, Pogue et al. 2009; Hanon, Assayag et al. 2013). 
An overview of pharmacological thromboprophylaxis in AF was presented in Table 2.4. 
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Table 2.4. An overview of pharmacological thromboprophylaxis in atrial fibrillation  
Drugs  Stroke reduction (95% 
CI) 
Highlights  
Antiplatelet drugs 
Aspirin vs. placebo 
(Hart, Pearce et al. 2007) 
All stroke: 19% (1%-
35%) 
Ischemic stroke: 21% 
(1%-38%) 
 
Aspirin was not effective in patients 
aged ≥ 75years and in the prevention of 
severe strokes 
Only 325mg daily shown to be 
beneficial, lower doses were similar to 
placebo 
Aspirin+clopidogrel vs. 
aspirin 
(ACTIVE A) 
(Connolly, Pogue et al. 
2009) 
28% 
RR 0.72 (0.62-0.84) 
The combination of aspirin and 
clopidogrel was associated with >50% 
higher risk of major bleeding compared 
with aspirin alone (RR 1.56, 95%CI 
1.28-1.89) 
Major bleeding rates were similar to 
warfarin 
VKAs 
Warfarin vs. placebo 
(Hart, Pearce et al. 2007) 
All strokes: 64% (49%-
74%) 
Ischemic stroke: 67% 
(54%-77%) 
Warfarin also reduced all-cause 
mortality to 26% (3%-43%) 
Warfarin vs. aspirin  
(Hart, Pearce et al. 2007) 
37% (23%-48%) The risk of intracranial bleeding was 
doubled with warfarin, but the absolute 
risk increase was small (0.2% per year) 
Warfarin vs. 
aspirin+clopidogrel 
(ACTIVE W)  
(Connolly, Pogue et al. 
2006) 
40% (18%-56%) The trial was stopped early because of 
clear evidence of VKAs superiority 
over aspirin plus clopidogrel 
NOACs 
Apixaban vs. aspirin 
(AVERROES)  
Stroke or systematic 
embolism: 55%, RR 0.45 
No significant difference in major 
bleeding versus aspirin (RR 1.13, 
27
(Connolly, Eikelboom et 
al. 2011) 
(0.32-0.62) 
Ischemic stroke: 63%, 
RR 0.37 (0.25-0.55) 
95%CI 0.74-1.75) 
No difference in intracranial bleeding 
(RR 0.85, 95%CI 0.38-1.90) 
Lower risk of permanent drug 
discontinuation with apixaban (RR 
0.88, 95%CI 0.78-0.99) 
NOACs vs. warfarin  
(Ruff, Giugliano et al. 
2014) 
Stroke or systematic 
embolism: 19%, RR 0.81 
(0.73-0.91) 
Ischemic stroke: 8%, RR 
0.92 (0.83-1.02) 
Significant reduction of haemorrhagic 
stroke (RR 0.49, 95%CI 0.38-0.64) 
Significant reduction of intracranial 
bleeding (RR 0.48, 95%CI 0.39-0.59) 
Significant reduction of all-cause 
mortality (RR 0.90, 95%CI 0.85-0.95) 
Increased risk of gastrointestinal 
bleeding (RR 1.25, 95%CI 1.01-1.55) 
Modified from Potpara and Lip (2015). VKAs: Vitamin K Antagonists; RR: Relative Risk. 
 
Rate/rhythm control therapies  
An irregular rhythm and rapid ventricular rate in AF can produce symptoms of palpitations, 
dyspnea, fatigue and dizziness. Appropriate control of ventricular rate may help reduce 
symptoms and help prevent of tachycardia-mediated cardiomyopathy and heart failure (Camm, 
Kirchhof et al. 2010). 
A “rhythm control” therapy attempts to restore and maintain sinus rhythm, using a combination 
of approaches such as cardioversion, antiarrhythmics and radiofrequency catheter ablation in the 
setting of appropriate anticoagulation and rate control (January, Wann et al. 2014). Common 
antiarrhythmic drugs for maintenance of sinus rhythm include amiodarone, flecainide, 
propafenone, dronedarone, dofetilide, and sotalol (Prystowsky, Padanilam et al. 2015). A rate 
control strategy is used when sinus rhythm is not necessary and the goal is to minimise 
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symptoms during AF. Digoxin, β-adrenergic blockers (metoprolol, atenolol, bisoprolol, 
carvedilol, propranolol, nadolol), non-dihydropyridine calcium channel blockers (diltiazem, 
verapamil) are common drugs for rate control (Prystowsky, Padanilam et al. 2015). Many 
randomised controlled trials have compared rhythm-control strategy using antiarrhythmic drugs 
with a rate-control strategy. These studies have found that rhythm control is not only non-
superior to rate control on mortality, but also results in more hospitalisations in patients who are 
candidates for both treatment strategies (rhythm or rate control) (January, Wann et al. 2014). 
Current guidelines recommend rate-control therapy as first line therapy, especially for older 
patients, as rhythm control is difficult to obtain in older patients and the use of antiarrhythmic 
drugs in older patients is limited due to the comorbidities and changes in pharmacokinetics, 
pharmacodynamics (Camm, Lip et al. 2012; Hanon, Assayag et al. 2013; January, Wann et al. 
2014). 
2.1.9. The relationship between AF and frailty in older patients 
There have been many studies exploring the relationship between frailty and increased risk of 
cardiovascular diseases in community-dwelling older adults (Afilalo, Alexander et al. 2014). 
However, the relationship between frailty and AF is not well understood. It is possible that AF 
might be a cause of frailty. In a post hoc analysis of two randomised controlled trials involving 
31546 patients, AF was associated with an increased risk of cognitive decline (HR 1.14, 95% CI 
1.03-1.26), new dementia (HR 1.30, 95%CI 1.14-1.49), loss of independence in performing 
activities of daily living (HR 1.35, 95%CI 1.19-1.54) and admission to long-term care 
institutions (HR 1.53, 95%CI 1.31-1.79) (Marzona, O'Donnell et al. 2012). In a cohort study in 
23174 patients in Italy, AF was significantly associated with worse metabolic profile and clinical 
outcomes, which are markers of frailty (Fumagalli, Tarantini et al. 2010). In another cross-
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sectional study in Italy, AF was strongly associated with frailty status (defined by a Frailty 
Index) independently of age, sex, hypertension, diabetes, stroke, acute myocardial infarction and 
heart failure (OR=4.09, 95%CI 1.51-11.07) (Polidoro, Stefanelli et al. 2013).  
Frailty status can have an impact on the treatment and outcomes of patients with AF. According 
to the French Society of Geriatrics and Gerontology and the French Society of Cardiology, the 
management of AF in older patients should involve a comprehensive geriatric assessment which 
enables the detection of “frailty”, a geriatric syndrome charactersied by decreased physiological 
adaptation to stress or environmental changes (Hanon, Assayag et al. 2013).  
2.2. Frailty 
Frailty is an emerging concept in geriatric medicine. Frailty predicts adverse outcomes for older 
people, such as comorbidities, polypharmacy, loss of independence, increasing hospitalisations, 
and mortality (Heuberger 2011). Clinically, frailty may have an impact on treatment strategies 
and responses to therapy and prognosis (Hubbard, O'Mahony et al. 2013). Understanding the 
etiology, prevalence and outcomes of frailty informs research and policy to optimise care for 
older people (Clegg, Young et al. 2013).  
2.2.1. Definition and history 
Frailty is defined as a state of decreased physiological reserve and increased vulnerability to 
stressors (Clegg, Young et al. 2013). Frailty is a complex multifactorial biological syndrome that 
is characterised by a cumulative dysregulation of physiological processes (Rockwood and 
Mitnitski 2011). Although “frailty” has been often used by clinicians to characterise the weakest 
and most vulnerable subset of older people, it is not a synonym for multi-comorbidities, 
disability or “very old” (Lang, Michel et al. 2009). The concept of frailty was first mentioned in 
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medical literature in 1968 (O'Brien, Roberts et al. 1968) and frailty was first quantitatively 
measured in 1988 (Winograd, Gerety et al. 1988). Although the concept of frailty has been 
emerging in geriatric medicine for many years, there is no gold standard for the definition of 
frailty. Research efforts have help to provide a better definition and description of frailty, with up 
to twenty frailty tools having been developed to measure frailty so far (de Vries, Staal et al. 
2011). However, there is still a lack of consensus regarding the criteria for identifying frailty 
(Martin and Brighton 2008). The two most commonly used definitions in research revolve 
around the frailty phenotype (Fried, Tangen et al. 2001) and around deficit accumulation 
(Rockwood and Mitnitski 2011).  
In 2001, Fried et al defined frailty with five criteria: unintentional weight loss (more than ten 
pounds in prior year), weakness (measured by grip strength), self-report exhaustion, slowness 
(measured by walking speed) and low physical activity (measured by energy expenditure). 
Having three or more criteria indicates a frailty phenotype, while one or two criteria indicate 
intermediate or pre-frail (Fried, Tangen et al. 2001). Fried’s frailty phenotype is the most well-
known and widely used criteria for identifying frailty. It is clinically coherent, reproducible and 
it can identify frailty as a wasting disorder, with sarcopenia as a key pathophysiological feature 
that can motivate research for a targeted therapy for frailty. However, Fried’s frailty phenotype 
relies on performance-based tests and is not easy to apply for older hospitalised patients 
(Hubbard, O'Mahony M et al. 2009).  
The second common way to approach frailty is the conceptualisation of frailty as an 
accumulation of deficits throughout lifetime. Rockwood et al used an accumulation of deficits 
which include physical dysfunction, cognitive deficits, comorbidities and socio-economic 
conditions to calculate a Frailty Index (Rockwood and Mitnitski 2011). The Frailty Index is 
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constructed as the proportion of deficits present in an individual out of the total number of age-
related health variables considered, with a value from 0 to 1. The Frailty Index can be established 
from almost any set of health related variables (Rockwood and Mitnitski 2011). The value of 0.2 
on the Frailty Index is recognised by many frailty measures as approaching a frail state (Searle, 
Mitnitski et al. 2008). The Frailty Index approach is more feasible for older hospitalised patients 
(Hubbard, O'Mahony M et al. 2009).  
Fried’s frailty phenotype and the Frailty Index can identify older people at high risk of death and 
correlate well with each other, with the deficit accumulation approach predicting mortality better 
(Rockwood, Andrew et al. 2007).  Another common definition of frailty is the Edmonton Frail 
Scale. This scale, which was elaborated by Rolfson in Cananda, involves nine frailty domains 
(cognition, general health status, functional independence, social support, medication use, 
nutrition, mood, continence and functional performance) (Rolfson, Majumdar et al. 2006). In 
Australia, the Reported Edmonton Frail Scale was adapted from the Edmonton Frail Scale for 
use with acute inpatients (Hilmer, Perera et al. 2009). It is based solely on a questionnaire and is 
less time-consuming than the original Edmonton Frailty Scale and may be practical for both 
outpatients and inpatients. This Scale has been applied in many studies in acute inpatients 
(Hilmer, Perera et al. 2009; Perera, Bajorek et al. 2009; Mitchell, Hilmer et al. 2011; Bennett, 
Gnjidic et al. 2014; Rose, Pan et al. 2014; Osborne, Charles et al. 2015). 
2.2.2. Prevalence of frailty  
Many studies have reported the prevalence of frailty in Western countries. The prevalence of 
frailty in community-dwelling older adults has ranged from 4% to 10% in studies in the United 
States, 6.5% in Italy, 7% in France, 8.1% in the United Kingdom (using Fried’s phenotype) 
32
(Mitnitski, Graham et al. 2002; Mitnitski, Song et al. 2005; Espinoza and Hazuda 2010; Collard, 
Boter et al. 2012).  In Australia, the prevalence of frailty has ranged from 9.4% (using Fried’s 
phenotype) (Rochat, Cumming et al. 2010) to 15.2% (using FRAIL scale) (Hyde, Flicker et al. 
2010) in community-dwelling older men and up to 64% in older patients admitted to hospital 
with AF (using the Reported Edmonton Frail Scale) (Perera, Bajorek et al. 2009).  
In developing countries, the prevalence of frailty in older people is also quite high, from 5.4% to 
44% in community-dwelling older adults, 27.8% to 71.3% in geriatric outpatients and 32.3% to 
49.3% in institutionalised older patients (Please see Chapter Nine: A review of frailty in 
developing countries) 
2.2.3. Pathophysiology of frailty 
Frailty occurs as a result of impacts from multiple physical, social and environmental factors, 
and is a changeable condition (Raphael, Cava et al. 1995). Although the pathophysiology of 
frailty has not been fully understood, multiple physiological factors are thought to be involved in 
the development of frailty, including the immune, cardiovascular, neuro-endocrine, metabolic 
and nervous systems (Clegg, Young et al. 2013) (Figure 2.6). Frailty is also consistently 
associated with inflammation and activation of thrombotic pathways (Kanapuru and Ershler 
2009). 
2.2.4 Changes in the coagulation system with frailty 
Changes in coagulation function 
Ageing has been well established to be associated with hypercoagulability (Bauer, Weiss et al. 
1987; Abbate, Prisco et al. 1993; Tracy 2003; Yamamoto, Takeshita et al. 2005; Franchini 2006; 
Mari, Coppola et al. 2008) (Table 2.5). However, the evidence on coagulation changes with 
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frailty is not clear. Because there has been no previous published review on the topic, a 
systematic literature review was conducted via MEDLINE and EMBASE (to September 2015). 
Keywords used for searching included “frail”, “frailty”, “coagulation”, “hypercoagulable”, 
“hypercoagulability”, “hypocoagulable”, “hypocoagulability”. The achieved studies were 
presented in Table 2.6. Studies measuring individual factors in the coagulation system suggest 
that frailty is associated with pro-coagulant changes (Walston, McBurnie et al. 2002; Cohen, 
Harris et al. 2003; Folsom, Boland et al. 2007; Reiner, Aragaki et al. 2009). In the 
Cardiovascular Health Study, frailty was associated with increased plasma fibrinogen, factor 
VIII and C reactive protein (CRP) (Walston, McBurnie et al. 2002). In another study in older 
women aged 65 years or older, frailty was associated with higher D-dimer and higher t-PA 
plasma levels but not with elevated factor VIII, fibrinogen and CRP (Reiner, Aragaki et al. 
2009). High levels of D-dimer and interleukin-6 were associated with increased mortality and 
functional decline (which may contribute to the development of frailty) in older people (Cohen, 
Harris et al. 2003). Clinically, frailty is reported to be associated with increased risk of idiopathic 
venous thromboembolism in the Cardiovascular Health Study (Folsom, Boland et al. 2007). On 
the other hand, evidence from clinical studies suggests that frail older people may be at an 
increased risk of bleeding complications with anticoagulant therapy (Johnson, Lim et al. 2005; 
Perera, Bajorek et al. 2009). 
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Table 2.5. Association between ageing and haemostatic factor plasma levels (Andreotti, 
Rocca et al. 2015) 
Haemostatic factors Effect of age 
Procoagulant factors 
Fibrinogen  Increased  
Factor VII Increased  
Factor VIII Increased  
Fibrinolytic system 
Plasminogen activator inhibitor-1 Increased  
Thrombin-activatable fibrinolysis inhibitor Increased  
Plasminogen  Decreased (in women) 
Antithrombotic factors 
Protein C Increased (in women) 
Antithrombin  Increased (in women) 
Tissue factor pathway inhibitor Increased (in women) 
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Table 2.6. A summary of studies focusing on the relationship between frailty and 
coagulation changes 
Studies  Population  Age  Findings  
Cross-sectional 
study  
(Walston, 
McBurnie et al. 
2002) 
Community-dwelling 
N = 4735  
57% female 
 
≥65 years,  
Mean 72.7±5.6,  
max 78 years 
 
Frailty is associated with 
increased plasma fibrinogen, 
factor VIII and CRP 
 
Cohort study 
(Cohen, Harris et 
al. 2003) 
 
Community-dwelling 
N = 2569 
Length of follow up: 5 
years for mortality, 4 
years for functional 
status 
 
>71 years 
Mean 78, max 
85 years 
High levels of D-dimer and 
interleukin-6 was reported to 
be associated with increased 
mortality and functional 
decline 
Cohort study 
(Folsom, Boland et 
al. 2007) 
 
Community-dwelling 
N = 4859 
Length of follow up: 
9.3 years 
 
≥65 years 
 
Incidence of idiopathic VTE 
was higher in participants with 
baseline frailty 
Cohort study 
(Reiner, Aragaki et 
al. 2009) 
 
Community-dwelling 
N = 1800 
(100% female) 
Length of follow up: 3 
years 
 
≥65 years, max 
79 years 
 
Frailty is associated with 
higher D-dimer and higher t-
PA plasma levels 
Little evidence on factor VIII, 
fibrinogen and CRP 
CRP: C-Reactive Protein; VTE: Venous Thromboembolism; t-PA: tissue Plasminogen Activator 
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 Change in platelet function 
There is evidence of a trend towards increased platelet aggregation with age (Kasjanovova and 
Balaz 1986; Terres, Weber et al. 1991; Gleerup and Winther 1995; O'Donnell, Larson et al. 
2001). Several studies have reported associations between frailty and reduced activity of plasma 
aspirin esterase, a hydrolysis enzyme that helps the conversion of aspirin (acetylsalicylic acid) to 
salicylic and acetic acid (Williams, Wynne et al. 1989; Hubbard, O'Mahony et al. 2008). 
However, there has been no study focusing on the impact of frailty on platelet aggregation and 
on platelet response to antiplatelet drugs. 
2.2.5. The impacts of frailty on health outcomes 
Frailty predicts adverse outcomes for older people, such as comorbidities, polypharmacy, loss of 
independence, increasing hospitalisations, and mortality (Heuberger 2011). In community-
dwelling older adults, those who are frail have higher risk of death, institutionalisation, and 
disability (Fried, Tangen et al. 2001; Rockwood, Mitnitski et al. 2006). Frailty has been found to 
be associated with increased adverse outcomes in older patients with cardiovascular diseases 
(Cacciatore, Abete et al. 2005; Lee, Buth et al. 2010; Ekerstad, Swahn et al. 2011; Singh, Rihal 
et al. 2011; Singh, Gallacher et al. 2012; Conroy and Dowsing 2013; Cacciatore, Della-morte et 
al. 2014; Le Maguet, Roquilly et al. 2014; Ambler, Brooks et al. 2015; Bo, Puma et al. 2015). 
There have been several studies reporting that frailty is associated with adverse outcomes in 
older hospitalised patients with heart failure and myocardial infarction, and in patients after 
cardiovascular surgery (Cacciatore, Abete et al. 2005; Lee, Buth et al. 2010; Ekerstad, Swahn et 
al. 2011; Ambler, Brooks et al. 2015; Green, Arnold et al. 2015).  
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2.3. The pharmacological treatment of atrial fibrillation in old and frail people  
2.3.1. Changes in pharmacokinetics and pharmacodynamics with ageing and frailty 
Ageing is associated with many physiological changes that can alter drug absorption, 
distribution, metabolism and excretion (Hubbard, O'Mahony et al. 2013; Andreotti, Rocca et al. 
2015). Pharmacokinetic and pharmacodynamics alterations can disturb the efficacy and safety of 
drugs in older people. Age-related changes in many organs and systems can result in different-
from-expected clinical outcomes in response to several drugs (Andreotti, Rocca et al. 2015). 
Older people seem to have an increased sensitivity to many drugs, including warfarin (Hubbard, 
O'Mahony et al. 2013). Table 2.7 presents pharmacokinetic changes with ageing, frailty and their 
potential impact on the pharmacological treatment of AF in frail patients. 
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Table 2.7. Pharmacokinetics in old age and frailty  
Physiological change 
with ageing 
Pharmacological change 
with ageing 
Evidence in the frail  Potential impact on the 
pharmacological treatment of AF 
in frail patients 
Gastrointestinal tract 
↑ gastric pH 
↓ gastric emptying 
↓ splanchnic blood flow 
↓ absorption surface 
↓ mobility 
(Klotz 2009; Andreotti, 
Rocca et al. 2015) 
 
Slightly decreased 
absorption 
Different bioavailability/ 
solubility of pH-sensitive 
drugs 
(Klotz 2009; Andreotti, 
Rocca et al. 2015) 
 
No evidence  
 
Body composition and 
drug distribution 
↑ body fat  
↓ lean body mass 
↓ total water 
↓ serum albumin 
Stable or increased α1-
acid glycoprotein 
(Klotz 2009; Andreotti, 
Rocca et al. 2015) 
 
Increased volume of 
distribution and half-life 
of lipophilic drugs 
Decreased volume of 
distribution and 
increased plasma 
concentration of 
hydrophilic drugs 
Increased free fraction in 
plasma of highly protein-
bound acidic drugs 
Variable free fraction of 
basic drugs 
(Klotz 2009; Andreotti, 
Rocca et al. 2015) 
Compared to the non-
frail, the frail had: 
↑ ↑ body fat  
↓ ↓ lean body mass 
↓ ↓ serum albumin 
(Clegg, Young et al. 
2013; Hubbard, 
O'Mahony et al. 2013) 
 
Accumulation of lipophilic drugs 
as warfarin, verapamil and slowly 
release of these drugs from fat 
storage may result in significant 
high plasma levels, particularly 
after repeated doses.  
When albumin decreases, for 
highly-protein bound drugs (eg. 
warfarin), more unbound drugs 
will passively diffuse to 
extravascular or tissue sites 
where the pharmacologic effects 
of the drugs happen. Frail 
patients taking these drugs are 
prone to toxicity even with 
normal drug levels, as most 
measured drug levels reflect total 
drug in serum (bound and 
unbound). 
(Hubbard, O'Mahony et al. 2013) 
Liver  
30-50% decrease in 
blood flow 
20-40% decrease in 
hepatocyte functional 
mass 
Modified architecture 
(Klotz 2009; Andreotti, 
First-pass metabolism 
less effective 
↓ phase I metabolism 
Phase II usually 
unaffected 
(Klotz 2009; Hubbard, 
O'Mahony et al. 2013) 
Compared to the non-
frail, the frail had: 
↓ phase I metabolism 
(e.g. reduced activity of 
plasma aspirin 
esterase) (Hubbard, 
O'Mahony et al. 2013) 
↓ phase II metabolism 
In the frail, reduced activity of 
plasma aspirin esterase, a 
hydrolysis enzyme that helps the 
conversion of aspirin 
(acetylsalicylic acid) to salicylic 
and acetic acid, can lead to 
increased plasma level of aspirin 
in the frail  
(Williams, Wynne et al. 1989; 
Hubbard, O'Mahony et al. 2008). 
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Rocca et al. 2015) (e.g. ↓ glucuronidation 
of paracetamol in the 
frail (Wynne, Cope et 
al. 1990); 
↓ clearance of 
metoclopramide by 
sulphation with frailty 
(Wynne, Yelland et al. 
1993) 
Kidney  
Decrease in renal blood 
flow 
Decrease in glomerular 
filtration rate 
Change in tissue 
histology 
(Klotz 2009; Andreotti, 
Rocca et al. 2015) 
 
↓ elimination 
(Klotz 2009; Andreotti, 
Rocca et al. 2015) 
↓ ↓ elimination 
Compared to the non-
frail, the frail had more 
reduced renal drug 
clearance (Johnston, 
Hilmer et al. 2014)  
Sarcopenia in the frail can 
jeopardise the estimation of 
glomerular filtration rate from 
serum creatinine (Hubbard, 
O'Mahony et al. 2013) 
Anti-arrhythmic drugs as beta-
blockers, digoxin, procainamide 
are excreted by the kidney and 
should be cautiously used in the 
frail. 
All NOACs are not 
recommended in older patients 
with severe renal impairment: 
Dabigatran: avoid if CrCl 
<30ml/min 
Rivaroxaban, apixaban, 
edoxaban: avoid if CrCl 
<15ml/min 
(Andreotti, Rocca et al. 2015) 
AF: Atrial Fibrillation; CrCl: Creatinine Clearance; NOACs: Newer Oral Anticoagulants  
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2.3.2. Safety and efficacy of anticoagulant therapy in the old and frail 
Despite the evident benefits of anticoagulants in preventing stroke, many published studies in 
Australia and elsewhere have shown that anticoagulants are underutilised in  patients with AF, 
especially in older patients (Antani, Beyth et al. 1996; Mendelson and Aronow 1998; Cohen, 
Almoznino-Sarafian et al. 2000; Jackson, Peterson et al. 2001; Waldo, Becker et al. 2005; 
Monte, Macchia et al. 2006; Perera, Bajorek et al. 2009; Radholm, Ostgren et al. 2011; Corvol, 
Gulsvik et al. 2014). Current guidelines do not provide specific guidance for treatment of AF in 
frail patients (Camm, Kirchhof et al. 2010; January, Wann et al. 2014). Antithrombotic treatment 
in older people is challenging, as older patients have multi-organ changes, multi-comorbidities, 
increased risk of both bleeding and ischaemic events, and reduced adherence to prescriptions 
(Andreotti, Rocca et al. 2015). Since the individual risk factors for stroke and for bleeding are 
similar (for examples, age ≥ 65 years, hypertension, stroke), older people with high risk of stroke 
are usually also at high risk of bleeding. However, recent studies have shown that the benefit 
associated with anticoagulants runs parallel with increasing embolic risk, even in those with 
higher bleeding risk  (Friberg, Rosenqvist et al. 2012; Andreotti, Rocca et al. 2015). The clinical 
benefit of anticoagulation compared to no anticoagulation (antiplatelet therapies or no 
antithrombotic therapy) – expressed as freedom from death, ischaemic stroke, and intracranial 
haemorrhage – is significant not only for patients at higher thromboembolic risk but also for 
patients at higher bleeding risk (Andreotti, Rocca et al. 2015). 
The incidence of major bleeding in older patients with AF taking warfarin has varied among 
studies, ranging from 1.8%-1.9% per year (Cleland, Cowburn et al. 1996; Mant, Hobbs et al. 
2007) in randomised controlled trials to as high as 13% in observational studies (Johnson, Lim et 
al. 2005; Hylek, Evans-Molina et al. 2007). Several studies have reported considerably lower 
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rates of major bleeding in old patients with AF.  In a study of patients 80 years or older in Isreal, 
the rate of major bleedings was 2.4 events per 1000 patient-months among 323 (2.1%) patients 
discharged with anticoagulant therapy (Kagansky, Knobler et al. 2004). Low incidence of major 
bleeds was also reported in a study of Italian patients aged ≥ 80 receiving antivitamin K, in 
which the rate of major bleeding was 1.87 per 100 patient-years (Poli, Antonucci et al. 2009). 
Similarly, incidence of hemorrhage was also very low among older patients treated by anti-
vitamin K for AF in a study in France (only 3 major bleeding events during 1 year follow up in 
150 patients aged ≥ 75) (Trinh, Estivin et al. 2012).  
In Australia, evidence on the efficacy of anticoagulation (incidence of strokes) in older patients 
with AF is rather consistent, while evidence on the safety (hemorrhage rates) is variable. A 
retrospective study on 505 consecutive patients admitted to a major teaching hospital in 
Tasmania between 1997 and 1999 (median age 76 years) reported an annual incidence of strokes 
of 3.4% in patients taking warfarin (compared to 7.8% in patients taking aspirin) and the annual 
incidence of major bleeds was 3.4% in patients taking warfarin (Jackson, Peterson et al. 2001). 
In a study of 228 hospitalised patients aged 76 or older in Victoria (mean age 81.1) between 
2001 and 2002, the annual stroke rate in patients taking warfarin was 2.6% and the annual rate of 
major bleeds in patients taking warfarin was 10.0% (Johnson, Lim et al. 2005). According to a 
study in Sydney, after 6 month follow-up, in patients taking warfarin the overall incidence of 
major bleeding was 22.9% and the overall incidence of strokes was 3.6%  (Perera, Bajorek et al. 
2009).  
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2.4. Observational studies investigating the impact of frailty on the pharmacological 
treatment of AF 
There have not been many published studies focused on frailty in the pharmacological treatment 
of AF. As there has been no previous published review on the topic, a literature search was 
conducted via MEDLINE and EMBASE (to September 2015). Keywords used for searching 
included “frail”, “frailty”, “atrial fibrillation”. The articles attained by this method of searching 
were screened by title and relevant papers were retrieved (language was restricted to English). 
Seven observational studies that focused on the impact of frailty or geriatric syndromes (in cases 
there was not a definition of frailty in the studies) on anticoagulation in older patients with AF 
were found (Table 2.8). The impact of frailty on anticoagulation therapy in older patients with 
AF was not consistent among these studies: some suggest that the presence of frailty or geriatric 
syndromes is significantly associated with non-prescription of anticoagulants (Perera, Bajorek et 
al. 2009; Frewen, Finucane et al. 2012; Lefebvre, St-Onge et al. 2015), while others have not 
found this (De Breucker, Herzog et al. 2010; Denoel, Mols et al. 2012; Ferguson, Inglis et al. 
2014; Bo, Puma et al. 2015). The study of Perera et al is the only one that reported the incidence 
of stroke and bleeding in frail and non-frail older patients on anticoagulant therapy (Perera, 
Bajorek et al. 2009). 
Observational studies have played a major role in geriatric research and in defining the scope of 
many health problems in older adults, their risk factors, and their natural history (Newman 
2010). Older people and especially frail people are often excluded from clinical trials (Van Spall, 
Toren et al. 2007; Hubbard, Lang et al. 2010). While there is a lack of clinical trials on drug 
effects in frail older patients, treatment decisions are therefore based on evidence extrapolated 
from more robust patient groups with fewer physiological deficits (Hubbard, O'Mahony et al. 
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2013). Observational studies in frail older patients provide more understanding of the impact of 
frailty on treatment strategies and responses to therapy, informs further research and policy to 
optimise care for older people (Rockwood, Fox et al. 1994). More specifically, in the treatment 
of AF, identifying the relationship between frailty and anticoagulation can help develop a 
tailored anticoagulation therapy to minimise major bleeding in these patients while waiting for 
clinical drug trials involving the frail and specific guidelines for treatment of AF in frail patients. 
In fact, the French Society of Geriatrics and Gerontology and the French Society of Cardiology, 
has recently called for a comprehensive geriatric assessment which enables the detection of 
frailty in the management of AF in older patients (Hanon, Assayag et al. 2013). There has been 
suggestion of a multidimensional anticoagulation-focused tool to identify frail older patients so 
that it can help doctors to take balanced decisions on anticoagulation (Granziera, Cohen et al. 
2015).   
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 Table 2.8. A summary of observational studies of the impact of frailty on the 
pharmacological treatment of atrial fibrillation 
Study design Country  Study population  Frailty definition Percentage of 
OAC 
prescription 
The impact of 
frailty on OAC 
utilisation 
Prospective 
observational 
study in 2014  
(Bo, Puma et al. 
2015) 
Italy  Hospitalised patients 
aged≥65 years 
(N=513) 
The Groningen 
Frailty Indicator (≥4 
points) 
Prevalence of frailty: 
77.5% 
 
48.7% at 
discharge 
 
No significant 
association 
between frailty 
and OAC use at 
discharge 
(adjusted OR 
0.80, 95%CI 
0.41-1.57) 
Prospective 
observational 
study in 2013 
(Lefebvre, St-
Onge et al. 
2015) 
Canada  Hospitalised patients 
aged≥80 years, 
N=682 
The Clinical Frailty 
Scale  
Prevalence of frailty: 
not presented 
69.6% Non-frail and 
moderately frail 
patients were 
more likely to 
receive OAC 
than the severely 
frail (adjusted 
OR 3.41, 95%CI 
1.84-6.33) 
Prospective 
observational 
study in 2013 
(abstract only, 
preliminary 
results of the 
first 74 
participants) 
(Ferguson, 
Inglis et al. 
2014) 
Australia  Hospitalised patients 
with concomitant AF 
and heart failure, 
mean age 73±15, 
N=74 
The SHARE Frailty 
Instrument  
Prevalence of frailty: 
61% 
73% Anticoagulation 
was not different 
between frail 
and non-frail 
patients (64% 
frail vs 87% 
non-frail, 
p>0.05) 
Prospective 
observational 
study in 2012 
(abstract only) 
(Frewen, 
Finucane et al. 
2012) 
Ireland  Community-dwellers 
aged>50 years, 
N=118 
Fried’s frailty criteria 40.9% Pre-frailty 
predicted non-
anticoagulation 
(OR 3.1, 
p=0.009) 
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Prospective 
observational 
study in 2011-
2012 (Denoel, 
Mols et al. 
2012) 
 
Belgium Hospitalised patients 
aged≥75 years, 
N=142 
The ISAR 
questionnaire 
(Identification of 
Seniors at Risk) 
Prevalence of frailty: 
84% (ISAR≥2) 
61% on 
admission 
No impact of 
frailty on 
anticoagulation 
(OR 1.12, 
95%CI 0.50-
2.96) 
Retrospective 
study in 2006-
2008 (De 
Breucker, 
Herzog et al. 
2010) 
Belgium Hospitalised patients 
aged≥70 years, 
N=111 
Geriatric syndromes 
were evaluated 
(cognitive disorders, 
malnutrition, 
depression, falls, 
incontinence) 
51% on 
admission 
Comparison the 
proportion of 
geriatric 
syndromes 
between patients 
receiving VKAs 
and patients not 
receiving VKAs 
showed no 
significant 
difference. 
Prospective 
observational 
study in 2007 
(Perera, 
Bajorek et al. 
2009) 
Australia  Hospitalised patients 
aged≥70 years, 
N=220 
The Reported 
Edmonton Frail Scale 
39.1% at 
discharge 
Frail patients 
were 
significantly less 
likely to receive 
warfarin at 
discharge (23% 
frail vs. 59% 
non-frail, 
p<0.001) 
AF: Atrial Fibrillation; OAC: Oral Anticoagulant; VKAs: Vitamin K Antagonists 
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Chapter Three  
Methods 
This chapter provides an overview of the methods for the whole thesis. Details of methods for 
each study are presented in the publications in chapters 6-10. 
3.1. Methods for the Australian study 
Study design 
This was a prospective observational study on a cohort of older patients admitted to Royal North 
Shore Hospital between October 2012 and January 2014.  
Patient recruitment 
The study was approved by The Northern Sydney Local Health District Human Research Ethics 
Committee and The University of Sydney Human Research Ethics Committee. Patients were 
identified daily using electronic handover sheets from the target wards (Aged Care, General 
Medicine and Cardiology). Patients were approached and asked to sign a consent form to 
participate in the study. Written consent was obtained from caregivers in the following 
situations: the patients were too sick or too tired to read through the participant information 
sheet; the patients did not want to read through the participant information sheet; the patient’s 
caregivers themselves wanted to read through the participant information sheet and sign on 
behalf of the patient. In those with significant cognitive impairment, consent was also obtained 
from their caregivers. In such cases the recruiting team made the best effort to interview both the 
participants and their caregivers to ensure the best possible accuracy of the information obtained. 
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Another consent form was also signed if the patient or their caregivers agreed to participate in 
the sub study about coagulation changes and platelet function changes with ageing and frailty. 
Data from participants were the de-identified using study codes before being entered into the 
electronic database. 
Inclusion/ Exclusion criteria 
All inpatients aged ≥65 years with a diagnosis of non-valvular AF admitted to Royal North 
Shore Hospital’s Aged Care department, Cardiology department and General Medicine 
department during the study period were eligible for the study. AF was first identified in the 
patient medical history, then confirmed by at least one ECG during hospitalisation (ECGs were 
read by the recruiting doctors). Patients who were dying or receiving intensive care or who were 
identified as “blind” or “deaf” and unable to see or hear the investigators respectively on initial 
contact were excluded from the study. Patients were also excluded when consent could not be 
obtained from them or their caregivers. 
Sample size calculation 
Based on previous studies, detection of a significant difference between frail and non-frail 
patients at a power of 80% and level of significance 0.05 required 700 participants to detect a 
difference in heamorrhage rate. (Johnson C, Lim W et al. 2005; Hylek, Evans-Molina et al. 2007; 
Perera, Bajorek et al. 2009). However, in January 2014 when we had follow up data from 210 
participants (52.2% frail) there were only 3 major bleeds in frail group and 5 major bleeds in 
non-frail group. The prevalence of major bleeds was 2.6% in frail patients and 5.2% in non-frail 
patients, which was much lower than that predicted from the literature. Using the observed 
haemorrhage rate, we recalculated that to detect a signiﬁcant difference in major bleeds between 
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frail and non-frail participants at a power of 80% and α = 0.05 will require up to 1515 
participants. This was not feasible for this study given the limited hospital’s catchment area and 
the time frame of the study. Therefore, we decided to stop recruiting. 
Data collection 
Data were collected from participant/ caregiver interviews and medical records. After the 
participant or their legal caregiver had signed the consent form, a questionnaire was completed to 
calculate the Reported Edmonton Frail Scale (details below). Further data collection (socio-
demographics, co-morbidities, reasons for admission, medication utilization before admission 
and upon discharge, blood tests) were obtained from patient records. All pre-admission 
medications were collected from the medical records. CHA2DS2-VASc score (for stroke risk 
evaluation) and HAS-BLED score (for bleeding risk evaluation) were calculated from these data 
(details of these scores were presented in Chapter 2). 
In a subgroup of participants who provided additional consent for the sub-study (the pilot studies 
about platelet and coagulation function), blood was collected during the admission to assess 
coagulation and platelet function. These tests were performed in the Northern Blood Research 
Centre, Kolling Institute of Medcical Research. This study aims to recruit at least 30 participants 
in each treatment arm (anticoagulants/ no anti-thrombotics, aspirin/ no antiplatelets) (Billingham, 
Whitehead et al. 2013; Moore, Carter et al. 2011). Please see chapter 8 and chapter 9 for details 
of methods. 
Follow up 
All participants were followed up for any haemorrhage events, ischemic strokes, hospitalisations 
and death by conducting structured phone interviews sixth months after recruitment. Where 
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participants or their caregivers could not be contacted, hospital medical records were assessed for 
outcomes over the six months after recruitment. A follow up time of six months was chosen as 
previous local study showed a high rate of death after six months in older inpatients with AF 
(Perera, Bajorek et al. 2009). 
Frailty assessment 
The Reported Edmonton Frail Scale (REFS) was used to identify frail participants. This scale 
was adapted from the Edmonton Frail Scale for use with Australian acute inpatients based on a 
questionnaire and has been validated (Hilmer, Perera et al. 2009) (Please see section 
2.2.1).Compared to other common frailty definitions such as frailty phenotype or the Frailty 
Index, it is more feasible for older inpatients and less time-sonsuming, and was the only frailty 
measure validated in Australian inpatients at the time this study was designed. The scale involves 
nine frailty domains (cognition, general health status, functional independence, social support, 
medication use, nutrition, mood, continence and functional performance). With a maximum 
score of 18, a score of 0 to 5 indicates robust, 6 to 7 indicates apparently vulnerable status, 8 to 9 
mild frailty, 10 to 11 moderate frailty and 12 or more indicates severe frailty. The cut point used 
to identify frailty was 8, consistent with previous studies using REFS (Perera, Bajorek et al. 
2009; Mitchell, Hilmer et al. 2011; Bennett, Gnjidic et al. 2014). 
Table 3.1. The Reported Edmonton Frail Scale 
Frailty domain Item 0  1  2  
General Health 
Status 
In the past year, how many times have you 
been admitted to a hospital? 
In general, how would you describe your 
health? 
0 
Excellent/ 
Very good/ 
Good 
1-2 
Fair 
>2 
Poor 
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Functional 
Independence 
Do you require help with: 
□ meal preparation 
□shopping 
□transportation 
□telephone 
□housekeeping 
□laundry 
□managing money 
□taking medications) 
0-1 2-4 5-8 
Social Support When you need help, can you count on 
someone who is willing and able to meet your 
needs? 
Always Sometimes Never 
Medication Use Do you use five or more different prescription 
medications on a regular basis? 
At times, do you forget to take your 
prescription medications? 
No 
 
No 
Yes 
 
Yes 
 
Nutrition Have you recently lost weight such that your 
clothing has become looser? 
No Yes  
Mood  Do you often feel sad or depressed? No Yes  
Continence Do you have a problem with losing control of 
urine when you don’t want to? 
No Yes  
Self Reported 
Performance 
Two weeks ago were you able to: 
(1) Do heavy work around the house like 
washing windows, walls, or floors without 
help? 
(2) Walk up and down stairs to the second 
floor without help?  
(3) Walk a 1 km without help? 
 
Yes 
 
 
Yes 
Yes 
 
No 
 
 
No 
No 
 
Cognition 
(Clock-drawing 
test) 
Please imagine that this pre-drawn circle is a 
clock. I would like you to place the numbers 
in the correct positions then place the hands to 
indicate a time of ‘ten after eleven’ 
No errors Minor 
spacing 
errors 
Other 
errors 
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Outcome variables 
Pharmacological treatment: 
- Antithrombotic prescriptions included anticoagulant prescription, anti-platelet 
prescription or non-prescription of any antithrombotic medications upon discharge. 
- Anti-arrhythmic drug prescription included rate control drugs only, rhythm control drugs 
only, both rate and rhythm control drugs and non-prescription of anti-arrhythmics. 
Clinical outcomes related to antithrombotic therapies: 
- Haemorrhage events were classified as minor (bleeding/bruising that did not require 
hospitalisation), major (internal bleeding or bleeding/bruising that required 
hospitalisation) or severe (intracranial or fatal bleeding) (Johnson, Lim et al. 2005). 
- Ischemic stroke 
Global outcomes: 
- Prolonged hospitalisation was defined as those with a length of stay equal to or greater 
than the 75th percentile of the length of stay of the whole cohort (measured in days).  
- Readmissions were defined as at least one readmission to hospitals for any cause during 
six months.  
- All-cause mortality included all deaths during hospitalisation and during follow up after 
discharge. Discharged participants or their caregivers were contacted after six months for 
information on re-admissions and whether the participant had died during this period.  
Biomarkers: 
- Changes in platelet aggregation parameters 
- Changes in coagulation parameters 
 
Data analysis 
Analysis of the data was performed using SPSS for Windows 20.0 (IBM Corp., Armonk, NY, 
USA). Continuous variables were shown as mean ± standard deviation (SD) or median and range 
for nonparametric variables. Categorical variables are presented as frequencies and percentages.  
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Due to the limit of the sample size, a binary value was chosen for frailty instead of analyzing the 
five groups of frailty (ie. Robust, Apparently Vulnerable, Mild Frailty, Moderate Frailty, 
Severely Frailty). Comparisons between frail and non-frail participants were assessed using the 
Chi-square test or Fisher’s exact test for categorical variables and Student’s t-test, Mann-
Whitney or one-way analysis of variance (ANOVA) test for continuous variables. Two-tailed P 
values <0.05 were considered significant. 
Table 3.2. Variables used in logistic regression models and Cox proportional-hazards 
regression model 
Potential predictor variables Outcome variables Methods  Chapter  
Frailty, age, gender, reported 
poor nutrition status, paroxysmal 
atrial fibrillation, permanent 
pacemaker, hypertension, 
ischemic heart disease, heart 
failure, stroke/systemic 
thromboembolism, type 2 
diabetes, peripheral vascular 
disease, dyslipidemia, chronic 
pulmonary disease, cancer, 
dementia, depression, severe 
renal impairment, abnormal liver 
function, alcohol abuse, history of 
bleeding/predisposition to 
bleeding, falls on admission 
Abel Latif, Peng et al. 2005; 
Baczek, Chen et al. 2012) 
Antithrombotic 
prescription  
Anti-arrhythmic 
prescription 
Multivariate 
logistic regression.  
Results are 
presented as odds 
ratios and 95% 
confidence 
intervals 
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Frailty, age, gender, Charlson 
comorbidity Index, CHA2DS2-
VASc score, HAS-BLED score, 
admission due to falls, delirium 
on admission, and the following 
medications on discharge: 
anticoagulants, digoxin, statin or 
psychotropic medication 
(Gheorghiade, Fonarow et al. 
All-cause mortality  Cox proportional-
hazards 
regression. 
Results presented 
as hazard ratios 
and 95% 
confidence 
Chapter 5 
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2013; Mulder, Van Veldhuisen et 
al. 2014; Eeles, White et al. 
2012). 
intervals  
Frailty, age, gender, Charlson 
comorbidity Index, CHA2DS2-
VASc score, HAS-BLED score, 
admission due to falls, or 
delirium on admission (Ambler, 
Brooks et al. 2015; Eeles, White 
et al. 2012). 
Prolonged 
hospitalisation 
Multivariate 
logistic regression.  
Results are 
presented as odds 
ratios and 95% 
confidence 
intervals 
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Multivariate logistic regression was used to identify whether frailty was associated with 
antithrombotic prescription and rate/rhythm control drug prescription. Results are presented as 
odds ratios (OR) and 95% confidence intervals. Univariate logistic regression was performed on 
all the potential predictors for anticoagulant prescription and rate/rhythm control drug 
prescription. Only variables that had a p-value <0.20 on univariate analysis were entered into 
multivariate analysis. Backward elimination method was applied and the final model retained the 
studied variable (which is frailty) and those variables significant at P<0.05.  
Incidence of strokes and bleeding over six months was compared between frail and non-frail 
participants according to antithrombotic regimes: anticoagulants ± antiplatelets, antiplatelets 
only, and no antithrombotics (small numbers of incidence of stroke and bleeding did not allow 
logistic regression).  
To compare the time to death in frail and non-frail participants, the Kaplan– Meier estimator was 
employed to compute survival curves over the six-month follow-up period and differences 
between frail and non-frail groups assessed using log rank tests. Cox proportional-hazards 
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regression was used to determine whether frailty assessed with the RFES predicted mortality, 
with results presented as hazard ratios (HR) and 95% confidence intervals (CIs). Follow up was 
censored at six months unless participant had died prior to that date. Logistic regression was 
applied to investigate predictors of prolonged hospitalisation and results were presented as odds 
ratios (OR) and 95% CIs. Univariate regression was performed on all the potential predictors for 
adverse outcomes. Those variables that had a p-value <0.20 on univariate analysis were entered 
into multivariate analysis. Backward elimination method was applied and the final model 
retained the studied variable (frailty) and those variables significant at P <0.05. 
Details of statistical analyses of the impact of frailty on platelet aggregation and coagulation 
parameters are presented in chapter 8 and chapter 9. 
In this study missing data only occurred with BMI and some coagulation measures (ASPItest: 5 
cases, ADPtest: 7 cases, D-dimer: 2 cases, Factor VIII: 2 cases, Prothrombin time: 1 case, Von 
Willebrand Factor: 1 case). BMI data were missed in 81 of 302 participants (as most of the 
participants were frail, their reported weight and height were not always stated in the medical 
records). The missing data were random, therefore only the available data were analysed (i.e. the 
missing data were ignored by SPSS). 
Patient recruitment 
Consecutive patients admitted to the targeted wards were recruited. From October 2012 to 
August 2013 (11 months), Ngoc Tu Nguyen was the only recruiter (Figure 1). For the final four 
months of the study (September 2013 to January 2014), three resident doctors joined the 
recruiting team and these doctors did not record details of the number of ineligible patients and 
refusals. Therefore, information on the characteristics of those that were excluded or refused 
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cannot be fully obtained. The recruiting team made their best effort to recruit consecutive 
patients. However, patients admitted to the hospital during weekends, holidays and during the 
time the team members were busy with other tasks were missed. 
Of the 302 participants of the study, 38 were lost to follow up and 65 died during follow up. 
Participants who were lost to follow up had lower prevalence of frailty compared to those 
remained (34.2% vs 56.1%, p=0.01) and there was no difference in gender (60.5% female vs 
48.5% female in those remained, p = 0.17) and age (83.58 ± 6.95 vs 84.80 ± 7.07 in those 
remained, p = 0.32). Compared to those survived, the participants who died during follow up 
were more frail (75.4% vs 47.3% in those survived, p<0.001), and there was no difference in age 
(85.92 ± 7.34 vs 84.30 ± 6.95 in those survived, p = 0.10) and gender (40.0% female vs 52.7% 
female in those survived, p=0.07).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Patient sample (from October 2012 to August 2013) 
381 eligible patients 
64 (16.8%) excluded: 
  45 (70.3%) receiving intensive care or dying 
  12 (18.7%) unable to give consent 
  6 (9.4%) deaf 
  1 (1.6%) blind 
 
 
 
65 (17.1%) refused participation 
 
252 (66.1%) patients interviewed (from 10/2012 to 
8/2013) 
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3.2. The Vietnam study 
Study population 
We used data from a study of the prevalence of frailty in older hospitalised patients at the 
National Geriatric Hospital in Hanoi, Vietnam. In this observational study, consecutive patients 
aged ≥ 60 years admitted to the hospital on weekdays between April 2015 and October 2015 
were recruited by two medically qualified master students. The National Geriatric Hospital in 
Hanoi is the only geriatric hospital in Vietnam and it provides care for older patients in Hanoi 
and the Northern provinces of Vietnam. The study was approved by the National Geriatric 
Hospital Ethics Committee. Hospitalised patients were eligible to participate if they were 60 
years or older. Participants who were dying or receiving intensive care or who were identified as 
“blind” or “deaf” were excluded from the study. Eligible patients were identified daily from the 
target wards (cardiology, general medicine, endocrinology, neurology and the private general 
medicine ward) and invited to participate. Informed verbal consent was obtained from all 
participants. The sample size for the study about the prevalence of frailty in older inpatients in 
Vietnam was calculated as follows: 
N = [Z2(1-α/2) x P x (1-P)]/ d2 
P: prevalence of frailty in literature. Based on previous studies, the prevalence of frailty in 
hospitalized patients ranged from 30% to 60% (Khandelwal et al., 2012; Perera, Bajorek et al, 
2009; Purser et al, 2006). With a 99% confidence interval (Z= 2.33) and a desired absolute 
precision of 5% (d=0.05), the estimated sample size would range from 456 to 521 participants. In 
fact, a total of 461 participants were recruited. 
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Data collection included socio-demographics, detailed medical history, co-morbidities, clinical 
assessments and prescribed medications and non-prescription medications. All pre-admission 
medications and discharged medications were collected from the medical records. All patients 
had an electrocardiogram on admission, and these electrocardiograms were reviewed by the 
study doctors. Atrial fibrillation was first identified based on the electrocardiogram on 
admission, then confirmed with at least one electrocardiogram during hospitalisation. Patients 
with AF were evaluated for stroke risk and bleeding risk using data collected on all study 
participants. Stroke risk was assessed with the CHA2DS2-VASc score and bleeding risk for 
anticoagulants was assessed with the HAS-BLED score. The Reported Edmonton Frail Scale 
(REFS) was used to identify frail participants.  
Statistical Analysis: 
Analysis of the data was performed using SPSS for Windows 20.0 (IBM Corp., Armonk, NY, 
USA). Continuous variables are presented as mean ± standard deviation, and categorical 
variables as frequency and percentage. Comparisons between frail and non-frail participants 
were assessed using the Chi-square test or Fisher’s exact test for categorical variables and 
Student’s t-test or Mann-Whitney test for continuous variables. Multivariate logistic regression 
was applied to identify risk factors for prevalent AF on admission. Univariate logistic regression 
was performed on all the potential risk factors for AF (age, gender, frailty status, nutrition status, 
overweight, smoking, alcohol abuse, hypertension, ischemic heart disease, heart failure, type 2 
diabetes, peripheral vascular disease, dyslipidemia, chronic pulmonary disease, dementia, 
depression, thyroid disorders, habits of using herbal medicine, using vitamins, and socio-
economic factors as education, residential status). Only variables that had a p-value <0.20 on 
univariate analysis were selected for multivariate analysis. Backward elimination method was 
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applied and the final model retained variables significant at P<0.05. All variables were examined 
for interaction and multicollinearity.  
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Chapter Four 
Atrial fibrillation in older inpatients: are there any differences in clinical 
characteristics and pharmacological treatment between the frail and  
the non-frail?
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Abstract 
Background. Frailty is common in patients with atrial fibrillation (AF) and may impact on 
antithrombotic and antiarrhythmic treatment. 
Aim. Describe differences in clinical characteristics, prescription of antithrombotic and 
antiarrhythmic medications and incidence of haemorrhage and stroke, between frail and non-
frail older inpatients. 
Methods. Prospective observational study in patients aged ≥65 years with AF admitted to a 
teaching hospital in Sydney, Australia. Frailty was assessed using the Reported Edmonton 
Frail Scale, stroke risk with CHA2DS2-VASc score and bleeding risk with HAS-BLED 
score. Participants were followed after six months for haemorrhages and strokes. 
Results. We recruited 302 patients (mean age 84.7±7.1, 53.3% frail, 50% female, mean 
CHA2DS2-VASc 4.61±1.44, mean HAS-BLED 2.97±1.04). Frail participants were older, 
had more comorbidities and higher risk of stroke but not haemorrhage. Upon discharge, 
55.7% participants were prescribed anticoagulants (49.3% frail, 62.6% non-frail, p=0.02). 
Thirty-three percent received antiplatelets only and 11.1% no antithrombotics, with no 
difference by frailty status. For antiarrhythmics, 52.6% received rate-control drugs only, 
11.8% rhythm-control drugs only, 13.5% both and 22.1% were not prescribed either, with no 
difference by frailty status.  On univariate logistic regression, frailty decreased the likelihood 
of anticoagulant prescription (OR 0.58, 95%CI 0.36-0.93), but this was not significant on 
multivariate analysis (OR 0.66 95%CI 0.40 - 1.11). After six months, overall incidence of 
ischemic stroke was 2.1% and, in patients taking anticoagulants, incidence of major/severe 
bleeding was 6.3%, with no significant difference between frailty groups. 
Conclusions. Frailty status had little impact on antithrombotic prescription and no impact on 
anti-arrhythmic prescription.  
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Introduction  
 
As the population ages, the prevalence and clinical importance of frailty is increasing 
(Morley, Vellas et al. 2013). Frailty is a clinical syndrome resulting from multisystem 
impairments and characterised by increased vulnerability and disabilities (Buchner and 
Wagner 1992). Multiple physiological factors are thought to be involved in the development 
of frailty, including the cardiovascular systems and thrombotic pathways (Chaves, Semba et 
al. 2005; Kanapuru and Ershler 2009). A relationship between frailty and cardiovascular 
disease has been observed, in which frailty has strong relationships with ischemic heart 
disease, heart failure and atrial fibrillation (Polidoro, Stefanelli et al. 2013; Von Haehling, 
Anker et al. 2013). Frailty predicts adverse outcomes such as comorbidities, polypharmacy, 
loss of independence, increasing hospitalisations, and mortality in older patients and 
especially in patients with cardiovascular diseases (Heuberger 2011; Von Haehling, Anker et 
al. 2013).  
Atrial fibrillation (AF) is a common cardiac arrhythmia in older adults. The prevalence of AF 
in published studies in Western countries ranges from 0.5% to 3% in the general population, 
5% to 6% in people older than 65 years old and up to 5% to15% among those aged 80 years 
or older (Camm, Kirchhof et al. 2010; Ball, Carrington et al. 2013; Hubbard, O'Mahony et al. 
2013). In Australia, the prevalence of AF in the community-dwelling people aged 30 years or 
older is 4% (Sturm, Davis et al. 2002). People with atrial fibrillation have an increased risk of 
stroke (Fuster, Ryden et al. 2001).  The annual incidence of stroke in people with AF is 
approximately 5%, which is 2 to 7 times higher than the average rate of stroke in the general 
population, depending on the presence of other stroke risk factors (Fuster, Ryden et al. 2001). 
According to the Framingham study, the annual risk of stroke in patients with AF was 1.5% 
in those aged 50–59 years and 23.5% in those aged 80–89 years (Wolf, Abbott et al. 1991). 
Strokes associated with AF tend to be more severe and result in greater disability, longer 
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hospital stays and less likelihood of discharge to patients’ own homes than strokes not 
associated with AF (Goto, Bhatt et al. 2008). Treatment of AF aims at stroke prevention with 
antithrombotic therapy, reducing symptoms with rate-control or rhythm-control strategies, 
and management of associated medical conditions (Camm, Kirchhof et al. 2010). 
Antithrombotic therapy in patients with AF has been shown to reduce the frequency, severity 
and mortality from stroke (Hylek, Go et al. 2003; January, Wann et al. 2014). However, 
despite the evident benefits of anticoagulants in preventing stroke, studies have shown that 
anticoagulants are underutilised in patients with AF, especially in older patients (Antani, 
Beyth et al. 1996; Mendelson and Aronow 1998; Waldo, Becker et al. 2005; Perera, Bajorek 
et al. 2009; Radholm, Ostgren et al. 2011; Corvol, Gulsvik et al. 2014). The prevalence of 
chronic diseases, polypharmacy and adverse drug reactions all increase with ageing (Hilmer, 
Gnjidic et al. 2012). Changes in pharmacokinetics and pharmacodynamics with aging, frailty 
and multimorbidity also increase inter- and intra-individual variability (Hardy and Hilmer 
2011; Hilmer, Gnjidic et al. 2012). Only a few published studies have focused on frailty and 
pharmacological treatment of AF, and these have been limited to anticoagulation (Perera, 
Bajorek et al. 2009; De Breucker, Herzog et al. 2010; Frewen, Finucane et al. 2012; 
Ferguson, Inglis et al. 2014; Bo, Puma et al. 2015). 
This study aims to investigate in frail and non-frail older inpatients with AF the differences in 
clinical characteristics, prescription of antithrombotic and antiarrhythmic medications, 
incidence of major bleeding and strokes over 6 months, and to identify whether frailty is 
independently associated with prescription of these medications. 
Methods 
Participant selection.  
A prospective observational study was performed on a cohort of patients aged ≥65 years with 
non-valvular AF admitted to Royal North Shore Hospital, Sydney, Australia, between 
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October 2012 and January 2014. The study was approved by The Northern Sydney Local 
Health District Human Research Ethics Committee and The University of Sydney Human 
Research Ethics Committee. Patients were eligible to participate if they were aged ≥ 65 years 
and diagnosed with AF. Exclusion criteria were severe illness and severe hearing or visual 
impairment. Eligible patients were identified daily from the target wards (aged care, 
cardiology and general medicine) and invited to participate. Consent was obtained from all 
participants or their caregivers. Baseline data collection included sociodemographics, medical 
history, reasons for admission, individual components of the Charlson co-morbidity index 
and the Reported Edmonton Frail Scale (see details below), and medication prescribed on 
admission and discharge. Medications on admission were obtained from the medical record, 
using the best available medication history from medication reconciliation where available.  
Medications on discharge were obtained from the hospital discharge summary, which was 
routinely reconciled by a clinical pharmacist as part of usual care. 
All participants were followed up for any bleeding events, ischemic strokes, and death by 
conducting structured phone interviews sixth months after recruitment. Where participants or 
their caregivers could not be contacted, hospital medical records were assessed for outcomes 
over the six months after recruitment. Hemorrhage events were classified as minor 
(bleeding/bruising that did not require hospitalisation), major (internal bleeding or 
bleeding/bruising that required hospitalisation) or severe (intracranial or fatal bleeding) 
(Johnson, Lim et al. 2005). 
Stroke risk and bleeding risk assessment.  
In patients with non-valvular AF, the CHA2DS2-VASc score is recommended for assessment 
of stroke risk and oral anticoagulants are recommended for patients with high risk of stroke 
on this scale (January, Wann et al. 2014). The individual components of the CHA2DS2-
72
VASc score include: congestive heart failure (1 point), hypertension (1 point), age ≥75 years 
(2 points), diabetes mellitus (1 point), stroke/TIA (2 points), vascular disease (prior 
myocardial infarction, peripheral artery disease or aortic plaque) (1 point), age 65-74 years (1 
point), female gender (1 point). The maximum score is nine and a total score of two or above 
indicates a high risk of stroke. 
The HAS-BLED score reflects the risk of bleeding among patients with AF and on 
anticoagulants. One point is assigned for each individual components, including 
hypertension, abnormal renal function (dialysis, kidney transplant, creatinine clearance 
>200µmol/L), abnormal liver function (cirrhosis or bilirubin>2x normal or AST - Aspartate 
aminotransferase/ALT - Alanine aminotransferase/ALP - alkaline phosphatase >3x normal), 
stroke history, history of major bleeding or predisposition to bleeding, labile INRs 
(international normalised ratios)  if on warfarin, age >65 years, concomitant antiplatelet or 
non-steroidal anti-inflammatory drugs (NSAIDs) use, and alcohol abuse. The maximum score 
is nine and a total score of three or above indicates a high risk of bleeding (Pisters, Lane et al. 
2010). 
Frailty assessment.  
The Reported Edmonton Frail Scale (REFS) was used to identify frail participants. This scale 
was adapted from the Edmonton Frail Scale for use with Australian acute inpatients based on 
a questionnaire and has been validated (Hilmer, Perera et al. 2009). The scale involves nine 
frailty domains (cognition, general health status, functional independence, social support, 
medication use, nutrition, mood, continence and functional performance). With a maximum 
score of 18, a score of 0 to 5 indicates robust, 6 to 7 indicates apparently vulnerable status, 8 
to 9 mild frailty, 10 to 11 moderate frailty and 12 or more indicates severe frailty. The cut 
73
point used to identify frailty was 8, consistent with previous studies using REFS (Perera, 
Bajorek et al. 2009; Mitchell, Hilmer et al. 2011; Bennett, Gnjidic et al. 2014).  
Statistical Analysis: 
Analysis of the data was performed using SPSS for Windows 20.0 (IBM Corp., Armonk, NY, 
USA). Continuous variables are presented as mean ± standard deviation, and categorical 
variables as frequency and percentage. Comparisons between frail and non-frail participants 
were assessed using the Chi-square test for categorical variables and Student’s t-test or 
Mann-Whitney test for continuous variables.  Multivariate logistic regression was used to 
identify whether frailty was associated with antithrombotic prescription and rate/rhythm 
control drug prescription. Results are presented as odds ratios (OR) and 95% confidence 
intervals. Univariate logistic regression was performed on all the potential predictors for 
anticoagulant prescription and rate/rhythm control drug prescription (frailty, age, gender, 
reported poor nutrition status, paroxysmal atrial fibrillation, permanent pacemaker, 
hypertension, ischemic heart disease, heart failure, stroke/systemic thromboembolism, type 2 
diabetes, peripheral vascular disease, dyslipidemia, chronic pulmonary disease, cancer, 
dementia, depression, severe renal impairment, abnormal liver function, alcohol abuse, 
history of bleeding/predisposition to bleeding, falls on admission). Only variables that had a 
p-value <0.20 on univariate analysis were entered into multivariate analysis. Backward 
elimination method was applied and the final model retained the studied variable (which is 
frailty) and those variables significant at P<0.05. Incidence of strokes and bleeding over 6 
months was compared between frail and non-frail participants according to antithrombotic 
regimes: anticoagulants ± antiplatelets, antiplatelets only, and no antithrombotics. Two-tailed 
P values <0.05 were considered significant. 
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Results 
Three hundred and two patients were recruited. The mean age of the participants was 
84.7±7.1 years (range 65-100) and 50% (151/302) were female. The prevalence of frailty was 
53.3% (161/302). Hypertension (68.9%) was the most prevalent comorbidity, followed by 
ischemic heart disease (44.4%) and heart failure (43.4%). Falls (22.2%) and shortness of 
breath (22.8%) were the most common reasons for admission with no difference between 
frail and non-frail participants. Overall, compared to non-frail participants, frail participants 
were significantly older, had higher scores on the Charlson Comorbidity Index, higher 
prevalence of heart failure and peripheral vascular disease, and lower serum albumin 
concentrations (Table 4.1). Nearly all participants had high risk of stroke (99.3% had 
CHA2DS2-VASc score ≥2) and frail participants had higher mean CHA2DS2-VASc score 
compared to the non-frail (Table 4.2). There was no difference in terms of bleeding risk 
between frail and non-frail participants taking anticoagulants as reflected by HASBLED 
score (Table 4.3).  
Prescription of antithrombotic medication  
On admission 51.3% of participants were prescribed anticoagulants (46.6% frail, 56.7% non-
frail, p=0.08), 35.1% were prescribed antiplatelets only (37.3% frail, 32.6% non-frail, 
p=0.40) and 13.6% were not prescribed any antithrombotic medication (16.1% frail, 10.6% 
non-frail, p=0.16). During hospitalisation 13 participants died, leaving 289 participants 
discharged. Of discharged participants, 161 were prescribed anticoagulants (150 warfarin, 7 
dabigatran, 3 rivaroxaban, 1 fondaparinux for treatment of DVT/AF), 96 were prescribed 
antiplatelet therapy only (63 aspirin, 16 aspirin plus clopidogrel, and 17 clopidogrel only), 
and 32 patients were not prescribed any antithrombotic medications. Upon discharge, the 
prevalence of anticoagulant prescription increased to 55.7%, while the prescription of 
antiplatelets decreased to 33.2% and non-prescription of any antithrombotic decreased to 
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11.1% (Figure 4.1). Of those prescribed antiplatelets only, 42.7% had a history of ischemic 
heart disease. The prevalence of anticoagulant prescription on discharge was lower in frail 
participants (49.3% frail, 62.6% non-frail, p=0.02). There was no difference between frail and 
non-frail in the prescription of antiplatelets only (36.7% frail, 29.5% non-frail, p=0.20). Non-
prescription of any antithrombotic medication was not significantly more common in the frail 
(14.0% frail, 7.9% non-frail, p=0.10). 
Predictors of anticoagulant prescription upon discharge (Table 4.4)  
On univariate logistic regression, frailty significantly decreased the likelihood of 
anticoagulant prescription on discharge (OR 0.58, 95%CI 0.36-0.93). However, the strength 
of this association reduced slightly and was no longer significant on multivariate analysis 
(OR 0.66, 95%CI 0.40-1.11). The covariates that were independently associated with 
decreased anticoagulant prescription on discharge were increased age, history of 
bleeding/predisposition to bleeding and abnormal renal function, while congestive heart 
failure was associated with increased likelihood of prescription of anticoagulants.  
Predictors of prescription of antiplatelets only upon discharge (Table 4.5)  
Multivariate analysis showed that increased age and paroxysmal AF but not frailty 
significantly increased the likelihood of antiplatelet prescription without concurrent 
anticoagulant therapy. 
Predictors of non-prescription of any antithrombotic medications upon discharge (Table 4.6)  
Logistic regression was also performed to identify which factors were associated with non-
prescription of any antithrombotic medication, which occurred for 11.1% of all participants. 
Frailty was not associated with non-prescription of antithrombotic medications on univariate 
analysis or on multivariate analysis. In the multivariate logistic model, only dementia and a 
history of bleeding/predisposition to bleeding increased the likelihood of non-prescription. 
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Prescription of rate/rhythm control medication upon discharge (Table 4.7) 
Upon discharge, 52.6% of the participants received rate control therapy only, 11.8% received 
rhythm control therapy only, 13.5% received both therapies and 22.1% were not prescribed 
any anti-arrhythmic medication, with no difference between frail and non-frail. Further 
examination showed that digitalis prescription was more common in frail than non-frail 
participants (29.1% overall, 34.7% frail, 23.0% non-frail, p=0.03). 
Predictors of non-prescription of any anti-arrhythmic medication (Table 4.8) 
Univariate analysis as well as multivariate analysis showed that frailty was not associated 
with the likelihood of non-prescription of anti-arrhythmic medication upon discharge. In the 
multivariable model, falls were associated with non-prescription of these medications (OR 
2.40, 95%CI 1.28-4.53) while female participants (OR 0.51, 95%CI 0.28-0.91) and 
participants with heart failure (OR 0.43, 95%CI 0.23-0.81 for heart failure) were less likely 
not to receive anti-arrhythmic drugs upon discharge.  
Incidence of bleeding and strokes over 6 months (Table 4.9) 
Data for follow-up were available in 251 participants (83.1% of all participants, 86.9% of the 
discharged participants). Overall, there were five stroke events (2.0%). The incidence of 
stroke in patients taking anticoagulants was 2.1%. This incidence was not significantly higher 
in frail patients compared to the non-frail (2.9% frail versus 1.4% non-frail, p=0.61). Overall, 
there were 19 bleeding events (11.6%) and major/severe bleeding events were observed in 11 
participants (4.4%). In patients taking anticoagulants, the incidence of major/severe bleeding 
was 6.3%, with no difference between frail and non-frail patients (5.8% frail versus 6.8% 
non-frail, p=0.96). 
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Discussion 
In this study, compared to non-frail, frail participants were significant older, had more 
comorbidities, lower serum albumin level and higher risk of stroke on the CHA2DS2-VASc, 
but no difference in bleeding risk according to HASBLED score. These findings are in 
accordance with the literature, in which frailty is associated with increased comorbidities and 
procoagulant changes (Heuberger 2011; Hubbard, O'Mahony et al. 2013; Von Haehling, 
Anker et al. 2013).  
Anticoagulant prescription 
In this study, only around half of older patients were prescribed an anticoagulant upon 
discharge. This finding is similar to many published studies in Australia and elsewhere in the 
world (Gage, Boechler et al. 2000; De Breucker, Herzog et al. 2010; Tulner, Van Campen et 
al. 2010; Bang and McGrath 2011; Frewen, Finucane et al. 2012; Ferguson, Inglis et al. 
2014). We found that frail participants were less likely to be prescribed an anticoagulant upon 
discharge (55.7% overall, 49.3% frail, 62.6% non-frail, p=0.02). However, the impact of 
frailty on anticoagulant prescription was reduced in multivariate analysis. On multivariate 
logistic regression, chronological age, history of bleeding/predisposition to bleeding and 
abnormal renal function significantly decreased the likelihood of anticoagulant prescription. 
Current guidelines do not provide specific guidance for treatment in frail patients (Camm, 
Kirchhof et al. 2010; January, Wann et al. 2014). Evidence of the impact of frailty on 
anticoagulant prescription is conflicting. Some studies suggest that presence of frailty and 
geriatric syndromes is associated with non-prescription of anticoagulants (Perera, Bajorek et 
al. 2009; Frewen, Finucane et al. 2012) while others have not found this (De Breucker, 
Herzog et al. 2010; Ferguson, Inglis et al. 2014). Interestingly, in our study a diagnosis of 
dementia predicted non-prescription of any antithrombotic medication, which is consistent 
with previous studies (Abel Latif, Peng et al. 2005; Baczek, Chen et al. 2012).  
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At Royal North Shore Hospital in Sydney, the prevalence of anticoagulant prescription in 
older patients with AF has increased over the years: from 35.0% in 1997 (Krass, Ogle et al. 
2002) to 39.1% in 2007 (23.6% in the frail and 66.3% in the non-frail) (Perera, Bajorek et al. 
2009) and 55.7% in this study (49.3% in the frail, 62.6% in the non-frail). The increase in 
anticoagulation in older patients with AF, including the frail, over this period may reflect the 
translation of new evidence into clinical practice (Mant, Hobbs et al. 2007). A significant 
percentage of participants with AF received antiplatelets with no evidence of ischemic heart 
disease, suggesting that antiplatelets may be used for stroke prevention in AF. 
Incidence of major bleeding and strokes in patients treated with anticoagulants 
In this study the incidence of major bleeding in patients taking anticoagulants was 6.3% 
overall (5.8% in frail and 6.8% non-frail, p=0.96) over six months of follow-up. 
Internationally, similar low rates of major bleeding have been observed in older patients post-
discharge (Kagansky, Knobler et al. 2004; Trinh, Estivin et al. 2012) and in geriatric 
outpatient settings (Poli, Antonucci et al. 2009). The incidence of major bleeding in older 
patients with AF taking warfarin has ranged from 1.8%-1.9% per year (Cleland, Cowburn et 
al. 1996; Mant, Hobbs et al. 2007) in randomised clinical trials to as high as 13% in an 
observational study (Hylek, Evans-Molina et al. 2007). In Australia, the observed incidence 
of major bleeding in older patients taking anticoagulants is also variable, from 3.4% to 20.8% 
(Jackson, Peterson et al. 2001; Johnson, Lim et al. 2005; Perera, Bajorek et al. 2009).  
In this study in very old patients (mean age 84.7±7.1), the incidence of strokes over 6 months 
in patients taking anticoagulants was 2.1% overall. This is consistent with the incidence of 
strokes in previous Australian studies, ranging from 2.6% to 3.6% (Jackson, Peterson et al. 
2001; Johnson, Lim et al. 2005; Perera, Bajorek et al. 2009).  
 
79
Digoxin utilisation 
In this study, half of the participants received rate control therapy only and 22.1% were not 
prescribed any anti-arrhythmic medication with no difference between frail and non-frail. 
Nearly one third of the participants received digoxin on discharge and this prevalence was 
higher in frail participants (34.7% frail, 23.0% non-frail, p=0.03). There is a long-standing 
controversy around the safety of digoxin in older people. Several studies in older patients 
have shown that digoxin prescription is common and is associated with increased adverse 
drug reactions (Cooper 1999; Gambassi, Lapane et al. 2000; Misiaszek, Heckman et al. 2005) 
while other studies reported that the use of digoxin in older patients with AF was not 
associated with increased morbidity and mortality (Gheorghiade, Fonarow et al. 2013; 
Mulder, Van Veldhuisen et al. 2014). There are many factors contributing to increased 
toxicity of digoxin in older patients, including age related changes in renal function, reduced 
lean body mass and polypharmacy (Hanratty, McGlinchey et al. 2000). The volume of 
distribution for digoxin is known to reduce with age, resulting in higher serum concentrations 
(Cusack, Kelly et al. 1979; Hanratty, McGlinchey et al. 2000), which may be even higher in 
frail people with sarcopenia and reduced renal drug clearance (Johnston, Hilmer et al. 2014; 
Jung, Kim et al. 2014; Morley, von Haehling et al. 2014). Guidelines are needed on dosing 
and plasma concentration monitoring of digoxin in older frail and non-frail patients.  
Strengths and limitations 
This study has several strengths. The study comprised a sample of very old and frail people, 
who are often excluded from studies (Ridda, MacIntyre et al. 2010). We used the validated 
Reported Edmonton Frail Scale and high quality detailed clinical information (Hilmer, Perera 
et al. 2009). This study did not focus only on anticoagulants but on comprehensive 
pharmacological treatment of AF. 
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A major limitation of this study is that it was done in the acute care setting at a tertiary 
hospital in Sydney which may not be representative for all older patients with AF. Small 
sample size may have limited the power of this study to detect differences between frail and 
non-frail participants. Therefore, results should be cautiously interpreted and generalised to 
older inpatients with atrial fibrillation.  
Conclusion 
Anticoagulants were potentially underutilised in this cohort of older patients with AF. While 
frail participants were less likely to use anticoagulants, frailty status had no independent 
impact on pharmacological treatment of AF. This may reflect the detailed complex 
prescribing decisions made for our cohort, which cannot be captured by a simple frailty score. 
The low rate of major bleeding complications may reflect careful patient selection and 
management of anticoagulation. 
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Table 4.1. Participant characteristics (N=302) 
Variables  All (N=302) Frail (161) Non-frail (141) P 
Age (y), mean±SD 84.7 ± 7.1 85.7 ± 6.7 83.5 ± 7.3 0.008 
Age subgroups (y), n (%) 
65-74 31 (10.3%) 11 (6.8%) 20 (14.2%) 
0.03 
75-79 35 (11.6%) 17 (10.6%) 18 (12.8%) 
80-84 64 (21.2%) 28 (17.4%) 36 (25.5%) 
85-89 97 (32.1%) 58 (36.0%) 39 (27.7%) 
≥ 90 75 (24.8%) 47 (29.2%) 28 (19.9%) 
Female, n (%) 151 (50%) 86 (53.4%) 65 (46.1%) 0.21 
Paroxysmal AF 50 (16.6%) 20 (12.4%) 30 (21.3%) 0.04 
Permanent pacemaker 68 (22.50%) 39 (24.2%) 29 (20.6%) 0.45 
Charlson comorbidity index 3.8 ± 2.2 4.32 ± 2.14 3.18 ± 2.12 <0.001 
Cardiovascular Diseases and risk factors: 
    Hypertension 208 (68.9%) 114 (70.8%) 94 (66.7%) 0.44 
    Ischemic Heart Disease 134 (44.4%) 74 (46%) 60 (42.6%) 0.55  
    Congestive Heart Failure 131 (43.4%) 86 (53.4%) 45 (31.9%) <0.001 
    Dyslipidemia 89 (29.5%) 49 (30.4%) 40 (28.4%) 0.70 
    History of stroke/ TIA 76 (25.2%) 44 (27.3%) 32 (22.7%) 0.36 
    Type 2 diabetes 64 (21.2%) 40 (24.8%) 24 (17%) 0.10 
    Peripheral Vascular Disease 27 (8.9%) 21 (13%) 6 (4.3%) 0.008 
Other co-morbidities: 
Chronic pulmonary disease 83 (27.5%) 53 (32.9%) 30 (21.3%) 0.02 
Cancer 76 (25.2%) 44 (27.3%) 32 (22.7%) 0.36 
Dementia 27 (8.9%) 19 (11.8%) 8 (5.7%) 0.06 
Depression  22 (7.3%) 19 (11.8%) 3 (2.1%) <0.001 
Serum albumin (g/l) 33.94 ± 4.86 33.12 ± 4.82 34.91 ± 4.75 0.002 
eGFR<30 (mL/min/1.73 m2) 36 (11.9%) 24 (14.9%) 12 (8.5%) 0.09 
Recruitment wards 
    Aged Care   109 (36.1%) 74 (46%) 35 (24.8%) 
<0.001     Cardiology 124 (41.1%) 53 (32.9%) 71 (50.4%) 
    General Medicine 69 (22.8%) 34 (21.1%) 35 (24.8%) 
Residential status on admission 
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Nursing home 18 (6.0%) 15 (9.4%) 3 (2.1%) 
<0.001 
Hostel 25 (8.3%) 21 (13.2%) 4 (2.8%) 
Community  with family 143 (47.4%) 76 (47.8%) 67 (47.5%) 
Community alone 103 (34.1%) 42 (26.4%) 61 (43.3%) 
Other  11 (3.6%) 5 (3.1%) 6 (4.3%) 
Reported nutrition status on admission 
Poor  23 (7.7 %) 20 (12.7%) 3 (2.1%) 
<0.001 Stable  90 (30.3%) 56 (35.7%) 34 (24.3%) 
Healthy  184 (62.0%) 81 (51.6%) 103 (73.6%) 
Reasons for admission 
     Shortness of breath 69 (22.8%) 44 (27.3%) 25 (17.7%) 
0.15 
     Falls 67 (22.2%) 35 (21.7%) 32 (22.7%) 
     Infection  30 (9.9%) 17 (10.6%) 13 (9.2%) 
     Delirium  30 (9.9%) 16 (9.9%) 14 (9.9%) 
     Chest pain/discomfort 26 (8.6%) 11 (6.8%) 15 (10.6%) 
     General unwell 21 (7.0%) 11 (6.8%) 10 (7.1%) 
     Palpitation 15 (5.0%) 2 (1.2%) 13 (9.2%) 
     Musculoskeletal pain 14 (4.6%) 8 (5.0%) 6 (4.3%) 
     GI disorder 7 (2.3%) 6 (3.7%) 1 (0.7%) 
     Elective surgery 6 (2.0%) 3 (1.9%) 3 (2.1%) 
     Dizziness  3 (1%) 1 (0.6%) 2 (1.4%) 
     High INR/bleeding 3 (1.0%) 1 (0.6%) 2 (1.4%) 
     Stroke  2 (0.7%) 1 (0.6%) 1 (0.7%) 
     Other  9 (3.0%) 5 (3.1%) 4 (2.8%) 
Number of medications on 
discharge (mean, SD) 
 11.3 ± 4.0 12.3 ± 3.9 10.4 ± 3.8 <0.001 
Length of stay (mean, SD) 12.8 ± 9.0 14.3 ± 9.6 11.1 ± 7.8 0.002 
Continuous data are presented as mean ± standard deviation. Categorical data are shown as n (%). AF, 
atrial fibrillation; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; INR, international 
normalised ratio; TIA, transient ischaemic attack. 
 
 
 
83
  
 
Table 4.2. Stroke risk identified by CHA2DS2-VASc score 
Variables  All (N=302) Frail (161) Non-frail (141) P 
Mean CHA2DS2-VASc score 4.61 ± 1.44 4.92 ± 1.44 4.29 ± 1.37 <0.001 
CHA2DS2-VASc score ≥2 300 (99.3%) 161 (100%) 139 (98.6%) 0.22 
Individual components of CHA2DS2-VASc score, n (%) 
     Congestive heart failure  131 (43.4%) 86 (53.4%) 45 (31.9%) <0.001 
     Hypertension  208 (68.9%) 114 (70.8%) 94 (66.7%) 0.44 
     Age≥75 271 (89.7%) 150 (93.2%) 121 (85.8%) 0.04 
     Age 65-74 31 (10.3%) 11 (6.8%) 20 (14.2%) 0.04 
     Diabetes mellitus  64 (21.2%) 40 (24.8%) 24 (17%) 0.10 
     History of 
stroke/TIA/systemic 
thromboembolism 
76 (25.2%) 44 (27.3%) 32 (22.7%) 0.36 
     Vascular disease 113 (37.4%) 63 (39.1%) 50 (35.5%) 0.51  
     Female  151 (50.0%) 86 (53.4%) 65 (46.1%) 0.21 
Continuous data are presented as mean ± standard deviation. Categorical data are shown as n 
(%).TIA, transient ischaemic attack. 
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Table 4.3. Bleeding risk assessment with HASBLED score (only applied for participants 
prescribed anticoagulants upon discharge) 
Variables  All (N=161) Frail (74) Non-frail (87) P 
Mean HAS-BLED score 2.91 ± 1.01 3.00 ± 1.07 2.83 ± 0.94 0.28 
HAS-BLED score ≥3 100 (62.1%) 49 (66.2%) 51 (58.6%) 0.32  
Individual components of HAS-BLED score, n (%) 
     Hypertension 111 (68.9%) 52 (70.3%) 59 (67.8%) 0.74 
     Abnormal renal function 9 (5.6%) 3 (4.1%) 6 (6.9%) 0.51 
     Abnormal liver function 13 (8.1%) 6 (8.1%) 7 (8.0%) 0.99 
     History of stroke/TIA/systemic 
thromboembolism 
44 (27.3%) 25 (33.8%) 19 (21.8%) 0.09 
     Bleeding history/ predisposition 
to bleeding 
78 (48.4%) 41 (55.4%) 37 (42.5%) 0.10 
     Age ≥ 65 161 (100%) 74 (100%) 87 (100%) N/A 
     Labile INR 42 (26.1%) 20 (27.0%) 21 (25.3%) 0.80 
     Aspirin/NSAIDs using 6 (3.7%) 1 (1.4%) 5 (5.7%) 0.22 
     Alcohol abuse 5 (3.1%) 1 (1.4%) 4 (4.6%) 0.38 
Continuous data are presented as mean ± standard deviation. Categorical data are shown as n 
(%).INR, international normalised ratio; NSAIDs, non-steroidal anti-inflammatory drugs; TIA, 
transient ischaemic attack. 
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Table 4.4. Factors associated with anticoagulant prescription upon discharge 
Variables 
Univariate Multivariate 
OR for anticoagulant 
prescription (95% CI) 
P OR for anticoagulant 
prescription (95% CI) 
P 
Frailty 0.58 (0.36 - 0.93) 0.02 0.66 (0.40 - 1.11) 0.12 
Age  0.94 (0.90 - 0.97) <0.001 0.93 (0.89-0.96) <0.001 
Bleeding history/ 
predisposition to bleeding 
0.53 (0.33 - 0.85) 0.008 0.57 (0.34-0.95) 0.03 
Congestive heart failure 1.59 (0.99 - 2.56) 0.06 1.95 (1.16 - 3.27) 0.01 
Abnormal renal function 0.48 (0.20 - 1.15) 0.10 0.33 (0.13 - 0.87) 0.03 
Dementia  0.56 (0.25 - 1.26) 0.16 - - 
Reported poor nutrition 0.52 (0.22 - 1.27) 0.15 - - 
Only variables that had a P-value <0.20 in univariate regression were entered into multiple regression 
model together with frailty. OR, odds ratio. 
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Table 4.5. Predictors of antiplatelet prescription without concurrent anticoagulant upon 
discharge 
Variables 
Univariate Multivariate 
OR for antiplatelet 
prescription (95% CI) 
P OR for antiplatelet 
prescription (95% CI) 
P 
Frailty 1.38 (0.85 – 2.27) 0.20 1.32 (0.79-2.20) 0.29 
Age  1.06 (1.02-1.10) 0.003 1.06 (1.02-1.10) 0.002 
Paroxysmal AF 1.75 (0.94-3.26) 0.08 2.24 (1.16-4.33) 0.02 
Reported poor nutrition 
status 
2.14 (0.89-5.13) 0.09 - - 
Congestive heart failure 0.70 (0.42-1.16) 0.16 - - 
Dyslipidemia  1.44 (0.85-2.43) 0.17 - - 
Female gender 2.34 (0.82-6.69) 0.11 - - 
PPM 0.66 (0.36-1.22) 0.19 - - 
Only variables that had a P-value <0.20 in univariate regression were entered into multiple regression 
model together with frailty. PPM, permanent pacemaker. 
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Table 4.6. Predictors of antithrombotic non-prescription upon discharge 
Variables 
Univariate Multivariate 
OR for antithrombotic 
non-prescription 
(95% CI) 
P OR for antithrombotic 
non-prescription  
(95% CI) 
P 
Frailty 1.89 (0.88-4.09) 0.10 1.44 (0.65-3.21) 0.37 
Dementia 3.49 (1.34-9.12) 0.01 3.19 (1.19-8.55) 0.02 
Bleeding history/ 
predisposition to bleeding 
2.67 (1.16-6.16) 0.02 2.44 (1.03-5.78) 0.04 
PPM 1.96 (0.89-4.31) 0.09 - - 
Only variables that had a P-value <0.20 in univariate regression were entered into multiple regression 
model together with frailty. PPM, permanent pacemaker. 
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Table 4.7. Prescription of anti-arrhythmic drugs and other medications upon discharge 
Variables  All (N=290) Frail (150) Non-frail (139) P 
Rate control therapy only 152 (52.6%) 79 (52.7%) 73 (52.5%) 0.980 
Rhythm control therapy only 34 (11.8%) 17 (11.3%) 17 (12.2%) 0.813 
Both  39 (13.5%) 17 (11.3%) 22 (15.8%) 0.264 
Nil 64 (22.1%) 37 (24.7%) 27 (19.4%) 0.284 
Rate control drugs      
    Beta-blockers 
    (except Sotalol) 
126 (43.6%) 61 (40.7%) 65 (46.8%) 0.298 
    Digitalis  84 (29.1%) 52 (34.7%) 32 (23.0%) 0.029 
    Non DHP CCBs 23 (8.0%) 12 (8%) 11 (7.9%) 0.978 
       Verapamil 10 (3.5%) 3 (2%) 7 (5%) 0.204 
Rhythm control drugs     
    Amiodarone 32 (11.1%) 20 (13.3%) 12 (8.6%) 0.203 
    Sotalol 27 (9.3%) 10 (6.7%) 17 (12.1%) 0.104 
    Flecainide  14 (4.8%) 4 (2.7%) 10 (7.2%) 0.073 
    Disopyramide 1 (0.3%) 1 (0.7%) 0 (0%) - 
Data are presented as n (%). Non DHP CCBs: non-dihydropyridine calcium channel blockers 
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Table 4.8. Predictors of non-prescription of any anti-arrhythmic drugs 
Variables 
Univariate Multivariate 
Odds ratio for non- 
prescription (95% CI) 
P-value Odds ratio for non- 
prescription (95% CI) 
P-value 
Frailty 1.36 (0.78 - 2.38) 0.28 1.73 (0.95 - 3.14) 0.07 
Falls 2.28 (1.23 - 4.22) 0.009 2.40 (1.28 - 4.53) 0.007 
Congestive heart failure 0.50 (0.28 - 0.91) 0.02 0.43 (0.23 - 0.81) 0.009 
Female 0.59 (0.34 - 1.03) 0.07 0.51 (0.28 - 0.91) 0.02 
Dementia 2.84 (1.23 - 6.53) 0.01 - - 
Only variables that had a P-value <0.20 in univariate regression were entered into multiple regression 
model together with frailty.  
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Table 4.9. Bleeding and stroke events during six months follow up according to antithrombotic 
regimes and frailty status 
 Overall   Frail  Non-frail  p-value  
Strokes 
   Anticoagulants (n=142)  3/142 (2.1%) 2/69 (2.9%) 1/73 (1.4%) 0.61 
   Antiplatelet only (n=83) 2/83 (2.4%) 2/49 (4.1%) 0/34 (0%) 0.51 
   None (n=26) 0/26 (0%) 0/19 (0%) 0/7 (0%) N/A 
Any Bleeding 
   Anticoagulants (n=142) 19/142 (13.4%) 9/69 (13.0%) 10/73 (13.7%) 0.91 
   Antiplatelet only (n=83) 9/83 (10.8%) 4/49 (8.2%) 5/34 (14.7%) 0.48 
   None (n=26) 1/26 (3.8%) 1/19 (5.3%) 0/7 (0%) 1.00 
Major/severe bleeding 
   Anticoagulants (n=142) 9/142 (6.3%) 4/69 (5.8%) 5/73 (6.8%) 0.96 
   Antiplatelet only (n=83) 2/83 (2.4%) 1/49 (2.0%) 1/34 (2.9%) 0.39 
   None (n=26) 0/26 (0%) 0/19 (0%) 0/7 (0%) N/A 
Incidence of stroke and bleeding are presented as n, per cent within frailty 
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Figure 4.1. Prevalence of antithrombotic prescription prior to admission and on discharge 
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 Abstract 
Background. Frailty has been found to be associated with increased adverse outcomes in 
older patients, especially in patients with cardiovascular diseases. There has been no study 
focusing on the prognostic value of frailty amongst older hospitalised patients with atrial 
fibrillation. This study aims to investigate the impact of frailty on mortality, length of stay 
and re-hospitalisation in older hospitalised patients with atrial fibrillation. 
Methods. Prospective observational study in patients aged ≥65 years with atrial fibrillation 
admitted to a teaching hospital in Sydney, Australia. Frailty was assessed using the Reported 
Edmonton Frail Scale. Participants were followed up for six months for adverse outcomes. 
Results. We recruited 302 patients (mean age 84.7±7.1, 53.3% frail, 50% female). Frailty was 
associated with prolonged length of stay and increased mortality but not re-admission during 
6 months after discharge. The coexistence of frailty and delirium significantly increased the 
risk of mortality. 
Conclusions. Frailty is a common geriatric syndrome in older inpatients with atrial fibrillation 
and is associated with poor outcomes. Screening for frailty along with other clinically 
important factor like delirium should be considered in older patients with atrial fibrillation to 
optimise individualised treatment plans. 
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Introduction 
Atrial fibrillation (AF) is a common cardiac arrhythmia in older adults. The prevalence of AF 
in published studies in Western countries ranges from 0.5% to 3% in the general population, 
5% to 6% in people older than 65 years and up to 5% to 15% among those aged 80 years or 
older (Camm, Kirchhof et al. 2010; Ball, Carrington et al. 2013; Hubbard, O'Mahony et al. 
2013). The global burden of AF has been increasing due to the ageing of the world 
population (Rahman, Kwan et al. 2014). The rates of AF related hospitalisation have 
increased worldwide over the last decades (Friberg, Buch et al. 2003; Wellens and Smith Jr 
2006; Keech, Punekar et al. 2012; Patel, Deshmukh et al. 2014). Older hospitalised patients 
are at increased risk of adverse outcomes and these outcomes can be predicted by many 
factors like advanced age, comorbidities, immobility, malnutrition, delirium, falls, 
polypharmacy and especially by a frailty status (Clegg, Young et al. 2013; De Buyser, 
Petrovic et al. 2014). Frailty is an emerging concept in geriatric medicine. There have been 
many studies exploring the relationship between frailty and increased risk of cardiovascular 
diseases in community-dwelling older adults (Afilalo, Alexander et al. 2014). Frailty has 
been also found to be associated with increased adverse outcomes in older patients, especially 
in patients with cardiovascular diseases (Cacciatore, Abete et al. 2005; Lee, Buth et al. 2010; 
Ekerstad, Swahn et al. 2011; Singh, Rihal et al. 2011; Singh, Gallacher et al. 2012; Conroy 
and Dowsing 2013; Cacciatore, Della-morte et al. 2014; Le Maguet, Roquilly et al. 2014; 
Ambler, Brooks et al. 2015; Bo, Puma et al. 2015). There have been several studies reporting 
that frailty is associated with adverse outcomes in older hospitalised patients with heart 
failure and myocardial infarction, and in patients after cardiovascular surgery (Cacciatore, 
Abete et al. 2005; Lee, Buth et al. 2010; Ekerstad, Swahn et al. 2011; Ambler, Brooks et al. 
2015; Green, Arnold et al. 2015). However, there has been no study focusing on the 
prognostic value of frailty amongst older hospitalised patients with atrial fibrillation. In this 
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study we aim to investigate the impact of frailty on outcomes in older hospitalised patients 
with atrial fibrillation, including prolonged length of stay, re-admission and all-cause 
mortality 6 months after discharge. 
Methods 
Participant selection. During a period of 15 consecutive months, a prospective observational 
study was performed on a cohort of patients aged ≥ 65 years with chronic nonvalvular AF 
admitted to Royal North Shore Hospital, Sydney, Australia (between October 2012 and 
January 2014). The study was approved by The Northern Sydney Local Health District 
Human Research Ethics Committee and The University of Sydney Human Research Ethics 
Committee. Patients were eligible to participate if they were aged ≥ 65 years and diagnosed 
with AF. Participants who were dying or receiving intensive care or who were identified as 
“blind” or “deaf” and unable to see or hear the investigators respectively on initial contact 
were excluded from the study. Eligible patients were identified daily from the target wards 
(aged care, cardiology and general medicine) and invited to participate. Consent was obtained 
from all participants or their caregivers. All participants were followed up for 6 months by 
conducting phone calls at the end of the sixth month after recruitment. In cases where 
participants or their caregivers could not be contacted, hospital medical records were assessed 
for outcomes during 6 months.  
Definition of frailty. The Reported Edmonton Frail Scale (REFS) was used to identify frail 
participants. This scale was adapted from the Edmonton Frail Scale for use with Australian 
acute inpatients based on a questionnaire and has been validated (Hilmer, Perera et al. 2009). 
The scale involves 9 frailty domains (cognition, general health status, functional 
independence, social support, medication use, nutrition, mood, continence and functional 
performance). With a maximum score of 18, the cut point used to identify frailty was 8, 
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consistent with previous studies using this scale (Perera, Bajorek et al. 2009; Mitchell, Hilmer 
et al. 2011; Bennett, Gnjidic et al. 2014). 
Other variables. For each participant, the number of comorbidities and the number of 
medications prescribed on discharge were taken from the medical records. Comorbidities 
were assessed with the Charlson Comorbidity Index (Charlson, Pompei et al. 1987). The 
CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years [doubled], 
diabetes, stroke/transient ischemic attack/thromboembolism [doubled], vascular disease 
[prior myocardial infarction, peripheral artery disease, or aortic atherosclerosis], age 65-75 
years, female gender) was used to assess stroke risk and bleeding risk for anticoagulants were 
assessed with the HAS-BLED score (hypertension, abnormal renal/liver function, stroke, 
bleeding history or predisposition, labile international normalised ratio, age ≥ 65 years, drugs 
or alcohol use) (January, Wann et al. 2014). 
Outcome variables. Prolonged hospitalisation, hospital readmissions and deaths were 
assessed as adverse outcomes in this study. Prolonged hospitalisation was defined as those 
with a length of stay equal to or greater than the 75th percentile of the length of stay of the 
whole cohort (measured in days). Readmissions were defined as at least one readmission to 
hospitals for any cause during 6 months. All deaths during hospitalisation were recorded. 
Discharged participants or their caregivers were contacted after 6 months for information on 
re-admissions and whether the participant had died during this period. In those cases (n=20) 
where participants or their caregivers could not be contacted, hospital records were used to 
ascertain study outcomes.  
Analysis of the data was performed using SPSS for Windows 20.0 (IBM Corp., Armonk, NY, 
USA). Continuous variables are presented as mean ± standard deviation, and categorical 
variables as frequency and percentage. Comparisons between frail and non-frail participants 
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were assessed using Chi-square tests for categorical variables and Student’s t-tests or Mann-
Whitney tests for continuous variables. Two-tailed P values < 0.05 were considered 
statistically significant. To compare the time to death in frail and non-frail participants, the 
Kaplan– Meier estimator was employed to compute survival curves over the 6 month follow-
up period and differences between frail and non-frail groups assessed using log rank tests. 
Cox proportional-hazards regression was used to determine whether frailty assessed with the 
RFES predicted mortality, with results presented as hazard ratios (HR) and 95% confidence 
intervals (CIs). Potential predictors of mortality in this cohort of older patients with AF were 
frailty status, age, gender, Charlson comorbidity Index, CHA2DS2-VASc score, HAS-BLED 
score, admission due to falls, delirium on admission, and the following medications on 
discharge: anticoagulants, digoxin, statin or psychotropic medication (Gheorghiade, Fonarow 
et al. 2013; Mulder, Van Veldhuisen et al. 2014). Based on a previous study that showed a 
combined effect of frailty and delirium on mortality in older inpatients (Eeles, White et al. 
2012), we also used Cox regression to analyse the combined association of frailty and 
delirium. Logistic regression was applied to investigate predictors of prolonged 
hospitalisation and results are presented as odds ratios (OR) and 95% CIs. Potential 
predictors of prolonged hospitalisation were frailty status, age, gender, Charlson comorbidity 
Index, CHA2DS2-VASc score, HAS-BLED score, admission due to falls, or delirium on 
admission. Univariate regression was performed on all the potential predictors for adverse 
outcomes. Those variables that had a p-value <0.20 on univariate analysis were entered into 
multivariate analysis. Backward elimination method was applied and the final model retained 
the studied variable (frailty) and those variables significant at P <0.05. 
Results 
A total of 302 participants were recruited. They had a mean age of 84.7±7.1 years (range 65-
100), 50.0% were female, and 53.3% were frail (RFES score of 8 or more). Participant 
103
characteristics were presented in Table 5.1. Overall, frail participants were older, had more 
comorbidities and were prescribed more medication upon discharged. There was no 
difference between frail and non-frail participants in the prevalence of falls or delirium on 
admission. Upon discharge, frail participants were less likely to be prescribed anticoagulants 
for stroke prevention. However, the prescription of digoxin and psychotropic medication 
were more common in the frail (Table 5.2). 
During 6 months of follow-up, 65 participants (21.5%) died. Mortality was higher in frail 
(30.4% died) than non-frail participants (11.3% died), p<0.001. Only 2 participants died due 
to intracranial bleeding: 1 during hospitalisation (this participant was on warfarin prior to 
admission) and 1 during follow up after discharged (subdural hematoma after falls). Two 
participants died due to embolic stroke. Twenty participants died due to heart failure, 6 died 
due to acute myocardial infarction and 35 died of other non-cardiovascular related causes. 
The Kaplan-Meier survival function for death indicated that at all points in time during the 
six- month follow-up, frail participants had a higher probability of dying compared to the 
non-frail (Log Rank Chi-Square 12.79, 1df, p <0.001 and Breslow Chi-Square 12.49, 1df, p 
<0.001) (Figure 5.1). 
Univariate Cox regression analysis showed that the probability of death over 6 months was 
nearly three-fold higher in frail participants (HR 2.69, 95% CI 1.53 – 4.74). The association 
between frailty and mortality persisted after adjustment for potential confounders (adjusted 
HR 2.33, 95% CI 1.31 – 4.14). The other significant predictors of mortality were the 
Charlson Comorbidity Index (adjusted HR per 1 unit increase 1.16, 95% CI 1.04 – 1.28) and 
delirium on admission (adjusted HR 2.07, 95% CI 1.05 – 4.10) (Table 5.3).  
The mortality rate after 6 months was highest amongst participants with both frailty and 
delirium (37.5%) compared to those with neither frailty nor delirium (9.4%), those with 
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frailty alone (29.7%) and those with delirium alone (28.6%), p<0.001. On Cox regression 
analysis of the combined effect of frailty and delirium, compared to those with neither frailty 
nor delirium, the risk of mortality increased 4 times in those with both frailty and delirium 
(HR 4.39, 95% CI 1.65 – 11.69), and increased 3 times in those with either frailty or delirium 
(HR 3.15, 95% CI 1.66 – 5.99 for frailty alone and HR 3.39, 95% CI 1.09 – 10.53 for 
delirium alone). 
Length of stay was compared between frail and non-frail participants who were discharged 
from hospital (N = 289). Overall, the mean length of stay was 12.8± 9.0 days and the median 
was 10 days (range 2 to 47 days).  The length of stay in frail participants was longer than in 
the non-frail (14.1 ± 9.5 days in the frail, 11.0 ± 7.9 days in the non-frail, p=0.002). Of the 
289 discharged participants, 70 (24.2%) had a prolonged length of stay, defined as a length of 
stay equal to or longer than 17 days (≥ 75th percentile of the length of stay). Frail participants 
were more likely to have a prolonged length of stay (31.3% of frail participants versus 18.5% 
of non-frail, p=0.01). The unadjusted odd ratio for frailty and prolonged hospitalisation was 
2.00 (95% CI 1.14 – 3.50). After adjustment for age, gender, comorbidities, stroke risk and 
bleeding risk, falls or delirium on admission, the odd ratio for frailty and prolonged length of 
stay was unchanged (OR=2.05, 95% CI 1.15 – 3.65). 
Overall, 118 (40.8%) of the discharged participants were readmitted to hospitals within 6 
months. The incidence of re-admission was not statistically significantly different between 
frail and non-frail participants (42.7% of frail, 38.8% of non-frail, p=0.51). 
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Discussion 
Our study demonstrated that frailty was common in older inpatients with AF, with just over 
half of the participants in our study being classified as frail by the RFES, consistent with 
previous studies using the same frailty scale (Perera, Bajorek et al. 2009; Rose, Pan et al. 
2014). We found that frailty was associated with prolonged length of stay and more than a 
two-fold increase in 6-month mortality among older in-patients with AF. Previous studies 
have consistently found that frailty defined by a range of different tools is associated with 
increased mortality in older patients (Lee, Buth et al. 2010; Ekerstad, Swahn et al. 2011; 
Singh, Rihal et al. 2011; Singh, Gallacher et al. 2012; Conroy and Dowsing 2013; Cacciatore, 
Della-morte et al. 2014; Le Maguet, Roquilly et al. 2014; Ambler, Brooks et al. 2015; Bo, 
Puma et al. 2015).  
In our study frailty also predicted prolonged length of stay, which is similar to previous 
studies using the same frailty criteria. In a study in Victoria, Australia, frailty defined by the 
REFS was associated with increased length of stay amongst patients admitted to the acute 
general medical unit (Rose, Pan et al. 2014) and, in a recent study in the United Kingdom, 
frailty defined by the REFS predicted length of stay in urology patients (Osborne, Charles et 
al. 2015). We did not find an association between frailty and re-admission to hospitals among 
older inpatients with AF after discharge. This may be partly attributed to the higher mortality 
rate in frail participants during follow-up. 
We found that delirium on admission was independently associated with a two-fold increase 
in mortality after 6 months. Delirium was present in 10% of participants on admission. 
Delirium is a common syndrome in older inpatients, with reported prevalence ranging from 
11% to 24% in hospitalised older patients (Saxena and Lawley 2009). Evidence for the 
association between delirium and increased mortality is not consistent. Early studies 
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suggested that delirium was not significantly associated with increased mortality (Francis, 
Martin et al. 1990; O'Keeffe and Lavan 1997; Inouye, Rushing et al. 1998). However, in 
many recent studies delirium has been found to be an independent predictor of subsequent 
death in older patients (Rockwood, Cosway et al. 1999; McCusker, Cole et al. 2002; Silva, 
Jerussalmy et al. 2009; Eeles, White et al. 2012). In older patients, delirium is an independent 
predictor of sustained poor cognitive and functional status during the year after a medical 
admission to hospital and is associated with an increased risk of readmission (McCusker, 
Cole et al. 2001). Besides that, we found that the coexistence of frailty and delirium can 
significantly increase the risk of death in the participants, which is consistent with a previous 
study (Eeles, White et al. 2012).  
This study has several strengths. It is the first study reporting the predictive value of frailty 
for mortality in older inpatients with AF. The study comprised a sample of very old and frail 
people, who are often excluded from studies (Ridda, MacIntyre et al. 2010). It used the 
validated Reported Edmonton Frailty Scale with high quality detailed clinical information 
(Hilmer, Perera et al. 2009). A major limitation of this study is that it was done in the acute 
care setting at a tertiary hospital in Sydney which may not be representative for all older 
patients with AF. Small sample size may have limited the power of this study to detect 
differences in re-admissions between frail and non-frail participants.  
Conclusion 
Frailty is a common geriatric syndrome in older inpatients with AF and is associated with 
poor outcomes. Screening for frailty along with other clinically important factor like delirium 
should be considered in older patients with AF to optimise individualised treatment plans. 
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Table 5.1. Participant general characteristics  
Variables  All (N=302) Frail (161) Non-frail (141) P 
Age (years) 84.7 ± 7.1 85.7 ± 6.7 83.5 ± 7.3 0.008 
Female 151 (50%) 86 (53.4%) 65 (46.1%) 0.21 
Charlson comorbidity index 3.8 ± 2.2 4.32 ± 2.14 3.18 ± 2.12 <0.001 
Cardiovascular Diseases and risk factors: 
    Hypertension 208 (68.9%) 114 (70.8%) 94 (66.7%) 0.44 
    Ischemic Heart Disease 134 (44.4%) 74 (46%) 60 (42.6%) 0.55  
    Congestive Heart Failure 131 (43.4%) 86 (53.4%) 45 (31.9%) <0.001 
    Dyslipidemia 89 (29.5%) 49 (30.4%) 40 (28.4%) 0.70 
    History of stroke/ TIA 76 (25.2%) 44 (27.3%) 32 (22.7%) 0.36 
    Type 2 diabetes 64 (21.2%) 40 (24.8%) 24 (17%) 0.10 
    Peripheral Vascular Disease 27 (8.9%) 21 (13%) 6 (4.3%) 0.008 
Other co-morbidities: 
Chronic pulmonary disease 83 (27.5%) 53 (32.9%) 30 (21.3%) 0.02 
Cancer 76 (25.2%) 44 (27.3%) 32 (22.7%) 0.36 
Dementia 27 (8.9%) 19 (11.8%) 8 (5.7%) 0.06 
Depression  22 (7.3%) 19 (11.8%) 3 (2.1%) <0.001 
Severe chronic kidney disease 
(eGFR<30 mL/min/1.73 m2) 
36 (11.9%) 24 (14.9%) 12 (8.5%) 0.09 
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Reasons for admission 
     Shortness of breath 69 (22.8%) 44 (27.3%) 25 (17.7%) 
0.15 
     Falls 67 (22.2%) 35 (21.7%) 32 (22.7%) 
     Infection  30 (9.9%) 17 (10.6%) 13 (9.2%) 
     Delirium  30 (9.9%) 16 (9.9%) 14 (9.9%) 
     Chest pain/discomfort 26 (8.6%) 11 (6.8%) 15 (10.6%) 
     General unwell 21 (7.0%) 11 (6.8%) 10 (7.1%) 
     Palpitation 15 (5.0%) 2 (1.2%) 13 (9.2%) 
     Musculoskeletal pain 14 (4.6%) 8 (5.0%) 6 (4.3%) 
     Gastro-intestinal disorders 7 (2.3%) 6 (3.7%) 1 (0.7%) 
     Elective surgery 6 (2.0%) 3 (1.9%) 3 (2.1%) 
     Dizziness  3 (1%) 1 (0.6%) 2 (1.4%) 
     High INR/bleeding 3 (1.0%) 1 (0.6%) 2 (1.4%) 
     Stroke  2 (0.7%) 1 (0.6%) 1 (0.7%) 
     Other  9 (3.0%) 5 (3.1%) 4 (2.8%) 
Continuous variables are presented as mean ± standard deviation, and categorical variables as frequency and 
percentage. TIA: transient ischemic attack, eGFR: estimated glomerular filtration rate, INR: international 
normalised ratio. 
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Table 5.2. Medications upon discharge   
Variables  All (N=290) Frail (150) Non-frail (139) P 
Number of medication  11.3 ± 4.0 12.3 ± 3.9 10.4 ± 3.8 <0.001 
Anticoagulants  161 (55.7%) 74 (49.3%) 87 (62.6%) 0.02 
Anti-arrhythmics 
    Beta-blockers (except Sotalol) 126 (43.6%) 61 (40.7%) 65 (46.8%) 0.30 
    Digitalis  84 (29.1%) 52 (34.7%) 32 (23.0%) 0.03 
    Amiodarone 32 (11.1%) 20 (13.3%) 12 (8.6%) 0.20 
    Sotalol 27 (9.3%) 10 (6.7%) 17 (12.1%) 0.10 
    Non-DHP CCBs 23 (8.0%) 12 (8%) 11 (7.9%) 0.98 
    Flecainide  14 (4.8%) 4 (2.7%) 10 (7.2%) 0.07 
    Disopyramide 1 (0.3%) 1 (0.7%) 0 (0%) - 
Other cardiovascular drugs 
    ARBs 63 (21.8%) 32 (21.3%) 31 (22.3%) 0.84 
    ACE inhibitors 54 (18.7%) 28 (18.7%) 26 (18.7%) 0.99 
Statins 136 (47.1%) 65 (43.3%) 71 (51.1%) 0.19 
Psychotropics 93 (32.2%) 58 (38.7%) 35 (25.2%) 0.01 
Continuous variables are presented as mean ± standard deviation, and categorical variables as frequency and 
percentage. Non-DHP CCBs: non-dihydropyridine calcium channel blockers.  ACE inhibitors: angiotensin-
converting enzyme inhibitors. ARBs: angiotensin receptor blockers. 
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Table 5.3. Predictors of all-cause mortality after 6 months in older patients with atrial 
fibrillation 
Variables 
Univariate analysis Multivariate analysis 
Unadjusted HR 
(95% CI) 
P Adjusted HR  
(95% CI) 
P 
Frailty 2.69 (1.53 – 4.74) 0.001 2.33 (1.31 – 4.14) 0.004 
Age  1.03 (0.99 – 1.07) 0.10 - - 
Gender  0.70 (0.43 – 1.16) 0.17 - - 
Charlson Comorbidity Index 1.18 (1.07 – 1.31) 0.001 1.16 (1.04 – 1.28) 0.007 
CHA2DS2-VASc score 1.14 (0.96 – 1.35) 0.13 - - 
HAS-BLED score 1.29 (1.00 – 1.66) 0.05 - - 
Admission due to falls 1.16 (0.65 – 2.07) 0.62 - - 
Delirium on admission  1.84 (0.94 – 3.62) 0.08 2.07 (1.05 – 4.10) 0.036 
Anticoagulant prescription on discharge 0.63 (0.37 – 1.09) 0.09 - - 
Digoxin prescription on discharge 1.66 (0.95 – 2.91) 0.07 - - 
Psychotropic prescription on discharge 1.62 (0.93 – 2.80) 0.09 - - 
Statin prescription on discharge 0.89 (0.51 – 1.53) 0.67 - - 
Only variables that had a P-value <0.20 in univariate regression were entered into multiple regression model 
together with frailty. Backward elimination method was applied and the final model retained the studied 
variable (which is frailty) and those variables significant at P<0.05 
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Figure 5.1. The Kaplan-Meier survival curves in frail and non-frail participants 
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Chapter Six 
Effect of frailty and age on platelet aggregation and response to aspirin  
in older patients with atrial fibrillation 
Chapter Six is published as: 
Nguyen T.N, Pepperell D., Morel-Kopp MC., Cumming R., Ward C., Hilmer S. Effect 
of Frailty and Age on Platelet Aggregation and Response to Aspirin in Older Patients with 
Atrial Fibrillation: A Pilot Study. Cardiology and Therapy. 2016; 5(1):51-62. 
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 Abstract 
Background and aims. Frailty is associated with changes in inflammation, coagulation and 
possibly platelet function. Aspirin is still prescribed for stroke prevention in older patients 
with atrial fibrillation, although not recommended by current guidelines. In frail older people 
it is unclear whether platelet aggregability and response to aspirin are altered. This study aims 
to investigate the effects of frailty and chronological age on platelet aggregability and on 
responses to aspirin in older patients with atrial fibrillation. 
Methods. Inpatients with atrial fibrillation aged ≥65years were recruited from a tertiary 
referral hospital in Sydney, Australia. Frailty was determined using the Reported Edmonton 
Frail Scale. Platelet aggregation studies were performed using Whole Blood Impedance 
Aggregometry.  
Results. Data from 115 participants were analysed (mean age 85±6 years, 41% female, 52% 
frail). Spearman correlation coefficients found no significant associations of platelet 
aggregation with chronological age or with frailty score. Comparison between frail and non-
frail groups showed that there was no impact of frailty status on aggregation assays amongst 
participants who were not taking any antiplatelet drugs. Amongst participants taking aspirin, 
the frail had higher adjusted arachidonic acid agonist (ASPI) test measures (AU per platelet) 
than the non-frail (0.11±0.11 versus 0.05±0.04; p=0.04), suggesting that in frail participants, 
platelet aggregation is less responsive to aspirin than in non-frail. 
Conclusions. There is no effect of chronological age or frailty status on platelet aggregation 
amongst older patients with atrial fibrillation. However, frailty could be associated with 
reduced aspirin responsiveness among older patients with atrial fibrillation. 
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Introduction 
There is marked heterogeneity amongst people aged over 65 years. Some of this may be 
captured by increasing chronological age. However, much of this variability is thought to be 
due to biological age or frailty (Clegg, Young et al. 2013). Frailty is a state of vulnerability 
that carries an increased risk of poor outcomes in older adults (Clegg, Young et al. 2013). 
The prevalence and clinical importance of frailty are increasing with ageing of the population 
(Raphael, Cava et al. 1995; Clegg, Young et al. 2013). Frailty is associated with changes in 
inflammation, coagulation and possibly platelet function (Gleerup and Winther 1995; 
Kanapuru and Ershler 2009).  
Atrial fibrillation (AF) is a common cardiac arrhythmia in older adults. The prevalence of AF 
in published studies in Western countries ranges from 0.5% to 3% in the general population, 
5% to 6% in people older than 65 years and up to 5% to15% among those aged 80 years or 
older (Camm, Kirchhof et al. 2010; Ball, Carrington et al. 2013; Chugh, Roth et al. 2014). 
Treatment of AF aims at stroke prevention with antithrombotic therapy, reducing symptoms 
with rate-control or rhythm-control strategies, and management of associated medical 
conditions (Camm, Kirchhof et al. 2010). According to the current guidelines, aspirin is not 
recommended for stroke prevention in AF unless patients refuse the use of any oral 
anticoagulant (Hanon, Assayag et al. 2013; January, Wann et al. 2014). International drug 
utilisation studies show that in practice 17-45% of older adults use aspirin for stroke 
prevention in AF (Gage, Boechler et al. 2000; Lleva, Aronow et al. 2009; Corvol, Gulsvik et 
al. 2014; Ferguson, Inglis et al. 2014).  The evidence for stroke prevention in AF with aspirin 
is weak and the risk of major bleeding with aspirin is not significantly different to that of oral 
anticoagulants, especially in older people (Go, Hylek et al. 2001; Mant, Hobbs et al. 2007; 
Hanon, Assayag et al. 2013).  
The efficacy of antiplatelet drugs has not been rigorously tested in older people and older 
people are generally more vulnerable to adverse drug effects due to changes in 
pharmacokinetics and pharmacodynamics associated with aging and an increased risk of 
drug-drug and drug-disease interactions in the presence of polypharmacy and multimorbidity 
(Capodanno and Angiolillo 2010). In frail older people it is unclear whether response to 
antiplatelet therapies is altered. Some studies have suggested that platelet aggregability may 
increase in old age (Kasjanovova and Balaz 1986; Terres, Weber et al. 1991; Gleerup and 
Winther 1995) and plasma aspirin esterase activity is reduced in frail people (Williams, 
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Wynne et al. 1989; Summerbell, Yelland et al. 1990; Hubbard, O'Mahony et al. 2008). 
However, there has been no study exploring the association between frailty and platelet 
aggregation. Therefore, the aims of this study were to investigate the effects of frailty and 
chronological age on platelet aggregability and on platelet responses to aspirin in older 
patients with AF. 
Methods 
A total of 302 inpatients aged ≥65 years with AF at Royal North Shore Hospital, a tertiary 
referral teaching hospital in Sydney, Australia, were recruited for a study of anticoagulant 
utilisation and outcomes in frail and non-frail older inpatients with AF. Of these, 134 patients 
participated in this sub-study on platelet aggregation. Among these patients, 82 patients who 
were not taking any antiplatelet drugs for at least a week before bloods were taken for testing 
and 33 patients who were taking regular aspirin (100 mg daily) and no other antiplatelet 
agents are eligible for this analysis. Consent was obtained from all participants or their 
caregivers. The study was approved by The Northern Sydney Local Health District Human 
Research Ethics Committee and The University of Sydney Human Research Ethics 
Committee. 
Frailty was determined using the Reported Edmonton Frail Scale. This scale, which was 
adapted from the Edmonton Frail Scale for use in Australian acute inpatients, assesses nine 
frailty domains: cognition, general health status, functional independence, social support, 
medication use, nutrition, mood, continence and reported functional performance. With a 
maximum score of 18, a score of 0 to 5 indicates robust, 6 to 7 indicates apparently 
vulnerable status, 8 to 9 mild frailty, 10 to 11 moderate frailty and 12 or more indicates 
severe frailty. The cut point to identify frailty is 8 (Hilmer, Perera et al. 2009). 
Blood was collected from the participants in the morning, from the antecubital vein into tubes 
containing hirudin. Platelet aggregation studies were performed between 30 minutes and 2 
hours after blood was taken, using Whole Blood Impedance Aggregometry (WBIA, 
Multiplate Analyser, Roche Diagnostics). The Multiplate Analyser measures aggregation in 
whole blood samples through changes in electrical impedance between 2 electrodes and has 
been applied to detect platelet inhibition by aspirin in many studies (Von Pape, Dzijan-Horn 
et al. 2007; Rahe-Meyer, Winterhalter et al. 2008; Pedersen, Grove et al. 2009; Sibbing, 
Schulz et al. 2010; Calderaro, Pastana et al. 2013; Wurtz, Hvas et al. 2014). More details 
about the test have been described elsewhere (Tóth, Calatzis et al. 2006; Sibbing, Braun et al. 
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2008). Platelet agonists used in this assay were arachidonic acid (ASPItest) to trigger 
arachidonic acid-induced platelet aggregation, which is affected by aspirin; adenosine 
diphosphate (ADPtest) to trigger ADP-induced platelet aggregation, which is affected 
bythienopyridines (eg. clopidogrel, prasugrel, ticlopidine); and Thrombin Receptor 
Activating Peptide 6 (TRAPtest) to trigger TRAP-6 induced platelet aggregation, which is 
only affected by glycoprotein IIb/IIIa receptor antagonists (eg. tirofiban, abciximab, 
eptifibatide).  ADPtest and TRAPtest were used as positive controls for platelet reactivity. 
Platelet aggregation is defined by the area under the aggregation-time curve which represents 
the aggregation over 6 minutes and values are reported in arbitrary aggregation units (AU). 
Suggested normal ranges in healthy blood donors as provided by the manufacturer are 71 AU 
– 115 AU for ASPItest, 57 AU – 113 AU for ADPtest and 84 AU – 128 AU for TRAPtest 
(Roche Diagnostics GmbH). 
Analysis of the data was performed using SPSS for Windows 20.0 (IBM Corp., Armonk, NY, 
USA). Continuous variables are presented as mean ± standard deviation, and categorical 
variables as frequency and percentage. Clinical characteristics and laboratory parameters 
were compared between frailty and treatment groups using Mann-Whitney U test for 
continuous variables, and Chi-square or Fisher’s exact test for binary variables. Correlation of 
platelet aggregation with age, frailty score and other variables that have previously been 
shown to have impacts on platelet aggregation (O'Donnell, Larson et al. 2001) was assessed 
with Spearman correlation. Two-sided p values <0.05 were considered significant.  Platelet 
function was considered separately for each treatment regimen and by frailty status. The 
platelet counts in this study showed a marked degree of variation (mean 220 ± 95 x109/l, 
median 202x109/l, range 30-502 x109/l).  Twenty-five patients had platelet counts below the 
normal range, and as expected these patients had significantly lower AU values than patients 
with platelet counts in the normal range (p<0.001). Spearman correlation also showed that 
platelet count had a very strong association with platelet aggregation (r=0.59, p<0.001 for 
ASPI test; r=0.63, p<0.001 for ADP test; r=0.69, p<0.001 for TRAP test). Therefore, we 
adjusted the test results to control for the effect of the platelet counts and provide a purer 
representation of platelet aggregability by dividing the AU value by the platelet count, giving 
a value of AU per platelet. We compared aggregability between frail and non-frail 
participants with and without aspirin treatment based on these adjusted values. Sensitivity 
analyses were also performed to assess the robustness of the finding after excluding those 
participants with platelet counts <100 x109/l or >400 x109/l. 
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Results 
A total of 115 participants were included in the study (mean age 85±6 years, age range 71-97 
years, 41% female, 52% frail). Among the 82 participants who did not take any antiplatelet 
therapy in the week prior to sampling (Table 6.1), mean age was 84±6 years and 49% of the 
participants were frail. Compared to the non-frail, frail participants had a significantly higher 
score on the Charlson Comorbidity Index, with a higher prevalence of heart failure and renal 
impairment. There was no quantitative difference in any of the platelet aggregation assays 
between frail and non-frail participants. Spearman correlation coefficients were performed 
for each test of platelet aggregation with age, frailty score and other variables that may 
impact on platelet aggregation (Table 6.2). There were no significant correlations between 
platelet aggregation and any of these variables.  
Among the 33 participants who were taking aspirin, the frail (n=20) had higher ASPI test 
results than the non-frail (0.11±0.11 AU per platelet in the frail versus 0.05±0.04 AU per 
platelet in the non-frail; p=0.04), suggesting that platelets in the frail are less responsive to 
aspirin (Table 6.3).  Representative curves from the ASPI tests of a frail and non-frail 
participant are shown in Figure 1. Spearman correlation coefficients of the ASPI test results 
with age, frailty score and other variables found that the only significant correlation was of 
the presence of a diagnosis of heart failure with increased AU (correlation coefficient 0.40, 
p=0.02) (Table 6.4). Sensitivity analyses showed that the difference between the frail and the 
non-frail remained significant amongst the participants with platelet counts from 100-
400x109/l (n=26), consistent with the analyses amongst those with platelet counts from 30-
502 x109/l (n=33) (Table 6.5). 
 
Discussion 
In this study of older inpatients with AF there was no significant relationship between platelet 
aggregation and chronological age. This result is different to many previous studies in which 
there was a trend towards increased platelet aggregation with age (Kasjanovova and Balaz 
1986; Terres, Weber et al. 1991; Gleerup and Winther 1995; O'Donnell, Larson et al. 2001). 
However, all of these studies were designed to compare platelet aggregation between younger 
groups and older groups (participant age ranged from around 20 to 80 years old, with the cut 
point to determine older groups usually around 60 years old). In contrast, in our study the 
mean age of participants was around 84-86 years, with an age range from 71 to 97 years. 
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Furthermore, unlike our study of acutely unwell older inpatients, previous studies 
demonstrating increased platelet aggregation with age were in healthy volunteers from the 
community without a history of cardiovascular disease. Additionally, in this study we used 
the Multiplate assay - a new method to evaluate platelet aggregation, which is different from 
light transmission aggregometry that was used in the previous studies (Kasjanovova and 
Balaz 1986; Terres, Weber et al. 1991; Gleerup and Winther 1995; O'Donnell, Larson et al. 
2001).  
Amongst participants not taking antiplatelet drugs, there was no association between frailty 
status, a marker of biological age, and platelet aggregation. Amongst those taking aspirin, 
there was a significant difference in platelet aggregation to arachidonic acid (ASPI test): the 
frail exhibited a degree of aspirin resistance compared to the non-frail. The reduced 
responsiveness to aspirin observed in the frail may be partly attributed to the higher 
prevalence of heart failure in the frail participants. In participants taking aspirin we found a 
moderate positive correlation between heart failure and arachidonic acid-induced platelet 
aggregation, which means that compared to participants without a history of heart failure, 
those with heart failure tend to have a higher on-treatment platelet aggregation. The 
relationship between heart failure and decreased aspirin effectiveness has been reported in 
several studies (Sane, McKee et al. 2002; Kaplon-Cieslicka, Rosiak et al. 2013). Although 
not comprehensively understood, this could be explained by several mechanisms such as 
increased levels of circulating catecholamines, angiotensin II and b-thromboglobulin, platelet 
factor 4, P-selectin, platelet-endothelial cell adhesion molecule in patients with heart failure 
(Airee, Draper et al. 2008). The observed  reduced platelet responsiveness to aspirin in the 
frail supports the current guidelines that do not recommend aspirin for stroke prevention in 
AF, and raises a question about the risk benefit ratio of aspirin prescription in older patients 
with AF, which ironically is commoner in the frail (Perera, Bajorek et al. 2009), in whom 
prescribers may be more concerned about using anticoagulants. 
The study comprised a sample of very old and frail people, who are often excluded from 
studies (Ridda, MacIntyre et al. 2010). Recently, objective measures of frailty, including the 
Reported Edmonton Frail Scale used in our study (23), have facilitated study of the 
physiology and management of frailty (1).  The physiological etiology of frailty is still not 
comprehensively understood. Multiple physiological factors are thought to be involved in the 
development of frailty, including activation of inflammation, coagulation systems and 
changes in pharmacokinetics and pharmacodynamics (Chaves, Semba et al. 2005; Hubbard, 
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O'Mahony et al. 2008; Kanapuru and Ershler 2009; Clegg, Young et al. 2013). Studies 
measuring individual factors in the coagulation system suggest that frailty is associated with 
pro-coagulant changes such as increased plasma fibrinogen, factor VIII, C reactive protein, 
D-dimer and tissue plasminogen activator (t-PA) plasma levels (Walston, McBurnie et al. 
2002; Cohen, Harris et al. 2003; Folsom, Boland et al. 2007; Reiner, Aragaki et al. 2009). To 
our knowledge, there has been no previous study focusing on the impact of frailty on platelet 
aggregation and platelet response to antiplatelet drugs. There have only been several studies 
reporting the association between frailty and reduced activity of plasma aspirin esterase, a 
hydrolysis enzyme that helps the conversion of aspirin (acetylsalicylic acid) to salicylic and 
acetic acid  (Williams, Wynne et al. 1989; Hubbard, O'Mahony et al. 2008).  
In this study we used the Multiplate method to study platelet aggregation. Since the 
introduction of the bleeding time test, different methodologies have been developed to obtain 
the optimal platelet function test and to assess platelet reactivity in response to antiplatelet 
drugs (Duke 1983; Karathanos and Geisler 2013; Steiner and Moertl 2013). The Multiplate is 
a new method to evaluate platelet aggregation and is one of the point-of-care assays for 
monitoring antiplatelet therapy (Tóth, Calatzis et al. 2006). It can be performed in whole 
blood, does not require specifically trained laboratory personnel and is simple to interpret 
(Steiner and Moertl 2013). This method has been widely used in clinical trials and is also 
implemented in daily practice in catheterization laboratories, predominantly in Europe 
(Karathanos and Geisler 2013). However, it should be noted that the correlation of this test 
with other tests of platelet aggregation and with clinical outcomes is not perfect (Pedersen, 
Grove et al. 2009; Grove, Hvas et al. 2010) and that this test has not been validated in very 
old or frail participants. The Multiplate assay provides a reproducible measure of reduced 
platelet aggregation in response to defined agonists.  However, unlike assays measuring 
platelet response to very low doses of agonists, which were used in previous studies of 
platelet function in ageing (Kasjanovova and Balaz 1986; Terres, Weber et al. 1991; Gleerup 
and Winther 1995; O'Donnell, Larson et al. 2001), the Multiplate assay is not designed to 
detect platelet hyperaggregability.  
A major limitation of this study is that it was done in the acute care setting, in which platelet 
aggregation may be influenced by acute inflammation (Stokes and Granger 2012). This is a 
pilot study testing the hypothesis of altered platelet aggregation with frailty that relies on a 
convenience sample. Small sample size may have limited the power of this study to observe 
small changes with age and frailty. This study sample is based on volunteers from inpatients 
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recruited for a study on anticoagulant utilisation. Approximately half of the participants in 
that study agreed to a blood test, so the sample may be not representative of older inpatients 
with AF. Furthermore, all of the participants in this study had AF, which may be 
procoagulant (Kamath, Blann et al. 2002). Therefore, results should be cautiously interpreted 
and generalised to older inpatients without AF who may be prescribed aspirin for other 
indications. 
Conclusion 
There is no effect of chronological age or frailty status on platelet aggregation amongst 
hospitalised older patients with AF. Response to aspirin is reduced in the frail and in those 
with heart failure. This may have implications for efficacy of aspirin in this population.  
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 Table 6.1. Characteristics of 82 participants not taking any antiplatelet therapy 
 All  
(n=82) 
Frail  
(n=40) 
Non-frail 
(n=42) 
P-
values 
Age (years) 84.00 ± 6.08 84.98 ± 6.40 83.05 ± 5.67 0.08 
Female gender 33 (40.20%)  18 (45.00%)  15 (35.70%)  0.39 
Hypertension 51 (62.20%) 23 (57.50%) 28 (66.70%) 0.39 
Heart failure 38 (46.30%) 24 (60.00%) 14 (33.30%) 0.02 
Ischemic heart disease 35 (42.70%) 18 (45.00%) 17 (40.50%) 0.68 
Diabetes mellitus type 2 15 (18.30%) 9 (22.50%)  6 (14.30%)  0.31 
Dyslipidemia  25 (30.50%) 10 (25.00%)  15 (35.70%)  0.29 
Peripheral vascular disease 8 (9.80%)  7 (17.50%)  1 (2.40%)  0.02 
Stroke  24 (29.30%)  13 (32.50%) 11 (26.20%)  0.53 
History of cancer/current cancer 22 (26.80%)  10 (25.00%)  12 (28.60%) 0.72 
Female gender 37 (45.10%) 25 (62.50%) 12 (28.60%) 0.002 
Reported Edmonton Frail score 7.48 ± 2.84 9.88 ± 1.64 5.19 ± 1.55 <0.001 
Charlson Comorbidity Index  3.84 ± 2.30 4.50 ± 2.10  3.21 ± 2.32 0.004 
Hemoglobin (g/l) 178 ± 122  119 ± 21 125 ± 21  0.26 
White cell count(x109/l) 7.43 ± 2.53 7.34 ± 2.40 7.50 ± 2.68 0.99 
Platelet count (x109/l) 226 ± 92 217 ± 107 234 ± 74 0.22 
Platelet aggregation (AU)     
ADPtest 58 ± 26 56 ± 28 60 ± 24 0.29 
ASPItest 68 ± 28 65 ± 30 70 ± 26 0.41 
TRAPtest 77 ± 29 75 ± 32 80 ± 26 0.53 
Adjusted platelet aggregation (AU per platelet) 
ASPItest 0.31 ± 0.09 0.31 ± 0.11 0.30 ± 0.07 0.43 
ADPtest 0.26 ± 0.11 0.27 ± 0.12 0.26 ± 0.10 0.95 
TRAPtest 0.36 ± 0.13 0.37 ± 0.15 0.35 ± 0.11 0.81 
Continuous data are presented as mean± standard deviation or median (range). Categorical data are shown as n 
(%) 
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Table 6.2. Spearman correlation coefficients for platelet aggregation with age, frailty scores and 
other variables in 82 participants not taking antiplatelet agents 
Variables  ASPI test  
(AU per platelet) 
ADP test  
(AU per platelet) 
TRAP test  
(AU per platelet) 
Age (year) 0.10 0.10 0.05 
Reported Edmonton Frail score -0.03 0.12 0.01 
Charlson comorbidity index -0.15 0.01 0.02 
Body mass index (kg/m2) 0.01 0.09 0.11 
Dyslipidemia -0.18 -0.07 -0.12 
Diabetes mellitus  0.10 0.19 0.14 
Heart failure -0.01 0.13 0.06 
Ischemic heart disease -0.06 -0.13 -0.05 
History of cancer/current cancer -0.04 0.03 0.09 
Female gender 0.04 0.01 0.09 
Anticoagulant users 
(warfarin/heparin) 
-0.07 -0.07 -0.01 
Hemoglobin  (g/dl) -0.17 -0.16 -0.09 
White cell count (x109/l) 0.09 0.16 -0.08 
A positive correlation indicates that the variable is associated with increased platelet aggregation. All p-values 
were >0.05. 
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Table 6.3. Characteristics of the 33 participants taking aspirin 
 All  
(n=33) 
Frail  
(n=20) 
Non-frail 
(n=13) 
P-values 
Age (years) 86.52 ±6.90 86.60 ±6.64 86.38±7.57 0.96 
Reported Edmonton Frail Score 8.03 ± 2.69 9.75 ± 1.48 5.38 ± 1.81 <0.001 
Charlson 3.33 ± 2.03 3.55 ± 2.04 3.00 ± 2.04 0.52 
Female gender 14 (42.40%) 6 (30.00%) 8 (61.50%) 0.07 
Hypertension 22 (66.70%) 14 (70.00%) 8 (61.50%) 0.61 
Heart failure 15 (45.50%) 13 (65.00%) 2 (15.40%) 0.005 
Ischemic heart disease 16 (48.50%) 11 (55.00%) 5 (38.50%) 0.35 
Diabetes mellitus type 2 6 (18.20%) 4 (20.00%) 2 (15.40%) 1.00 
Dyslipidemia  9 (27.30%) 7 (35.00%) 2 (15.40%) 0.26 
Peripheral vascular disease 5 (15.20%) 4 (20.00%) 1 (7.70%) 0.63 
Stroke  9 (27.30%) 5 (25.00%) 4 (30.80%) 0.72 
Cancer 7 (21.20%) 5 (25.00%) 2 (15.40%) 0.67 
eGFR<60(ml/min/1.73 m2) 15 (45.50%) 7 (35.00%) 8 (61.50%) 0.14 
Hemoglobin (g/l) 114±19 112±21 116±16 0.41 
White cell count(x109/l) 7.69  ±2.89 8.11±3.37 7.08 ±1.93 0.34 
Platelet count (x109/l) 205±104 186±100 235±107 0.28 
Platelet aggregation (AU)     
ASPItest 15 ± 13 18 ± 15 11 ± 8 0.21 
ADPtest 51 ± 31 47 ± 31 58 ± 31 0.37 
TRAPtest 66 ± 34 61 ± 35 74 ± 31 0.27 
Adjusted platelet aggregation (AU per platelet) 
ASPItest 0.09 ± 0.09 0.11 ± 0.11 0.05 ± 0.04 0.04 
ADPtest 0.25 ± 0.09 0.25 ± 0.10 0.24 ± 0.07 1.00 
TRAPtest 0.35 ± 0.17 0.36 ± 0.21 0.33 ± 0.09 0.90 
Continuous data are presented as mean±SD. Categorical data are shown as n (%). eGFR: Estimated Glomerular 
Filtration Rate. 
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Table 6.4. Spearman correlation for platelet aggregation in response to aspirin with age, frailty 
score and other variables in 33 participants taking aspirin 
Variables  ASPI test  
(AU per platelet) 
P-values 
Age (year) 0.03 0.87 
Reported Edmonton Frail score 0.19 0.29 
Charlson comorbidity index 0.10 0.56 
Body mass index (kg/m2) 0.30 0.24 
Dyslipidemia 0.16 0.38 
Diabetes mellitus  0.14 0.44 
Heart failure 0.40 0.02 
Ischemic heart disease 0.19 0.29 
History of cancer/current cancer -0.17 0.34 
Female gender -0.08 0.64 
Anticoagulant users (warfarin/heparin) 0.20 0.26 
Hemoglobin (g/dl) 0.04 0.84 
White cell count (x109/l) 0.29 0.11 
A positive correlation indicates that the variable is associated with increased arachidonic acid-induced platelet 
aggregation (eg. less responded to aspirin). 
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Table 6.5. Results from sensitivity analyses assessing the impact of frailty on antiplatelet 
responsiveness 
 All  
 
Frail  
 
Non-frail  P-
values 
All participants on aspirin  
(platelet counts 30-502 x109/l) 
N=33 N=20 N=13  
Adjusted platelet aggregation (AU per platelet) 
ASPItest 0.090 ± 0.090 0.110 ± 0.110 0.050 ± 0.035 0.036 
ADPtest 0.245 ± 0.091 0.252 ± 0.104 0.241 ± 0.068 1.000 
TRAPtest 0.349 ± 0.173 0.363 ± 0.213 0.327 ± 0.088 0.899 
 
Participants with platelet counts  
100-400 x109/l 
 
N=26 
 
N=15 
 
N=11 
 
Adjusted platelet aggregation (AU per platelet) 
ASPItest 0.078 ± 0.056 0.096 ± 0.063 0.055 ± 0.036 0.047 
ADPtest 0.241 ± 0.092 0.240 ± 0.105 0.243 ± 0.075 0.799 
TRAPtest 0.329 ± 0.133 0.322 ± 0.160 0.339 ± 0.089 0.540 
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Figure 6.1. Arachidonic acid-induced platelet aggregation (ASPItest) in participants taking 
aspirin. A: from a representative frail participant. B: from a representative non-frail participant. 
(One Multiplate test cell includes two independent sensor units. The increase of impedance due to the attachment of 
platelets to the electrodes is detected for each sensor unit separately and transformed to arbitrary aggregation units that 
are plotted against time. The duplicate sensors work as an internal control) (Sibbing D et al. 2010). 
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Chapter Seven 
The impact of frailty on coagulation and responses to warfarin in acute older 
hospitalised patients with atrial fibrillation 
Chapter Seven has been submitted to a peer review journal as: 
Nguyen T.N., Morel-Kopp MC., Pepperell D., Cumming R., Hilmer S., Ward C. (2016): The 
impact of frailty on coagulation and responses to warfarin in acute older hospitalised patients 
with atrial fibrillation: A Pilot Study. 
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Abstract 
Background and aims. The evidence on coagulation changes with frailty is not consistent. This 
study aims to assess the impact of frailty on coagulation function and on response to warfarin.  
Methods. Inpatients aged over 65 years with atrial fibrillation were recruited. Frailty was 
determined using the Reported Edmonton Frail Scale. The Overall Haemostatic Potential and 
Calibrated Automated Thrombogram were used to globally assess coagulation function. 
Results. Data of 95 participants were analysed, mean age 85.5 ± 6.2, 40% female, 50.5% frail. 
Among participants not on anticoagulants (N=36), there was an increased fibrin generation and 
decreased thrombin generation compared to the local established normal ranges in young healthy 
volunteers; the frail had significantly reduced fibrin generation compared to the non-frail. In the 
warfarin group (N=59), there was no difference on coagulation profiles between the frail and the 
non-frail from any of the coagulation tests.  
Conclusion. In this cohort of acute hospitalised patients with atrial fibrillation, the observed 
decreased fibrin generation in the frail may reflect decreased acute phase response as suggested 
with the lower plasma fibrinogen in that group. There was no difference in coagulation profiles 
between the frail and the non-frail amongst those taking warfarin. The findings reflect the 
complex interaction between age, frailty, acute illness and coagulation. Further studies with these 
global coagulation assays in community dwelling older people may help contribute to the 
knowledge about the pathophysiology of frailty. 
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Introduction 
The prevalence and clinical importance of frailty have been increasingly recognised. Frailty is 
defined as a state of increased vulnerability to poor resolution of homeostasis after a stressor 
event, which increases the risk of having adverse outcomes (Fried, Tangen et al. 2001; Clegg, 
Young et al. 2013). The physiological aetiology of frailty is still not comprehensively 
understood. Multiple physiological factors are thought to be involved in the development of 
frailty, including activation of inflammation and coagulation systems (Chaves, Semba et al. 
2005; Hubbard, O'Mahony et al. 2008; Kanapuru and Ershler 2009; Clegg, Young et al. 2013).  
Ageing has been well established to be associated with hypercoagulability (Bauer, Weiss et al. 
1987; Abbate, Prisco et al. 1993; Tracy 2003; Yamamoto, Takeshita et al. 2005; Franchini 2006; 
Mari, Coppola et al. 2008) while the evidence on coagulation changes with frailty is not clear. 
Studies measuring individual factors in the coagulation system suggest that frailty is associated 
with pro-coagulant changes (Walston, McBurnie et al. 2002; Cohen, Harris et al. 2003; Folsom, 
Boland et al. 2007; Reiner, Aragaki et al. 2009). In the Cardiovascular Health study, frailty was 
associated with increased plasma fibrinogen, factor VIII and C reactive protein (CRP) (Walston, 
McBurnie et al. 2002). In another study in older women aged 65 years or older, frailty was 
associated with higher D-dimer and higher t-PA plasma levels but not with elevated factor VIII, 
fibrinogen and CRP (Reiner, Aragaki et al. 2009). High levels of D-dimer and interleukin-6 were 
associated with increased mortality and functional decline (which may contribute to the 
development of frailty) in older people (Cohen, Harris et al. 2003).  
Clinically, frailty is reported to be associated with increased risk of idiopathic venous 
thromboembolism in the Cardiovascular Health Study (Folsom, Boland et al. 2007). On the other 
hand, evidence from clinical studies suggests that frail older people may be at an increased risk 
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of bleeding complications with anticoagulant therapy (Johnson, Lim et al. 2005; Perera, Bajorek 
et al. 2009). Therefore, this study has two objectives. First, we aimed to comprehensively assess 
the impact of ageing and frailty on coagulation function in a cohort of older inpatients with atrial 
fibrillation (AF) who were not taking any anticoagulants. Secondly, we investigated the impact 
of frailty on responses to warfarin. 
 
Methods 
Study Population 
A total of 302 inpatients aged ≥65 years with AF at Royal North Shore Hospital, a tertiary 
referral teaching hospital in Sydney, Australia, were recruited for a study about anticoagulant 
utilisation and outcomes in frail and non-frail older inpatients with AF. Of these, 139 patients 
agreed to participate in the sub-study on coagulation. Among these, 36 participants were not 
administered any anticoagulant drugs for at least three days before bloods were taken for the 
study, 59 participants were administered regular warfarin, 27 participants were given 
prophylactic heparin (enoxaparin or unfractionated heparin), 7 therapeutic heparin, 7 warfarin 
plus heparin, 2 dabigatran and 1 rivaroxaban. This paper used the data from the 36 participants 
who were not anticoagulated and the 59 participants who were taking regular warfarin.  Consent 
was obtained from all participants or their caregivers. The study was approved by The Northern 
Sydney Local Health District Human Research Ethics Committee and The University of Sydney 
Human Research Ethics Committee. 
Criteria for identifying frailty 
The Reported Edmonton Frail Scale (REFS) was used to identify frail participants. This scale 
was adapted from the Edmonton Frail Scale for use with Australian acute inpatients (Hilmer, 
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Perera et al. 2009).  It does not require objective measures of physical function that can be 
strongly influenced by acute illness, has been validated for administration by non-medically 
trained researchers, and is quick to apply. The scale involves nine frailty domains (cognition, 
general health status, functional independence, social support, medication use, nutrition, mood, 
continence and functional performance). With a maximum score of 18, the cut point to identify 
frailty is 8 (Hilmer, Perera et al. 2009). All participants were also assessed for stroke risk with 
CHA2DS2-VASc score (January, Wann et al. 2014), bleeding risk for anticoagulants with HAS-
BLED score (Pisters, Lane et al. 2010) and comorbidity with the Charlson Comorbidity Index 
(Charlson, Pompei et al. 1987). 
Laboratory studies 
Blood samples were taken in the morning from an antecubital vein into tubes containing 0.129 M 
tri-sodium citrate (3.2%). The blood samples were centrifuged at 3000 g for 10 minutes within 2 
hours post collection. Another centrifugation of the supernatant was done immediately after that 
to produce platelet poor plasma, which was then stored in 1mL aliquots at -80oC until being 
analyzed. 
In this study, two global coagulation assays, the Overall Haemostatic Potential (OHP) and 
Calibrated Automated Thrombogram (CAT) were used to assess coagulation. The Calibrated 
Automated Thrombogram measured ex vivo thrombin generation potential and the Overall 
Haemostatic Potential measured ex vivo fibrin generation and fibrinolysis over time.  
Overall Haemostatic Potential  (OHP) assay 
The assay was performed as previously described (He, Bremme et al. 1999; Curnow, Morel-
Kopp et al. 2007; Antovic 2008; Reddel, Curnow et al. 2013; White, Edelman et al. 2014). 
Briefly, PPPs were tested in duplicate in microtiter plate wells at 37 °C. Fibrin generation curves 
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were obtained following mixing 75 µl PPP with 75 µl OHP buffer containing 0.06 IU/ml 
thrombin. For the fibrinolysis curves, 300ng/ml recombinant tissue plasminogen activator (rtPA) 
was added to the OHP buffer. Automated absorption measurements were taken at 390 nm every 
minute for 60 min. Values for OCP and OHP represent the area under the relevant fibrin 
generation and fibrinolysis curves calculated by summation of absorption values. The overall 
fibrinolysis potential (OFP45) value is calculated by (OCP-OHP)/OCP × 100% over a 45 minute 
period since onset of clotting (delay + 45 minutes) and represents the area under the fibrinolytic 
portion of the curve as a percentage of the total OCP value. The delay in onset of fibrin 
generation is expressed in seconds). Max OD is the mean of the maximum optical density (OD) 
reached in the duplicate OCP curves. Maximum slope is calculated using three time points.  
The Calibrated Automated Thrombogram (CAT)  
Thrombin generation was measured according to the method described by Hemker et al. in a 
Fluoroscan Ascent fluorometer (Thermo Labsystems, Helsinki, Finland) (Hemker, Giesen et al. 
2002). Briefly, 80 μl of PPP were dispensed into the wells of 96 well microplate with 20 μl of 
calibrator (Diagnostica Stago, Doncaster, VIC, Australia) or PPP reagent containing 9 pM rTF 
and 24 μM procoagulant phospholipids. Thrombin generation was triggered by the automatic 
dispensing of 20 μl of a solution containing 0.1 M CaCl2 and 2.5 mM fluorescent substrate (Z-
Gly-Gly-Arg-AMC, Merck Millipore, Bayswater, VIC, Australia). Fluorescence was measured 
every 20 seconds over a 60 minute period. All tests were performed in triplicate. The 
endogenous thrombin potential (ETP, total thrombin generated), peak thrombin, lag time and 
time to peak were automatically calculated by thrombinoscope software (Thrombinoscope BV, 
Maastricht, The Netherlands). 
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After storage, frozen samples were thawed and PT, APTT, fibrinogen, FVIII and d-dimer were 
measured on a STAR analyser (Diagnostica Stago, Doncaster, Vic, Australia) using 
manufacturer’s kits and reagents. Fibrinogen was measured using the Clauss method; von 
Willebrand factor (vWF) antigen and D-dimers were assayed using an immunoturbidimetric 
method while the FVIII activity was measured using an APTT clot base assay. The international 
normalised ratios (INR) were calculated from the PT data. 
Statistical analysis  
Analysis of the data was performed using SPSS for Windows 20.0 (IBM Corp., Armonk, NY, 
USA). Continuous variables were presented as mean ± standard deviation for normally 
distributed variables and median (range) for non-normally distributed variables, and categorical 
variables as frequency and percentage. Differences in clinical characteristics and laboratory 
parameters between frail and non-frail participants were compared using t-test for normally 
distributed variables and Mann-Whitney U test for non-normally distributed variables, and Chi-
square or Fisher’s exact test for binary variables. Two-sided p values <0.05 were considered 
significant. To investigate the effect of ageing on coagulation function, comparison of 
coagulation measures was made between the older participants not taking anticoagulants and the 
local established normal ranges in young healthy volunteers (N = 64, 62.5% female, mean age 
39.1±13.0 for OHP assays; N=131, 70.2% female, mean age 40.4±11.4 for CAT assays). 
Comparison between frail and non-frail older participants was analysed according to 
anticoagulant treatment regime (no anticoagulant, warfarin, prophylactic heparin) to investigate 
the effect of frailty on coagulation function and response to anticoagulant therapy. 
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Results 
Data of 95 participants were analysed, mean age 85.5 ± 6.2 (median 86.0, range 71 – 96), female 
40.0%. Frailty was identified in 50.5% of the participants (N=48).  
The effect of ageing and frailty on coagulation parameters amongst the 36 participants not 
taking anticoagulants  
In older patients not taking any anticoagulants (N=36, age range 73-96, median age 88, 38.9% 
female), OHP parameters suggested significantly increased fibrin generation compared to young 
healthy volunteers (median OCP  62.02 versus 45.61, p<0.001; OHP 17.28 versus 9.17, p<0.001; 
Max OD 1.27 versus 0.93 , p<0.001; Max slope 295.00 versus 169.00, p<0.001; Delay 402.50 
versus 462.00, p<0.001 in the older group and in young healthy volunteers, respectively) and 
decreased fibrinolysis (median OFP45min 63.41 older group versus 76.81  young reference, 
p<0.001) in the older group compared to the younger normal range. In contrast, CAT parameters 
showed decreased thrombin generation in the old group: longer median lag time (3.89 versus 
2.93, p<0.001), longer median time to peak (6.94 versus 6.22 ± 1.18, p<0.001), decreased 
median ETP (1321.84 versus 1448.03, p<0.001) and decreased median Peak thrombin (241.17 
versus 256.90, p=0.06). (Figure 1) 
Compared to non-frail participants, the frail had significantly reduced fibrin generation as shown 
on OHP assays which, as expected, correlated with reduced plasma fibrinogen concentrations. 
There was no difference between frail and non-frail participants on CAT assay and other 
standard coagulation tests (Table 7.1 and Figure 7.1). The strong correlation between 
OHP assays and plasma fibrinogen concentration is shown on Figure 7.2.
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The effect of frailty on coagulation parameters amongst the 59 participants taking warfarin  
Using the results of participants not taking anticoagulants as control (N=36), thrombin 
generation was significantly reduced in participants taking warfarin: median Lag time 8.56 in 
warfarin group versus 3.89 control, p<0.001, median ETP 499.40 warfarin group versus 1321.84 
control, p<0001, median Peak thrombin 112.09 warfarin group versus 241.17 control, p<0.001, 
median time to peak 10.84 warfarin group versus 6.94 control, p<0.001. The OHP assays showed 
a variable reduction in fibrin generation in participants taking warfarin: median OCP 51.66 
versus 62.02 control, p=0.07, median OHP 16.40 versus 17.28 control, p=0.30, median Max OD 
1.16 versus 1.27 control, p=0.74, median Max slope 177.00 versus 295.00 control, p<0.001, 
median Delay 553.50 versus 402.50 control, p=0.001. 
Among the 59 participants on warfarin, there was no difference on coagulation profiles between 
the frail and the non-frail from any of the coagulation tests (Table 7.2). There was no difference 
between the frail and the non-frail in terms of the prevalence of medications that can potentially 
interact with warfarin. A representative result of OHP assays is presented in Figure 7.3. 
Discussion and conclusion 
The impact of frailty and aging amongst participants not taking any anticoagulants 
In this study of older hospitalised patients, the OHP assay found a significant increase in fibrin 
generation compared to the normal local established ranges in young healthy adults. This is 
mainly due to fibrinogen which is increased during the acute phase response, up to two to tenfold 
(Weisel 2005), and we also observed elevated fibrinogen levels in our studied older participants 
compared to the normal ranges. Under an acute stressful event, there are a series of reactions that 
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result in cell activation and cytokine production, which then result in an increased production of 
inflammatory markers and changes in the levels of plasma proteins synthesized by the liver, 
including fibrinogen (Weisel 2005), FVIII and vWF (Jain, Gautam et al. 2011). The reduced 
fibrin generation in the frail compared to the non-frail participants in this study could be 
explained by the fact that frailty, by its definition, is a state of decreased physiological 
reserve and resistance to stressors (Fried, Tangen et al. 2001). Frailty has been shown to be 
associated with reduced levels of proteins that have a primarily hepatic origin, such as albumin 
and alanine transaminase (Schalk, Visser et al. 2004; Le Couteur, Blyth et al. 2010). 
Interestingly, while the OHP assay suggested significantly increased fibrin generation in this 
cohort of older patients, the CAT assay suggested a reduced thrombin generation capacity 
compared to the established local normal ranges in young healthy adults suggestive of lower 
prothrombin plasma levels or reduced prothrombinase activity,. In a study in 742 participants 
(aged 36 to 85 years) in Japan, the authors also found that the levels of prothrombin 
activity were decreased in both sexes in the oldest group (aged 76-85 years) (Sakata, 
Okamoto et al. 2007). This could help explain why the bleeding rates are variable and usually 
high in older patients in clinical studies of anticoagulant therapy (Johnson, Lim et al. 2005; 
Perera, Bajorek et al. 2009). 
While our study suggests reduced fibrin generation in the frail compared to the non-frail, 
previous studies in community-dwelling older adults suggest that frailty defined by 
Fried’s frailty phenotype was associated with pro-coagulant changes (Walston, McBurnie et 
al. 2002; Folsom, Boland et al. 2007; Reiner, Aragaki et al. 2009). This difference could be 
explained by the decreased acute phase response in the frail, which could help contribute to the 
understanding about the pathophysiology of frailty. Different tools for identifying frailty could 
also explain this difference.  
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The impact of frailty on warfarin responsiveness 
Amongst those taking warfarin, there was no difference in coagulation profiles between the frail 
and the non-frail. This finding may suggest that warfarin therapy reverses hypercoagulability in 
the non-frail and may have less effect on the frail cohort. It could also suggest that there was no 
risk of over-responsiveness to anticoagulants in the frail. It seems that the frail on warfarin are 
not at higher risk of bleeding despite a lower fibrin generation at baseline. Studies in Australia 
have shown that frailty did not increase the risk of major bleeding on warfarin in older patients 
with atrial fibrillation (Perera, Bajorek et al. 2009; Nguyen, Cumming et al. 2015).  
 
This study has several strengths. The study comprised a sample of very old and frail people, who 
are often excluded from studies (Ridda, MacIntyre et al. 2010). It used the validated Reported 
Edmonton Frail Scale and high quality detailed clinical information (Hilmer, Perera et al. 2009). 
It also used the global coagulation tests OHP and CAT to assess coagulation function. To our 
knowledge, this is the first study to examine the association between frailty and coagulation in 
acute phase of illness. Acute care settings are common sites for anti-coagulant use and adverse 
clotting or bleeding events. However, the interpretation of the coagulation parameters may be 
limited by the influence of acute inflammation (Stokes and Granger 2012). Furthermore, 
polypharmacy and the utilisation of many drugs that have a potential interaction with warfarin 
were common in the studied subjects. Time of the last dose of warfarin was also not recorded 
exactly, which could have influence on the coagulation parameters in participants taking 
warfarin. This is a pilot study testing the hypotheses of altered coagulation function and altered 
responses to anticoagulants with frailty that relies on a convenience sample. Small sample size 
may have limited the power of this study to observe small changes with frailty. This study 
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sample is based on volunteers from inpatients recruited for a study on anticoagulant utilisation. 
Approximately half of the participants in that study agreed to a blood test, so the sample may not 
be representative of older inpatients with atrial fibrillation. Furthermore, all of the participants in 
this study had atrial fibrillation, which may be procoagulant (Kamath, Blann et al. 2002). 
Therefore, results should be cautiously interpreted and generalised to older inpatients without 
atrial fibrillation. 
In this study in acute hospitalised patients with atrial fibrillation, compared to the non-frail, fibrin 
generation is markedly reduced in the frail, but thrombin generation does not differentiate 
between the groups. This may reflect decreased acute phase response in the frail. There was no 
difference in coagulation profiles between the frail and the non-frail amongst those taking 
warfarin. The findings highlight the complex interaction between age, frailty, acute illness and 
coagulation. Further studies with these global coagulation assays in community dwelling older 
people may help contribute to the knowledge about the pathophysiology of frailty. 
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Table 7.1. Clinical characteristics of frail and non-frail older patients not on anticoagulants 
Variables All 
(N=36) 
Frail 
(N=22) 
Non-frail 
(N=14) 
P 
Mean age 87.3 ± 6.3 89.0 ± 5.5 84.6 ± 6.6 0.05 
Female  14 (38.9%) 9 (40.9%) 5 (35.7%) 0.75 
CHA2DS2-VASc score  4.4 ± 1.3 4.7 ± 1.2 3.8 ± 1.1 0.17 
Body mass index (kg/m2) 22.7 
(14.2-34.1) 
22.6 
(16.6-34.1) 
23.9 
(14.2-31.2) 
0.33 
Charlson Comorbidity Index 3.5 
(1.0-9.0) 
4.0 
(1.0-9.0) 
3.0 
(1.0-5.0) 
0.01 
Serum albumin (g/L) 35.0 
(20.0-40.0) 
35.0 
(20.0-40.0) 
34.5 
(32.0-31.2) 
0.41 
Blood hemoglobin (g/L) 114 
(88-167) 
114 
(94-150) 
115 
(88-167) 
0.16 
Blood white cell counts 
(x109/L) 
6.9 
(4.2-14.5) 
6.1 
(4.2-14.5) 
7.6 
(5.2-14.3) 
0.62 
Blood platelet counts 
(x109/L) 
238 
(30-444) 
213 
(30-423) 
296 
(105-444) 
0.06 
INR 1.15 
(0.86-2.55) 
1.14 
(0.86-2.55) 
1.19 
(0.99-1.44) 
0.76 
aPTT 28.60 
(21.80-40.00) 
28.40 
(21.80-40.00) 
28.60 
(23.30-37.90) 
0.71 
Fibrinogen (g/l) 4.69 
(1.66-7.00) 
4.22 
(1.66-6.03) 
5.30 
(1.98-7.00) 
0.02 
Factor VIII 2.50 
(1.32-7.92) 
2.54 
(1.61-4.05) 
2.41 
(1.32-7.92) 
0.76 
vWF 229.37 
(127.00-636.00) 
229.37 
(127.00-582.37) 
236.39 
(135.30-636.00) 
1.00 
D-dimer 1.70 
(0.27-6.38) 
1.70 
(0.30-3.20) 
2.02 
(0.27-6.38) 
0.45 
Continuous variables were presented as mean ± standard deviation for normally distributed variables and 
median (range) for non-normally distributed variables; categorical variables as frequency and percentage. 
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Table 7.2. Coagulation measures in frail and non-frail older patients taking warfarin 
Variables  All 
(N=59) 
Frail 
(N=26) 
Non-frail 
(N=33) 
P 
Mean age 84.44 ± 6.05 84.65 ± 6.21 84.27 ± 6.01 0.81 
Female 24 (40.7%) 11 (42.3%) 13 (39.4%) 0.82 
Mean dose of warfarin (mg) 3.47 ± 0.23 3.32 ± 1.79 3.58 ± 1.77 0.62 
Body mass index (kg/m2) 25.7 
(15.8-39.3) 
27.7 
(15.8-39.3) 
24.4 
(16.8-37.9) 
0.04 
CHA2DS2-VASc score  5.00 
(2.00-8.00) 
5.00 
(2.00-7.00) 
4.50 
(2.00-8.00) 
0.31 
HAS-BLED score  3.00 
(1.00-5.00) 
3.00 
(1.00-5.00) 
3.00 
(1.00-5.00) 
0.77 
Charlson Comorbidity Index 4.0 
(0-12.0) 
4.5 
(0-11.0) 
3.0 
(0-12.0) 
0.13 
Renal impairment  3 (5.1%) 1 (3.8%) 2 (6.1%) 1.00 
Hepatic impairment  3 (5.1%) 0 (0.0%) 3 (9.1%) 0.25 
Serum albumin (g/L) 35.0 
(25.0-45.0) 
34.5 
(27.0-42.0) 
36.0 
(25.0-45.0) 
0.50 
Blood hemoglobin (g/L) 123 
(84-171) 
126 
(84-162) 
122 
(99-171) 
1.00 
Blood white cell counts 
(x109/L) 
6.8 
(3.7-14.3) 
6.2 
(4.1-12.1) 
7.5 
(3.7-14.3) 
0.20 
Blood platelet counts 
(x109/L) 
197 
(62-386) 
184 
(62-381) 
206 
(98-386) 
0.11 
Overall Haemostatic Potential assay (OHP): 
OCP 51.66 
(0.00-81.96) 
49.86 
(18.83-74.66) 
53.64 
(0.00-81.96) 
0.63 
OHP 16.40 
(0.00-34.20) 
15.11 
(3.53-28.32) 
17.21 
(0.00-34.20) 
0.57 
OFP45min 65.73 
(0.00-92.32) 
67.41 
(46.58-92.32) 
64.79 
(0.00-90.55) 
0.29 
Max OD 1.16 
(0.00-1.66) 
1.13 
(0.35-1.54) 
1.17 
(0.00-1.66) 
0.98 
Max slope 177.00 
(0.00-471.00) 
169.00 
(40.00-379.00) 
177.00 
(0.00-471.00) 
0.58 
Delay  553.50 
(0.00-1406.00) 
587.00 
(348.00-1406.00) 
517.50 
(0.00-1110.00) 
0.27 
Calibrated automated thrombogram (CAT): 
Lag time 8.56 
(0.00-42.00) 
8.17 
(4.28-28.54) 
9.17 
(0.00-42.00) 
0.55 
ETP 499.40 432.89 551.33 0.70 
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(0.00-1009.33) (144.31-890.33) (0.00-1009.33) 
Peak thrombin 112.09 
(0.00-213.58) 
98.91 
(31.52-188.53) 
120.58 
(0.00-213.58) 
0.72 
Time to peak 10.84 
(0.00-45.67) 
10.56 
(6.62-31.88) 
11.50 
(0.00-45.67) 
0.82 
Other coagulation tests: 
INR 2.41 
(1.27-3.78) 
2.37 
(1.27-3.59) 
2.47 
(1.34-3.78) 
0.62 
aPTT 38.15 
(27.80-54.80) 
37.85 
(31.10-50.90) 
38.15 
(27.80-54.80) 
0.50 
Fibrinogen (g/l) 4.28 
(1.76-7.04) 
4.18 
(1.76-6.61) 
4.43 
(1.79-7.04) 
0.59 
Factor VIII 2.57 
(1.20-4.00) 
2.53 
(1.20-4.00) 
2.57 
(1.60-4.00) 
0.91 
vWF 240.72 
(100.51-521.00) 
259.00 
(119.00-521.00) 
204.66 
(100.51-507.00) 
0.16 
D-dimer 0.84 
(0.20-3.40) 
0.85 
(0.27-2.27) 
0.84 
(0.20-3.40) 
0.80 
Outcomes: 
Stroke  3 (5.1%) 1 (4.0%) 2 (6.9%) 1.00 
Major bleeding 4 (6.8%) 2 (8.0%) 2 (6.9%) 1.00 
Continuous variables were presented as mean ± standard deviation for normally distributed variables and median 
(range) for non-normally distributed variables; categorical variables as frequency and percentage. 
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Figure 7.1. The effects of age and frailty on differences in CAT parameters (above) 
and OHP parameters (below) 
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 Figure 7.2. Correlation between Max OD and plasma fibrinogen concentration 
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 Figure 7.3. Representative results of OHP assays (top) and CAT assays (bottom). A: in 
participants not on anticoagulants, the frail had significantly reduced fibrin generation compared 
to the non-frail. B: participants taking warfarin, there was no significant difference between the 
frail and the non-frail. 
Representatives were chosen from participants who had the values closest to the medians in each 
group. 
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Abstract  
Background. Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmia. In 
developing countries, AF is a growing public health problem with the epidemiologic transition 
from communicable to non-communicable diseases. However, relatively little is known about 
AF in the developing world. The aim of this review is to examine in developing countries the 
prevalence, associated medical conditions and management of AF. 
Methods. A literature search was conducted via MEDLINE and EMBASE (1990-2012). 
Results. Seventy studies were included in the review. The prevalence of AF in the general 
population ranged from 0.03% to 1.25%, while the prevalence of AF in hospital-based studies 
varied from 0.7% to 55.7%. Prevalence of AF in Africa was lower than in other regions. The 
most common conditions associated with AF were hypertension (10.3%-71.9%) and valvular 
heart disease (5.6%-66.3%). The prevalence of stroke in patients with AF ranged from 6.7% to 
27%. The utilisation of anticoagulants was highly variable (2.7%-72.7%). Approximately half of 
the patients with AF using warfarin had therapeutic International Normalised Ratios (INR). 
There was a high prevalence of use of rate control therapies (55.3%-87.3%). 
Conclusions. The limited studies available suggest that in the developing world there is a 
significant prevalence of AF, which is predominantly associated with hypertension and valvular 
heart disease, and carries a risk of stroke. Highly variable use of anticoagulants may be related to 
different health care and socioeconomic settings. More studies are needed to improve 
understanding of the epidemiology and management of AF in developing countries. 
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Introduction 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. There have been many 
studies in Western countries reporting the prevalence of AF. Approximately 2.3 million 
American people and six million Europeans are affected by AF (Russell ; Zateyshchikov, 
Brovkin et al. 2010). The prevalence of AF in the general population in some Western countries 
ranges from 0.5% to 2% (Chugh, Blackshear et al. 2001; Go, Hylek et al. 2001; Stewart, Hart et 
al. 2001). According to the Framingham study, the incidence of AF increases significantly with 
age. The incidence doubles with each decade after the age of 50 and reaches around 10% at the 
age of 80 years (Wolf, Abbott et al. 1991). According to the Cardiovascular Health study, the 
prevalence of AF in patients older than 65 years old is 6.2% in men and 4.8% in women 
(Furberg, Psaty et al. 1994). People with AF have an increased risk of stroke (Fuster, Ryden et al. 
2001).   
Risk factors for AF include old age, male sex, hypertension, heart failure, ischemic heart disease, 
valvular heart diseases, diabetes, obesity, hyperthyroidism, alcohol abuse, smoking, and 
pulmonary disease. Mainstay therapy for AF includes assessment of thromboembolic risk and 
stroke prevention, applying appropriate rate-control or rhythm-control strategies, and 
management of associated diseases (Fuster, Ryden et al. 2001; Lip, Tse et al. 2012). 
 
In developing countries, AF is a growing public health problem in the context of the 
epidemiologic transition from communicable to non-communicable diseases (Gaziano, Bitton et 
al. 2010; Sala, Stigliano et al. 2010; WHO. 2010; Nshisso, Reese et al. 2012; Wagner and Brath 
2012). The effect of AF on mortality and morbidity is likely to be substantial. In addition, AF 
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puts a great burden on the socioeconomic system in these countries. The estimated annual costs 
of AF are high in these countries (Rizzo, Mallow et al. 2012). Anticoagulant use and monitoring 
are major challenges for health system in developing countries. Accessibility to the monitoring 
tests for anticoagulants, unreliability of test results, lack of compliance of patients, and 
interactions with diet and complementary medicines are all substantial issues in developing 
countries (Aalbers 2011; Anakwue, Ocheni et al. 2011; Bronzetti, Corzani et al. 2012).   
However, there have been few published studies about AF in developing world. Therefore, the 
aim of this review is to examine the prevalence of AF, the associated medical conditions, the 
impacts of AF on stroke rate and the management of AF (antithrombotic therapy and rate or 
rhythm control strategy) in developing countries. 
Methods  
A literature search was conducted via MEDLINE and EMBASE (from 1990 to May 2012). 
Keywords used for searching included “atrial fibrillation”, “epidemiology”, “prevalence”, “risk 
factors”, “associated medical conditions”, “associated diseases”, “stroke”, “antithrombotic”, 
“anticoagulant”, “INR”, “rate control”, ‘rhythm control”, “developing country”, “developing 
world”, and the names of developing countries according to the classification of the World Bank 
(The World Bank 2012). The articles attained by this method of searching were screened by title 
and they were reviewed further for prevalence of AF, stroke in patients with AF, diseases 
associated with AF, treatment of AF including antithrombotic therapy, INR report, rate control 
and rhythm control strategies. Both community and hospital-based studies were included. 
Languages were restricted to English and French. Information extracted from papers included 
sample size, prevalence of AF, prevalence of stroke in patients with AF, frequency of associated 
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medical conditions, rate of anticoagulant and antiplatelet treatment. When necessary, percentages 
were calculated from data reported in published studies. 
Results 
A total of 70 articles were included in the review. There were 16 articles from East Asia and the 
Pacific, 17 from Europe and Central Asia, 12 from Latin America and the Caribbean, 3 from the 
Middle East and North Africa, 9 from South Asia and 11 from sub-Saharan Africa. China had the 
leading number of articles (13 articles), following by Brazil (7 articles), Pakistan (6 articles), 
Turkey (4 articles), and Bosnia and Herzegovina (3 articles). Russia Federation, Thailand, 
Romania, Serbia, Argentina, Mexico, Iran, India, Ethiopia and South Africa each had 2 articles. 
One article was found for each of Malaysia, Belarus, Kosovo, Moldova, Ukraine, Chile, Jordan, 
Nepal, Cameroon, Cote d’Ivoire, Kenya, Nigeria, Senegal, Tanzania and Zimbabwe. There were 
two articles from multinational studies that involved developing countries. There were 12 
community-based studies (3 in China, 2 in Thailand, 1 in Belarus, 1 in Russia, 1 in Turkey, 1 in 
Brazil, 2 in India, and 1 in Tanzania). The remaining studies were based in hospitals or specialty 
clinics. 
Prevalence of AF in community-based studies (Table 8.1). The prevalence of AF varied 
among countries. The prevalence of AF in the general population ranged from 0.03% in India to 
1.25% in Turkey (Kaushal, DasGupta et al. 1995; Kiatchoosakun, Pachirat et al. 1999; Uyarel, 
Onat et al. 2008; Zhou and Hu 2008; Chen, Wang et al. 2011; Long, Jiang et al. 2011; Hingorani, 
Natekar et al. 2012). The prevalence of AF in studies in older adults (≥ 60 years old) was 0.67% 
in Tanzania (Dewhurst, Adams et al. 2012), 2.2% in Thailand (Assantachai, Panchavinnin et al. 
2002), 2.4% in Brazil (Kawabata-Yoshihara, Bensenor et al. 2009), and 5.6% in Russia 
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(Platonov, Shkolnikova et al. 2011).  In a study in Belarus, the prevalence of AF in people after a 
first stroke was 23.1% (Kulesh, Filina et al. 2010). 
Prevalence of AF in hospital-based studies (Table 8.2). The prevalence of AF in hospital-
based studies varied widely, according to the patient population studied.  
The prevalence of AF in patients with a stroke ranged from 1.6% in Nigeria to 55.7% in Bosnia 
and Herzegovina (Buturovic, Jusufbegovic et al. 2000; Bahou, Hamid et al. 2004; Ghandehari 
and Izadi Mood 2006; Khan, Afridi et al. 2006; Rojas, Zurru et al. 2007; Pieri, Spitz et al. 2008; 
Comes, Mocan et al. 2010; Salihovic, Smajlovic et al. 2010; Watila, Nyandaiti et al. 2010; 
Chwojnicki, Yagensky et al. 2011; Diaconu, Grosu et al. 2011; Gao, Fu et al. 2011; Macavei, 
Huza et al. 2011; Medic and Kuljic-Obradovic 2011; Mallmann, Fuchs et al. 2012). Prevalence 
of AF in patients with a stroke was similar in Turkey, Mexico, Nepal and Pakistan (12.3% to 
12.5%) (Shafqat, Kelly et al. 2004; Devkota, Thapamagar et al. 2006; Cantu, Arauz et al. 2011; 
Inee, Benbir et al. 2011).  Compared with other regions, the prevalence of AF in patients with a 
stroke in Africa was lower: 1.6% in Nigeria (Watila, Nyandaiti et al. 2010), 4.5% in Ethiopia 
(Zenebe, Alemayehu et al. 2005), and 6.9% in South Africa (Rosman 1986). 
Prevalence of AF in cardiology patients was rather consistent among countries, from 4.6% in 
South Africa (Sliwa, Carrington et al. 2010) to 5.35% in Senegal (Mbaye, Pessinaba et al. 2010), 
5.5% in Cote d’Ivoire (Coulibaly, Anzouan-Kacou et al. 2010), 7.9% in China (Wen-Hang 
2005), 8% in Brazil (Fornari, Calderaro et al. 2007), 9.1% in Turkey (Karacaglar, Atar et al. 
2012) and 9.75% in Kosovo (Elezi, Qerkini et al. 2010).  
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There were two studies that reported the prevalence of AF in patients in geriatric services: one 
from Brazil with AF prevalence of 4.8% in patients attending an out-patient geriatric medicine 
clinic (De Carvalho Filho, Miotta et al. 1991) and one from Pakistan with AF prevalence of 20% 
of inpatients older than 77 years old (Khan and Ghosh 2002).  
Among general patients, the prevalence of AF was lower, ranging from 0.7% in Kenya 
(Shavadia, Otieno et al. 2011), 2.8% in Malaysia (Freestone, Rajaratnam et al. 2003) and Iran 
(Habibzadeh, Yadollahie et al. 2004), 2.44% to 3.78% in Russia (Bulanova, Stazhadze et al. 
2011), and  6.5% in Pakistan (Haq and Lip 2009). 
Prevalence of associated diseases (Table 8.3).  
Hypertension was the most frequent condition associated with AF. The prevalence of 
hypertension in people with AF was high in some countries, ranging from 40% in Malaysia to 
71.9% in Turkey and Argentina (De Carvalho Filho, Miotta et al. 1991; Randhawa 1998; Bhagat 
and Tisocki 1999; Freestone, Rajaratnam et al. 2003; Wen-Hang 2005; Haq and Lip 2009; Liu, 
Yang et al. 2009; Ortiz, Pardo et al. 2009; Rasool and Haq 2009; Coulibaly, Anzouan-Kacou et 
al. 2010; Liu, Ma et al. 2010; Ntep-Gweth, Zimmermann et al. 2010; Sliwa, Carrington et al. 
2010; Bulanova, Stazhadze et al. 2011; Fitz Maurice, Di Tommaso et al. 2011; Long, Jiang et al. 
2011; Shavadia, Otieno et al. 2011; Karacaglar, Atar et al. 2012; Mallmann, Fuchs et al. 2012), 
and much lower in others (27.4% in Kosovo and 10.3% in Ethiopia) (Maru 1997; Elezi, Qerkini 
et al. 2010).   
Prevalence of valvular heart diseases in patients with AF ranged from 5.6% in Russia to 66.3% 
in Ethiopia (De Carvalho Filho, Miotta et al. 1991; Maru 1997; Wen-Hang 2005; Haq and Lip 
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2009; Coulibaly, Anzouan-Kacou et al. 2010; Elezi, Qerkini et al. 2010; Mbaye, Pessinaba et al. 
2010; Ntep-Gweth, Zimmermann et al. 2010; Sliwa, Carrington et al. 2010; Bulanova, Stazhadze 
et al. 2011; Shavadia, Otieno et al. 2011). High prevalence of rheumatic heart disease was 
reported in 6 studies: 21% in South Africa (Sliwa, Carrington et al. 2010), 23.9% in China (Wen-
Hang 2005), 25.6% in Cameroon (Ntep-Gweth, Zimmermann et al. 2010), 28% in Cote d’Ivoire 
(Coulibaly, Anzouan-Kacou et al. 2010), 36.7% in Senegal (Mbaye, Pessinaba et al. 2010), and 
66.3% in Ethiopia (Maru 1997). In the multinational study involving 15293 AF patients in 47 
countries, the prevalence of rheumatic disease reported was 15% in China and 31% in India 
(Chin, Commerford et al. 2012). 
Prevalence of ischemic heart disease in patients with AF varied among countries. The prevalence 
was high in studies in Pakistan (47%) (Haq and Lip 2009), Malaysia (42.5%) (Freestone, 
Rajaratnam et al. 2003), China (12.3% to 34.8%) (Wen-Hang 2005; Liu, Ma et al. 2010), Kosovo 
(21.4%) (Elezi, Qerkini et al. 2010), Russia (20.1%) (Bulanova, Stazhadze et al. 2011), Kenya 
(19%) (Shavadia, Otieno et al. 2011), Chile (17%) (Ortiz, Pardo et al. 2009). Studies in 
Cameroon, South Africa and Ethiopia reported lower rate of ischemic heart disease (6.4%, 6.5% 
and 6.6%, respectively) (Maru 1997; Ntep-Gweth, Zimmermann et al. 2010; Sliwa, Carrington et 
al. 2010).  
Prevalence of heart failure in patients with AF varied from 10.4% in China to 62.6% in Cote 
d’Ivoire (Bhagat and Tisocki 1999; Freestone, Rajaratnam et al. 2003; Wen-Hang 2005; Ortiz, 
Pardo et al. 2009; Rasool and Haq 2009; Coulibaly, Anzouan-Kacou et al. 2010; Elezi, Qerkini 
et al. 2010; Liu, Ma et al. 2010; Ntep-Gweth, Zimmermann et al. 2010; Sliwa, Carrington et al. 
2010; Bulanova, Stazhadze et al. 2011; Fitz Maurice, Di Tommaso et al. 2011; Shavadia, Otieno 
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et al. 2011). Heart failure frequency was high and rather consistent among studies from Africa: 
38% in Kenya (Shavadia, Otieno et al. 2011), 48.7% in Zimbabwe (Bhagat and Tisocki 1999), 
56% in South Africa (Sliwa, Carrington et al. 2010), 58.1% in Cameroon (Ntep-Gweth, 
Zimmermann et al. 2010), and 62.6% in Cote d’Ivoire (Coulibaly, Anzouan-Kacou et al. 2010).  
Diabetes prevalence in patients with AF varied greatly: 3.3% in Zimbabwe (Bhagat and Tisocki 
1999), 4.1% to 17.7% in China (Wen-Hang 2005; Liu, Ma et al. 2010; Long, Jiang et al. 2011), 
14.3% in Kosovo (Elezi, Qerkini et al. 2010), 15.7% in Russia (Bulanova, Stazhadze et al. 2011), 
14.6% in Argentina (Fitz Maurice, Di Tommaso et al. 2011), 16.3% to 33.8% in Brazil (De 
Carvalho Filho, Miotta et al. 1991; Mallmann, Fuchs et al. 2012), 16% in Chile (Ortiz, Pardo et 
al. 2009), 10.5% in Cameroon (Ntep-Gweth, Zimmermann et al. 2010) and 33% in Kenya 
(Shavadia, Otieno et al. 2011). 
Hyperthyroidism was reported in 5 studies: 2.5% and 6.9% in China (Wen-Hang 2005; Long, 
Jiang et al. 2011), 3.7% in Kenya (Shavadia, Otieno et al. 2011), 7.5% in Pakistan (Randhawa 
1998), and 14.3% in Brazil (De Carvalho Filho, Miotta et al. 1991).  Alcohol abuse was reported 
in several studies: 58.5% in one study in China (Long, Jiang et al. 2011), 48% in South Africa 
(Sliwa, Carrington et al. 2010), 29.3% in Brazil (Mallmann, Fuchs et al. 2012), and 5% in Kenya 
(Shavadia, Otieno et al. 2011). Chronic obstructive pulmonary disease was reported in 2 studies: 
6.7% in Kosovo (Elezi, Qerkini et al. 2010) and 7% in Kenya (Shavadia, Otieno et al. 2011). 
Prevalence of stroke in patients with AF was consistent among studies: 10.7% to 22.8% in 
China(Wen-Hang 2005; Zuo, Su et al. 2007; Zhou and Hu 2008; Sun, Hu et al. 2009; Liu, Ma et 
al. 2010; Chen, Wang et al. 2011; Xiao-Bin, Shu-Long et al. 2011), 15.4% in Ethiopia (Maru 
1997), 17.4% in Cameroon (Ntep-Gweth, Zimmermann et al. 2010), 17.6% in Brazil (Fornari, 
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Calderaro et al. 2007), 23% to 27% in Pakistan (Khan and Ghosh 2002; Rasool and Haq 2009), 
and rather low in Argentina in a study including both patients with atrial fibrillation and atrial 
flutter (6.7%) (Fitz Maurice, Di Tommaso et al. 2011).   
Antithrombotic treatment (Table 8.4) 
The frequency of anticoagulant and antiplatelet utilisation varied greatly among studies with the 
country studied, population studied and year that the study was performed. In 13 studies in 
China, the rates of anticoagulant use ranged from 2.7% to 50% (Wen-Hang 2005; Han, Shen et 
al. 2006; Zuo, Su et al. 2007; Zhou and Hu 2008; Sun, Hu et al. 2009; Yao, Yan-Min et al. 2010; 
Chen, Wang et al. 2011; Gao, Fu et al. 2011; Guo, Wang et al. 2011; Healey, Oldgren et al. 
2011; Xiao-Bin, Shu-Long et al. 2011). The rate was 16% in Malaysia (Freestone, Rajaratnam et 
al. 2003), 27% in Kosovo (Elezi, Qerkini et al. 2010), 7.1% in Moldova (Diaconu, Grosu et al. 
2011), 13% to 53.9% in Serbia (Potpara, Stankovic et al. 2012), 30.1% to 67.3% in Turkey 
(Ertas, Duygu et al. 2009; Karacaglar, Atar et al. 2012), 72.7% in Argentina (Fitz Maurice, Di 
Tommaso et al. 2011), 46.7% to 57.8% in Brazil (Fornari, Calderaro et al. 2007), and 36.8% in 
Mexico (Cortes-Ramirez, Cortes-De La Torre et al. 2011). In Pakistan the prevalence of 
anticoagulant treatment ranged from 5% in a study conducted in 1998 to 26% and 44% in studies 
in 2009 (Randhawa 1998; Haq and Lip 2009; Rasool and Haq 2009). The prevalence of 
anticoagulant use among patients with AF was consistent across several African countries: South 
Africa (33%) (Sliwa, Carrington et al. 2010), Cameroon (34.2%) (Ntep-Gweth, Zimmermann et 
al. 2010), Zimbabwe (11.5% in rural area and 26.5% in urban) (Bhagat and Tisocki 1999) but 
rather higher in Senegal (62%) (Mbaye, Pessinaba et al. 2010). 
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Antiplatelets (mostly aspirin) were highly prescribed in China (from 34.1% to 94.3%) (Wen-
Hang 2005; Han, Shen et al. 2006; Zuo, Su et al. 2007; Zhou and Hu 2008; Liu, Ma et al. 2010; 
Yao, Yan-Min et al. 2010; Chen, Wang et al. 2011; Guo, Wang et al. 2011), Kosovo (72%) 
(Elezi, Qerkini et al. 2010), Turkey (55.6%) (Ertas, Duygu et al. 2009), Argentina (63%) (Fitz 
Maurice, Di Tommaso et al. 2011), Mexico (63%) (Cortes-Ramirez, Cortes-De La Torre et al. 
2011), Cameroon (61%) (Ntep-Gweth, Zimmermann et al. 2010), Pakistan (60% in 2009 
compared with 10% in 1998) (Randhawa 1998; Rasool and Haq 2009). Studies in Malaysia, 
Zimbabwe, Brazil and South Africa reported lower rates (8%, 10%, 19.9%-21.2% and 23%, 
respectively) (Bhagat and Tisocki 1999; Freestone, Rajaratnam et al. 2003; Fornari, Calderaro et 
al. 2007; Sliwa, Carrington et al. 2010). 
Percentages of therapeutic INR values (Table 8.4) 
Eight studies reported the proportion of patients with AF having INR within the therapeutic 
range. Except for one study in Turkey where this percentage was rather high (83.5%) 
(Karacaglar, Atar et al. 2012), all the other studies found that just around half the patients with 
AF had therapeutic INRs: 39.1%-40% in China (Zuo, Su et al. 2007; Yao, Yan-Min et al. 2010), 
51.77%-53.62% in Bosnia and Herzegovina (Kulo, Mulabegovic et al. 2009), 50.1% in Brazil 
(Lavitola Pde, Spina et al. 2009), 47.7% in another study in Turkey (Ertas, Duygu et al. 2009), 
32.6% in India (Healey, Oldgren et al. 2011), and even lower in Moldova with 28.5% (Diaconu, 
Grosu et al. 2011).    
Prevalence of rate control medications was high: 55.3% to 82.8% in China (Wen-Hang 2005; 
Liu, Ma et al. 2010), 79.5% in Brazil (Oliveira, Mallmann et al. 2012), 83.7% in Cameroon 
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(Ntep-Gweth, Zimmermann et al. 2010), and 87.33% in Senegal (Mbaye, Pessinaba et al. 2010) 
(Table 8.4).     
Discussion  
The prevalence of AF in the general population in community based studies in this review 
ranged from 0.03% to 1.25%, which is similar to that reported in some developed countries such 
as North America, the United Kingdom and Iceland (from 0.5% to 1%) (Chugh, Blackshear et al. 
2001; Go, Hylek et al. 2001; Murphy, Simpson et al. 2007) but lower than the prevalence 
reported in Australia (4%) (Sturm, Davis et al. 2002). The low prevalence of AF in both studies 
in India (0.03% and 0.1%) may be related to the populations studied: one study was in people 
living high altitude in a tribal Himalayan village (Kaushal, DasGupta et al. 1995) and the other 
was conducted in healthy volunteers in a clinical trial (Hingorani, Natekar et al. 2012).    
In older people, this review found a prevalence of AF from 0.67% to 5.6%, which was higher 
than the rate in general population. This finding was consistent with studies in Western countries 
(Go, Hylek et al. 2001; Hobbs, Fitzmaurice et al. 2005; Murphy, Simpson et al. 2007; Reardon, 
Nelson et al. 2012). Aging increases the risk of AF, possibly through the change in atrial 
myocardium and degeneration of the conductive system (Camm, Kirchhof et al. 2010).  
The prevalence of AF in hospital-based studies in this review is rather consistent with findings 
from developed countries. For example, the prevalence of AF in stroke patients was 24% in a 
study in New Zealand (Bang and McGrath 2011), the prevalence of AF in a cardiology 
department was 15% in a study in France (Levy, Maarek et al. 1999), and AF has been reported 
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to be present in 3-6% of acute medical admissions in developed countries (Camm, Kirchhof et al. 
2010).  
Overall, it seems that the prevalence of AF in Africa is lower than other regions in the 
developing world: only 1.6%-6.9% in stroke patients, 4.6%-5.5% in cardiology patients, 0.67% 
in elderly people, and 0.7% in general patients. There has been a suggestion that AF is less 
common among African people. Genetic disparities in the stability of atrial membrane and atrial 
conduction system may cause differences in AF sensitivity between races (Turagam, Velagapudi 
et al. 2012). In a meta-analysis of ten studies involving 1031351 people in the United States, 
Hernandez et al showed that in the general population as well as in hospitalised patients, the 
prevalence of AF in African - Americans was consistently lower than in Caucasians (Hernandez, 
Asher et al. 2012). In the ASSERT study which involved 2580 AF patients from North America, 
Europe and Asia, compared to Europeans, Black Africans and Chinese had a lower incidence of 
AF, even though Black Africans had higher prevalence of risk factors for AF (Lau, Gbadebo et 
al. 2012).  
The prevalence of diseases associated with AF was well reported in many of the reviewed 
studies. Hypertension was the most commonly associated disease, ranging from 10.3% to 71.9%. 
Some variability in the prevalence of hypertension was also reported in many studies in the 
general population in the developing world: from 9% in Latin America to 36% in India 
(Hernandez-Hernandez, Silva et al. 2010; Khashayar, Meybodi et al. 2010; Mittal and Singh 
2010; Fuchs, Picon et al. 2011; Rungaramsin, Vathesatogkit et al. 2011; Ma, Tang et al. 2012; 
Nshisso, Reese et al. 2012; Prasad, Kabir et al. 2012; Suleiman and Amogu 2012; Zhao, Lu et al. 
2012). In developed countries, hypertension has also been reported as the most frequent disease 
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associated with AF, with prevalence ranging from 30% in Switzerland to 72% in the United 
States (Benjamin, Levy et al. 1994; Levy, Maarek et al. 1999; O'Hara, Charbonneau et al. 2005; 
Meiltz, Zimmermann et al. 2008). The prevalence of heart failure in this review ranged from 
10.4% to 62.6% and this rate was especially high in Africa. This prevalence was generally higher 
than that reported in developed countries: 16% to 30% (O'Hara, Charbonneau et al. 2005; 
Nabauer, Gerth et al. 2009; Camm, Kirchhof et al. 2010; Guertin, Dorais et al. 2011). This 
review found a variable prevalence of ischemic heart disease in patients with AF from 
developing countries, from 6.4% to 47%. Studies in developed countries have also reported 
varying prevalence of coronary heart disease in patients with AF, from 15% to 39% (Levy, 
Maarek et al. 1999; O'Hara, Charbonneau et al. 2005; Meiltz, Zimmermann et al. 2008; Nabauer, 
Gerth et al. 2009; Guertin, Dorais et al. 2011). The relationship between uncomplicated coronary 
artery disease and AF is not fully understood (Camm, Kirchhof et al. 2010).  
The prevalence of diabetes ranged from 3.3% to 33.8%. In contrast, studies in developed 
countries reported rather consistent prevalence of diabetes in AF patients (around 15%-22%) 
(Benjamin, Levy et al. 1994; O'Hara, Charbonneau et al. 2005; Nabauer, Gerth et al. 2009; 
Camm, Kirchhof et al. 2010). The prevalence of hyperthyroidism in patients with AF was 
reported in 5 studies in developing countries, ranging from 2.5% to 14.3%. Approximately 10% 
to 15% of patients with uncontrolled hyperthyroidism will develop atrial fibrillation (Lip, 
Beevers et al. 1995). The prevalence of excess alcohol intake in this review was quite high in 
some countries like China, South Africa and Brazil (29.3% to 58.5%). Alcohol abuse could be 
associated with dilated cardiomyopathy and atrial fibrillation (Lip, Beevers et al. 1995). Atrial 
fibrillation is often associated with valvular heart disease (Camm, Kirchhof et al. 2010). The 
prevalence of valvular heart disease in this review ranged from 5.6% to 66.3%, with a high rate 
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of rheumatic disease from 21% to 66.3%. Rheumatic valvular disease was a frequent finding in 
the past and is becoming relatively rare now in developed countries (Camm, Kirchhof et al. 
2010). However, it is still frequent in developing countries. In a study about rheumatic heart 
disease that involved 15293 patients from 47 countries who presented to an emergency 
department with AF, the overall prevalence of rheumatic heart disease was 11.7%, low in North 
America and Western Europe (2%), and higher in the Middle East and China (15%), Africa 
(22%) and India (31%) (Chin, Commerford et al. 2012).  
The prevalence of stroke in patients with AF in developing countries was quite high: 10% to 
27%. This may be related to the prevalence of additional risk factors for stroke in AF patients. 
Stroke in AF patients is usually severe and leads to long-term disability, increased risk of death 
and increased costs (Camm, Kirchhof et al. 2010; Hu, Zhan et al. 2012).   
Many studies have shown the benefits of anticoagulants in stroke prevention in patients with AF 
(Connolly, Laupacis et al. 1991; Hylek, Go et al. 2003; Fuster, Ryden et al. 2006; Parkash, Wee 
et al. 2007). This review found a variable rate of anticoagulant utilisation among developing 
countries.  Interestingly, the study in Zimbabwe reported different rates of anticoagulant use 
between rural (11.5%) and urban areas (26.5%) (Bhagat and Tisocki 1999). The variable 
prevalence of warfarin use is consistent with studies in developed countries (Meiltz, 
Zimmermann et al. 2008; Nabauer, Gerth et al. 2009; Bang and McGrath 2011; Evers, O'Neil et 
al. 2011; Baczek, Chen et al. 2012).  Recently, newer oral anticoagulants that do not require such 
intensive monitoring or complex dose adjustment as the previous standard of care, warfarin, have 
been approved for stroke prevention in AF in many developed countries (Connolly, Ezekowitz et 
al. 2009; Camm, Kirchhof et al. 2010; Cairns, Connolly et al. 2011; Wann, Curtis et al. 2011).  In 
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August 2011 Namibia was the first country in Africa to approve dabigatran for anticoagulation 
therapy in AF patients (Wagenaar 2011). However, this review did not find any studies that 
reported the usage of new oral anticoagulants in developing countries.  
In this review, the proportion of patients with therapeutic INRs was around 30%-50%. Labile 
INR is associated with negative clinical outcomes (Wilke and Muller 2012). A review of 
anticoagulant utilisation and INR control in developed countries found that 30% to 92% of 
patients on anticoagulants were poorly controlled (Evers, O'Neil et al. 2011). 
This review found that high percentages of patients received rate control treatment. Rate control 
therapies are favored by European and North American Guidelines as first line therapy (Camm, 
Kirchhof et al. 2010; Wann, Curtis et al. 2011). Rate control is not inferior to rhythm control 
therapies in terms of stroke prevention, mortality reduction and even better than rhythm control 
in reducing risk of hospitalisation and reducing costs (Van Gelder, Hagens et al. 2002; Wyse, 
Waldo et al. 2002; Kumana, Cheung et al. 2005; Testa, Biondi-Zoccai et al. 2005; Roy, Talajic et 
al. 2008).  
This review has some limitations. First, the articles were restricted to English and French. 
Secondly, there may be bias and a lack of generalisability from some small size studies with 
variable sampling techniques from epidemiologic surveys to convenience samples. Small studies 
are also prone to random error, as reflected in wider confidence intervals. The quality of data 
also varies from objective data collection to self-report of AF, medical therapy and co-
morbidities.  In many studies, there is not adequate data to assess the appropriateness of therapy 
and this was beyond the scope of our review. Older studies may not reflect current practice. The 
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strength of our study is that it is a systematic review that comprehensively addresses prevalence, 
risk factors and management of AF in developing countries. 
Conclusion 
The limited studies available suggest that in the developing world there is a significant 
prevalence of AF, which is predominantly associated with hypertension and rheumatic heart 
disease, and carries a high risk of stroke. Highly variable use of anticoagulants may be related to 
different health care and socioeconomic settings. Large studies of representative populations are 
needed to improve understanding of the epidemiology and management of AF in developing 
countries. 
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Table 8.1. Prevalence of atrial fibrillation in community studies   
Country  Authors and year Sample size Population 
(age in years) 
Prevalence of AF 
(95% CI) 
East Asia and Pacific 
China  Chen, Wang et al. (2011) 
Long, Jiang et al. (2011) 
Zhou and Hu (2008) 
9309 
19964 
29079 
Adults (≥ 20)  
Adults (≥ 50) 
Adults (≥ 30) 
0.9% (0.71%-1.09%) 
0.8% (0.68%-0.92%) 
0.65% (0.56%-0.74%) 
Thailand Assantachai, Panchavinnin et al. (2002) 
Kiatchoosakun, Pachirat et al. (1999) 
963  
8791 
Adults (≥ 60) 
Adults (≥ 30) 
2.2% (1.27%-3.13%) 
0.36% (0.23%-0.49%) 
Europe and Central Asia 
Belarus  Kulesh, Filina et al. (2010) 2069 People after the first stroke 
(mean age at stroke onset 65.8 ± 
11.6 years) 
23.1% (21.28%-
24.92%) 
Russia Platonov, Shkolnikova et al. (2011) 1800  Adults (≥ 60) 5.6% (4.54%-6.66%) 
Turkey Uyarel, Onat et al. (2008) 3450 Adults (39-65) 1.25% (0.88%-1.62%) 
Latin America and the Caribbean 
Brazil Kawabata-Yoshihara, Bensenor et al. (2009) 1524  Adults (> 65) 1.5% in control group 
(0.89%-2.11%) 
South Asia 
India Kaushal, DasGupta et al. (1995) 
Hingorani, Natekar et al. (2012) 
984  
3978 
Adults (≥ 15) 
Adults (≥ 18) 
0.1% (0-0.56%) 
0.03%(0-0.37%) 
Sub-Saharan Africa 
Tanzania Dewhurst, Adams et al. (2012) 2232 Adults (≥ 70)  0.67% (0.33%-1.01%) 
(age-adjusted: 0.64%) 
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Table 8.2. Prevalence of atrial fibrillation in hospital-based studies  
Country  Authors and year  Setting   Population  Prevalence of AF (95% CI) 
East Asia and Pacific 
China  Gao, Fu et al. (2011) 
 
Wen-Hang (2005) 
 
 Institute of 
Neurosciences 
41 hospitals  
 4782 stroke patients (mean 
age 70 ± 12 years) 
9297 patients hospitalized 
for cardiovascular diseases 
(mean age 66.5 years) 
 10% (9.15%-
10.85%) 
7.65% in 1999 
(7.11%-8.19%) 
7.90% in 2000 
(7.35%-8.45%) 
8.16% in 2001 
(7.6%-8.72%) 
Malaysia Freestone, Rajaratnam et al. 
(2003) 
 General Hospital  1435 patients  2.8%  
(1.95%-3.65%) 
Europe and Central Asia 
Bosnia and 
Herzegovina 
Salihovic, Smajlovic et al. 
(2010) 
 
 
Buturovic, Jusufbegovic et al. 
(2000) 
 Neurology Department 
 
 
 
Emergency Center 
 2833 stroke patients 
 
 
 
126 stroke patients 
 22% in female 
(20.47%-23.53%) 
14% in male 
(12.72%-15.28%) 
55.7%  
(47.03%-64.37%) 
 
Kosovo 
 
Elezi, Qerkini et al. (2010) 
  
Cardiology Service 
  
5382 patients  
  
9.75% 
(8.96%-10.54%) 
Moldova Diaconu, Grosu et al. (2011)  Hospital   735 stroke patients  28.4% 
(25.14%-31.66%) 
Romania Macavei, Huza et al. (2011) 
 
Comes, Mocan et al. (2010) 
 Neurology Clinic 
 
Internal Medicine 
Department 
 973 stroke patients 
 
1219 stroke patients 
 23.39% 
(20.73%-26.05%) 
17.39% 
(15.26%-19.52%) 
Russia Bulanova, Stazhadze et al.  Polyclinic     2.44% in 2002   
175
(2011)  3.78% in 2009 
Serbia  Medic and Kuljic-Obradovic 
(2011) 
 Hospital   300 stroke patients  27% 
(21.98%-32.02%) 
Turkey Karacaglar, Atar et al. (2012) 
 
Inee, Benbir et al. (2011) 
 Cardiology Outpatient 
Clinic 
Stroke Unit 
 4721 patients 
 
2169 stroke patients 
 9.1% 
(8.28%-9.92%) 
12.3% 
(10.92%-13.68%) 
Ukraine Chwojnicki, Yagensky et al. 
(2011) 
 Urban areas of Poland 
and Ukraine 
 440 stroke patients  7% in Ukraine  
(4.62%-9.38%) 
 
Latin America and the Caribbean 
Argentina Rojas, Zurru et al. (2007)  Neurology Service  179 stroke patients > 80 
years old 
 24.6% 
(18.3%-30.9%) 
Brazil  Mallmann, Fuchs et al. (2012) 
(case-control study) 
 
 
 
 
 
Pieri, Spitz et al. (2008) 
 
 
 
 
 
 
 
Fornari, Calderaro et al. (2007) 
 
De Carvalho Filho, Miotta et 
al. (1991) 
 Emergency Department 
 
 
 
 
 
 
Hospital 
 
 
 
 
 
 
 
Cardiology Hospital  
 
Out-patient Geriatric 
Clinic 
 133 stroke patients 
(“cases” group) 
272 control patients 
(Emergency Department) 
 
 
 
215 stroke patients 
 
 
 
 
 
 
 
3764 patients 
 
1020 patients 
 14.3% (8.35%-
20.25%) in stroke 
patients 
1.5% (0.06%-
2.94%) in control 
group 
 
16.3% (11.36%-
21.24%) 
(5% in patients 
aged < 65 years, 
12% in patients 
65-79 years, 26% 
in patients ≥ 80 
years old) 
8%  
(7.13%-8.87%) 
4.8% 
(3.49%-6.11%) 
Mexico Cantu, Arauz et al. (2011)  Hospital   3194 stroke patients  12.5% 
176
(11.35%-13.65%) 
Middle East and North Africa 
Iran Habibzadeh, Yadollahie et al. 
(2004) 
 
 
 
  
 
 
Ghandehari and Izadi Mood 
(2006) 
 Primary Health Care 
Centre 
 
 
 
 
 
 
General Hospital  
 463 patients aged ≥ 50 
years 
 
 
 
 
 
 
302 stroke patients 
 2.8% (1.3%-
4.3%) 
(0.6% in patients 
aged 50-59 years,  
1.4% in patients 
60-69 years, 6.4% 
in patients 70-79 
years) 
8.94% 
(5.72%-12.16%) 
Jordan Bahou, Hamid et al. (2004)  Hospital   200 patients with first 
ischemic stroke (mean age 
61.2 years) 
 7.5% 
(3.85%-11.15%) 
South Asia 
Nepal Devkota, Thapamagar et al. 
(2006) 
 
 Hospital, Department of 
Medicine 
 72  stroke patients  12.5% 
(4.86%-20.14%) 
Pakistan  Haq and Lip (2009) 
 
Khan, Afridi et al. (2006) 
 
 
Shafqat, Kelly et al. (2004) 
 
Khan and Ghosh (2002) 
 
 Hospital 
 
Hospital 
 
 
Hospital 
 
Hospital 
 3766 acute medical 
admissions 
211 stroke patients 
(included both ischemic 
and hemorrhage stroke) 
465 stroke patients aged ≥ 
18 years 
783 inpatients > 77 years 
old 
 6.5% 
(5.71%-7.29%) 
3.31% 
(0.9%-5.72%) 
 
12.3% 
(9.31%-15.29%) 
20% 
(17.2%-22.8%) 
 
Sub-Saharan Africa 
Côte d'Ivoire Coulibaly, Anzouan-Kacou et  Cardiology Institute  3908 patients  5.5% 
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al. (2010) (4.79%-6.21%) 
Ethiopia Zenebe, Alemayehu et al. 
(2005) 
 Hospital  128 stroke patients  4.5% 
(0.91%-8.09%) 
Kenya Shavadia, Otieno et al. (2011)  Hospital   22144 patients   0.7% 
(0.59%-0.81%) 
Nigeria Watila, Nyandaiti et al. (2010)  Hospital  376 stroke patients  1.6% 
(0.33%-2.87%) 
Senegal Mbaye, Pessinaba et al. (2010)  Cardiology Department  2803 patients  5.35% 
(4.52%-6.18%) 
South Africa Sliwa, Carrington et al. (2010) 
Rosman (1986) 
 Cardiology Unit 
Hospital 
 5328 patients 
116 stroke patients ≥ 20 
years old 
 4.6% 
(4.04%-5.16%) 
6.9% 
(2.29%-11.51%) 
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Table 8.3. Medical conditions associated with AF 
Country  Author and year Associated medical conditions 
HTN 
(%) 
VHD/ 
RHD 
(%) 
HF 
(%) 
IHD 
(%) 
DM 
(%) 
Hyper-
thyroidism 
(%) 
Stroke 
(%) 
Other 
 
China Chin, Commerford et al. 
(2012) 
 15*       
Chen, Wang et al. (2011)       10.7  
Long, Jiang et al. (2011) 
 
56.6    13.2 6.9  History of regular 
alcohol intake 58.5% 
Dyslipidemia 54.7% 
Xiao-Bin, Shu-Long et 
al. (2011) 
      16.4  
Liu, Ma et al. (2010) 68.8 23.9* 10.4 12.3 17.7  20 Smoking 27.7% 
Liu, Yang et al. (2009) 58.2        
Sun, Hu et al. (2009)       24.15  
Zhou and Hu (2008)       12.95  
Zuo, Su et al. (2007)       22.8  
Wen-Hang (2005) 
 
40.3  33.1 
 
34.8 
 
4.1 
 
2.5 17.5 Cardiomyopathy 
5.4% 
Idiopathic 7.4% 
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Malaysia Freestone, Rajaratnam et 
al. (2003) 
40  40 42.5     
Kosovo Elezi, Qerkini et al. 
(2010) 
27.4 17.4 47 21.4 14.3   COPD 6.7% 
Russia  Bulanova, Stazhadze et 
al. (2011) 
71 5.6 13 20.1 15.7    
Turkey  Karacaglar, Atar et al. 
(2012) 
71.9        
Argentina  Fitz Maurice, Di 
Tommaso et al. (2011) 
71.9  42.2  14.6  6.7  
Brazil  Mallmann, Fuchs et al. 
(2012) 
58.9 
 
   33.8 
 
  Alcohol abuse 
29.3% 
Smoking 28.6% 
Fornari, Calderaro et al. 
(2007) 
      17.6  
De Carvalho Filho, 
Miotta et al. (1991) 
51 33.6   16.3 14.3   
Chile  Ortiz, Pardo et al. (2009) 62  15 17 16   Smoking 13% 
India Chin, Commerford et al. 
(2012) 
 31*       
Pakistan  Haq and Lip (2009) 54 54  47     
Rasool and Haq (2009) 39  46.3    23  
Khan and Ghosh (2002)       27  
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Randhawa (1998) 50     7.5   
Cameroon  Ntep-Gweth, 
Zimmermann et al. 
(2010) 
47.7 25.6* 58.1 6.4 10.5  17.4  
Côte 
d'Ivoire 
Coulibaly, Anzouan-
Kacou et al. (2010) 
48 28* 62.6      
Ethiopia  Maru (1997) 10.3 66.3*  6.6   15.4 Cardiomyopathy  
8.8% 
Kenya  Shavadia, Otieno et al. 
(2011) 
68 12 38 19 33 3.7  Alcohol abuse 5% 
COPD 7% 
Senegal  Mbaye, Pessinaba et al. 
(2010) 
 36.7*        
South 
Africa 
Sliwa, Carrington et al. 
(2010) 
60 21* 56 6.5    History of regular 
alcohol intake 48% 
Smoking 47% 
Zimbabwe Bhagat and Tisocki 
(1999) 
45.3   48.7   3.3     
 
HTN: Hypertension; RHD (*): Rheumatic Heart Disease; VHD: Valvular Heart Diseases; HF: Heart Failure; IHD: Ischemic Heart 
Disease; DM: Diabetes Mellitus; COPD: Chronic Obstructive Pulmonary Disease. 
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Table 8.4. Treatment of atrial fibrillation in developing countries 
Country  Authors and year Number of AF 
patients 
Antithrombotic 
Treatment 
Percentage of 
therapeutic INR 
values 
Rate-control or 
rhythm-control 
East Asia and Pacific 
China Chen, Wang et al. 
(2011) 
84 AF patients Warfarin 26.1% 
Aspirin 41.7% 
  
Gao, Fu et al. (2011) 
 
499 stroke patients 
with AF 
 
OAC 20% 
 
  
Guo, Wang et al. (2011) 
 
105 AF patients (mean 
age 85±6 years) 
 
Warfarin 5.7% 
Antiplatelets 94.3% 
(84.8% on a single drug, 
9.5% on 
Aspirin+Clopidogrel) 
 
  
Healey, Oldgren et al. 
(2011) 
 
1905 Chinese patients 
participating in  
Multinational survey 
of 14,434 AF patients 
 
OAC 19% 
 
  
Xiao-Bin, Shu-Long et 
al. (2011) 
1207 AF patients   Warfarin 19.4% 
 
  
Liu, Ma et al. (2010) 372 AF patients  >65 
years old 
Warfarin 50% 
Aspirin 34.1% 
 Rate control: 
55.3% 
  
Yao, Yan-Min et al. 
(2010) 
638 AF patients Warfarin 16.3% 
Aspirin 55.5% 
 
40%  
Liu, Yang et al. (2009) 298 AF patients with a 
history of 
Warfarin 9.7% 
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hypertension 
 
Sun, Hu et al. (2009) 3425 AF patients OAC 9.27%   
Zhou and Hu (2008) 190 AF patients 
 
Warfarin 2.7% 
Aspirin 39.7% 
 
  
Zuo, Su et al. (2007) 583 AF patients 
 
Warfarin 18.9% 
Aspirin 59.3% 
 
39.1%  
Han, Shen et al. (2006) AF patients > 75 years 
old 
Warfarin 19% 
Aspirin 73.4% 
 
  
Wen-Hang (2005) 735 AF patients 
 
OAC 6.6% 
Antiplatelets 57.9% 
(Aspirin >90%) 
 Rate control: 
82.8% 
 
 
Malaysia Freestone, Rajaratnam 
et al. (2003) 
40 AF patients Warfarin 16% 
Aspirin 8% 
   
Europe and Central Asia 
Bosnia and 
Herzegovina 
Kulo, Mulabegovic et 
al. (2009) 
117 AF patients   51.8% -53.6%  
Kosovo Elezi, Qerkini et al. 
(2010) 
525 AF patients OAC 27% 
Aspirin 72% 
Both 11% 
 
   
Moldova Diaconu, Grosu et al. 
(2011) 
21 AF patients OAC 7.1% 28.5%  
Serbia Potpara, Stankovic et 
al. (2012) 
346 patients with lone 
AF 
At baseline: 
OAC 13% 
Antiplatelets 38.1% 
During the study: 
OAC 53.9% 
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Antiplatelets 74.6% 
 
Turkey Karacaglar, Atar et al. 
(2012) 
 
 
 
Ertas, Duygu et al. 
(2009) 
432 AF patients 
 
 
 
 
426 AF patients 
OAC rate in those with 
CHADS2VASC score ≥2 
was 67.3%, 43.2% with 
score 1, 55.6% with 
score 0 
OAC 30.1% 
(25.1% warfarin+ aspirin 
4.9% warfarin alone) 
Aspirin 55.6% 
83.5% 
 
 
 
 
47.7% 
 
Latin America and the Caribbean 
Argentina Fitz Maurice, Di 
Tommaso et al. (2011) 
872 AF/ AFL patients OAC 72.7% 
Antiplatelets 63% 
 
  
 
Brazil  Fornari, Calderaro et al. 
(2007) 
 
Lavitola Pde, Spina et 
al. (2009) 
 
Oliveira, Mallmann et 
al. (2012) 
301 AF patients 
 
 
338 AF patients on 
warfarin 
 
167 AF patients 
OAC 46.7%-57.8% 
Antiplatelets 19.9%-
21.2% 
 
 
 
 
 
 
50.1% 
 
 
 
 
 
 
 
 
 
 
Rate control 
79.5% 
 
Mexico  Cortes-Ramirez, 
Cortes-De La Torre et 
al. (2011) 
19 AF patients OAC 36.8% 
Aspirin 63% 
   
South Asia 
India Healey, Oldgren et al. 
(2011) 
2450  AF patients 
from India   
 
 32.6%  
Pakistan  Haq and Lip (2009) 221 patients with AF OAC 44%   
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Rasool and Haq (2009) 
 
 
Randhawa (1998) 
 
218 patients with AF 
 
 
80 patients with AF 
 
 
Warfarin 26% 
Aspirin 60% 
 
Warfarin 5% 
Aspirin 10% 
 
 
 
 
 
Sub-Saharan Africa 
Cameroon Ntep-Gweth, 
Zimmermann et al. 
(2010) 
172 AF patients 
 
OAC 34.2% 
Aspirin 61% 
 
 
 
Rate control 
83.7% 
 
Senegal 
 
Mbaye, Pessinaba et al. 
(2010) 
 
150 AF patients 
 
Warfarin 62% 
  
Rate control 
87.3% 
 
South 
Africa 
 
Sliwa, Carrington et al. 
(2010) 
 
246 AF patients 
 
Warfarin 33% 
Aspirin 23% 
 
   
Zimbabwe Bhagat and Tisocki 
(1999) 
150 AF patients  Warfarin 
  21.3% 
(Urban 26.5%, Rural 
11.5%) 
Aspirin 10% 
(Urban 11.2%, Rural 
7.7%) 
  
AF: Atrial Fibrillation; AFL: Atrial Flutter; INR: International Normalised Ratio; OAC: Oral Anticoagulant. 
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Abstract  
Background. As the population ages, the prevalence and clinical importance of frailty are 
increasing. There have been few published studies about frailty in developing world. This study 
aims to review the evidence from developing countries on the prevalence of frailty, definition of 
frailty and factors associated with frailty. 
Method. A literature search was conducted via MEDLINE and EMBASE. Keywords included 
“frail”, “frailty”, “prevalence”, “criteria”, “definition”, “risk factors”, “outcomes”, “developing 
country”, “developing world”, and names of low and middle income countries according to the 
classification of the World Bank.  
Result. A total of 14 articles were reviewed from Brazil (n=6), China (n=3), Mexico (n=2), and 
one each from Russia, India, and Peru. There were 9 articles from community-based studies and 
5 articles from hospital-based studies. Fried’s phenotype for frailty was used to define frailty in 
the majority of studies. The prevalence of frailty in community-dwelling older people was 17%-
31% in Brazil, 15% in Mexico, 5%-31% in China, and 21%-44% in Russia. The prevalence of 
frailty was 49% in institutionalised older patients in Brazil and 32% in hospitalised older patients 
in India. The prevalence of frailty in outpatient clinics was 55%-71% in Brazil and 28% in Peru. 
Frailty was associated with increased mortality and comorbidities, decreased physical and 
cognitive function, and poor perceptions of health. 
Conclusion. The limited studies available suggest that frailty occurs frequently in older people in 
the developing world and it appears to be associated with adverse outcomes. This has 
implications for policy and health care provision for these ageing populations.   
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Introduction 
The world’s population is ageing, not only in developed countries but also in developing 
countries. In 2010 about two third of the world’s population 60 years and older lived in less 
developed countries and it is estimated that the speed of aging in middle- and low-income 
countries will outpace that of the high-income countries (He, Muenchrath et al. 2012). As the 
population ages, the prevalence and clinical importance of frailty are increasing. 
Frailty is a clinical syndrome resulting from multisystem impairments and characterised by 
increased vulnerability and disabilities (Clegg, Young et al. 2013). Frailty occurs as a result of 
impacts from multiple physical, social and environmental factors, and is a changeable condition. 
Multiple physiological factors are thought to be involved in the development of frailty, including 
the immune, cardiovascular, metabolic and nervous systems. Frailty is also consistently 
associated with inflammation and activation of thrombotic pathways. Frailty predicts adverse 
outcomes for older people, such as comorbidities, polypharmacy, loss of independence, 
increasing hospitalisations, and mortality. Clinically, frailty may have an impact on treatment 
strategies and responses to therapy and prognosis. For hospitalised patients, frailty status prior to 
admission has been shown to predict poor outcomes (Hilmer and Gnjidic 2014). Understanding 
the etiology, prevalence and outcomes of frailty informs research and policy to optimise care for 
older people (Clegg, Young et al. 2013).  
Although the concept of frailty has been emerging in geriatric medicine for many years, there is 
no gold standard for the definition of frailty. The two most commonly used definitions in 
research revolve around deficit accumulation and around the frailty phenotype (Clegg, Young et 
al. 2013). Rockwood et al used an accumulation of deficits which include physical dysfunction, 
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cognitive deficits, comorbidities and socio-economic conditions to calculate a Frailty Index (FI) 
(Clegg, Young et al. 2013). On the other hand, Fried et al defined frailty with five criteria: 
unintentional weight loss (more than 10 pounds in prior year), weakness (measured by grip 
strength), self-report exhaustion, slowness (measured by walking speed) and low physical 
activity (measured by energy expenditure). Having three or more criteria indicates a frailty 
phenotype, while one or two criteria indicate intermediate or prefrail (Clegg, Young et al. 2013). 
Recently, the Edmonton Frail Scale has been applied in many studies. This scale, which was 
elaborated by Rolfson in Cananda, involves 9 frailty domains (cognition, general health status, 
functional independence, social support, medication use, nutrition, mood, continence and 
functional performance). With a maximum score of 17, 0 to 4 score indicates robust, 5 to 6 
scores indicates apparently vulnerable status, 7 to 8 mild frailty, 9 to 10 moderate frailty and 11 
or more indicates severe frailty (Rolfson, Majumdar et al. 2006). In terms of feasibility, the 
Edmonton Frail Scale seems to be the quickest, FI requires simple measures, while phenotype 
requires specific equipment. The FI can be done retrospectively, others need specific data 
collection or modification of the tools. The frailty phenotype seems to be the most affected by 
acute illness for studies in acute setting. 
Many studies have reported the prevalence of frailty in Western countries. The prevalence of 
frailty in the community has ranged from 4% to 10% in studies in the United States, 6.5% in 
Italy, 7% in France, 8.1% in the United Kingdom (using Fried’s phenotype) (Collard, Boter et al. 
2012; Hilmer and Gnjidic 2014).  In Australia, the prevalence of frailty has ranged from 9.4% 
(using Fried’s phenotype)  to 15.2% (using FRAIL scale)  in community-dwelling older men and 
up to 64% in older patients admitted to hospital with atrial fibrillation (using the Reported 
Edmonton Frail Scale) (Hilmer and Gnjidic 2014). However, there have been few published 
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studies about frailty in the developing world. Therefore, the aim of this paper is to systematically 
review the evidence from developing countries on the prevalence of frailty, definitions of frailty 
and outcomes associated with frailty. 
 
Methods 
A literature search was conducted via MEDLINE and EMBASE (from 1990 to January 2014). 
Keywords used for searching included “frail”, “frailty”, “prevalence”, “criteria”, “definition”, 
“risk factors”, “outcomes”, “developing country”, “developing world”, and the names of low and 
middle countries according to the classification of the World Bank . The articles attained by this 
method of searching were screened by title and relevant papers were retrieved. Both community 
and hospital/institutional-based studies were included. Studies were stratified by study 
population into those that studied prevalence of frailty in the community and those that studied 
prevalence in institutionalised or hospitalised older people. In cases where there are many 
publications based on one study, the first publication was chosen and full papers were chosen 
instead of letters to the editor. Language was restricted to English. Information extracted from 
papers included sample size, sampling methodology, prevalence of frailty, definition of frailty 
and outcomes. When necessary, percentages were calculated from data reported in published 
studies.  
Results 
A total of 110 abstracts was obtained. After further screening for prevalence, definition, and 
outcomes of frailty, 79 abstracts were rejected. Another 6 abstracts were rejected because full 
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texts in English could not be obtained, leaving 25 papers. Among these 25 papers, there were 
some studies with several reports. In these cases, the first publication was chosen and full papers 
were chosen instead of letters to the editor, leaving a total of 14 papers from 14 studies included 
in this review (Fabricio-Wehbe, Schiaveto et al. 2009; Garcia-Gonzlez, Garcia-Pea et al. 2009; 
Gu, Dupre et al. 2009; da Silva, de Souza et al. 2011; Gurina, Frolova et al. 2011; Lee, Auyeung 
et al. 2011; Shi, Song et al. 2011; Batista, de Oliveira Gomes et al. 2012; Castrejon-Perez, 
Borges-Yanez et al. 2012; de Albuquerque Sousa, Dias et al. 2012; Khandelwal, Goel et al. 
2012; Asmar Alencar, Domingues Dias et al. 2013; Nobrega, Maciel et al. 2014; Runzer-
Colmenares, Samper-Ternent et al. 2014). There were 6 studies from Brazil, 3 from China, 2 
from Mexico, and one each from Russia, India, and Peru. There were 9 studies from community-
based studies (3 in Brazil, 3 in China, 2 in Mexico, and one from Russia). The remainder were in 
institutions or hospitals. Most of the publications in Brazil, Mexico and China were based on 
large cohort studies about ageing and frailty, such as the study on Frailty in Elderly Brazilians 
(the FIBRA study), the Mexican Study on Nutritional and Psychosocial Markers of Frailty, the 
Mexican Health and Aging Study, the Beijing Longitudinal Study of Ageing and the Chinese 
Longitudinal Healthy Longevity Survey.  
The 14 reviewed papers were all published between 2009 and 2014 and, apart from the Beijing 
Longitudinal Study of Ageing (Shi, Song et al. 2011), the studies were conducted after 2000. All 
the studies of community-dwelling older people used a probability sampling methodology except 
the study from China by Lee et al, which involved volunteers recruited via advertisements on 
noticeboards (Lee, Auyeung et al. 2011).  Response rates were reported in 6 of the community 
studies and were above 80% in all but the study from Russia (Gurina, Frolova et al. 2011). It is 
difficult to compare age distributions between studies because of differences in reporting; 
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however, it appears that most subjects in the community studies were in their 70s. The exception 
is the Chinese Longitudinal Healthy Longevity Survey, where more than 40% of subjects were 
aged 90 years and over. 
Prevalence of frailty in community-dwelling older adults, outpatients and institutionalised 
patients varied between countries. The prevalence of frailty in older people in the community 
ranged from 17.1% to 31.4% in Brazil (data from 2 studies), 15% in Mexico (from 1 study), 
5.4% to 30.8% in China (2 studies), and 21.1% to 43.9% in Russia (from 1 study) (Table 9.1). 
The low prevalence of 5.4% was from the only study involving a convenience sample (Lee, 
Auyeung et al. 2011).  Three studies in geriatric medicine outpatients found that the prevalence 
of frailty was 55.3% to 71.3% in Brazil and 27.8% in Peru. The prevalence of frailty in older 
people in long stay institutions was 49.3% in one study in Brazil and the prevalence of older 
inpatients was 32.3% in one study in India (Table 9.2). 
Fried’s phenotype was used to define frailty in the majority of studies. Only one study (from 
Brazil) used the Edmonton Frail Scale, one from Russia reported the Steverink-Slaets and Puts 
score. The Frailty Index was used in three community-based studies: the Beijing Longitudinal 
Study of Ageing (35 deficits, mean FI 0.11±0.1 in men and 0.14±0.11 in women), the Chinese 
Longitudinal Healthy Longevity Survey (39 deficits, mean FI 0.19 in men and 0.26 in women) 
and The Mexican Health and Aging Study (34 deficits, mean FI 0.16±0.11).  
Outcomes of frailty were inconsistently assessed in the reviewed studies. Cross-sectional 
approach for examining the relationship between frailty and the various outcomes was applied in 
seven out of the fourteen studies (Fabricio-Wehbe, Schiaveto et al. 2009; da Silva, de Souza et 
al. 2011; Batista, de Oliveira Gomes et al. 2012; Castrejon-Perez, Borges-Yanez et al. 2012; de 
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Albuquerque Sousa, Dias et al. 2012; Nobrega, Maciel et al. 2014; Runzer-Colmenares, Samper-
Ternent et al. 2014). In the reviewed studies, frailty was associated with increased health care 
utilisation, increased mortality and comorbidities such as cardiovascular diseases, depression, 
falls and fractures, incontinence, anemia, increased hospitalisations, increased number of 
medications, increased use of medical and dental services, increased physical dependence and 
decreased physical and cognitive function, and poor perception of health. One publication from 
the Mexican Study on Nutritional and Psychosocial Markers of Frailty reported that frailty was 
not associated with quality of social networks (Castrejon-Perez, Borges-Yanez et al. 2012). 
 
Discussion 
A total of 14 articles describing 14 studies about frailty in developing countries were included in 
this review. Most of the studies of community-dwelling older adults were conducted using 
probability sampling methods and achieved high response rates. The quality of the sampling 
methods for the studies in health care settings was more variable. The prevalence of frailty in 
older people in developing countries was quite variable, from 5.4% to 44% in community-
dwelling older adults, 27.8% to 71.3% in geriatric outpatients and 32.3% to 49.3% in 
institutionalised older patients.  
Fried’s phenotype was the most common approach used to determine frailty, not only in 
community setting but also in hospital based studies in these developing countries. This finding 
is rather consistent with studies from developed countries. The phenotypic approach to frailty is 
the most widely used approach and it has been shown to correlate well with both the risk of 
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adverse outcomes and with many important clinical parameters (Rockwood and Mitnitski 2011). 
In studies using Fried’s frailty phenotype, the prevalence of frailty in community-dwelling adults 
was variable, ranging from 5.4% in China, 17.1% to 23.2% in Brazil, 15% in Mexico, and 21.1% 
in Russia. Except for the study in China in which the sample may not be representative 
(participants were recruited by placing recruitment notices in community centers for the older 
persons and housing estates), the prevalence of frailty in the developing countries in this review 
prevalence was high compared to developed countries, in which the prevalence of frailty has 
ranged from 4% to 17% in the United States, Australia, Canada, the United Kingdom, France 
and Italy, and other European countries (Collard, Boter et al. 2012). Poor nutritional health, high 
prevalence of physical labor during lifetimes and disability may contribute to this result. 
According to the Study on Global Ageing and Adult Health (SAGE), which was conducted in six 
countries - China, Ghana, India, Mexico, Russia, and South Africa- approximately 70% of the 
population aged 50 and over had some types of disability, with up to 90% of older Indians and 
Russians suffering from disabilities (He, Muenchrath et al. 2012). In a recent published study 
based on the SAGE study data, average walking speeds were slower in SAGE countries than 
commonly reported in Western countries (Capistrant, Glymour et al. 2014). Variations in 
measurement when applying the frailty phenotypes in these countries may also explain why the 
prevalence of frailty in developing countries was more variable and generally higher compared 
to Western countries.  
Only three studies, all in the community, used the Frailty Index to define frailty. All Frailty 
Indices included symptoms, diseases and physical function. The Beijing Longitudinal Study of 
Ageing also included cognitive function. The mean Frailty Index in these studies is consistent 
and rather similar to studies in developed countries. In the Survey of Health, Ageing and 
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Retirement in 12 European countries (based on 40 deficits), the mean FI was 0.08 for those aged 
50, 0.10 for those aged 60, 0.14 for those aged 70, 0.21 for those aged 80, 0.30 for those aged 90, 
and 0.43 for those aged 100 (Romero-Ortuno 2013). According to the National Population 
Health Survey of Canada, the mean values of the Frailty Index were 0.046 for non-frail, 0.156 
for pre-frail, and 0.310 for frail people (Song, Mitnitski et al. 2010).  
The number of institution-based and hospital-based studies in this review was small and all used 
Fried’s frailty phenotype. There were three studies in geriatric outpatient clinics. One study in 
Peru in participants aged 60 years or older found that the prevalence of frailty was 27.8% 
(Runzer-Colmenares, Samper-Ternent et al. 2014) while studies from Brazil found a prevalence 
of 55.3% in a convenience sample involving patients aged 80 years or older and 71.3% inpatients 
aged 60 years or older with functional impairment  (da Silva, de Souza et al. 2011; Batista, de 
Oliveira Gomes et al. 2012). One study in India found that the prevalence of frailty in 
hospitalised older patients was 32.3% and one study in Brazil showed that frailty was present in 
49.3% of older residents of long stay institutions (Table 9.2).  
Frailty has been reported to be associated with many adverse outcomes (Hilmer and Gnjidic 
2014). The outcomes for frail people in the studies reviewed in this paper are consistent with 
reports from the developed world. 
Most of the studies in this review were from Latin America and Asia and all were middle income 
countries. The prevalence of frailty was variable among these regions. There was no data from 
low income countries where the prevalence of frailty may be higher. A recent study in Europe 
found that a country’s level of frailty and fitness in older adults was strongly correlated with 
national economic indicators, such that lower income countries had higher levels of frailty and 
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lower levels of fitness when compared with the higher-income countries (Theou, Brothers et al. 
2013). There appear to have been no studies on frailty from Africa. In the United States, studies 
have found that African Americans have a higher prevalence of frailty than Caucasians using 
Fried’s frailty phenotype model (Hirsch, Anderson et al. 2006). 
The Fried’s phenotype and the Frailty Index can identify older people at high risk of death and 
correlate well with each other, with the deficit accumulation approach predicting mortality better 
(Rockwood and Mitnitski 2007). Although the Frailty Index has been shown to be more 
applicable for predicting mortality than the phenotypic criteria, in this review there were no 
studies in hospital settings using the Frailty Index. These findings raise a question regarding the 
most feasible approaches for frailty research in developing countries. The newer deficit 
accumulation scales, The Edmonton Frail Scale (Rolfson, Majumdar et al. 2006), and the 
Reported Edmonton Frail Scale that was adapted from the Edmonton Frail Scale for use with 
Australian acute inpatients (Hilmer, Perera et al. 2009), are both based on a questionnaire and 
seem to be easy to apply. This scale is less time-consuming and may be practical for both 
outpatients and inpatients in the developing world where there are limited resources for 
conducting research. 
This review has some limitations. First, the articles were restricted to English only. We may have 
missed some papers that were not available in English fulltext or in journals that were not 
indexed on MEDLINE and EMBASE. Secondly, there may be bias due to inadequate sampling 
techniques, including use of convenience samples. Thirdly, comparison of prevalence between 
studies using different frailty assessment methods is complicated by the fact that, even within the 
same population, different frailty assessments classify different participants as frail (Hilmer and 
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Gnjidic 2014). Since within populations the prevalence of frailty increases with age (Song, 
Mitnitski et al. 2010; Hilmer and Gnjidic 2014), another limitation of this study was comparing 
studies that included people of different ages. The strength of our study is that it is a systematic 
review that comprehensively addresses the published English language literature on prevalence, 
definition and outcomes of frailty in developing countries. 
Conclusions 
Frailty is an important issue in geriatric medicine. There is emerging evidence that frailty can be 
used clinically to individualise treatment plans, predict therapeutic outcomes and inform public 
policy for older people. At the societal level, understanding frailty can help to identify groups of 
people who need extra medical care. The limited studies available suggest that frailty occurs 
frequently in the developing world. This has implications for policy and health care provision for 
these ageing populations.   
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Table 9.1. Studies of frailty in community-dwelling older adults 
Authors and year 
of publication 
N Participants Sampling method and time 
period 
Prevalence of 
frailty/ Mean FI 
Definition of 
frailty 
Brazil 
Asmar Alencar, 
Domingues Dias et 
al. (2013)  
207 Aged 65 years or older. 
Mean age ± SD: 
74.5 ± 6.4 (non-frail) 
78.3 ± 8.0 (pre-frail) 
82.3 ± 7.1 (frail) 
Simple random 
probabilistic sampling, 
response rate not provided 
in the paper. 
Data collected 2009. 
 
23.2% Fried’s criteria 
Fabricio-Wehbe, 
Schiaveto et al. 
(2009)  
 
137 Aged 65 years or older. 
65-79: 67% 
≥80: 33% 
 
Representative sample 
based on a probabilistic 
double-stage sampling 
process in the population. 
Response rate 80%. 
Data collected 2007-2008. 
31.4% The Edmonton 
Frail Scale 
The FIBRA Study, 
2011 de 
Albuquerque 
Sousa, Dias et al. 
(2012)  
391 Aged 65 years or older. 
65-74: 60% 
75-84: 33% 
≥85: 7% 
 
Representative sample 
based on a probabilistic 
multi-stage sampling 
process in the population. 
Response rate not provided 
in the paper. 
Data collected 2007-2008. 
17.1% Fried’s criteria 
Mexico 
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Mexican Study on 
Nutritional and 
Psychosocial 
Markers of Frailty, 
2012 (Castrejon-
Perez, Borges-
Yanez et al. 2012) 
838 Aged 70 years or older. 
Mean  age ± SD: 77.9 ± 
6.3 
Representative sample 
based on a random 
sampling process in the 
population, stratified by 
age and gender. Response 
rate 86.9%. 
Data collected 2008-2009. 
15% Fried’s criteria 
The Mexican 
Health and Aging 
Study, 2009 
(Garcia-Gonzlez, 
Garcia-Pea et al. 
2009)  
  
4082 Aged 65 years or older. 
Mean age: 73.0 
 
Representative sample. 
Response rate 84.2%. 
(Participants and their 
spouse/partners were 
selected from a nationally 
representative sample of 
non-institutionalised 
Mexicans who had 
previously participated in 
the fourth quarter of 2000 
in an employment survey). 
Data collected 2001. 
Mean FI: 
0.16 ± 0.11 
Frailty Index 
(34 deficits) 
China 
Lee, Auyeung et 
al. (2011)  
 
4000 Aged 65 years or older.  
Mean age ± SD: 
72.3 ± 5.0 (men) 
72.5 ± 5.3 (women) 
 
Sample may be not 
representative (recruiting 
by placing recruitment 
notices in community 
centers for older persons 
and housing estates). 
Response rate not provided 
in the paper. 
5.4% 
1.8% in people 
from 65-69 
years old 
3% in people 
70-74 years old  
11.8% in people 
Fried’s criteria 
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Data collected 2001-2003 ≥75 years old 
The Beijing 
Longitudinal Study 
of Ageing, 2011 
(Shi, Song et al. 
2011)  
 
3257 Aged 55 years or older. 
55-64: 32.0% 
65-74:34.0% 
75-84: 28.6% 
85-94: 5.2% 
≥95: 0.2% 
Representative sample 
based on a random 
sampling process in the 
population. Response rate 
91.2%.  
Data collected 1992-2000. 
Mean FI: 
0.11±0.1 in men 
and 0.14±0.11 
in women. 
Prevalence of 
frailty (cut-off 
0.22): 28.9% in 
men and 30.8% 
in women 
Frailty Index  
(35 deficits) 
The Chinese 
Longitudinal 
Healthy Longevity 
Survey, 2009 (Gu, 
Dupre et al. 2009)  
 
13717 Aged 65 years or older. 
65-79: 30.7% 
80-89: 26.8% 
90-99: 23.7% 
≥100: 18.8% 
Representative sample 
based on a random 
sampling process in the 
population. Response rate 
88%.  
Data collected 2002 -2005. 
Mean FI: 
0.19 in men 
0.26 in women 
Frailty Index 
(39 deficits) 
Russia 
Gurina, Frolova et 
al. (2011)  
 
611 Aged 65 years or older. 
65-74: 50% (mean±SD: 
69.7 ± 2.4 for male, 70.2 
± 2.3 for female) 
≥75: 50% (mean±SD: 
78.8 ± 3.2  for male, 80.5 
± 2.4 for female) 
 
Representative sample 
based on a random 
sampling process in the 
population, stratified by 
age. 
Response rates: 
59.5% in male aged 65-74 
70.1% in female aged 65-
21.1% (Fried’s 
criteria) 
32.6% 
(Steverink-
Slaets model) 
43.9% (Puts 
model) 
Fried’s criteria 
Steverink-
Slaets model 
Puts model 
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74 
61.3% in male aged ≥75 
70.3% in female aged ≥75 
Data collected 2009. 
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Table 9.2. Studies of frailty in health care settings 
Authors and 
year of 
publication 
N Participants Sampling Method Definition of 
frailty 
Prevalence of 
frailty  
Nobrega, 
Maciel et al. 
(2014)  
69 Older residents of six long 
stay institutions. (in 
Brazil) 
Representative sample based 
on a random sampling 
process. Response rate 80%.  
Fried’s criteria 49.3% 
Batista, de 
Oliveira 
Gomes et al. 
(2012)  
 
150 Older patients aged ≥80 
years, or patients aged ≥60 
years with functional 
impairment at the 
outpatient clinic. (in 
Brazil) 
Non-probabilistic 
convenience sampling 
method. 
Fried’s criteria 55.3% 
da Silva, de 
Souza et al. 
(2011)  
 
100 Older patients aged ≥80 
years, or patients aged ≥60 
years with functional 
impairment at the 
outpatient clinic. (in 
Brazil) 
Non-probabilistic 
convenience sampling 
method. 
Fried’s criteria 71.3% 
Runzer-
Colmenares, 
Samper-
Ternent et al. 
(2014)  
311 Older patients aged 60 
years or older at the 
outpatient clinic (mostly 
men and retired military 
personnel). (in Peru) 
Random sampling method. 
Response rate 52.5%.  
 
Fried’s criteria 27.8% 
Khandelwal, 
Goel et al. 
(2012)  
250 Hospitalised patients aged 
60 years or older. (in 
India) 
Consecutive series of patients 
were recruited. 
Fried’s criteria 32.3% 
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Chapter Ten 
Prevalence, risk factors and pharmacological treatment of atrial fibrillation in 
older hospitalised patients in Vietnam 
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Abstract 
Background. The evidence about prevalence of atrial fibrillation (AF) in Vietnam is very limited and 
there have been no published studies about the pharmacological treatment of AF in older Vietnamese 
patients. This study aims to investigate the prevalence of AF, its associated factors and pharmacological 
treatment in older hospitalised patients in Vietnam. The secondary aim is to investigate the impact of 
frailty, an emerging geriatric syndrome which is still a new concept in Vietnam, on the pharmacological 
treatment of AF. 
Methods. We used data from a study of the prevalence of frailty in older hospitalised patients at the 
National Geriatric Hospital in Hanoi, Vietnam. Consecutive patients aged ≥60 years were recruited from 
4/2015 to 10/2015.  
Results. A total of 461 patients was recruited, 56.8% were female, and mean age was 76.2±8.9. The 
prevalence of AF was 3.9% (18 patients). Amongst patients with AF, the most common medical 
conditions were hypertension (72.2%), followed by stroke (55.6%), heart failure (50.0%), type 2 diabetes 
(44.4%). Living alone (OR=10.2, 95%CI 1.5–70.1), having a habit of using vitamins at home (OR=3.8, 
95%CI 1.1–13.4), having heart failure (OR=31.3, 95%CI 9.6–101.8), and having type 2 diabetes 
(OR=3.5, 95%CI 1.2–10.7) were associated with the presence of AF on admission. All patients with AF 
had a high risk of stroke (CHA2DS2-VASc score≥2) and 72.2% of them had a high risk of bleeding with 
anticoagulant medications (HAS-BLED score≥3). Only 22.2% were anticoagulated on admission and 
22.2% upon discharge, with no difference between frail and non-frail patients. 
Conclusions. The prevalence of AF among older hospitalised patients in Vietnam is similar to that 
reported in other countries. Anticoagulation for stroke prevention was underused, without any significant 
difference between frail and non-frail patients. 
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Introduction  
Atrial fibrillation (AF) is a common cardiac arrhythmia in older adults. The global burden of AF has been 
increasing due to the ageing of the world’s population (Rahman, Kwan et al. 2014). The rates of AF 
related hospitalisations have increased worldwide over the last decades (Friberg, Buch et al. 2003; 
Wellens and Smith Jr 2006; Keech, Punekar et al. 2012; Patel, Deshmukh et al. 2014). The prevalence of 
AF in Western countries ranges from 0.5% to 4% in the general population (Chugh, Blackshear et al. 
2001; Go, Hylek et al. 2001; Stewart, Hart et al. 2001; Sturm, Davis et al. 2002) and 3% to 24% in 
hospitalised patients (Levy, Maarek et al. 1999; Camm, Kirchhof et al. 2010; Bang and McGrath 2011). 
In developing countries, the prevalence of AF in studies conducted in the community has ranged from 
0.03% to 1.25%, while the prevalence of AF in hospital-based studies has varied from 0.7% to 55.7% 
(Nguyen, Hilmer et al. 2013). People with AF have an increased risk of stroke (Fuster, Ryden et al. 2001). 
Treatment of AF aims at stroke prevention with anticoagulant therapies, reducing symptoms with rate-
control or rhythm-control strategies, and management of associated medical conditions (Camm, Kirchhof 
et al. 2010). Anticoagulation therapy (with anti-vitamin K or newer oral anticoagulants) in patients with 
AF has been shown to reduce the frequency, severity and mortality from stroke (Hylek, Go et al. 2003; 
January, Wann et al. 2014). However, despite the evident benefits of anticoagulants in preventing stroke, 
studies have shown that anticoagulants are underutilised in patients with AF, especially in older patients 
due to increased bleeding risk (Antani, Beyth et al. 1996; Mendelson and Aronow 1998; Waldo, Becker et 
al. 2005; Perera, Bajorek et al. 2009; Radholm, Ostgren et al. 2011; Corvol, Gulsvik et al. 2014). 
In Vietnam the population is aging rapidly, with the older population (aged 60 or over) increasing from 
8.7% of the total population in 2009 to 26.1% in 2049 (United Nations Population Fund (UNFPA) in 
Vietnam 2011). One study found that nearly 40% of older people in the community in Vietnam had 
multimorbidity (Ha, Le et al. 2015). Cardiovascular disease is the leading cause of death in Vietnam 
(Hoang, Dao et al. 2006; Islam, Purnat et al. 2014; Nhung, Long et al. 2014). The evidence of prevalence 
of AF in the general population or in hospitalised patients in Vietnam is very limited: a study found that 
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around 1.3% of patients hospitalised with a first acute myocardial infarction had AF (Nguyen, Nguyen et 
al. 2014) and another found AF prevalence of to 6.6% in patients hospitalised with a first stroke (Nguyen, 
Do et al. 2015). There have been no published studies about the pharmacological treatment of AF in older 
patients in Vietnam. Therefore, the primary aims of this study were to investigate the prevalence of AF 
among older hospitalised patients, its risk factors and pharmacological treatment. The secondary aim was 
to investigate the impact of frailty, an emerging geriatric syndrome which is still a new concept in 
Vietnam, on the pharmacological treatment of AF. 
Methods 
Study population 
We used data from a study of the prevalence of frailty in older hospitalised patients at the National 
Geriatric Hospital in Hanoi, Vietnam. In this observational study, consecutive patients aged ≥60 years 
admitted to the hospital on weekdays between April 2015 and October 2015 were recruited by two 
medically qualified master students. The National Geriatric Hospital in Hanoi is the only geriatric hospital 
in Vietnam and it provides care for older patients in Hanoi and the Northern provinces of Vietnam. The 
study was approved by the National Geriatric Hospital Ethics Committee. Hospitalised patients were 
eligible to participate if they were aged ≥60 years. Participants who were dying or receiving intensive 
care or who were identified as “blind” or “deaf” were excluded from the study. Eligible patients were 
identified daily from the target wards (cardiology, general medicine, endocrinology, neurology and the 
private general medicine ward) and invited to participate. Oral consent was obtained from all participants.  
Data collection included socio-demographics, detailed medical history, co-morbidities, clinical 
assessments and prescribed medications and non-prescription medications. All patients had an 
electrocardiogram on admission, and these electrocardiograms were reviewed by the study doctors. Atrial 
fibrillation was first identified based on the electrocardiogram on admission, then confirmed with at least 
one electrocardiogram during hospitalisation. Patients with AF were evaluated for stroke risk using the 
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CHA2DS2-VASc score (oral anticoagulants are recommended for patients with high risk of stroke on this 
scale) (January, Wann et al. 2014). The individual components of the CHA2DS2-VASc score include: 
congestive heart failure (1 point), hypertension (1 point), age ≥75 years (2 points), diabetes mellitus (1 
point), stroke/TIA (2 points), vascular disease (prior myocardial infarction, peripheral artery disease or 
aortic plaque) (1 point), age 65-74 years (1 point), female gender (1 point). The maximum score is nine 
and a total score of two or above indicates a high risk of stroke. Bleeding risk for anticoagulants was 
assessed with the HAS-BLED score. One point is assigned for each individual components, including 
hypertension, abnormal renal function (dialysis, kidney transplant, creatinine clearance >200µmol/L), 
abnormal liver function (cirrhosis or bilirubin>2x normal or AST - Aspartate aminotransferase/ALT - 
Alanine aminotransferase/ALP - alkaline phosphatase >3x normal), stroke history, history of major 
bleeding or predisposition to bleeding, labile INRs (international normalized ratios)  if on warfarin, age 
>65 years, concomitant antiplatelet or non-steroidal anti-inflammatory drugs (NSAIDs) use, and alcohol 
abuse. The maximum score is nine and a total score of three or above indicates a high risk of bleeding 
(Pisters, Lane et al. 2010). The Reported Edmonton Frail Scale (REFS) was used to identify frail 
participants. This scale has been applied in many studies in acute inpatients (Hilmer, Perera et al. 2009; 
Perera, Bajorek et al. 2009; Mitchell, Hilmer et al. 2011; Bennett, Gnjidic et al. 2014; Rose, Pan et al. 
2014; Osborne, Charles et al. 2015). The scale involves nine frailty domains (cognition, general health 
status, functional independence, social support, medication use, nutrition, mood, continence and 
functional performance). With a maximum score of 18, the cut point used to identify frailty was eight, 
consistent with previous studies using this scale (Hilmer, Perera et al. 2009; Perera, Bajorek et al. 2009; 
Mitchell, Hilmer et al. 2011; Bennett, Gnjidic et al. 2014; Rose, Pan et al. 2014; Osborne, Charles et al. 
2015). 
Statistical Analysis: 
Analysis of the data was performed using SPSS for Windows 20.0 (IBM Corp., Armonk, NY, USA). 
Continuous variables are presented as mean ± standard deviation, and categorical variables as frequency 
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and percentage. Comparisons between frail and non-frail participants were assessed using the Chi-square 
test or Fisher’s exact test for categorical variables and Student’s t-test or Mann-Whitney test for 
continuous variables. Multivariate logistic regression was applied to identify risk factors for prevalent AF 
on admission. Univariate logistic regression was performed on all the potential risk factors for AF (age, 
gender, frailty status, nutrition status, overweight, smoking, alcohol abuse, hypertension, ischemic heart 
disease, heart failure, type 2 diabetes, peripheral vascular disease, dyslipidemia, chronic pulmonary 
disease, dementia, depression, thyroid disorders, habits of using herbal medicine, using vitamins, and 
socio-economic factors as education, residential status). Only variables that had a p-value <0.20 on 
univariate analysis were selected for multivariate analysis. A backward elimination method was applied 
and the final model retained variables significant at p<0.05. All variables were examined for interaction 
and multicollinearity.  
Results 
Prevalence of atrial fibrillation and associated medical conditions 
A total of 461 participants was recruited, with 56.8% female, and a mean age of 76.2 ± 8.9 (median 77.0, 
range 60 - 98). The prevalence of AF was 3.9% (18/461). Compared to patients without AF, patients with 
AF had significantly higher prevalences of overweight, heart failure, type 2 diabetes, living alone and 
higher Charlson comorbidities index. Amongst patients with AF, the most common associated medical 
conditions were hypertension (72.2%), followed by stroke (55.6%), heart failure (50.0%), type 2 diabetes 
(44.4%), ischemic heart disease (16.7%) and chronic pulmonary disease (16.7%) (Table 10.1). 
Risk factors for prevalent AF on admission 
In the final model, living alone (OR=10.23, 95%CI 1.49 – 70.11), having a habit of using vitamins at 
home as self-medication (OR=3.77, 95%CI 1.06 – 13.37), having heart failure (OR=31.29, 95%CI 9.62 – 
101.75), and having type 2 diabetes (OR=3.53, 95%CI 1.17 - 10.69) were associated with the presence of 
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AF on admission. These variables significantly predicted risk factors for prevalent AF on admission 
(Table 10.2).  
Stroke risk and bleeding risk 
All patients with AF had a high risk of stroke (CHA2DS2-VASc score ≥2) and 72.2% of them had a high 
risk of bleeding with anticoagulant medications (HAS-BLED score ≥3) (Table 10.3 and Table 10.4). 
Treatment of AF 
On admission, only 4 of the 18 patients with AF (22.2%) were using anti-vitamin K (Sintrom, 
acenocoumarol). Upon discharge, the prevalence of oral anticoagulant prescription was also 4/18 (22.2%) 
(3 patients prescribed anti-vitamin K and 1 patient prescribed dabigatran). During hospitalisation, anti-
vitamin K was stopped in two patients and started in two patients. Upon discharge, half of the patients 
with AF did not receive any anti-arrhythmic drugs. Rate control therapy was prescribed in 8/18 (44.4%), 
digoxin was the most common rate-control medication 6/18 (33.3%), followed by beta-blockers 3/18 
(16.7%) and amiodarone 1/18 (5.6%).    
The impact of a frailty status on the pharmacological treatment of AF 
Among the 18 patients with AF, 7 were frail (38.9%). The prevalence of anticoagulant use was lower in 
the frail compared to the non-frail, however the difference was not statistically significant: 1/7 (14.3%) 
frail versus 3/11 (27.3%) non-frail on admission (p=1.00), and 0/7 (0%) frail versus 4/11 (36.4%) non-
frail on discharge (p=0.12). There was also no significant difference in anti-arrhythmic medication use 
between the frail and the non-frail. On admission, 6/7 (85.8%) frail patients were not prescribed any anti-
arrhythmic medication versus 9/11 (81.8%) in the non-frail (p=1.00). Upon discharge, 4/7 (57.1%) frail 
patients and 5/11 (45.5%) non-frail patients were not prescribed any anti-arrhythmic medication (p=1.00). 
Small sample size did not allow any further analysis. 
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Discussion 
In this study in Hanoi in Vietnam we found that AF was present in 3.9% of older patients in internal 
medicine wards. This finding is consistent with studies elsewhere, in which AF has been reported to be 
present in 3%-6% of acute medical admissions in some developed countries (Camm, Kirchhof et al. 2010) 
and 1% to nearly 6.5% in general patients in some developing countries (Nguyen, Hilmer et al. 2013). 
In this study, hypertension, heart failure and diabetes were the diagnoses most commonly associated with 
AF. This finding is similar to many other studies (Nguyen, Hilmer et al. 2013). Our study showed that the 
likelihood of the presence of AF on admission increased in patients with heart failure or type 2 diabetes, 
and in patients living alone or having a habit of using vitamins at home. Although the pathophysiology of 
AF is complicated and not fully understood, there is a close relationship between heart failure and AF, in 
which changes in atrial structure and increased left atrial pressure are closely linked to the development of 
AF (Lubitz, Benjamin et al. 2010). Patients with metabolic syndrome have a higher risk of AF (Menezes, 
Lavie et al. 2013). Interestingly, our study suggests that the habit of using vitamins at home as self-
medication may increase the risk of having AF. This could be a public health concern as the prevalence of 
self-medication is very high in Vietnam (Okumura, Wakai et al. 2002). In fact, the link between excessive 
vitamin D intake and an increased risk of AF has been reported in several studies (Vanga, Vacek et al. 
2011; Menezes, Lavie et al. 2013). Studies on the utilisation of self-medications, especially vitamins, in 
Vietnam are needed in the future. In Vietnam, most older people live with their children (Nguyen and 
Cihlar 2013). In this study, only 1.6% of patients without AF were living alone, but the frequency was 
significantly higher in those with AF (11.1%), which could be a concern for anticoagulant using and 
monitoring.    
The prevalence of stroke in this study was quite high: 40.3% in the study population overall and 55.6% in 
patients with AF. Although age-adjusted stroke incidence has nearly halved in high-income countries over 
the past 40 years, it has increased by more than 100% in low and middle income countries over the same 
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period (Feigin, Lawes et al. 2009). The prevalence of stroke in our study was also higher compared to the 
prevalence of stroke in hospitalised patients with AF in other developing countries, which has ranged 
from 10% to 27% (Nguyen, Hilmer et al. 2013).  
In this study, all patients with AF had a high risk of stroke as shown by a CHA2DS2-VASc score of two 
or above, which is the indication for anticoagulants, but the prevalence of patients with high risk of 
bleeding for anticoagulant was also high (72.2%). Anticoagulation was underused in patients with AF. 
Only 22.2% were anticoagulated on admission (4/18) and the same percentage upon discharge (4/18), 
which is consistent with a previous study in Vietnam (17.3%) (Nguyen, Do et al. 2015). This finding 
could help explain the high prevalence of stroke in this cohort of older patients. Rate control therapy was 
favored over rhythm control therapy, which is consistent which studies around the world (Nguyen, Hilmer 
et al. 2013). 
This study has several strengths. The study comprised a sample of very old patients with high quality 
detailed clinical information. To our knowledge, this is the first study to comprehensively address 
prevalence, risk factors and management of AF in older patients in Vietnam. The major limit of this study 
is the small number of participants with AF, which may make the comparisons of anticoagulant use in 
frail and non-frail patients less meaningful. This study was not designed to investigate the prevalence of 
AF in older patients although this was a pre-planned sub-analysis. Another limitation is that patients 
admitted to the hospital during weekends and holidays were missed, and not all wards were included. We 
also recognise that patients admitted to the National Geriatric Hospital may not be representative of all 
older patients in Vietnam.  
Conclusion 
In this study the prevalence of AF among older hospitalised patients in Vietnam was 3.9%. Predictive 
factors for AF were heart failure, type 2 diabetes, living alone, and a habit of using vitamins as self-
medication. Anticoagulation for stroke prevention was underused, without any significant difference 
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between frail and non-frail patients. These findings suggest that in patients with AF, it is important to 
check for heart failure and diabetes. These findings support further development of cohort studies in 
Vietnam on the management of AF in older people with larger sample sizes to examine the impact of 
frailty on anticoagulation prescription and outcomes, and to identify whether the high prevalence of 
stroke in older patients in Vietnam is partly due to poor anticoagulation management and follow up. 
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Table 10.1. Sociodemographic and clinical characteristics of participants (N=461) 
Variables  All  
(N=461) 
Without AF 
(N = 443) 
With AF 
(N = 18) 
P 
Age (years) 76.2 ± 8.9 76.0 ± 8.9 79.1 ± 8.9 0.16 
Female 262 (56.8%) 251 (56.7%) 11 (61.1%) 0.71 
Education: did not graduate high 
school 
286 (62.0%) 272 (61.4%) 14 (77.8%) 0.16 
Living alone 9 (2.0%) 7 (1.6%) 2 (11.1%) 0.04 
Frail 147 (31.9%) 140 (31.6%) 7 (38.9%) 0.51 
Poor nutrition status (reported) 39 (8.5%) 39 (8.8%) 0 (0.0%) 0.19 
Underweight (BMI<18.5) 114 (24.7%) 111 (25.1%) 3 (16.7%) 0.42 
Overweight (BMI≥25) 53 (11.5%) 48 (10.8%) 5 (27.8%) 0.04 
Having a habit of using vitamins 
at home as self-medication 
65 (14.1%) 60 (13.5%) 5 (27.8%) 0.16 
Having a habit of using herbal 
medicine at home as self-
medication 
93 (20.2%) 87 (19.6%) 6 (33.3%) 0.16 
Charlson comorbidity index 2.93 ± 1.68 2.89 ± 1.67 3.76 ± 1.79 0.04 
Cardiovascular Disease and risk factors: 
    Hypertension 288 (62.5%) 275 (62.1%) 13 (72.2%) 0.38 
    History of stroke 186 (40.3%) 176 (39.7%) 10 (55.6%) 0.22 
    Type 2 diabetes 110 (23.9%) 102 (23.0%) 8 (44.4%) 0.04 
    Dyslipidemia 56 (12.1%) 54 (12.2%) 2 (11.1%) 1.00 
    Ischemic Heart Disease 29 (6.3%) 26 (5.9%) 3 (16.7%) 0.09 
    Congestive Heart Failure 29 (6.3%) 20 (4.5%) 9 (50.0%) <0.001 
    Peripheral Vascular Disease 29 (6.3%) 28 (6.3%) 1 (5.6%) 1.00 
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    Alcohol abuse 32 (6.9%) 32 (7.2%) 0 (0.0%) 0.63 
    Current smoking 23 (5.0%) 23 (5.2%) 0 (0.0%) 1.00 
Other co-morbidities: 
Chronic pulmonary disease 57 (12.4%) 54 (12.2%) 3 (16.7%) 0.48 
Cancer 16 (3.5%) 16 (3.6%) 0 (0.0%) 1.00 
Dementia 7 (1.5%) 6 (1.4%) 1 (5.6%) 0.25 
Depression  65 (14.1%) 63 (14.2%) 2 (11.1%) 0.71 
Thyroid disorders 7 (1.5%) 7 (1.6%) 0 (0.0%) 0.59 
AF: Atrial Fibrillation; BMI: Body Mass Index 
 
 
 
 
 
 
 
 
Table 10.2. Independent risk factors for atrial fibrillation 
Variables Unadjusted OR (95% CI) Adjusted OR (95% CI) 
Heart failure 21.15 (7.57 – 59.07) 31.29 (9.62 – 101.75) 
Living alone 7.79 (1.50 – 40.49) 10.23 (1.49 – 70.11) 
Using vitamins at home 2.46 (0.85 – 7.13) 3.77 (1.06 – 13.37) 
Type 2 diabetes  2.68 (1.03 – 6.96) 3.53 (1.17 - 10.69) 
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Table 10.3. Stroke risk identified by CHA2DS2-VASc score 
Variables  All (N=18) 
Mean CHA2DS2-VASc score  5.11 ± 1.81 
CHA2DS2-VASc score ≥2  18 (100%) 
Individual components of CHA2DS2-VASc score, n (%) 
     Congestive heart failure  9 (50.0%) 
     Hypertension  13 (72.2%) 
     Age≥75 13 (72.2%) 
     Age 65-74 3 (16.7%) 
     Diabetes mellitus  8 (44.4%) 
     Stroke 10 (55.6%) 
     Vascular disease 1 (5.6%) 
     Female  11 (61.1%) 
 
 
 
 
 
 
 
 
226
 
 
 
 
 
 
 
 
 
 
Table 10.4. Bleeding risk assessment with HASBLED score  
Variables  All (N=18) 
Mean HAS-BLED score 3.56 ± 1.89 
HAS-BLED score ≥3 13 (72.2%) 
Individual components of HAS-BLED score, n (%) 
     Hypertension 13 (72.2%) 
     Abnormal renal function 4 (22.2%) 
     Abnormal liver function 1 (5.6%) 
     Stroke 10 (55.6%) 
     Bleeding history/ predisposition to bleeding 5 (27.8%) 
     Age ≥ 65 16 (88.9%) 
     Labile INR 0 (0.0%) 
     Aspirin/NSAIDs using 11 (61.1%) 
     Alcohol abuse 0 (0.0%) 
INR: International Normalised Ratio; NSAIDs: Non-steroidal Anti-inflammatory Drugs  
 
 
 
227
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10.5. Pharmacological treatment of atrial fibrillation 
 Treatment on admission 
(N= 18) 
Treatment on discharge 
(N= 18) 
Anticoagulants 4 (22.2%)  
(all acenocoumarol) 
4 (22.2%) 
(3 acenocoumarol,  
1 dabigatran) 
Aspirin  2 (11.1%) 3 (16.7%) 
Rate control only 3 (16.7%) 8 (44.4%) 
Rhythm control only 0 (0%) 1 (5.6%) 
No anti-arrhythmics  15 (83.3%) 9 (50.0%) 
Details of anti-arrhythmic drugs: 
Digoxin  1 (5.6%) 6 (33.3%) 
Beta-blockers 2 (11.1%) 3 (16.7%) 
Calcium channel blockers 0 (0%) 0 (0%) 
Amiodarone  0 (0%) 1 (5.6%) 
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Chapter Eleven  
Thesis Summary, Discussion and Conclusion 
 
11.1. Principle findings 
 
The broad aim of this thesis was to investigate the impact of frailty on the pharmacological 
treatment and outcomes in older patients with AF by performing studies in these research areas. 
Some aims changed during the course of the study. A dominant part of this thesis involved a 
prospective observational study in Australia about the impact of frailty on the pharmacological 
treatment, coagulation changes and outcomes in older inpatients with AF. This thesis also 
aimed to investigate the evidence on research about AF and frailty in developing countries with 
two systematic reviews and an observational study in Vietnam. 
Chapter Four is a prospective observational study that described the differences in clinical 
characteristics, pharmacological treatment and incidence of stroke and major bleeding over six 
months between the frail and the non-frail. In this study, a cohort of 302 inpatients aged ≥65 
years with AF at Royal North Shore Hospital, a tertiary referral teaching hospital in Sydney, 
Australia, was recruited. Of these, 134 patients participated in the sub-study on coagulation 
function. Compared to the non-frail, frail participants were older, had more comorbidities and 
higher risk of strokes (as reflected by CHA2DS2-VASc score) but not haemorrhage (as 
reflected by HASBLED score). Upon discharge, 55.7% participants were prescribed 
anticoagulants (49.3% frail, 62.6% non-frail, p=0.02). Compared to non-frail, frail participants 
were less likely to be prescribed an anticoagulant and were more likely to receive digoxin upon 
discharge, although the impact of frailty on these prescriptions was reduced in multivariate 
analysis. Compared to previous studies in Australia, prevalence of prescription of 
anticoagulants has increased in older patients with AF over the last decades, especially in the 
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frail (Krass, Ogle et al. 2002; Perera, Bajorek et al. 2009). A significant percentage of 
participants with AF received antiplatelets with no evidence of ischemic heart disease, 
suggesting that antiplatelets may be used for stroke prevention in AF although current 
guidelines do not recommend aspirin for stroke prevention in AF unless patients refuse the use 
of any oral anticoagulant (Camm, Lip et al. 2012; January, Wann et al. 2014). After six months, 
overall incidence of ischemic stroke was 2.1% and, in patients taking anticoagulants, incidence 
of major/severe bleeding was 6.3%, with no significant difference between frailty groups. The 
findings from Chapter Five established that in older inpatients with AF, frailty was associated 
with prolonged length of stay and increased all-cause mortality but not re-admission during six 
months after discharge. The coexistence of frailty and delirium during hospitalisation 
significantly increased the risk of mortality.  
The findings from Chapter Six and Chapter Seven revealed several impacts of frailty on 
responses to antithrombotic therapies and coagulation function. In Chapter Six, platelet 
aggregation studies were performed using Whole Blood Impedance Aggregometry. While 
there was no significant relationship between frailty and platelet aggregation in participants not 
taking any antiplatelet drugs, there was a reduced responsiveness to aspirin in the frail amongst 
those taking aspirin. The observed reduced platelet responsiveness to aspirin in the frail 
supports the current guidelines that do not recommend aspirin for stroke prevention in AF. In 
Chapter Seven, the Overall Haemostatic Potential (OHP) and Calibrated Automated 
Thrombogram (CAT) were used to globally assess coagulation function. Compared to non-frail 
participants, frail participants had significantly reduced fibrin generation, which may reflect 
decreased acute phase response in the frail. There was no difference in coagulation profiles 
between the frail and the non-frail on warfarin, suggesting that frail warfarinised patients are 
not at higher risk of bleeding, which was consistent with the clinical follow up findings.  
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Table 11.1. Summary of the impact of frailty on pharmacological treatment, outcomes, 
responses to antithrombotic drugs and coagulation function in older inpatients with atrial 
fibrillation in Australia  
Factors  The impact of frailty 
Anticoagulant prescription upon discharge  
 
Little impact  
(adjusted OR 0.7, 95%CI 0.4-1.1) 
Anti-arrhythmic prescription upon discharge No impact 
Length of stay Prolonged (adjusted OR 2.1, 95%CI 1.2-3.7) 
Re-admission after six months No impact 
Mortality after six months Increased (adjusted HR 2.3, 95%CI 1.3-4.1) 
Efficacy of anticoagulants (incidence of 
stroke after six months) 
No impact 
Safety of anticoagulants (incidence of major 
bleeding after six months) 
No impact 
Coagulation function Reduced fibrin generation in acute illnesses 
Response to warfarin No impact 
Platelet function (aggregation) No impact 
Response to aspirin Reduced responsiveness 
 
Chapter Eight and Chapter Nine provided insights into the current state of research of AF and 
frailty in developing countries. Chapter Eight presented a summary of 70 studies of AF in low 
and middle income countries. The prevalence of AF in the community-based studies ranged 
from 0.03% to 1.25%, while the prevalence of AF in hospital-based studies varied from 0.7% 
to 55.7%. The most common conditions associated with AF were hypertension and valvular 
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heart disease. The prevalence of stroke in patients with AF ranged from 6.7% to 27%. The 
utilisation of anticoagulants was highly variable (2.7%-72.7%). Approximately half of the 
patients with AF using warfarin had therapeutic International Normalised Ratios. There was a 
high prevalence of use of rate control therapies (55.3%-87.3%). Chapter Nine presented a 
summary from 20 studies of frailty in low and middle income countries. The prevalence of 
frailty in community-dwelling older people was 8%-31% in Brazil, 14%-15% in Mexico, 5%-
31% in China, and 21%-44% in Russia. The prevalence of frailty was 49% in institutionalised 
older patients in Brazil and 32% in hospitalised older patients in India. The prevalence of frailty 
in outpatient clinics was 55%-71% in Brazil and 28% in Peru. Fried’s phenotype for frailty was 
used to define frailty in the majority of studies. Frailty was associated with increased mortality 
and comorbidities, decreased physical and cognitive function, and poor perceptions of health. 
In these two reviews, there were no published studies of the pharmacological treatment of AF 
in older patients and no published studies related to frailty in Vietnam, a typical developing 
country with rapidly ageing population in the Southeast of Asia.  
Chapter Ten presented a cross-sectional study of the prevalence of AF among older hospitalised 
patients in Vietnam and the clinical characteristics and treatment of these patients. Of the 461 
older patients recruited at the National Geriatric Hospital in Vietnam during seven months, the 
prevalence of AF was 3.9%, which is similar to that reported in other countries. Amongst 
patients with AF, the most common medical conditions were hypertension (72.2%), followed 
by stroke (55.6%), heart failure (50.0%), type 2 diabetes (44.4%). Living alone (OR=10.2, 
95%CI 1.5–70.1), having a habit of using vitamins at home (OR=3.8, 95%CI 1.1–13.4), having 
heart failure (OR=31.3, 95%CI 9.6–101.8), and having type 2 diabetes (OR=3.5, 95%CI 1.2–
10.7) were associated with the presence of AF on admission. All patients with AF had a high 
risk of stroke and 72.2% of them had a high risk of bleeding with anticoagulant medications. 
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Only 22.2% were anticoagulated on admission and 22.2% upon discharge, with no difference 
between frail and non-frail patients. 
11.2. Strengths and limitations of the thesis 
The review of AF in developing countries has some limitations. First, the articles were restricted 
to English and French. Secondly, there may be bias and a lack of generalizability from some 
small size studies with variable sampling techniques from epidemiologic surveys to 
convenience samples. Small studies are also prone to random error, as reflected in wider 
confidence intervals. The quality of data also varies from objective data collection to self-report 
of AF, medical therapy and co-morbidities. In many studies, there is not adequate data to assess 
the appropriateness of therapy and this was beyond the scope of our review. Older studies may 
not reflect current practice.  
The review of frailty in developing countries also has some limitations. First, the articles were 
restricted to English only. We may have missed some papers that were not available in English 
full-text or in journals that were not indexed on MEDLINE and EMBASE. Secondly, there 
may be bias due to inadequate sampling techniques, including use of convenience samples. 
Thirdly, comparison of prevalence between studies using different frailty assessment methods 
is complicated by the fact that, even within the same population, different frailty assessments 
classify different participants as frail (Hilmer and Gnjidic 2014). Since within populations the 
prevalence of frailty increases with age (Song, Mitnitski et al. 2010; Hilmer and Gnjidic 2014), 
another limitation of this study was comparing studies that included people of different ages.  
The observational studies in Australia and in Vietnam also have potential flaws. Single site 
hospitals with local cultures for prescribing and exposure to differing specialties with differing 
perceptions of benefit risk balance for prescribing in frailer older adults may effect on the 
comparisons between the frail and the non-frail. They were done in the acute care setting at 
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tertiary hospitals in Sydney and in Hanoi, which may not be representative for all older patients 
with AF in each country. In both studies, information on the characteristics of those that were 
excluded/ refused/ lost to follow up cannot be fully obtained. Prevalent anticoagulant use was 
not differentiated from incident anticoagulant use. All pre-admission medications were just 
collected from the medical records. For the Australian study, power calculation assumptions were 
not met, which could partly explain why the impact of frailty on anticoagulant prescription became 
insignificant on multivariable logistic regression. The major limit of the Vietnam study is the small 
number of participants with AF, which may make the comparisons of anticoagulant use in frail and non-
frail patients less meaningful. This also reflects by the wide confidence intervals of the risk factors for 
AF. Therefore, results should be cautiously interpreted and generalised to older inpatients with AF. 
This thesis has several strengths. The two systematic reviews of AF and frailty in developing countries 
were the first reviews of these issues in the developing world. The clinical studies in this thesis did not 
focus only on anticoagulants but on comprehensive pharmacological treatment of AF. The Australian 
study was the first study reporting the predictive value of frailty for mortality in older inpatients with 
AF and it comprised a sample of very old and frail people, who are often excluded from studies. The 
two pilot studies in this thesis were the first studies to examine the association between frailty and 
coagulation in acute phase of illness, and between frailty and platelet aggregation. This thesis also 
included the first study to comprehensively address prevalence, risk factors and management of AF in 
older patients in Vietnam. 
 
11.3. Conclusions, implications and suggestions for future research  
11.3.1. The impact of frailty on anticoagulant utilisation and outcomes in frail older 
patients with AF 
Anticoagulants were potentially underutilised in the cohort of older Australian patients with 
AF. While frail participants were less likely to use anticoagulants, frailty status had no 
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independent impact on anticoagulant prescription and major bleeding over six months of follow 
up. This may reflect the detailed complex prescribing decisions made for our cohort, which 
cannot be captured by a simple frailty score. The low rate of major bleeding complications may 
reflect careful patient selection and management of anticoagulation in Australia. The clinical 
findings, together with the coagulation tests suggesting that frail warfarinised patients are not 
at higher risk of bleeding, support the utilisation of warfarin in frail older patients with AF in 
whom anticoagulation is indicated for stroke prevention. A large size, multi-centre prospective 
cohort study or pharmaco-epidemiological study using existing linked healthcare data looking 
at outcomes in frail and non-frail patients on anticoagulants is needed to derive accurate results 
about the impact of frailty on anticoagulation utilisation, efficacy and complications. Future 
studies are also needed to investigate the impact of frailty on the utilisation and outcomes of 
newer direct anticoagulants such as dabigatran, rivaroxaban, apixaban, edoxaban, and potential 
issues with these new oral anticoagulants in the frail. As potential therapies for frailty are 
emerging (Jeffery, Shum et al. 2013; Cherniack, Florez, et al. 2007), more studies are needed 
to investigate the interactions of anticoagulants with these new drugs in older patients with AF 
in the future when these new drugs are implemented into clinical practice. 
In the study in this thesis frailty was a common geriatric syndrome in older inpatients with AF 
and was associated with increased all-cause mortality and prolonged hospitalisation. Screening 
for frailty along with other clinically important factors should be considered in older patients 
with AF to optimise individualised treatment plans. There is a conflict in the literature about 
the role of frailty in treatment planning amongst older patients with AF. Some have argued that 
frailty is an important factor in determining outcomes in older people with AF and an 
anticoagulant focused geriatric assessment should be developed (Hanon et al 2013; Granziera 
et al 2015). Such an approach may help clinicians use anticoagulants more cautiously in frail 
patients and follow them up more regularly. In addition, a tailored anticoagulation therapy can 
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be prescribed for frail patients (i.e. in favour of vitamin K antagonists or newer oral 
anticoagulants according to different frailty aspects) (Granziera et al 2015). In contrast, others 
suggested that the measurement of frailty is not necessary because frailty, like age, correlate 
with both ischaemic and bleeding events (Andreotti, Rocca et al. 2015). The low prevalence of 
anticoagulant utilisation and low prevalence of complications observed in this study suggest a 
high level of caution in Australian practice. 
11.3.2. The utilisation of aspirin in older patients with AF 
The observed reduced platelet responsiveness to aspirin in the frail supports the current 
guidelines that do not recommend aspirin for stroke prevention in AF, especially in patients 
aged 75 years or older (Camm, Lip et al. 2012; January, Wann et al. 2014). There is clinical 
evidence that the efficacy of antiplatelet therapy for stroke prevention decreases with age (van 
Walraven, Hart et al. 2009). This finding also raises a question about the risk benefit ratio of 
aspirin prescription in older patients with AF. Aspirin utilisation for stroke prevention is 
usually commoner in the frail, in whom prescribers may be more concerned about using 
anticoagulants. More well designed studies with larger sample sizes to investigate the impact 
of frailty on aspirin responsiveness are needed to confirm this finding. Besides secondary 
prevention, the role of aspirin in primary prevention for other cardiovascular diseases (such as 
ischemic heart disease and peripheral vascular disease) has been investigated in several large 
trials over the past three decades, and yet the issue remains controversial (Ward, Demos et al. 
2012). A recent systematic review showed that there is a lack of data in patients 80 years of 
age and older and it is difficult to make a decision on the initiation of aspirin therapy in this 
population (Sarbacker, Lusk et al. 2016). Additional research of the effect of aspirin in old and 
frail patients, both clinical and laboratory, is necessary to better balance the risk versus benefit 
of this treatment option. At the moment, ASPREE (ASPirin in Reducing Events in the Elderly) 
is the largest primary prevention aspirin study in older people in Australia and in the USA 
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(ASPREE Investigator Group 2013). Results of the principal ASPREE study would be released 
in 2018, which will answer the questions whether daily low-dose aspirin prevents or delays the 
onset of age-related illness such as cardiovascular disease, dementia, depression and certain 
cancers and if the benefits outweigh the risks, such as bleeding (ASPREE Investigator Group 
2013). 
11.3.3. Coagulation changes in the frail 
The reduced fibrin generation observed in study in this thesis in frail hospitalised patients 
contributes to the understanding of frailty, particularly during the acute phases of illness. Most 
of the studies regarding pathophysiology of frailty have been conducted in stable, community-
dwelling older adults (Zaslavsky, Cochrane et al. 2013). More studies in acute hospitalised frail 
older patients are needed to provide more insights into changes in pathophysiology, 
pharmacodynamics, pharmacokinetics and adverse drug reactions, as acute health care settings 
are common sites for drug utilisations and interactions.  
Coagulation is a complicated process. There is some evidence that most coagulation reactions 
take place on different cell surfaces and a new cell-based model of coagulation has been 
proposed to replace the “cascade” model of coagulation that describes the intrinsic and extrinsic 
pathways (Hoffman 2003; Antovic 2008). The diagnosis of haemostasis abnormalities is very 
demanding work which cannot be captured with measurements of individual clotting factors. 
Patients with similar level of clotting factors could exhibit variable severity of clinical 
symptoms and bleeding tendency as there are many other factors that could impact on bleeding 
risk other than simple concentration of a clotting factor (Antovic 2008). Hypocoagulation or 
hypercoagulation are designated by derangements in thrombin generation, clot formation, clot 
stability, and disruption in fibrinolysis (Antovic 2008). The formation of detectable fibrin clots, 
which is the end-point in standard clotting assays (such as activated partial thromboplastin time 
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– aPTT, prothrombin time – PT), happens when around 5% of the total amount of thrombin 
produced and subsequent haemostatic reactions or potential abnormalities in the haemostatic 
process cannot be observed by these tests (Mann, Brummel et al. 2003). New global 
coagulation assays such as Overall Haemostatic Potential assay (OHP) and the Calibrated 
Automated Thrombogram (CAT) have advantages over conventional coagulation tests. OHP 
measures ex-vivo fibrin generation and fibrinolysis overtime and CAT measures ex-vivo 
thrombin generation potential. Further studies with global coagulation assays such as OHP and 
CAT (rather than the measurement of individual clotting factors) in community dwelling older 
people may help contribute to the knowledge about the pathophysiology of frailty. 
11.3.4. Research on AF and frailty in developing countries 
In the developing world there is a significant prevalence of AF, which is predominantly 
associated with hypertension and valvular heart disease, and carries a risk of stroke. Highly 
variable use of anticoagulants may be related to different health care and socioeconomic 
settings. The health care systems in developing countries are facing many challenges in 
providing safe and cost-effectiveness treatment for patients (Bista, Chalmers et al. 2014). In 
addition, ethnopharmacologic research has affirmed the significant impact of ethnicity on drugs 
responses (Munoz and Hilgenberg 2006). As most of current clinical guidelines in developing 
countries come from developed countries, genetic factors or cultural factors may lead to 
differences in drug responses in patients in the developing world. The introduction of newer 
anticoagulants in these countries provides some advantages in terms of monitoring compared 
to vitamin K antagonists. Subgroup analysis in anticoagulant studies showed that the benefits 
of newer anticoagulants such as dabigatran may be better than warfarin in developing countries, 
as  the hemorrhagic stroke rates were higher on warfarin in Asians versus non-Asians, despite 
similar blood pressure, younger age, and lower international normalised ratio values (Hori, 
Connolly et al. 2013). However, there are also many challenges regarding budget concerns and 
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lack of evidence of the safety of these new drugs in developing countries (Bista, Chalmers et 
al. 2014). More studies are needed to improve understanding of the epidemiology and 
management of AF in developing countries. 
The limited studies available suggest that the prevalence of frailty is quite consistent across 
those developing countries where research has been conducted. However, there was no data 
from low income countries where the prevalence of frailty may be higher. The limited studies 
available suggest that frailty occurs frequently in the developing world and it appears to be 
associated with adverse outcomes. This has implications for policy and health care provision 
for these ageing populations. These findings support the need for more research on frailty in 
developing countries and also raise a question regarding the feasible approaches for frailty 
research in developing countries.  
11.3.5. Atrial fibrillation in older people in Vietnam 
In the cross-sectional study in Vietnam, factors associated with AF were heart failure, type 2 
diabetes, living alone and a habit of using vitamins at home (as a self-medication). 
Anticoagulation for stroke prevention was underused, without any significant difference 
between frail and non-frail patients. The prevalence of stroke amongst patients with AF was 
quite high (55.6%). These findings suggest that in older patients with AF in Vietnam, it is 
important to check for heart failure and diabetes. These findings support the need for future 
cohort studies in Vietnam on the management of AF in older people with larger sample sizes 
to examine the impact of frailty on anticoagulation prescription and outcomes. Future studies 
should also focus on time in therapeutic ranges amongst patients on warfarin to identity 
whether the high prevalence of stroke in older patients in Vietnam was due to poor 
anticoagulation management and follow up. The findings from this study also suggest that there 
should be studies on self-medications in older people in Vietnam.  
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Compared to Australia, older inpatients with AF in Vietnam were younger (mean age 79 years 
in patients in Vietnam versus 85 years in Australia). The cardiovascular risk factors were rather 
similar, with hypertension being the most common associated disease (72% in Vietnam versus 
69% in Australia), followed by heart failure (50% in Vietnam versus 43% in Australia). The 
prevalence of frailty in older patients with AF in Vietnam was lower than in Australia (39% 
versus 53%, respectively). The prevalence of anticoagulation in older patients with AF in 
Vietnam was much lower than in Australia (22.2% versus 55.7% upon discharge). 
Antiarrhythmic medications were less commonly prescribed in Vietnam compared to Australia 
(non-prescription 50% versus 22%, respectively).  
11.3.6. Conclusion 
In conclusion, AF and frailty are growing public health concerns in developed countries as well 
as in the developing world. The studies in this thesis in Australia and Vietnam provide new 
evidence on the frequency, treatment and prognosis for patients with AF. Frailty was common 
in older patients with AF in both Australia and in Vietnam. In both countries there was evidence 
of sub-optimal use of anticoagulant medications: among frail people with AF in Australia and 
among all patients with AF in Vietnam. The interaction between frailty and coagulation 
requires further laboratory investigation. Further clinical epidemiological research is needed 
on AF and frailty in developing countries such as Vietnam. Such research will become 
increasingly important as population ageing leads to rapidly increasing numbers of people with 
AF and/or frailty. 
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Abstract
Background: Frailty is common in patients with atrial fibrillation and may impact on
antithrombotic and anti-arrhythmic treatment.
Aim: To describe differences in clinical characteristics, prescription of antithrombotic and
anti-arrhythmic medications and incidence of haemorrhage and stroke, between frail and
non-frail older inpatients.
Methods: Prospective observational study in patients aged ≥65years with atrial fibrillation
admitted to a teaching hospital in Sydney, Australia. Frailty was assessed using the Reported
Edmonton Frail Scale, stroke risk with CHA2DS2-VASc score and bleeding risk with
HAS-BLED score. Participants were followed after 6months for haemorrhages and strokes.
Results: We recruited 302 patients (mean age 84.7 ± 7.1 years, 53.3% frail, 50% female,
mean CHA2DS2-VASc 4.61 ± 1.44, mean HAS-BLED 2.97 ± 1.04). Frail participants were
older and had more co-morbidities and higher risk of stroke but not haemorrhage. Upon
discharge, 55.7% participants were prescribed with anticoagulants (49.3% frail, 62.6%
non-frail, P = 0.02). Thirty-three per cent received antiplatelets only and 11.1% no
antithrombotics, with no difference by frailty status. For anti-arrhythmics, 52.6% received
rate-control drugs only, 11.8% rhythm-control drugs only and 13.5% both and 22.1%
were not prescribed either, with no difference by frailty status. On univariate logistic regres-
sion, frailty decreased the likelihood of anticoagulant prescription (odds ratio (OR) 0.58,
95%CI 0.36–0.93), but this was not significant on multivariate analysis (OR 0.66, 95%CI
0.40–1.11). After 6months, overall incidence of ischaemic stroke was 2.1%, and in patients
taking anticoagulants, incidence ofmajor/severe bleedingwas 6.3%, with no significant dif-
ference between frailty groups.
Conclusions: Frailty status had little impact on antithrombotic prescription and no impact
on anti-arrhythmic prescription.
Introduction
As the population ages, the prevalence and clinical impor-
tance of frailty are increasing.1 Frailty is a clinical syndrome
resulting from multisystem impairments and characterised
by increased vulnerability and disabilities.2Multiple physio-
logical factors are thought to be involved in the develop-
ment of frailty, including the cardiovascular systems and
thrombotic pathways.3,4 A relationship between frailty
and cardiovascular disease has been observed, in which
frailty has strong relationships with ischaemic heart disease,
heart failure and atrial fibrillation (AF).5,6 Frailty predicts
adverse outcomes, such as co-morbidities, polypharmacy,
loss of independence, increasing hospitalisations and mor-
tality in older patients and especially in patientswith cardio-
vascular diseases.5,7
AF is a common cardiac arrhythmia in older adults. The
prevalence of AF in published studies in Western countries
ranges from 0.5% to 3% in the general population, 5% to
6% in people older than 65years old and up to 5%
to15% among those aged 80years or older.8–10 In Austra-
lia, the prevalence of AF in the community-dwelling people
aged 30years or older is 4%.11 People with AF have an
increased risk of stroke.12 The annual incidence of stroke
in people with AF is approximately 5%, which is two to
seven times higher than the average rate of stroke in the
general population, depending on the presence of other
stroke risk factors.12 According to the Framingham study,
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the annual risk of stroke in patients with AF was 1.5% in
those aged 50–59years and 23.5% in those aged
80–89years.13 Strokes associated with AF tend to be
more severe and result in greater disability, longer hospi-
tal stays and less likelihood of discharge to patients’ own
homes than strokes not associated with AF.14 Treatment
of AF aims at stroke prevention with antithrombotic ther-
apy, reducing symptoms with rate-control or rhythm-
control strategies, and management of associated medical
conditions.15 Antithrombotic therapy in patients with AF
has been shown to reduce the frequency, severity and
mortality from stroke.16–18 However, despite the evident
benefits of anticoagulants in preventing stroke, studies
have shown that anticoagulants are underutilised in
patients with AF, especially in older patients.19–24 The
prevalence of chronic diseases, polypharmacy and ad-
verse drug reactions all increase with ageing.25 Changes
in pharmacokinetics and pharmacodynamics with ageing,
frailty and multimorbidity also increase inter-individual
and intra-individual variabilities.25,26 Only a few pub-
lished studies have focused on frailty and pharmacologi-
cal treatment of AF, and these have been limited to
anticoagulation.24,27–30
This study aims to investigate in frail and non-frail
older inpatients with AF the differences in clinical
characteristics, prescription of antithrombotic and anti-
arrhythmic medications, incidence of major bleeding
and strokes over 6months, and to identify whether
frailty is independently associated with prescription of
these medications.
Methods
Participant selection
A prospective observational study was performed on
a cohort of patients aged ≥65years with nonvalvular
AF admitted to Royal North Shore Hospital, Sydney,
Australia, between October 2012 and January 2014. The
study was approved by The Northern Sydney Local Health
District Human Research Ethics Committee and The
University of Sydney Human Research Ethics Committee.
Patients were eligible to participate if they were aged
≥65years and diagnosed with AF. Exclusion criteria were
severe illness and severe hearing or visual impairment. El-
igible patients were identified daily from the target wards
(aged care, cardiology and general medicine) and invited
to participate. Consent was obtained from all participants
or their caregivers. Baseline data collection included
sociodemographics, medical history, reasons for admis-
sion, individual components of the Charlson co-morbidity
index and the Reported Edmonton Frail Scale (REFS) (see
details in the succeeding texts) and medication prescribed
on admission and discharge. Medications on admission
were obtained from the medical record, using the best
available medication history from medication reconcilia-
tion where available. Medications on discharge were ob-
tained from the hospital discharge summary, which was
routinely reconciled by a clinical pharmacist as part of
usual care.
All participants were followed up for any bleeding
events, ischaemic strokes and death by conducting struc-
tured phone interviews 6months after recruitment. Where
participants or their caregivers could not be contacted, hos-
pital medical records were assessed for outcomes over the
6months after recruitment. Haemorrhage events were
classified as minor (bleeding/bruising that did not require
hospitalisation), major (internal bleeding or bleeding/
bruising that required hospitalisation) or severe (intracra-
nial or fatal bleeding).31
Stroke risk and bleeding risk assessment
In patients with nonvalvular AF, the CHA2DS2-VASc
score is recommended for assessment of stroke risk,
and oral anticoagulants are recommended for patients
with high risk of stroke on this scale.32 The individual
components of the CHA2DS2-VASc score include the
following: congestive heart failure (1 point), hyperten-
sion (1 point), age ≥75 years (2 points), diabetes mellitus
(1 point), stroke/transient ischaemic attack (2 points),
vascular disease (prior myocardial infarction, peripheral
artery disease or aortic plaque) (1 point), age
65–74 years (1 point) and female gender (1 point). The
maximum score is 9, and a total score of 2 or above indi-
cates a high risk of stroke.
The HAS-BLED score reﬂects the risk of bleeding
among patients with AF and on anticoagulants. One
point is assigned for each individual components, includ-
ing hypertension, abnormal renal function (dialysis,
kidney transplant, creatinine clearance >200 μmol/L),
abnormal liver function (cirrhosis or bilirubin > two
times normal or AST – aspartate aminotransferase/ALT
– alanine aminotransferase/ALP – alkaline phosphatase
> three times normal), stroke history, history of major
bleeding or predisposition to bleeding, labile International
Normalised Ratios if on warfarin, age >65years, con-
comitant antiplatelet or non-steroidal anti-inﬂammatory
drugs use and alcohol abuse. The maximum score is 9,
and a total score of 3 or above indicates a high risk of
bleeding.33
Frailty assessment
The REFS was used to identify frail participants. This scale
was adapted from the Edmonton Frail Scale for use with
Frailty and atrial fibrillation
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Australian acute inpatients based on a questionnaire and
has been validated.34 The scale involves nine frailty
domains (cognition, general health status, functional inde-
pendence, social support, medication use, nutrition, mood,
continence and functional performance).With amaximum
score of 18, a score of 0 to 5 indicates robust, 6 to 7 indicates
apparently vulnerable status, 8 to 9 mild frailty, 10 to 11
moderate frailty and 12 or more indicates severe frailty.
The cut point used to identify frailty was 8, consistent with
previous studies using REFS.35–37
Statistical analysis
Analysis of the data was performed using SPSS forWindows
20.0 (IBM Corp., Armonk, NY, USA). Continuous variables
are presented asmean ± standard deviation, and categorical
variables as frequency and percentage. Comparisons be-
tween frail and non-frail participants were assessed using
the chi-square test for categorical variables and Student’s
t-test or Mann–Whitney test for continuous variables. Mul-
tivariate logistic regression was used to identify whether
frailty was associated with antithrombotic prescription
and rate/rhythm control drug prescription. Results are
presented as odds ratios (OR) and 95% confidence inter-
vals. Univariate logistic regression was performed on all
the potential predictors for anticoagulant prescription and
rate/rhythm control drug prescription (frailty, age, gender,
reported poor nutrition status, paroxysmal AF, permanent
pacemaker, hypertension, ischaemic heart disease, heart
failure, stroke/systemic thromboembolism, type 2 diabetes,
peripheral vascular disease, dyslipidaemia, chronic pulmo-
nary disease, cancer, dementia, depression, severe renal
impairment, abnormal liver function, alcohol abuse, his-
tory of bleeding/predisposition to bleeding and falls on
admission). Only variables that had a P-value < 0.20 on
univariate analysis were entered into multivariate analysis.
Backward elimination method was applied, and the final
model retained the studied variable (which is frailty) and
those variables significant at P < 0.05. Incidence of strokes
and bleeding over 6months was compared between frail
and non-frail participants according to antithrombotic
regimens: anticoagulants ± antiplatelets, antiplatelets only
and no antithrombotics. Two-tailed P-values < 0.05 were
considered significant.
Results
Three hundred and two patients were recruited. The mean
age of the participants was 84.7 ± 7.1 years (range 65–100),
and 50% (151/302) were female. The prevalence of frailty
was 53.3% (161/302). Hypertension (68.9%)was themost
prevalent co-morbidity, followed by ischaemic heart
disease (44.4%) and heart failure (43.4%). Falls (22.2%)
and shortness of breath (22.8%) were the most common
reasons for admission with no difference between frail
and non-frail participants. Overall, compared with non-
frail participants, frail participants were significantly older,
had higher scores on the Charlson co-morbidity index,
higher prevalence of heart failure and peripheral vascular
disease and lower serum albumin concentrations (Table 1).
Nearly all participants had high risk of stroke (99.3% had
CHA2DS2-VASc score ≥2), and frail participants had higher
mean CHA2DS2-VASc score compared with the non-frail
(Table 2). There was no difference in terms of bleeding risk
between frail and non-frail participants taking anticoagu-
lants as reﬂected by HAS-BLED score (Table 3).
Prescription of antithrombotic medication
On admission, 51.3% of participants were prescribed with
anticoagulants (46.6% frail, 56.7% non-frail, P = 0.08),
35.1%were prescribed with antiplatelets only (37.3% frail,
32.6% non-frail, P = 0.40) and 13.6% were not prescribed
with any antithrombotic medication (16.1% frail, 10.6%
non-frail, P = 0.16). During hospitalisation, 13 participants
died, leaving 289 participants discharged. Of the discharged
participants, 161 were prescribed with anticoagulants (150
warfarin, seven dabigatran, three rivaroxaban and one
fondaparinux for treatment of deep vein thrombosis/AF),
96 were prescribed with antiplatelet therapy only (63 aspi-
rin, 16 aspirin plus clopidogrel and 17 clopidogrel only) and
32 patients were not prescribed with any antithrombotic
medications. Upon discharge, the prevalence of anticoagu-
lant prescription increased to 55.7%, while the prescription
of antiplatelets decreased to 33.2%, and non-prescription of
any antithrombotic decreased to 11.1% (Fig. 1). Of those
prescribed antiplatelets only, 42.7%had a history of ischae-
mic heart disease. The prevalence of anticoagulant prescrip-
tion on discharge was lower in frail participants (49.3%
frail, 62.6% non-frail, P = 0.02). There was no difference
between frail and non-frail in the prescription of
antiplatelets only (36.7% frail, 29.5% non-frail, P = 0.20).
Non-prescription of any antithrombotic medication was not
signiﬁcantly more common in the frail (14.0% frail, 7.9%
non-frail, P = 0.10).
Predictors of anticoagulant prescription upon
discharge (Table 4)
On univariate logistic regression, frailty signiﬁcantly
decreased the likelihood of anticoagulant prescription on
discharge (OR 0.58, 95%CI 0.36–0.93). However, the
strength of this association reduced slightly and was no
longer signiﬁcant on multivariate analysis (OR 0.66, 95%
CI 0.40–1.11). The covariates that were independently
associatedwith decreased anticoagulant prescription ondis-
charge were increased age, history of bleeding/
Nguyen et al.
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Table 1 Participant characteristics
Variables All (n = 302) Frail (161) Non-frail (141) P
Age (years) 84.7 ± 7.1 85.7 ± 6.7 83.5 ± 7.3 0.008
Age subgroups (years)
65–74 31 (10.3%) 11 (6.8%) 20 (14.2%) 0.03
75–79 35 (11.6%) 17 (10.6%) 18 (12.8%)
80–84 64 (21.2%) 28 (17.4%) 36 (25.5%)
85–89 97 (32.1%) 58 (36.0%) 39 (27.7%)
≥90 75 (24.8%) 47 (29.2%) 28 (19.9%)
Female 151 (50%) 86 (53.4%) 65 (46.1%) 0.21
Paroxysmal AF 50 (16.6%) 20 (12.4%) 30 (21.3%) 0.04
Permanent pacemaker 68 (22.50%) 39 (24.2%) 29 (20.6%) 0.45
Charlson co-morbidity index 3.8 ± 2.2 4.32 ± 2.14 3.18 ± 2.12 <0.001
Cardiovascular diseases and risk factors
Hypertension 208 (68.9%) 114 (70.8%) 94 (66.7%) 0.44
Ischaemic heart disease 134 (44.4%) 74 (46%) 60 (42.6%) 0.55
Congestive heart failure 131 (43.4%) 86 (53.4%) 45 (31.9%) <0.001
Dyslipidaemia 89 (29.5%) 49 (30.4%) 40 (28.4%) 0.70
History of stroke/TIA 76 (25.2%) 44 (27.3%) 32 (22.7%) 0.36
Type 2 diabetes 64 (21.2%) 40 (24.8%) 24 (17%) 0.10
Peripheral vascular disease 27 (8.9%) 21 (13%) 6 (4.3%) 0.008
Other co-morbidities
Chronic pulmonary disease 83 (27.5%) 53 (32.9%) 30 (21.3%) 0.02
Cancer 76 (25.2%) 44 (27.3%) 32 (22.7%) 0.36
Dementia 27 (8.9%) 19 (11.8%) 8 (5.7%) 0.06
Depression 22 (7.3%) 19 (11.8%) 3 (2.1%) <0.001
Serum albumin (g/L) 33.94 ± 4.86 33.12 ± 4.82 34.91 ± 4.75 0.002
eGFR < 30 (mL/min/1.73m2) 36 (11.9%) 24 (14.9%) 12 (8.5%) 0.09
Recruitment wards
Aged care 109 (36.1%) 74 (46%) 35 (24.8%) <0.001
Cardiology 124 (41.1%) 53 (32.9%) 71 (50.4%)
General medicine 69 (22.8%) 34 (21.1%) 35 (24.8%)
Residential status on admission
Nursing home 18 (6.0%) 15 (9.4%) 3 (2.1%) <0.001
Hostel 25 (8.3%) 21 (13.2%) 4 (2.8%)
Community with family 143 (47.4%) 76 (47.8%) 67 (47.5%)
Community alone 103 (34.1%) 42 (26.4%) 61 (43.3%)
Other 11 (3.6%) 5 (3.1%) 6 (4.3%)
Reported nutrition status on admission
Poor 23 (7.7%) 20 (12.7%) 3 (2.1%) <0.001
Stable 90 (30.3%) 56 (35.7%) 34 (24.3%)
Healthy 184 (62.0%) 81 (51.6%) 103 (73.6%)
Reasons for admission
Shortness of breath 69 (22.8%) 44 (27.3%) 25 (17.7%) 0.15
Falls 67 (22.2%) 35 (21.7%) 32 (22.7%)
Infection 30 (9.9%) 17 (10.6%) 13 (9.2%)
Delirium 30 (9.9%) 16 (9.9%) 14 (9.9%)
Chest pain/discomfort 26 (8.6%) 11 (6.8%) 15 (10.6%)
General unwell 21 (7.0%) 11 (6.8%) 10 (7.1%)
Palpitation 15 (5.0%) 2 (1.2%) 13 (9.2%)
Musculoskeletal pain 14 (4.6%) 8 (5.0%) 6 (4.3%)
GI disorder 7 (2.3%) 6 (3.7%) 1 (0.7%)
Elective surgery 6 (2.0%) 3 (1.9%) 3 (2.1%)
Dizziness 3 (1%) 1 (0.6%) 2 (1.4%)
High INR/bleeding 3 (1.0%) 1 (0.6%) 2 (1.4%)
Stroke 2 (0.7%) 1 (0.6%) 1 (0.7%)
(Continues)
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predisposition to bleeding and abnormal renal function,
while congestive heart failure was associated with
increased likelihood of prescription of anticoagulants.
Predictors of prescription of antiplatelets only
upon discharge (Supporting Information
Table 1)
Multivariate analysis showed that increased age and
paroxysmal AF but not frailty signiﬁcantly increased
the likelihood of antiplatelet prescription without con-
current anticoagulant therapy.
Predictors of non-prescription of any
antithrombotic medications upon discharge
(Supporting Information Table 2)
Logistic regression was also performed to identify which
factors were associated with non-prescription of any anti-
thrombotic medication, which occurred for 11.1% of all
Table 1. (Continued)
Variables All (n = 302) Frail (161) Non-frail (141) P
Other 9 (3.0%) 5 (3.1%) 4 (2.8%)
Number of medications on discharge 11.3 ± 4.0 12.3 ± 3.9 10.4 ± 3.8 <0.001
Length of stay 12.8 ± 9.0 14.3 ± 9.6 11.1 ± 7.8 0.002
Continuous data are presented as mean ± standard deviation. Categorical data are shown as n (%). AF, atrial ﬁbrillation; eGFR, estimated glomerular ﬁltration
rate; GI, gastrointestinal; INR, international normalised ratio; TIA, transient ischaemic attack.
Table 2 Stroke risk identiﬁed by CHA2DS2-VASc score
Variables All (n = 302) Frail (161) Non-frail (141) P
Mean CHA2DS2-VASc score 4.61 ± 1.44 4.92 ± 1.44 4.29 ± 1.37 <0.001
CHA2DS2-VASc score ≥2 300 (99.3%) 161 (100%) 139 (98.6%) 0.22
Individual components of CHA2DS2-VASc score
Congestive heart failure 131 (43.4%) 86 (53.4%) 45 (31.9%) <0.001
Hypertension 208 (68.9%) 114 (70.8%) 94 (66.7%) 0.44
Age ≥ 75 years 271 (89.7%) 150 (93.2%) 121 (85.8%) 0.04
Age 65–74 years 31 (10.3%) 11 (6.8%) 20 (14.2%) 0.04
Diabetes mellitus 64 (21.2%) 40 (24.8%) 24 (17%) 0.10
History of stroke/TIA/systemic thromboembolism 76 (25.2%) 44 (27.3%) 32 (22.7%) 0.36
Vascular disease 113 (37.4%) 63 (39.1%) 50 (35.5%) 0.51
Female 151 (50.0%) 86 (53.4%) 65 (46.1%) 0.21
Continuous data are presented as mean ± standard deviation. Categorical data are shown as n (%). TIA, transient ischaemic attack.
Table 3 Bleeding risk assessment with HAS-BLED score (only applied for participants prescribed with anticoagulants upon discharge)
Variables All (n = 161) Frail (74) Non-frail (87) P
Mean HAS-BLED score 2.91 ± 1.01 3.00 ± 1.07 2.83 ± 0.94 0.28
HAS-BLED score ≥3 100 (62.1%) 49 (66.2%) 51 (58.6%) 0.32
Individual components of HAS-BLED score
Hypertension 111 (68.9%) 52 (70.3%) 59 (67.8%) 0.74
Abnormal renal function 9 (5.6%) 3 (4.1%) 6 (6.9%) 0.51
Abnormal liver function 13 (8.1%) 6 (8.1%) 7 (8.0%) 0.99
History of stroke/TIA/systemic thromboembolism 44 (27.3%) 25 (33.8%) 19 (21.8%) 0.09
Bleeding history/predisposition to bleeding 78 (48.4%) 41 (55.4%) 37 (42.5%) 0.10
Age ≥ 65 years 161 (100%) 74 (100%) 87 (100%) N/A
Labile INR 42 (26.1%) 20 (27.0%) 21 (25.3%) 0.80
Aspirin/NSAID using 6 (3.7%) 1 (1.4%) 5 (5.7%) 0.22
Alcohol abuse 5 (3.1%) 1 (1.4%) 4 (4.6%) 0.38
Continuous data are presented as mean ± standard deviation. Categorical data are shown as n (%). INR, international normalised ratio; NSAID, non-steroidal
anti-inﬂammatory drugs; TIA, transient ischaemic attack.
Nguyen et al.
© 2016 Royal Australasian College of Physicians90
249
participants. Frailty was not associated with non-
prescription of antithrombotic medications on univariate
analysis or on multivariate analysis. In the multivariate
logistic model, only dementia and a history of bleeding/
predisposition to bleeding increased the likelihood of
non-prescription.
Prescription of rate/rhythm control
medication upon discharge (Table 5)
Upon discharge, 52.6% of the participants received rate
control therapy only, 11.8% received rhythm control ther-
apy only, 13.5% received both therapies and 22.1% were
not prescribed with any anti-arrhythmic medication, with
no difference between frail and non-frail. Further examina-
tion showed that digitalis prescription was more common
in frail than non-frail participants (29.1% overall, 34.7%
frail, 23.0% non-frail, P = 0.03).
Predictors of non-prescription of any
anti-arrhythmic medication (Supporting
Information Table 3)
Univariate analysis as well as multivariate analysis showed
that frailty was not associated with the likelihood of non-
prescription of anti-arrhythmic medication upon discharge.
In the multivariable model, falls were associated with non-
prescription of these medications (OR 2.40, 95%CI 1.28–
4.53), while female participants (OR 0.51, 95%CI 0.28–
0.91) and participants with heart failure (OR 0.43, 95%CI
0.23–0.81 for heart failure) were less likely not to receive
anti-arrhythmic drugs upon discharge.
Incidence of bleeding and strokes over
6months (Table 6)
Data for follow up were available in 251 participants
(83.1% of all participants, 86.9% of the discharged par-
ticipants). Overall, there were ﬁve stroke events
(2.0%). The incidence of stroke in patients taking antico-
agulants was 2.1%. This incidence was not signiﬁcantly
higher in frail patients compared with the non-frail
(2.9% frail versus 1.4% non-frail, P = 0.61). Overall, there
were 19 bleeding events (11.6%), andmajor/severe bleeding
events were observed in 11 participants (4.4%). In patients
taking anticoagulants, the incidence of major/severe
bleeding was 6.3%, with no difference between frail and
non-frail patients (5.8% frail versus 6.8%non-frail,P=0.96).
Discussion
In this study, compared with non-frail, frail participants
were signiﬁcant older, had more co-morbidities, lower
Figure 1 Prevalence of antithrombotic prescription prior to admission and upon discharge.
Table 4 Factors associated with anticoagulant prescription upon discharge
Variables Univariate Multivariate
OR for anticoagulant prescription (95%CI) P OR for anticoagulant prescription (95%CI) P
Frailty 0.58 (0.36–0.93) 0.02 0.66 (0.40–1.11) 0.12
Age 0.94 (0.90–0.97) <0.001 0.93 (0.89–0.96) <0.001
Bleeding history/predisposition to bleeding 0.53 (0.33–0.85) 0.008 0.57 (0.34–0.95) 0.03
Congestive heart failure 1.59 (0.99–2.56) 0.06 1.95 (1.16–3.27) 0.01
Abnormal renal function 0.48 (0.20–1.15) 0.10 0.33 (0.13–0.87) 0.03
Dementia 0.56 (0.25–1.26) 0.16 – –
Reported poor nutrition 0.52 (0.22–1.27) 0.15 – –
Only variables that had a P-value < 0.20 in univariate regression were entered into multiple regression model together with frailty. OR, odds ratio.
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serum albumin level and higher risk of stroke on the
CHA2DS2-VASc, but no difference in bleeding risk
according to HAS-BLED score. These ﬁndings are in
accordance with the literature, in which frailty is associ-
ated with increased co-morbidities and procoagulant
changes.5,7,8
Anticoagulant prescription
In this study, only around half of older patients were
prescribed an anticoagulant upon discharge. This ﬁnding
is similar to many published studies in Australia and else-
where in the world.28,30,38–41 We found that frail partici-
pants were less likely to be prescribed with an anti
coagulant upon discharge (55.7% overall, 49.3% frail,
62.6% non-frail, P = 0.02). However, the impact of frailty
on anticoagulant prescription was reduced in multivari-
ate analysis. On multivariate logistic regression, chrono-
logical age, history of bleeding/predisposition to
bleeding and abnormal renal function signiﬁcantly de-
creased the likelihood of anticoagulant prescription. Cur-
rent guidelines do not provide speciﬁc guidance for
treatment in frail patients.15,18 Evidence of the impact
of frailty on anticoagulant prescription is conﬂicting.
Some studies suggest that presence of frailty and geriatric
syndromes is associated with non-prescription of antico-
agulants,24,28 while others have not found this.29,30 Inter-
estingly, in our study, a diagnosis of dementia predicted
non-prescription of any antithrombotic medication, which
is consistent with previous studies.42,43
At Royal North Shore Hospital in Sydney, the preva-
lence of anticoagulant prescription in older patients with
AF has increased over the years: from 35.0% in 199744
to 39.1% in 2007 (23.6% in the frail and 66.3% in the
non-frail)24 and 55.7% in this study (49.3% in the frail,
62.6% in the non-frail). The increase in anticoagulation
in older patients with AF, including the frail, over this
period may reﬂect the translation of new evidence into
Table 5 Prescription of anti-arrhythmic drugs and other medications upon discharge
Variables All (n = 290) Frail (150) Non-frail (139) P
Rate control therapy only 152 (52.6%) 79 (52.7%) 73 (52.5%) 0.980
Rhythm control therapy only 34 (11.8%) 17 (11.3%) 17 (12.2%) 0.813
Both 39 (13.5%) 17 (11.3%) 22 (15.8%) 0.264
Nil 64 (22.1%) 37 (24.7%) 27 (19.4%) 0.284
Rate control drugs
Beta-blockers (except sotalol) 126 (43.6%) 61 (40.7%) 65 (46.8%) 0.298
Digitalis 84 (29.1%) 52 (34.7%) 32 (23.0%) 0.029
Non DHP CCB 23 (8.0%) 12 (8%) 11 (7.9%) 0.978
Verapamil 10 (3.5%) 3 (2%) 7 (5%) 0.204
Rhythm control drugs
Amiodarone 32 (11.1%) 20 (13.3%) 12 (8.6%) 0.203
Sotalol 27 (9.3%) 10 (6.7%) 17 (12.1%) 0.104
Flecainide 14 (4.8%) 4 (2.7%) 10 (7.2%) 0.073
Disopyramide 1 (0.3%) 1 (0.7%) 0 (0%) –
Data are presented as n (%). DHP CCB, dihydropyridine calcium-channel blockers.
Table 6 Bleeding and stroke events during 6months follow up according to antithrombotic regimens and frailty status
Overall Frail Non-frail P
Strokes
Anticoagulants (n = 142) 3/142 (2.1%) 2/69 (2.9%) 1/73 (1.4%) 0.61
Antiplatelet only (n = 83) 2/83 (2.4%) 2/49 (4.1%) 0/34 (0%) 0.51
None (n = 26) 0/26 (0%) 0/19 (0%) 0/7 (0%) N/A
Any bleeding
Anticoagulants (n = 142) 19/142 (13.4%) 9/69 (13.0%) 10/73 (13.7%) 0.91
Antiplatelet only (n = 83) 9/83 (10.8%) 4/49 (8.2%) 5/34 (14.7%) 0.48
None (n = 26) 1/26 (3.8%) 1/19 (5.3%) 0/7 (0%) 1.00
Major/severe bleeding
Anticoagulants (n = 142) 9/142 (6.3%) 4/69 (5.8%) 5/73 (6.8%) 0.96
Antiplatelet only (n = 83) 2/83 (2.4%) 1/49 (2.0%) 1/34 (2.9%) 0.39
None (n = 26) 0/26 (0%) 0/19 (0%) 0/7 (0%) N/A
Incidence of stroke and bleeding is presented as n, per cent within frailty.
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clinical practice.45 A signiﬁcant percentage of partici-
pants with AF received antiplatelets with no evidence
of ischaemic heart disease, suggesting that antiplatelets
may be used for stroke prevention in AF.
Incidence of major bleeding and strokes in
patients treated with anticoagulants
In this study, the incidence of major bleeding in patients
taking anticoagulants was 6.3% overall (5.8% in frail
and 6.8% non-frail, P = 0.96) over 6month follow up. In-
ternationally, similar low rates of major bleeding have
been observed in older patients post-discharge46,47 and
in geriatric outpatient settings.48 The incidence of major
bleeding in older patients with AF taking warfarin has
ranged from 1.8–1.9% per year45,49 in randomised clini-
cal trials to as high as 13% in an observational study.50
In Australia, the observed incidence of major bleeding in
older patients taking anticoagulants is also variable, from
3.4% to 20.8%.24,31,51
In this study in very old patients (mean age 84.7 ±
7.1years), the incidence of strokes over 6months in patients
taking anticoagulants was 2.1% overall. This is consistent
with the incidence of strokes in previous Australian studies,
ranging from 2.6% to 3.6%.24,31,51
Digoxin utilisation
In this study, half of the participants received rate con-
trol therapy only, and 22.1% were not prescribed with
any anti-arrhythmic medication with no difference
between frail and non-frail. Nearly one third of the
participants received digoxin on discharge, and this
prevalence was higher in frail participants (34.7% frail,
23.0% non-frail, P = 0.03). There is a long-standing
controversy around the safety of digoxin in older
people. Several studies in older patients have shown
that digoxin prescription is common and is associated
with increased adverse drug reactions,52–54 while other
studies reported that the use of digoxin in older
patients with AF was not associated with increased
morbidity and mortality.55,56 There are many factors
contributing to increased toxicity of digoxin in older
patients, including age-related changes in renal
function, reduced lean body mass and polypharmacy.57
The volume of distribution for digoxin is known to
reduce with age, resulting in higher serum concen
trations,57,58 which may be even higher in frail people
with sarcopenia and reduced renal drug clearance.59–61
Guidelines are needed on dosing and plasma concentra-
tion monitoring of digoxin in older frail and non-frail
patients.
Strengths and limitations
This study has several strengths. The study comprised a
sample of very old and frail people, who are often excluded
from studies.62 We used the validated REFS and high-
quality detailed clinical information.34 This study did not
focus only on anticoagulants but on comprehensive phar-
macological treatment of AF.
A major limitation of this study is that it was per-
formed in the acute care setting at a tertiary hospital in
Sydney, which may not be representative for all older
patients with AF. Small sample size may have limited
the power of this study to detect differences between
frail and non-frail participants. Therefore, results should
be cautiously interpreted and generalised to older inpa-
tients with AF.
Conclusion
Anticoagulants were potentially underutilised in this cohort
of older patients with AF. While frail participants were less
likely to use anticoagulants, frailty status had no independent
impact on pharmacological treatment of AF. This may reﬂect
the detailed complex prescribing decisions made for our co-
hort, which cannot be captured by a simple frailty score.
The low rate of major bleeding complications may reﬂect
careful patient selection andmanagement of anticoagulation.
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Introduction
Atrial fibrillation (AF) is a common cardiac arrhythmia in
older adults. The prevalence of AF in published studies in
Western countries ranges from 0.5% to 3% in the general
population, 5% to 6% in people older than 65 years and up to
5% to 15% among those aged 80 years or older [1–3]. The
global burden of AF has been increasing due to the ageing of
the world population [4]. The rates of AF related hospital-
isations have increased worldwide over the last decades [5–8].
Older hospitalised patients are at increased risk of adverse
outcomes and these outcomes can be predicted by many
factors like advanced age, comorbidities, immobility, malnu-
trition, delirium, falls, polypharmacy and especially by a
frailty status [9,10]. Frailty is an emerging concept in geriatric
medicine. There have been many studies exploring the rela-
tionship between frailty and increased risk of cardiovascular
diseases in community-dwelling older adults [11]. Frailty has
been also found to be associated with increased adverse
outcomes in older patients, especially in patients with
Background Frailty has been found to be associated with increased adverse outcomes in older patients, especially in
patients with cardiovascular diseases. There has been no study focussing on the prognostic value of frailty
amongst older hospitalised patients with atrial fibrillation. This study aims to investigate the impact of
frailty on mortality, length of stay and re-hospitalisation in older hospitalised patients with atrial
fibrillation.
Methods Prospective observational study in patients aged 65 years with atrial fibrillation admitted to a teaching
hospital in Sydney, Australia. Frailty was assessed using the Reported Edmonton Frail Scale. Participants
were followed up for six months for adverse outcomes.
Results We recruited 302 patients (mean age 84.77.1, 53.3% frail, 50% female). Frailty was associated with pro-
longed length of stay and increased mortality but not re-admission during six months after discharge. The
coexistence of frailty and delirium significantly increased the risk of mortality.
Conclusions Frailty is a common geriatric syndrome in older inpatients with atrial fibrillation and is associated with poor
outcomes. Screening for frailty along with other clinically important factors like delirium should be con-
sidered in older patients with atrial fibrillation to optimise individualised treatment plans.
Keywords Frailty  Atrial fibrillation  Mortality  Adverse outcomes
© 2015 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier
B.V. All rights reserved.
*Corresponding author at: Level 12 Kolling Institute of Medical Research, Royal North Shore Hospital, Pacific Hwy, St Leonards NSW 2065 Australia.
Tel.: +61 2 99264481; Fascimile: +61 2 99264053., Email: nngu9517@uni.sydney.edu.au
Heart, Lung and Circulation (2016) 25, 551–557
1443-9506/04/$36.00
http://dx.doi.org/10.1016/j.hlc.2015.12.002
ORIGINAL ARTICLE
255
cardiovascular diseases [12–21]. There have been several
studies reporting that frailty is associated with adverse out-
comes in older hospitalised patients with heart failure and
myocardial infarction, and in patients after cardiovascular
surgery [12,14,16,21,22]. However, there has been no study
focussing on the prognostic value of frailty amongst older
hospitalised patients with atrial fibrillation. In this study we
aimed to investigate the impact of frailty on outcomes in
older hospitalised patients with atrial fibrillation, including
prolonged length of stay, re-admission and all-cause mortal-
ity six months after discharge.
Methods
Participant Selection
During a period of 15 consecutive months, a prospective
observational study was performed on a cohort of patients
aged  65 years with chronic nonvalvular AF admitted to
Royal North Shore Hospital, Sydney, Australia (between
October 2012 and January 2014). The study was approved
by The Northern Sydney Local Health District Human
Research Ethics Committee and The University of Sydney
Human Research Ethics Committee. Patients were eligible to
participate if they were aged  65 years and diagnosed with
AF. Participants who were dying or receiving intensive care
or who were identified as ‘‘blind’’ or ‘‘deaf’’ and unable to see
or hear the investigators respectively on initial contact were
excluded from the study. Eligible patients were identified
daily from the target wards (aged care, cardiology and gen-
eral medicine) and invited to participate. Consent was
obtained from all participants or their caregivers. All partic-
ipants were followed up for six months by conducting phone
calls at the end of the sixth month after recruitment. In cases
where participants or their caregivers could not be contacted,
hospital medical records were assessed for outcomes during
six months.
Definition of Frailty
The Reported Edmonton Frail Scale (REFS) was used to
identify frail participants. This scale was adapted from the
Edmonton Frail Scale for use with Australian acute inpatients
based on a questionnaire and has been validated [23]. The
scale involves nine frailty domains (cognition, general health
status, functional independence, social support, medication
use, nutrition, mood, continence and functional perfor-
mance). With a maximum score of 18, the cutoff point used
to identify frailty was 8, consistent with previous studies
using this scale [24–26].
Other Variables
For each participant, the number of comorbidities and the
number of medications prescribed on discharge were taken
from the medical records. Comorbidities were assessed
with the Charlson Comorbidity Index [27]. The
CHA2DS2-VASc score (congestive heart failure, hyperten-
sion, age 75 years [doubled], diabetes, stroke/transient
ischaemic attack/thromboembolism [doubled], vascular
disease [prior myocardial infarction, peripheral artery dis-
ease, or aortic atherosclerosis], age 65-75 years, female
gender) was used to assess stroke risk, and bleeding risk
for anticoagulants were assessed with the HAS-BLED score
(hypertension, abnormal renal/liver function, stroke,
bleeding history or predisposition, labile international nor-
malised ratio, age  65 years, drugs or alcohol use) [28].
Outcome Variables
Prolonged hospitalisation, hospital readmissions and deaths
were assessed as adverse outcomes in this study. Prolonged
hospitalisation was defined as those with a length of stay
equal to or greater than the 75th percentile of the length of
stay of the whole cohort (measured in days). Readmissions
were defined as at least one readmission to hospital for any
cause during six months. All deaths during hospitalisation
were recorded. Discharged participants or their caregivers
were contacted after six months for information on re-admis-
sions and whether the participant had died during this
period. In those cases (n=20) where participants or their
caregivers could not be contacted, hospital records were used
to ascertain study outcomes.
Analysis of the data was performed using SPSS for Win-
dows 20.0 (IBM Corp., Armonk, NY, USA). Continuous var-
iables are presented as mean  standard deviation, and
categorical variables as frequency and percentage. Compar-
isons between frail and non-frail participants were assessed
using Chi-square tests for categorical variables and Student’s
t-tests or Mann-Whitney tests for continuous variables. Two-
tailed P values < 0.05 were considered statistically significant.
To compare the time to death in frail and non-frail partic-
ipants, the Kaplan–Meier estimator was employed to com-
pute survival curves over the six-month follow-up period
and differences between frail and non-frail groups assessed
using log rank tests. Cox proportional-hazards regression
was used to determine whether frailty assessed with the
RFES predicted mortality, with results presented as hazard
ratios (HR) and 95% confidence intervals (CIs). Potential
predictors of mortality in this cohort of older patients with
AF were frailty status, age, gender, Charlson comorbidity
Index, CHA2DS2-VASc score, HAS-BLED score, admission
due to falls, delirium on admission, and the following med-
ications on discharge: anticoagulants, digoxin, statin or psy-
chotropic medication [29,30]. Based on a previous study that
showed a combined effect of frailty and delirium on mortal-
ity in older inpatients [31], we also used Cox regression to
analyse the combined association of frailty and delirium.
Logistic regression was applied to investigate predictors of
prolonged hospitalisation and results are presented as odds
ratios (OR) and 95% CIs. Potential predictors of prolonged
hospitalisation were frailty status, age, gender, Charlson
comorbidity Index, CHA2DS2-VASc score, HAS-BLED score,
admission due to falls, or delirium on admission. Univariate
regression was performed on all the potential predictors for
adverse outcomes. Those variables that had a p-value <0.20
on univariate analysis were entered into multivariate
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analysis. Backward elimination method was applied and the
final model retained the studied variable (frailty) and those
variables significant at P <0.05.
Results
A total of 302 participants were recruited. They had a mean
age of 84.77.1 years (range 65-100), 50.0% were female, and
53.3% were frail (RFES score of 8 or more). Participant char-
acteristics are presented in Table 1. Overall, frail participants
were older, had more comorbidities and were prescribed
more medication upon discharge. There was no difference
between frail and non-frail participants in the prevalence of
falls or delirium on admission. Upon discharge, frail partic-
ipants were less likely to be prescribed anticoagulants for
stroke prevention. However, the prescription of digoxin and
psychotropic medications were more common in the frail
(Table 2).
During six months of follow-up, 65 participants (21.5%)
died. Mortality was higher in frail (30.4% died) than non-frail
participants (11.3% died), p<0.001. Only two participants
died due to intracranial bleeding: one during hospitalisation
(this participant was on warfarin prior to admission) and one
during follow-up after discharge (subdural haematoma after
falls). Two participants died due to embolic stroke. Twenty
participants died due to heart failure, six died due to acute
myocardial infarction and 35 died of other non-cardiovascu-
lar related causes.
The Kaplan-Meier survival function for death indicated
that at all points in time during the six-month follow-up, frail
Table 1 Participant characteristics.
Variables All (N=302) Frail (161) Non-frail (141) P
Age (years) 84.7  7.1 85.7  6.7 83.5  7.3 0.008
Female 151 (50%) 86 (53.4%) 65 (46.1%) 0.21
Charlson Comorbidity Index 3.8  2.2 4.32  2.14 3.18  2.12 <0.001
Cardiovascular Diseases and Risk Factors:
Hypertension 208 (68.9%) 114 (70.8%) 94 (66.7%) 0.44
Ischaemic Heart Disease 134 (44.4%) 74 (46%) 60 (42.6%) 0.55
Congestive Heart Failure 131 (43.4%) 86 (53.4%) 45 (31.9%) <0.001
Dyslipidaemia 89 (29.5%) 49 (30.4%) 40 (28.4%) 0.70
History of stroke/TIA 76 (25.2%) 44 (27.3%) 32 (22.7%) 0.36
Type 2 diabetes 64 (21.2%) 40 (24.8%) 24 (17%) 0.10
Peripheral Vascular Disease 27 (8.9%) 21 (13%) 6 (4.3%) 0.008
Other co-morbidities:
Chronic pulmonary disease 83 (27.5%) 53 (32.9%) 30 (21.3%) 0.02
Cancer 76 (25.2%) 44 (27.3%) 32 (22.7%) 0.36
Dementia 27 (8.9%) 19 (11.8%) 8 (5.7%) 0.06
Depression 22 (7.3%) 19 (11.8%) 3 (2.1%) <0.001
Severe chronic kidney disease (eGFR<30 mL/min/1.73 m2) 36 (11.9%) 24 (14.9%) 12 (8.5%) 0.09
Reasons for admission
Shortness of breath 69 (22.8%) 44 (27.3%) 25 (17.7%) 0.15
Falls 67 (22.2%) 35 (21.7%) 32 (22.7%)
Infection 30 (9.9%) 17 (10.6%) 13 (9.2%)
Delirium 30 (9.9%) 16 (9.9%) 14 (9.9%)
Chest pain/discomfort 26 (8.6%) 11 (6.8%) 15 (10.6%)
General unwell 21 (7.0%) 11 (6.8%) 10 (7.1%)
Palpitation 15 (5.0%) 2 (1.2%) 13 (9.2%)
Musculoskeletal pain 14 (4.6%) 8 (5.0%) 6 (4.3%)
Gastro-intestinal disorders 7 (2.3%) 6 (3.7%) 1 (0.7%)
Elective surgery 6 (2.0%) 3 (1.9%) 3 (2.1%)
Dizziness 3 (1%) 1 (0.6%) 2 (1.4%)
High INR/bleeding 3 (1.0%) 1 (0.6%) 2 (1.4%)
Stroke 2 (0.7%) 1 (0.6%) 1 (0.7%)
Other 9 (3.0%) 5 (3.1%) 4 (2.8%)
Continuous variables are presented as mean  standard deviation, and categorical variables as frequency and percentage. TIA: transient ischaemic attack, eGFR:
estimated glomerular filtration rate, INR: international normalised ratio.
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participants had a higher probability of dying compared to
the non-frail (Log Rank Chi-Square 12.79, 1df, p<0.001 and
Breslow Chi-Square 12.49, 1df, p<0.001). (Figure 1)
Univariate Cox regression analysis showed that the prob-
ability of death over six months was nearly three-fold higher
in frail participants (HR 2.69, 95% CI 1.53 – 4.74). The
association between frailty and mortality persisted after
adjustment for potential confounders (adjusted HR 2.33,
95% CI 1.31 – 4.14). The other significant predictors of mor-
tality were the Charlson Comorbidity Index (adjusted HR per
1 unit increase 1.16, 95% CI 1.04 – 1.28) and delirium on
admission (adjusted HR 2.07, 95% CI 1.05 – 4.10) (Table 3).
Table 2 Medications upon discharge.
Variables All (N=290) Frail (150) Non-frail (139) P
Number of medications 11.3  4.0 12.3  3.9 10.4  3.8 <0.001
Anticoagulants 161 (55.7%) 74 (49.3%) 87 (62.6%) 0.02
Anti-arrhythmics
Beta-blockers (except Sotalol) 126 (43.6%) 61 (40.7%) 65 (46.8%) 0.30
Digitalis 84 (29.1%) 52 (34.7%) 32 (23.0%) 0.03
Amiodarone 32 (11.1%) 20 (13.3%) 12 (8.6%) 0.20
Sotalol 27 (9.3%) 10 (6.7%) 17 (12.1%) 0.10
Non-DHP CCBs 23 (8.0%) 12 (8%) 11 (7.9%) 0.98
Flecainide 14 (4.8%) 4 (2.7%) 10 (7.2%) 0.07
Disopyramide 1 (0.3%) 1 (0.7%) 0 (0%) -
Other cardiovascular drugs
ARBs 63 (21.8%) 32 (21.3%) 31 (22.3%) 0.84
ACE inhibitors 54 (18.7%) 28 (18.7%) 26 (18.7%) 0.99
Statins 136 (47.1%) 65 (43.3%) 71 (51.1%) 0.19
Psychotropics 93 (32.2%) 58 (38.7%) 35 (25.2%) 0.01
Continuous variables are presented as mean  standard deviation, and categorical variables as frequency and percentage. Non-DHP CCBs: non-dihydropyridine
calcium channel blockers. ACE inhibitors: angiotensin-converting enzyme inhibitors. ARBs: angiotensin receptor blockers.
Figure 1 The Kaplan-Meier survival curves in frail and non-frail participants.
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The mortality rate after six months was highest amongst
participants with both frailty and delirium (37.5%) compared
to those with neither frailty nor delirium (9.4%), those with
frailty alone (29.7%) and those with delirium alone (28.6%),
p<0.001. On Cox regression analysis of the combined effect of
frailty and delirium, compared to those with neither frailty
nor delirium, the risk of mortality increased four times in
those with both frailty and delirium (HR 4.39, 95% CI 1.65 –
11.69), and increased three times in those with either frailty or
delirium (HR 3.15, 95% CI 1.66 – 5.99 for frailty alone and HR
3.39, 95% CI 1.09 – 10.53 for delirium alone).
Length of stay was compared between frail and non-frail
participants who were discharged from hospital (N = 289).
Overall, the mean length of stay was 12.8  9.0 days and the
median was 10 days (range 2 to 47 days). The length of stay in
frail participants was longer than in the non-frail (14.1  9.5
days in the frail, 11.0  7.9 days in the non-frail, p=0.002). Of
the 289 discharged participants, 70 (24.2%) had a prolonged
length of stay, defined as a length of stay equal to or longer
than 17 days ( 75th percentile of the length of stay). Frail
participants were more likely to have a prolonged length of
stay (31.3% of frail participants versus 18.5% of non-frail,
p=0.01). The unadjusted odds ratio for frailty and prolonged
hospitalisation was 2.00 (95% CI 1.14 – 3.50). After adjust-
ment for age, gender, comorbidities, stroke risk and bleeding
risk, falls or delirium on admission, the odds ratio for frailty
and prolonged length of stay was unchanged (OR=2.05, 95%
CI 1.15 – 3.65).
Overall, 118 (40.8%) of the discharged participants were
readmitted to hospitals within six months. The incidence of
re-admission was not statistically significantly different
between frail and non-frail participants (42.7% of frail,
38.8% of non-frail, p=0.51).
Discussion
Our study demonstrated that frailty was common in older
inpatients with AF, with just over half of the participants in
our study being classified as frail by the REFS, consistent
with previous studies using the same frailty scale [25,32]. We
found that frailty was associated with prolonged length of
stay and more than a two-fold increase in six-month mortal-
ity among older in-patients with AF. Previous studies have
consistently found that frailty defined by a range of different
tools is associated with increased mortality in older patients
[12–20].
In our study frailty also predicted prolonged length of stay,
which is similar to previous studies using the same frailty
criteria. In a study in Victoria, Australia, frailty defined by the
REFS was associated with increased length of stay amongst
patients admitted to the acute general medical unit [32] and,
in a recent study in the United Kingdom, frailty defined by
the REFS predicted length of stay in urology patients [33]. We
did not find an association between frailty and re-admission
to hospitals among older inpatients with AF after discharge.
This may be partly attributed to the higher mortality rate in
frail participants during follow-up.
We found that delirium on admission was independently
associated with a two-fold increase in mortality after six
months. Delirium was present in 10% of participants on
admission. Delirium is a common syndrome in older inpa-
tients, with reported prevalence ranging from 11% to 24% in
hospitalised older patients [34]. Evidence for the association
between delirium and increased mortality is not consistent.
Early studies suggested that delirium was not significantly
associated with increased mortality [35–37]. However, in
many recent studies delirium has been found to be an
Table 3 Predictors of all-cause mortality after 6 months in older patients with atrial fibrillation.
Variables Univariate analysis Multivariate analysis
Unadjusted HR
(95% CI)
P Adjusted HR
(95% CI)
P
Frailty 2.69 (1.53 – 4.74) 0.001 2.33 (1.31 – 4.14) 0.004
Age 1.03 (0.99 – 1.07) 0.10 - -
Gender 0.70 (0.43 – 1.16) 0.17 - -
Charlson Comorbidity Index 1.18 (1.07 – 1.31) 0.001 1.16 (1.04 – 1.28) 0.007
CHA2DS2-VASc score 1.14 (0.96 – 1.35) 0.13 - -
HAS-BLED score 1.29 (1.00 – 1.66) 0.05 - -
Admission due to falls 1.16 (0.65 – 2.07) 0.62 - -
Delirium on admission 1.84 (0.94 – 3.62) 0.08 2.07 (1.05 – 4.10) 0.036
Anticoagulant prescription on discharge 0.63 (0.37 – 1.09) 0.09 - -
Digoxin prescription on discharge 1.66 (0.95 – 2.91) 0.07 - -
Psychotropic prescription on discharge 1.62 (0.93 – 2.80) 0.09 - -
Statin prescription on discharge 0.89 (0.51 – 1.53) 0.67 - -
Only variables that had a P-value <0.20 in univariate regression were entered into multiple regression model together with frailty. Backward elimination method
was applied and the final model retained the studied variable (which is frailty) and those variables significant at P<0.05.
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independent predictor of subsequent death in older patients
[31,38–40]. In older patients, delirium is an independent
predictor of sustained poor cognitive and functional status
during the year after a medical admission to hospital and is
associated with an increased risk of readmission [41]. In
addition, we found that the coexistence of frailty and delir-
ium can significantly increase the risk of death in the partic-
ipants, which is consistent with a previous study [31].
This study has several strengths. It is the first study report-
ing the predictive value of frailty for mortality in older inpa-
tients with AF. The study comprised a sample of very old and
frail people, who are often excluded from studies [42]. It used
the validated Reported Edmonton Frailty Scale with high
quality detailed clinical information [23]. A major limitation
of this study is that it was done in the acute care setting at a
tertiary hospital in Sydney which may not be representative
for all older patients with AF. Small sample size may have
limited the power of this study to detect differences in re-
admissions between frail and non-frail participants.
Conclusions
Frailty is a common geriatric syndrome in older inpatients
with AF and is associated with poor outcomes. Screening for
frailty along with other clinically important factors like delir-
ium should be considered in older patients with AF to opti-
mise individualised treatment plans.
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ABSTRACT
Introduction: Frailty is associated with changes
in inflammation, coagulation, and possibly
platelet function. Aspirin is still prescribed for
stroke prevention in older patients with atrial
fibrillation, although not recommended by
current guidelines. In frail older people, it is
unclear whether platelet aggregability and
response to aspirin are altered. This study aims
to investigate the effects of frailty and
chronological age on platelet aggregability and
on responses to aspirin in older patients with
atrial fibrillation.
Methods: Inpatients with atrial fibrillation aged
C65 years were recruited from a tertiary referral
hospital in Sydney, Australia. Frailty was
determined using the Reported Edmonton
Frail Scale. Platelet aggregation studies were
performed using whole blood impedance
aggregometry.
Results: Data from 115 participants were
analyzed (mean age 85 ± 6 years, 41% female,
52% frail). Spearman correlation coefficients
found no significant associations of platelet
aggregation with chronological age or with
frailty score. Comparison between frail and
non-frail groups showed that there was no
impact of frailty status on aggregation assays
amongst participants who were not taking any
antiplatelet drugs. Amongst participants taking
aspirin, the frail had higher adjusted
arachidonic acid agonist (ASPI) test measures
(AU per platelet) than the non-frail (0.11 ± 0.11
vs. 0.05 ± 0.04; p = 0.04), suggesting that in
frail participants, platelet aggregation is less
responsive to aspirin than in non-frail.
Conclusions: We found no effect of
chronological age or frailty status on platelet
aggregation amongst older patients with atrial
fibrillation in this pilot study. However, frailty
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could be associated with reduced aspirin
responsiveness among older patients with
atrial fibrillation.
Keywords: Ageing; Aspirin; Atrial fibrillation;
Frailty; Platelet aggregation
INTRODUCTION
There is marked heterogeneity amongst people
aged over 65 years. Some of this may be
captured by increasing chronological age.
However, much of this variability is thought
to be due to biological age or frailty [1]. Frailty is
a state of vulnerability that carries an increased
risk of poor outcomes in older adults [1]. The
prevalence and clinical importance of frailty are
increasing with ageing of the population [1, 2].
Frailty is associated with changes in
inflammation, coagulation, and possibly
platelet function [3, 4].
Atrial fibrillation (AF) is a common cardiac
arrhythmia in older adults. The prevalence of
AF in published studies in Western countries
ranges from 0.5% to 3% in the general
population, 5–6% in people older than
65 years, and up to 5–15% among those aged
80 years or older [5–7]. Treatment of AF aims at
stroke prevention with antithrombotic therapy,
reducing symptoms with rate-control or
rhythm-control strategies, and management of
associated medical conditions [8]. According to
the current guidelines, aspirin is not
recommended for stroke prevention in AF
unless patients refuse the use of any oral
anticoagulant [9, 10]. International drug
utilization studies show that, in practice,
17–45% of older adults use aspirin for stroke
prevention in AF [11–14]. The evidence for
stroke prevention in AF with aspirin is weak
and the risk of major bleeding with aspirin is
not significantly different to that of oral
anticoagulants, especially in older people [9,
15, 16].
The efficacy of antiplatelet drugs has not
been rigorously tested in older people and older
people are generally more vulnerable to adverse
drug effects due to changes in pharmacokinetics
and pharmacodynamics associated with aging
and an increased risk of drug–drug and
drug–disease interactions in the presence of
polypharmacy and multimorbidity [17]. In
frail older people, it is unclear whether
response to antiplatelet therapies is altered.
Some studies have suggested that platelet
aggregability may increase in old age [4, 18,
19] and plasma aspirin esterase activity is
reduced in frail people [20–22]. However, there
has been no study exploring the association
between frailty and platelet aggregation.
Therefore, the aims of this study were to
investigate the effects of frailty and
chronological age on platelet aggregability and
on platelet responses to aspirin in older patients
with AF.
METHODS
A total of 302 inpatients aged C65 years with AF
at Royal North Shore Hospital, a tertiary referral
teaching hospital in Sydney, Australia, were
recruited for a study of anticoagulant utilization
and outcomes in frail and non-frail older
inpatients with AF. Of these patients, 134
participated in this sub-study on platelet
aggregation. Among these patients, 82 who
were not taking any antiplatelet drugs for at
least a week before blood samples were taken for
testing and 33 patients who were taking regular
aspirin (100 mg daily) and no other antiplatelet
agents were eligible for this analysis. Informed
consent was obtained from all participants or
52 Cardiol Ther (2016) 5:51–62
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their caregivers. The study was approved by The
Northern Sydney Local Health District Human
Research Ethics Committee and The University
of Sydney Human Research Ethics Committee.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in 2013.
Frailty was determined using the Reported
Edmonton Frail Scale [23]. This scale, which was
adapted from the Edmonton Frail Scale for use
in Australian acute inpatients, assesses nine
frailty domains: cognition, general health
status, functional independence, social
support, medication use, nutrition, mood,
continence, and reported functional
performance. With a maximum score of 18, a
score of 0–5 indicates robust, 6–7 indicates
apparently vulnerable status, 8–9 mild frailty,
10–11 moderate frailty, and 12 or higher
indicates severe frailty. The cut-off point to
identify frailty is 8 [23].
Blood was collected from the participants in
the morning from the antecubital vein into
tubes containing hirudin. Platelet aggregation
studies were performed between 30 min and 2 h
after blood was taken, using whole blood
impedance aggregometry (WBIA, Multiplate
Analyser, Roche Diagnostics). The Multiplate
Analyser measures aggregation in whole blood
samples through changes in electrical
impedance between two electrodes and has
been applied to detect platelet inhibition by
aspirin in many studies [24–29]. More details
about the test have been described elsewhere
[30, 31]. Platelet agonists used in this assay were
arachidonic acid (ASPItest) to trigger
arachidonic acid-induced platelet aggregation,
which is affected by aspirin; adenosine
diphosphate (ADPtest) to trigger ADP-induced
platelet aggregation, which is affected by
thienopyridines (e.g., clopidogrel, prasugrel,
ticlopidine); and Thrombin Receptor
Activating Peptide 6 (TRAPtest) to trigger
TRAP-6 induced platelet aggregation, which is
only affected by glycoprotein IIb/IIIa receptor
antagonists (e.g., tirofiban, abciximab,
eptifibatide). ADPtest and TRAPtest were used
as positive controls for platelet reactivity.
Platelet aggregation is defined by the area
under the aggregation-time curve, which
represents the aggregation over 6 min, and
values are reported in arbitrary aggregation
units (AU). Suggested normal ranges in
healthy blood donors as provided by the
manufacturer are 71–115 AU for the ASPItest,
57–113 AU for the ADPtest, and 84–128 AU for
the TRAPtest [32].
Analysis of the data was performed using
SPSS for Windows 20.0 (IBM Corp., Armonk,
NY, USA). Continuous variables are presented as
mean ± standard deviation, and categorical
variables as frequency and percentage. Clinical
characteristics and laboratory parameters were
compared between frailty and treatment groups
using the Mann–Whitney U test for continuous
variables, and Chi-square or Fisher’s exact test
for binary variables. Correlation of platelet
aggregation with age, frailty score, and other
variables that have previously been shown to
have an impact on platelet aggregation [33] was
assessed with Spearman correlation. Two-sided
p values \0.05 were considered significant.
Platelet function was considered separately for
each treatment regimen and by frailty status.
The platelet counts in this study showed a
marked degree of variation (mean
220 ± 95 9 109/l, median 202 9 109/l, range
30–502 9 109/l). Twenty-five patients had
platelet counts below the normal range, and,
as expected, these patients had significantly
lower AU values than patients with platelet
counts in the normal range (p\0.001).
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Spearman correlation also showed that platelet
count had a very strong association with
platelet aggregation (r = 0.59, p\0.001 for
ASPI test; r = 0.63, p\0.001 for ADP test;
r = 0.69, p\0.001 for TRAP test). Therefore,
we adjusted the test results to control for the
effect of the platelet counts and provide a purer
representation of platelet aggregability by
dividing the AU value by the platelet count,
giving a value of AU per platelet. We compared
aggregability between frail and non-frail
participants with and without aspirin
treatment based on these adjusted values.
Sensitivity analyses were also performed to
assess the robustness of the finding after
excluding those participants with platelet
counts\100 9 109/l or[400 9 109/l.
RESULTS
A total of 115 participants were included in the
study (mean age 85 ± 6 years, age range
71–97 years, 41% female, 52% frail). Among
the 82 participants who did not take any
antiplatelet therapy in the week prior to
sampling (Table 1), mean age was 84 ± 6 years
and 49% of the participants were frail.
Compared to the non-frail, frail participants
had a significantly higher score on the Charlson
Comorbidity Index, with a higher prevalence of
heart failure and renal impairment. There was
no quantitative difference in any of the
platelet-aggregation assays between frail and
non-frail participants. Spearman correlation
coefficients were performed for each test of
platelet aggregation with age, frailty score, and
other variables that may impact platelet
aggregation (Table 2). There were no
significant correlations between platelet
aggregation and any of these variables.
Among the 33 participants who were taking
aspirin, the frail (n = 20) had higher ASPI test
results than the non-frail (0.11± 0.11 AU per
platelet in the frail versus 0.05± 0.04 AU per
platelet in thenon-frail; p = 0.04), suggesting that
platelets in the frail are less responsive to aspirin
(Table 3). Representative curves from the ASPI
tests of a frail and non-frail participant are shown
in Fig. 1. Spearman correlation coefficients of the
ASPI test results with age, frailty score and other
variables found that the only significant
correlation was of the presence of a diagnosis of
heart failure with increased AU (correlation
coefficient 0.40, p = 0.02) (Table 4). Sensitivity
analyses showed that the difference between the
frail and the non-frail remained significant
amongst the participants with platelet counts
from 100–400 9 109/l (n = 26), consistent with
the analyses amongst those with platelet counts
from 30–5029 109/l (n = 33) (Table 5).
DISCUSSION
In this pilot study of older inpatients with AF,
there was no significant relationship between
platelet aggregation and chronological age. This
result is different to many previous studies in
which there was a trend towards increased
platelet aggregation with age [4, 18, 19, 33].
However, all of these studies were designed to
compare platelet aggregation between younger
groups and older groups (participant age ranged
from around 20 to 80 years old, with the cut-off
point to determine older groups usually around
60 years old). In contrast, in our study the mean
age of participants was around 84–86 years,
with an age range from 71 to 97 years.
Furthermore, unlike our study of acutely
unwell older inpatients, previous studies
demonstrating increased platelet aggregation
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with age were in healthy volunteers from the
community without a history of cardiovascular
disease. Additionally, in this study we used the
Multiplate assay—a new method to evaluate
platelet aggregation, which is different from
light transmission aggregometry that was used
in previous studies [4, 18, 19, 33].
Amongst participants not taking antiplatelet
drugs, there was no association between frailty
status, a marker of biological age, and platelet
aggregation. Amongst those taking aspirin,
there was a significant difference in platelet
aggregation to arachidonic acid (ASPI test): the
frail exhibited a degree of aspirin resistance
compared to the non-frail. The reduced
responsiveness to aspirin observed in the frail
may be partly attributed to the higher
prevalence of heart failure in the frail
Table 1 Characteristics of 82 participants not taking any antiplatelet therapy
All (n 5 82) Frail (n5 40) Non-frail (n5 42) p values
Age (years) 84.00 ± 6.08 84.98 ± 6.40 83.05 ± 5.67 0.08
Female gender 33 (40.20%) 18 (45.00%) 15 (35.70%) 0.39
Hypertension 51 (62.20%) 23 (57.50%) 28 (66.70%) 0.39
Heart failure 38 (46.30%) 24 (60.00%) 14 (33.30%) 0.02
Ischemic heart disease 35 (42.70%) 18 (45.00%) 17 (40.50%) 0.68
Diabetes mellitus type 2 15 (18.30%) 9 (22.50%) 6 (14.30%) 0.31
Dyslipidemia 25 (30.50%) 10 (25.00%) 15 (35.70%) 0.29
Peripheral vascular disease 8 (9.80%) 7 (17.50%) 1 (2.40%) 0.02
Stroke 24 (29.30%) 13 (32.50%) 11 (26.20%) 0.53
History of cancer/current cancer 22 (26.80%) 10 (25.00%) 12 (28.60%) 0.72
Female gender 37 (45.10%) 25 (62.50%) 12 (28.60%) 0.002
Reported Edmonton Frail Score 7.48 ± 2.84 9.88 ± 1.64 5.19 ± 1.55 \0.001
Charlson Comorbidity Index 3.84 ± 2.30 4.50 ± 2.10 3.21 ± 2.32 0.004
Hemoglobin (g/l) 178 ± 122 119 ± 21 125 ± 21 0.26
White cell count (9109/l) 7.43 ± 2.53 7.34 ± 2.40 7.50 ± 2.68 0.99
Platelet count (9109/l) 226 ± 92 217 ± 107 234 ± 74 0.22
Platelet aggregation (AU)
ADPtest 58 ± 26 56 ± 28 60 ± 24 0.29
ASPItest 68 ± 28 65 ± 30 70 ± 26 0.41
TRAPtest 77 ± 29 75 ± 32 80 ± 26 0.53
Adjusted platelet aggregation (AU per platelet)
ASPItest 0.31 ± 0.09 0.31 ± 0.11 0.30 ± 0.07 0.43
ADPtest 0.26 ± 0.11 0.27 ± 0.12 0.26 ± 0.10 0.95
TRAPtest 0.36 ± 0.13 0.37 ± 0.15 0.35 ± 0.11 0.81
Continuous data are presented as mean ± standard deviation or median (range). Categorical data are shown as n (%)
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participants. In participants taking aspirin, we
found a moderate positive correlation between
heart failure and arachidonic acid-induced
platelet aggregation, which means that
compared to participants without a history of
heart failure, those with heart failure tend to
have a higher on-treatment platelet
aggregation. The relationship between heart
failure and decreased aspirin effectiveness has
been reported in several studies [34, 35].
Although not comprehensively understood,
this could be explained by several mechanisms
such as increased levels of circulating
catecholamines, angiotensin II and
b-thromboglobulin, platelet factor 4,
P-selectin, and platelet-endothelial cell
adhesion molecules in patients with heart
failure [36]. The observed reduced platelet
responsiveness to aspirin in the frail supports
the current guidelines that do not recommend
aspirin for stroke prevention in AF, and raises a
question about the risk-to-benefit ratio of
aspirin prescription in older patients with AF,
which ironically is more common in the frail
[37], in whom prescribers may be more
concerned about using anticoagulants.
The study comprised a sample of very old
and frail people, who are often excluded from
studies [38]. Recently, objective measures of
frailty, including the Reported Edmonton Frail
Scale used in our study [23], have facilitated
study of the physiology and management of
frailty [1]. The physiological etiology of frailty is
still not comprehensively understood. Multiple
physiological factors are thought to be involved
in the development of frailty, including
activation of inflammation, coagulation
systems, and changes in pharmacokinetics and
pharmacodynamics [1, 3, 21, 39]. Studies
measuring individual factors in the
Table 2 Spearman correlation coefﬁcients for platelet aggregation with age, frailty scores, and other variables in 82
participants not taking antiplatelet agents
Variables ASPI test
(AU per platelet)
ADP test
(AU per platelet)
TRAP test
(AU per platelet)
Age (years) 0.10 0.10 0.05
Reported Edmonton Frail Score -0.03 0.12 0.01
Charlson Comorbidity Index -0.15 0.01 0.02
Body mass index (kg/m2) 0.01 0.09 0.11
Dyslipidemia -0.18 -0.07 -0.12
Diabetes mellitus 0.10 0.19 0.14
Heart failure -0.01 0.13 0.06
Ischemic heart disease -0.06 -0.13 -0.05
History of cancer/current cancer -0.04 0.03 0.09
Female gender 0.04 0.01 0.09
Anticoagulant users (warfarin/heparin) -0.07 -0.07 -0.01
Hemoglobin (g/dl) -0.17 -0.16 -0.09
White cell count (9109/l) 0.09 0.16 -0.08
A positive correlation indicates that the variable is associated with increased platelet aggregation. All p values were[0.05
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coagulation system suggest that frailty is
associated with pro-coagulant changes such as
increased plasma fibrinogen, factor VIII,
C-reactive protein, D-dimer, and tissue
plasminogen activator (t-PA) plasma levels
[40–43]. To our knowledge, there has been no
previous study focusing on the impact of frailty
on platelet aggregation and platelet response to
antiplatelet drugs. There have only been several
studies reporting the association between frailty
and reduced activity of plasma aspirin esterase,
a hydrolysis enzyme that helps the conversion
of aspirin (acetylsalicylic acid) to salicylic and
acetic acid [20, 21].
Table 3 Characteristics of the 33 participants taking aspirin
All (n5 33) Frail (n5 20) Non-frail (n 5 13) p values
Age (years) 86.52 ± 6.90 86.60 ± 6.64 86.38 ± 7.57 0.96
Reported Edmonton Frail Score 8.03 ± 2.69 9.75 ± 1.48 5.38 ± 1.81 \0.001
Charlson 3.33 ± 2.03 3.55 ± 2.04 3.00 ± 2.04 0.52
Female gender 14 (42.40%) 6 (30.00%) 8 (61.50%) 0.07
Hypertension 22 (66.70%) 14 (70.00%) 8 (61.50%) 0.61
Heart failure 15 (45.50%) 13 (65.00%) 2 (15.40%) 0.005
Ischemic heart disease 16 (48.50%) 11 (55.00%) 5 (38.50%) 0.35
Diabetes mellitus type 2 6 (18.20%) 4 (20.00%) 2 (15.40%) 1.00
Dyslipidemia 9 (27.30%) 7 (35.00%) 2 (15.40%) 0.26
Peripheral vascular disease 5 (15.20%) 4 (20.00%) 1 (7.70%) 0.63
Stroke 9 (27.30%) 5 (25.00%) 4 (30.80%) 0.72
Cancer 7 (21.20%) 5 (25.00%) 2 (15.40%) 0.67
eGFR\60(ml/min/1.73 m2) 15 (45.50%) 7 (35.00%) 8 (61.50%) 0.14
Hemoglobin (g/l) 114 ± 19 112 ± 21 116 ± 16 0.41
White cell count (9109/l) 7.69 ± 2.89 8.11 ± 3.37 7.08 ± 1.93 0.34
Platelet count (9109/l) 205 ± 104 186 ± 100 235 ± 107 0.28
Platelet aggregation (AU)
ASPItest 15 ± 13 18 ± 15 11 ± 8 0.21
ADPtest 51 ± 31 47 ± 31 58 ± 31 0.37
TRAPtest 66 ± 34 61 ± 35 74 ± 31 0.27
Adjusted platelet aggregation (AU per platelet)
ASPItest 0.09 ± 0.09 0.11 ± 0.11 0.05 ± 0.04 0.04
ADPtest 0.25 ± 0.09 0.25 ± 0.10 0.24 ± 0.07 1.00
TRAPtest 0.35 ± 0.17 0.36 ± 0.21 0.33 ± 0.09 0.90
Continuous data are presented as mean ± SD. Categorical data are shown as n (%)
eGFR estimated glomerular ﬁltration rate
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In this study, we used the Multiplate
method to study platelet aggregation. Since
the introduction of the bleeding time test,
different methodologies have been developed
to obtain the optimal platelet function test
and to assess platelet reactivity in response to
antiplatelet drugs [44–47]. The Multiplate is a
new method for evaluating platelet
aggregation and is one of the point-of-care
assays for monitoring antiplatelet therapy [30].
It can be performed in whole blood, does not
require specifically trained laboratory
personnel, and is simple to interpret [45].
This method has been widely used in clinical
trials and is also implemented in daily practice
in catheterization laboratories, predominantly
in Europe [44]. However, it should be noted
that the correlation of this test with other
tests of platelet aggregation and with clinical
outcomes is not perfect [29, 48] and that this
test has not been validated in very old or frail
participants. The Multiplate assay provides a
reproducible measure of reduced platelet
aggregation in response to defined agonists.
However, unlike assays measuring platelet
response to very low doses of agonists, which
were used in previous studies of platelet
function in ageing [4, 18, 19, 33], the
Multiplate assay is not designed to detect
platelet hyperaggregability.
A major limitation of this study is that it was
done in the acute care setting, in which platelet
aggregation may be influenced by acute
inflammation [49]. This is a pilot study testing
the hypothesis of altered platelet aggregation
with frailty that relies on a convenience sample.
Small sample size may have limited the power
of this study to observe small changes with age
and frailty. This study sample is based on
volunteers from inpatients recruited for a
study on anticoagulant utilization.
Approximately half of the participants in that
study agreed to a blood test, so the sample may
be not representative of older inpatients with
Fig. 1 Arachidonic acid-induced platelet aggregation
(ASPItest) in participants taking aspirin. a From a
representative frail participant. b From a representative
non-frail participant. (One Multiplate test cell includes two
independent sensor units. The increase of impedance due to
the attachment of platelets to the electrodes is detected for
each sensor unit separately and transformed to arbitrary
aggregation units that are plotted against time. The
duplicate sensors work as an internal control) [24]
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AF. Furthermore, all of the participants in this
study had AF, which may be procoagulant [50].
Therefore, results should be cautiously
interpreted and generalized to older inpatients
without AF who may be prescribed aspirin for
other indications.
Table 4 Spearman correlation for platelet aggregation in response to aspirin with age, frailty score, and other variables in 33
participants taking aspirin
Variables ASPI test (AU per platelet) p values
Age (years) 0.03 0.87
Reported Edmonton Frail Score 0.19 0.29
Charlson Comorbidity Index 0.10 0.56
Body mass index (kg/m2) 0.30 0.24
Dyslipidemia 0.16 0.38
Diabetes mellitus 0.14 0.44
Heart failure 0.40 0.02
Ischemic heart disease 0.19 0.29
History of cancer/current cancer -0.17 0.34
Female gender -0.08 0.64
Anticoagulant users (warfarin/heparin) 0.20 0.26
Hemoglobin (g/dl) 0.04 0.84
White cell count (9109/l) 0.29 0.11
A positive correlation indicates that the variable is associated with increased arachidonic acid-induced platelet aggregation
(e.g., less responded to aspirin)
Table 5 Results from sensitivity analyses assessing the impact of frailty on antiplatelet responsiveness
All Frail Non-frail p values
All participants on aspirin (platelet counts 30–502 9 109/l) N = 33 N = 20 N = 13
Adjusted platelet aggregation (AU per platelet)
ASPItest 0.090 ± 0.090 0.110 ± 0.110 0.050 ± 0.035 0.036
ADPtest 0.245 ± 0.091 0.252 ± 0.104 0.241 ± 0.068 1.000
TRAPtest 0.349 ± 0.173 0.363 ± 0.213 0.327 ± 0.088 0.899
Participants with platelet counts
100–400 9 109/l
N = 26 N = 15 N = 11
Adjusted platelet aggregation (AU per platelet)
ASPItest 0.078 ± 0.056 0.096 ± 0.063 0.055 ± 0.036 0.047
ADPtest 0.241 ± 0.092 0.240 ± 0.105 0.243 ± 0.075 0.799
TRAPtest 0.329 ± 0.133 0.322 ± 0.160 0.339 ± 0.089 0.540
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CONCLUSIONS
We found no effect of chronological age or
frailty status on platelet aggregation amongst
hospitalized older patients with AF in this pilot
study. Response to aspirin is reduced in the frail
and in those with heart failure. This may have
implications for efficacy of aspirin in this
population.
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Background: Atrial ﬁbrillation (AF) is the commonest sustained cardiac arrhythmia. In developing countries,
AF is a growing public health problem with the epidemiologic transition from communicable to
non-communicable diseases. However, relatively little is known about AF in the developing world. The aim
of this review is to examine in developing countries the prevalence, associated medical conditions and man-
agement of AF.
Methods: A literature search was conducted via MEDLINE and EMBASE (1990–2012).
Results: Seventy studies were included in the review. The prevalence of AF in the general population ranged
from 0.03% to 1.25%, while the prevalence of AF in hospital-based studies varied from 0.7% to 55.7%. Preva-
lence of AF in Africa was lower than in other regions. The most common conditions associated with AF
were hypertension (10.3%–71.9%) and valvular heart disease (5.6%–66.3%). The prevalence of stroke in pa-
tients with AF ranged from 6.7% to 27%. The utilization of anticoagulants was highly variable (2.7%–72.7%).
Approximately half of the patients with AF using warfarin had therapeutic International Normalized Ratios
(INR). There was a high prevalence of use of rate control therapies (55.3%–87.3%).
Conclusions: The limited studies available suggest that in the developing world there is a signiﬁcant preva-
lence of AF, which is predominantly associated with hypertension and valvular heart disease, and carries a
risk of stroke. Highly variable use of anticoagulants may be related to different health care and socioeconomic
settings. More studies are needed to improve understanding of the epidemiology and management of AF in
developing countries.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Atrial ﬁbrillation (AF) is the most common sustained cardiac arrhyth-
mia. There have been many studies in Western countries reporting the
prevalence of AF. Approximately 2.3 million American people and six
million Europeans are affected by AF [1,2]. The prevalence of AF in the
general population in some Western countries ranges from 0.5% to 2%
[3–5]. According to the Framingham study, the incidence of AF increases
signiﬁcantly with age. The incidence doubles with each decade after the
age of 50 and reaches around 10% at the age of 80 years [6]. According
to the Cardiovascular Health study, the prevalence of AF in patients
older than 65 years old is 6.2% in men and 4.8% in women [7]. People
with AF have an increased risk of stroke [8].
Risk factors for AF include old age, male sex, hypertension, heart
failure, ischemic heart disease, valvular heart diseases, diabetes, obesity,
hyperthyroidism, alcohol abuse, smoking, and pulmonary disease. Main-
stay therapy for AF includes assessment of thromboembolic risk and
stroke prevention, applying appropriate rate-control or rhythm-control
strategies, and management of associated diseases [8,9].partment, Royal North Shore
stralia.
Nguyen).
Ltd. All rights reserved.
27In developing countries, AF is a growing public health problem in
the context of the epidemiologic transition from communicable to
non-communicable diseases [10–14]. The effect of AF on mortality
and morbidity is likely to be substantial. In addition, AF puts a great
burden on the socioeconomic system in these countries. The estimat-
ed annual costs of AF are high in these countries [15]. Anticoagulant
use and monitoring are major challenges for health system in devel-
oping countries. Accessibility to the monitoring tests for anticoagu-
lants, unreliability of test results, lack of compliance of patients, and
interactions with diet and complementary medicines are all substan-
tial issues in developing countries [16–18].
However, there have been few published studies about AF in
developing world. Therefore, the aim of this review is to examine
the prevalence of AF, the associated medical conditions, the impacts
of AF on stroke rate and the management of AF (antithrombotic
therapy and rate or rhythm control strategy) in developing
countries.
2. Methods
A literature search was conducted via MEDLINE and EMBASE (from 1990 to May
2012). Keywords used for searching included “atrial ﬁbrillation”, “epidemiology”,
“prevalence”, “risk factors”, “associated medical conditions”, “associated diseases”,
“stroke”, “antithrombotic”, “anticoagulant”, “INR”, “rate control”, “rhythm control”,4
2413T.N. Nguyen et al. / International Journal of Cardiology 167 (2013) 2412–2420“developing country”, “developing world”, and the names of developing countries
according to the classiﬁcation of the World Bank [19]. The articles attained by this
method of searching were screened by title and they were reviewed further for prev-
alence of AF, stroke in patients with AF, diseases associated with AF, treatment of AF
including antithrombotic therapy, International Normalized Ratio (INR) report, rate
control and rhythm control strategies. Both community and hospital-based studies
were included. Languages were restricted to English and French. Information
extracted from papers included sample size, prevalence of AF, prevalence of stroke
in patients with AF, frequency of associated medical conditions, and rate of anticoag-
ulant and antiplatelet treatment. When necessary, percentages were calculated from
data reported in published studies.3. Results
A total of 70 articles were included in the review. There were 16
articles from East Asia and the Paciﬁc, 17 from Europe and Central
Asia, 12 from Latin America and the Caribbean, 3 from the Middle
East and North Africa, 9 from South Asia and 11 from sub-Saharan
Africa. China had the leading number of articles (13 articles),
followed by Brazil (7 articles), Pakistan (6 articles), Turkey (4 arti-
cles), and Bosnia and Herzegovina (3 articles). Russia Federation,
Thailand, Romania, Serbia, Argentina, Mexico, Iran, India, Ethiopia
and South Africa each had 2 articles. One article was found for each
of Malaysia, Belarus, Kosovo, Moldova, Ukraine, Chile, Jordan, Nepal,
Cameroon, Cote d'Ivoire, Kenya, Nigeria, Senegal, Tanzania and
Zimbabwe. There were two articles from multinational studies that
involved developing countries. There were 12 community-based
studies (3 in China, 2 in Thailand, 1 in Belarus, 1 in Russia, 1 in Turkey,
1 in Brazil, 2 in India, and 1 in Tanzania). The remaining studies were
based in hospitals or specialty clinics.3.1. Prevalence of AF in community-based studies (Table 1)
The prevalence of AF varied among countries. The prevalence of AF
in the general population ranged from 0.03% in India to 1.25% in
Turkey [20–26]. The prevalence of AF in studies in older adults
(≥60 years old) was 0.67% in Tanzania [27], 2.2% in Thailand
[28], 2.4% in Brazil [29], and 5.6% in Russia [30]. In a study in Belarus,
the prevalence of AF in people after a ﬁrst stroke was 23.1% [31].Table 1
Prevalence of atrial ﬁbrillation in community studies.
Country Authors and year Sample size
East Asia and Paciﬁc
China Chen X et al. (2011) [21] 9309
Long MJ et al. (2011) [22] 19,964
Zhou Z et al. (2008) [23] 29,079
Thailand Assantachai P et al. (2002) [28] 963
Kiatchoosakun S et al. (1999) [25] 8791
Europe and Central Asia
Belarus Kulesh SD et al. (2010) [31] 2069
Russia Platonov PG et al. (2011) [30] 1800
Turkey Uyarel H et al. (2008) [26] 3450
Latin America and the Caribbean
Brazil Kawabata-Yoshihara LA, et al. (2009) [29] 1524
South Asia
India Kaushal SS et al. (1995) [20] 984
Hingorani P et al. (2012) [24] 3978
Sub-Saharan Africa
Tanzania Dewhurst MJ et al. (2012) [27] 2232
2753.2. Prevalence of AF in hospital-based studies (Table 2)
The prevalence of AF in hospital-based studies varied widely,
according to the patient population studied.
The prevalence of AF in patients with a stroke ranged from 1.6% in
Nigeria to 55.7% in Bosnia and Herzegovina [32–46]. Prevalence of AF
in patients with a stroke was similar in Turkey, Mexico, Nepal and
Pakistan (12.3% to 12.5%) [47–50]. Compared with other regions, the
prevalence of AF in patients with a stroke in Africa was lower: 1.6% in
Nigeria [32], 4.5% in Ethiopia [51], and 6.9% in South Africa [52].
Prevalence of AF in cardiology patients was rather consistent
among countries, from 4.6% in South Africa [53] to 5.35% in Senegal
[54], 5.5% in Cote d'Ivoire [55], 7.9% in China [56], 8% in Brazil [57],
9.1% in Turkey [58] and 9.75% in Kosovo [59].
There were two studies that reported the prevalence of AF in
patients in geriatric services: one from Brazil with AF prevalence of
4.8% in patients attending an out-patient geriatric medicine clinic
[60] and one from Pakistan with AF prevalence of 20% of inpatients
older than 77 years old [61].
Among general patients, the prevalence of AF was lower, ranging
from 0.7% in Kenya [62], 2.8% in Malaysia [63] and Iran [64], 2.44%
to 3.78% in Russia [65], and 6.5% in Pakistan [66].
3.3. Prevalence of associated diseases (Table 3)
Hypertension was the most frequent condition associated with AF.
The prevalence of hypertension in people with AF was high in some
countries, ranging from 40% in Malaysia to 71.9% in Turkey and Ar-
gentina [22,42,53,55,56,58,60,62,63,65–74], and much lower in
others (27.4% in Kosovo and 10.3% in Ethiopia) [59,75].
Prevalence of valvular heart diseases in patients with AF ranged from
5.6% in Russia to 66.3% in Ethiopia [53–56,59,60,62,65,66,73,75]. High
prevalence of rheumatic heart disease was reported in 6 studies: 21% in
South Africa [53], 23.9% in China [56], 25.6% in Cameroon [73], 28% in
Cote d'Ivoire [55], 36.7% in Senegal [54], and 66.3% in Ethiopia [75]. In
the multinational study involving 15,293 AF patients in 47 countries,
the prevalence of rheumatic disease reported was 15% in China and 31%
in India [76].
Prevalence of ischemic heart disease in patientswith AF varied among
countries. The prevalence was high in studies in Pakistan (47%) [66],Population (age in years) Prevalence of AF (95% CI)
Adults (≥20) 0.9% (0.71%–1.09%)
Adults (≥50) 0.8% (0.68%–0.92%)
Adults (≥30) 0.65% (0.56%–0.74%)
Adults (≥60) 2.2% (1.27%–3.13%)
Adults (≥30) 0.36% (0.23%–0.49%)
People after the ﬁrst stroke
(mean age at stroke onset 65.8±11.6 years)
23.1% (21.28%–24.92%)
Adults (≥60) 5.6% (4.54%–6.66%)
Adults (39–65) 1.25% (0.88%–1.62%)
Adults (>65) 1.5% in control group
(0.89%–2.11%)
Adults (≥15) 0.1% (0–0.56%)
Adults (≥18) 0.03% (0–0.37%)
Adults (≥70) 0.67% (0.33%–1.01%)
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[59], Russia (20.1%) [65], Kenya (19%) [62], and Chile (17%) [70]. Studies
in Cameroon, South Africa and Ethiopia reported lower rate of ischemic
heart disease (6.4%, 6.5% and 6.6%, respectively) [53,73,75].
Prevalence of heart failure in patients with AF varied from 10.4% in
China to 62.6% in Cote d'Ivoire [53,55,56,59,62,63,65,67,69–71,73,74].
Heart failure frequency was high and rather consistent among studies
from Africa: 38% in Kenya [62], 48.7% in Zimbabwe [74], 56% in South
Africa [53], 58.1% in Cameroon [73], and 62.6% in Cote d'Ivoire [55].
Diabetes prevalence in patients with AF varied greatly: 3.3% in
Zimbabwe [74], 4.1% to 17.7% in China [22,56,67], 14.3% in Kosovo
[59], 15.7% in Russia [65], 14.6% in Argentina [69], 16.3% to 33.8% in
Brazil [42,60], 16% in Chile [70], 10.5% in Cameroon [73] and 33% in
Kenya [62].
Hyperthyroidismwas reported in 5 studies: 2.5% and 6.9% in China
[22,56], 3.7% in Kenya [62], 7.5% in Pakistan [72], and 14.3% in Brazil
[60]. Alcohol abuse was reported in several studies: 58.5% in one
study in China [22], 48% in South Africa [53], 29.3% in Brazil [42],
and 5% in Kenya [62]. Chronic obstructive pulmonary disease was
reported in 2 studies: 6.7% in Kosovo [59] and 7% in Kenya [62].
Prevalence of stroke in patients with AF was consistent among
studies: 10.7% to 22.8% in China [21,23,56,67,77–79], 15.4% in Ethio-
pia [75], 17.4% in Cameroon [73], 17.6% in Brazil [57], 23% to 27% in
Pakistan [61,71], and rather low in Argentina in a study including
both patients with atrial ﬁbrillation and atrial ﬂutter (6.7%) [69].3.4. Antithrombotic treatment (Table 4)
The frequency of anticoagulant and antiplatelet utilization
varied greatly among studies with the country studied, population
studied and year that the study was performed. In 13 studies in
China, the rates of anticoagulant use ranged from 2.7% to 50%
[21,23,34,56,77–83]. The rate was 16% in Malaysia [63], 27% in Kosovo
[59], 7.1% in Moldova [36], 13% to 53.9% in Serbia [84], 30.1% to 67.3%
in Turkey [58,85], 72.7% in Argentina [69], 46.7% to 57.8% in Brazil
[57], and 36.8% in Mexico [86]. In Pakistan the prevalence of anticoag-
ulant treatment ranged from 5% in a study conducted in 1998 to 26%
and 44% in studies in 2009 [66,71,72]. The prevalence of anticoagu-
lant use among patients with AF was consistent across several African
countries: South Africa (33%) [53], Cameroon (34.2%) [73], Zimbabwe
(11.5% in rural area and 26.5% in urban) [74] but rather higher in Sen-
egal (62%) [54].
Antiplatelets (mostly aspirin) were highly prescribed in China
(from 34.1% to 94.3%) [21,23,56,67,79,80,82,83], Kosovo (72%) [59],
Turkey (55.6%) [85], Argentina (63%) [69], Mexico (63%) [86], Camer-
oon (61%) [73], and Pakistan (60% in 2009 compared with 10% in
1998) [71,72]. Studies in Malaysia, Zimbabwe, Brazil and South Africa
reported lower rates (8%, 10%, 19.9%–21.2% and 23%, respectively)
[53,57,63,74].3.5. Prevalence of therapeutic anticoagulation with warfarin (INR
values) (Table 4)
Eight studies reported the proportion of patients with AF having
an INR within the therapeutic range. Except for one study in Turkey
where this percentage was rather high (83.5%) [58], all the other
studies found that just around half the patients with AF had therapeu-
tic INRs: 39.1%–40% in China [79,82], 51.77%–53.62% in Bosnia and
Herzegovina [87], 50.1% in Brazil [88], 47.7% in another study in Tur-
key [85], 32.6% in India [81], and even lower in Moldova with 28.5%
[36].
Prevalence of rate control medications was high: 55.3% to 82.8% in
China [56,67], 79.5% in Brazil [89], 83.7% in Cameroon [73], and
87.33% in Senegal [54] (Table 4).274. Discussion
The prevalence of AF in the general population in community
based studies in this review ranged from 0.03% to 1.25%, which is sim-
ilar to that reported in some developed countries such as North
America, the United Kingdom and Iceland (from 0.5% to 1%) [3,4,90]
but lower than the prevalence reported in Australia (4%) [91]. The
low prevalence of AF in both studies in India (0.03% and 0.1%) may
be related to the populations studied: one study was in people living
high altitude in a tribal Himalayan village [20] and the other was
conducted in healthy volunteers in a clinical trial [24].
In older people, this review found a prevalence of AF from 0.67% to
5.6%, which was higher than the rate in the general population.
This ﬁnding was consistent with studies in Western countries
[4,90,92,93]. Aging increases the risk of AF, possibly through the
change in atrial myocardium and degeneration of the conductive sys-
tem [94].
The prevalence of AF in hospital-based studies in this review is
rather consistent with ﬁndings from developed countries. For exam-
ple, the prevalence of AF in stroke patients was 24% in a study in
New Zealand [95], the prevalence of AF in a cardiology department
was 15% in a study in France [96], and AF has been reported to be
present in 3–6% of acute medical admissions in developed countries
[94].
Overall, it seems that the prevalence of AF in Africa is lower than
other regions in the developing world: only 1.6%–6.9% in stroke pa-
tients, 4.6%–5.5% in cardiology patients, 0.67% in elderly people, and
0.7% in general patients. There has been a suggestion that AF is less
common among African people. Genetic disparities in the stability
of atrial membrane and atrial conduction system may cause differ-
ences in AF sensitivity between races [97]. In a meta-analysis of ten
studies involving 1,031,351 people in the United States, Hernandez
et al. showed that in the general population as well as in hospitalized
patients, the prevalence of AF in African–Americans was consistently
lower than in Caucasians [98]. In the ASSERT study which involved
2580 AF patients from North America, Europe and Asia, compared
to Europeans, Black Africans and Chinese had a lower incidence of
AF, even though Black Africans had higher prevalence of risk factors
for AF [99].
The prevalence of diseases associated with AF was well reported
in many of the reviewed studies. Hypertension was the most com-
monly associated disease, ranging from 10.3% to 71.9%. Some variabil-
ity in the prevalence of hypertension was reported in studies in the
general population in the developing world: from 9% in Latin America
to 36% in India [14,100–108]. In developed countries, hypertension
has also been reported as the most frequent disease associated with
AF, with prevalence ranging from 30% in Switzerland to 72% in the
United States [96,109–111]. The prevalence of heart failure in this re-
view ranged from 10.4% to 62.6% and this rate was especially high in
Africa. This prevalence was generally higher than that reported in de-
veloped countries: 16% to 30% [94,111–113]. This review found a var-
iable prevalence of ischemic heart disease in patients with AF from
developing countries, from 6.4% to 47%. Studies in developed coun-
tries have also reported varying prevalence of coronary heart disease
in patients with AF, from 15% to 39% [96,110–113]. The relationship
between uncomplicated coronary artery disease and AF is not fully
understood [94].
The prevalence of diabetes in patients with AF ranged from 3.3% to
33.8%. In contrast, studies in developed countries reported more con-
sistent prevalence of diabetes in AF patients (around 15%–22%)
[94,109,111,112]. The prevalence of hyperthyroidism in patients
with AF was reported in 5 studies in developing countries, ranging
from 2.5% to 14.3%. Approximately 10% to 15% of patients with
uncontrolled hyperthyroidism will develop atrial ﬁbrillation [114].
The prevalence of excess alcohol intake in this review was quite
high in some countries like China, South Africa and Brazil (29.3% to6
Table 2
Prevalence of atrial ﬁbrillation in hospital-based studies.
Country Authors and year Setting Population Prevalence of AF
(95% CI)
East Asia and Paciﬁc
China Gao et al., 2011 [34] Institute of
Neurosciences
4782 stroke patients (mean age 70±
12 years)
10% (9.15%–10.85%)
Wen-Hang, 2005 [56] 41 hospitals 9297 patients hospitalized for
cardiovascular diseases (mean age
66.5 years)
7.65% in 1999 (7.11%–8.19%)
7.90% in 2000 (7.35%–8.45%)
8.16% in 2001 (7.6%–8.72%)
Malaysia Freestone et al., 2003 [63] General Hospital 1435 patients 2.8% (1.95%–3.65%)
Europe and Central Asia
Bosnia and
Herzegovina
Salihovic et al., 2010 [35] Neurology
Department
2833 stroke patients 22% in female (20.47%–23.53%)
14% in male (12.72%–15.28%)
Buturovic et al., 2000 [33] Emergency Center 126 stroke patients 55.7% (47.03%–64.37%)
Kosovo Elezi et al., 2010 [59] Cardiology Service 5382 patients 9.75% (8.96%–10.54%)
Moldova Diaconu et al., 2011 [36] Hospital 735 stroke patients 28.4% (25.14%–31.66%)
Romania Macavei et al., 2011 [37] Neurology Clinic 973 stroke patients 23.39% (20.73%–26.05%)
Comes et al,. 2010 [38] Internal Medicine
Department
1219 stroke patients 17.39% (15.26%–19.52%)
Russia Bulanova et al., 2011 [65] Polyclinic 2.44% in 2002 3.78% in 2009
Serbia Medic et al., 2011 [39] Hospital 300 stroke patients 27% (21.98%–32.02%)
Turkey Karacaglar et al., 2012 [58] Cardiology
Outpatient Clinic
4721 patients 9.1% (8.28%–9.92%)
Inee et al., 2011 [47] Stroke Unit 2169 stroke patients 12.3% (10.92%–13.68%)
Ukraine Chwojnicki et al., 2011 [40] Urban areas of
Poland and Ukraine
440 stroke patients 7% in Ukraine (4.62%–9.38%)
Latin America and the Caribbean
Argentina Rojas et al., 2007 [41] Neurology Service 179 stroke patients>80 years old 24.6% (18.3%–30.9%)
Brazil Mallmann et al., 2012 [42]
(case–control study)
Emergency
Department
133 stroke patients (“cases” group)
272 control patients (Emergency
Department)
14.3% (8.35%–20.25%) in stroke patients
1.5% (0.06%–2.94%) in control group
Pieri et al., 2008 [43] Hospital 215 stroke patients 16.3% (11.36%–21.24%)
(5% in patients agedb65 years, 12% in patients
65–79 years, 26% in patients≥80 years old)
Fornari et al., 2007 [57] Cardiology
Hospital
3764 patients 8% (7.13%–8.87%)
De Carvalho Filho et al., 1991 [60] Out-patient
Geriatric Clinic
1020 patients 4.8% (3.49%–6.11%)
Mexico Cantu et al., 2011 [48] Hospital 3194 stroke patients 12.5% (11.35%–13.65%)
Middle East and North Africa
Iran Habibzadeh et al., 2004 [64] Primary Health
Care Center
463 patients aged≥50 years 2.8% (1.3%–4.3%)
(0.6% in patients aged 50–59 years, 1.4% in patients
60–69 years, 6.4% in patients 70–79 years)
Ghandehari et al., 2006 [44] General Hospital 302 stroke patients 8.94% (5.72%–12.16%)
Jordan Bahou et al., 2004 [45] Hospital 200 patients with ﬁrst ischemic stroke
(mean age 61.2 years)
7.5% (3.85%–11.15%)
South Asia
Nepal Devkota et al., 2006 [49] Hospital,
Department of
Medicine
72 stroke patients 12.5% (4.86%–20.14%)
Pakistan Haq et al., 2009 [66] Hospital 3766 acute medical admissions 6.5% (5.71%–7.29%)
Khan et al., 2006 [46] Hospital 211 stroke patients (included both
ischemic and hemorrhage stroke)
3.31% (0.9%–5.72%)
Shafqat et al., 2004 [50] Hospital 465 stroke patients aged≥18 years 12.3% (9.31%–15.29%)
Khan et al., 2002 [61] Hospital 783 inpatients>77 years old 20% (17.2%–22.8%)
Sub-Saharan Africa
Côte d'Ivoire Coulibaly et al., 2010 [55] Cardiology
Institute
3908 patients 5.5% (4.79%–6.21%)
Ethiopia Zenebe et al., 2005 [51] Hospital 128 stroke patients 4.5% (0.91%–8.09%)
Kenya Shavadia et al., 2011 [62] Hospital 22,144 patients 0.7% (0.59%–0.81%)
Nigeria Watila et al., 2010 [32] Hospital 376 stroke patients 1.6% (0.33%–2.87%)
Senegal Mbaye et al., 2010 [54] Cardiology
Department
2803 patients 5.35% (4.52%–6.18%)
South Africa Sliwa et al., 2010 [53] Cardiology Unit 5328 patients 4.6% (4.04%–5.16%)
Rosman, 1986 [52] Hospital 116 stroke patients≥20 years old 6.9% (2.29%–11.51%)
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thy and atrial ﬁbrillation [114]. Atrial ﬁbrillation is often associated
with valvular heart disease [94]. The prevalence of valvular heart dis-
ease in this review ranged from 5.6% to 66.3%, with a high rate of277rheumatic disease from 21% to 66.3%. Rheumatic valvular disease
was a frequent ﬁnding in the past and is becoming relatively rare
now in developed countries [94]. However, it is still frequent in devel-
oping countries. In a study about rheumatic heart disease that
2416 T.N. Nguyen et al. / International Journal of Cardiology 167 (2013) 2412–2420involved 15,293 patients from 47 countries who presented to an
emergency department with AF, the overall prevalence of rheumatic
heart disease was 11.7%, low in North America and Western Europe
(2%), and higher in the Middle East and China (15%), Africa (22%)
and India (31%) [76].
The prevalence of stroke in patients with AF in developing coun-
tries was quite high: 10% to 27%. Stroke in AF patients is usually se-
vere and leads to long-term disability, increased risk of death and
increased costs [94,115].
Many studies have shown the beneﬁts of anticoagulants in stroke
prevention in patients with AF [116–121]. This review found a
variable rate of anticoagulant utilization among developing countries.
Interestingly, the study in Zimbabwe reported different rates
of anticoagulant use between rural (11.5%) and urban areas
(26.5%) [74]. The variable prevalence of warfarin use is consistent
with studies in developed countries [95,110,112,122,123]. Recently,
newer oral anticoagulants that do not require such intensive monitor-
ing or complex dose adjustment as the previous standard of care,
warfarin, have been approved for stroke prevention in AF in many
developed countries [94,124–126]. In August 2011 Namibia was the
ﬁrst country in Africa to approve dabigatran for anticoagulation
therapy in AF patients [127]. However, this review did not ﬁnd any
studies that reported the usage of new oral anticoagulants in develop-
ing countries.
In this review, the proportion of patients with therapeutic
anticoagulation with warfarin, measured using the INR, was around
30%–50%. Labile INR is associated with negative clinical outcomesTable 3
Medical conditions associated with AF.
Country Authors and year Associated medical conditions
HTN
(%)
VHD/RHD
(%)
HF
(%)
IHD
(%)
China Chin et al., 2012 [76] 15*
Chen et al., 2011 [21]
Long et al., 2011 [22] 56.6
Xiao-Bin et al., 2011 [77]
Liu et al., 2010 [67] 68.8 23.9* 10.4 12.
Liu et al., 2009 [68] 58.2
Sun et al., 2009 [78]
Zhou et al., 2008 [23]
Zuo et al., 2007 [79]
Wen-Hang, 2005 [56] 40.3 33.1 34.
Malaysia Freestone et al., 2003 [63] 40 40 42.
Kosovo Elezi et al., 2010 [59] 27.4 17.4 47 21.
Russia Bulanova et al., 2011 [65] 71 5.6 13 20.
Turkey Karacaglar et al., 2012 [58] 71.9
Argentina Fitz Maurice et al., 2011 [69] 71.9 42.2
Brazil Mallmann et al., 2012 [42] 58.9
Fornari et al., 2007 [57]
De Carvalho Filho et al., 1991 [60] 51 33.6
Chile Ortiz et al., 2009 [70] 62 15 17
India Chin et al., 2012 [76] 31*
Pakistan Haq et al., 2009 [66] 54 54 47
Rasool et al., 2009 [71] 39 46.3
Khan et al., 2002 [61]
Randhawa et al., 1998 [72] 50
Cameroon Ntep-Gweth et al., 2010 [73] 47.7 25.6* 58.1 6.
Côte d'Ivoire Coulibaly et al., 2010 [55] 48 28* 62.6
Ethiopia Maru et al., 1997 [75] 10.3 66.3* 6.
Kenya Shavadia et al., 2011 [62] 68 12 38 19
Senegal Mbaye et al., 2010 [54] 36.7*
South Africa Sliwa et al., 2010[53] 60 21* 56 6.
Zimbabwe Bhagat et al., 1999 [74] 45.3 48.7
HTN: hypertension; RHD (*): rheumatic heart disease; VHD: valvular heart diseases; HF: he
tive pulmonary disease.
27[128]. A review of anticoagulant utilization and INR control in devel-
oped countries found that 30% to 92% of patients on anticoagulants
were poorly controlled [123].
This review found that high percentages of patients received rate
control treatment. Rate control therapies are favored by European
and North American Guidelines as ﬁrst line therapy [94,125]. Rate
control is not inferior to rhythm control therapies in terms of stroke
prevention, mortality reduction and even better than rhythm control
in reducing risk of hospitalization and reducing costs [129–133].
This reviewhas some limitations. First, the articleswere restricted to
English and French. Secondly, there may be bias and a lack of generaliz-
ability from some small size studies with variable sampling techniques
from epidemiologic surveys to convenience samples. Small studies are
also prone to random error, as reﬂected in wider conﬁdence intervals.
The quality of data also varies from objective data collection to self
report of AF, medical therapy and co-morbidities. In many studies,
there is not adequate data to assess the appropriateness of therapy
and this was beyond the scope of our review. Older studies may not
reﬂect current practice. The strength of our study is that it is a system-
atic review that comprehensively addresses prevalence, risk factors
and management of AF in developing countries.
5. Conclusion
The limited studies available suggest that in the developing world
there is a signiﬁcant prevalence of AF, which is predominantly associ-
ated with hypertension and rheumatic heart disease, and carries aDM
(%)
Hyperthyroidism
(%)
Stroke
(%)
Other
10.7
13.2 6.9 History of regular alcohol intake 58.5%
Dyslipidemia 54.7%
16.4
3 17.7 20 Smoking 27.7%
24.15
12.95
22.8
8 4.1 2.5 17.5 Cardiomyopathy 5.4%
Idiopathic 7.4%
5
4 14.3 COPD 6.7%
1 15.7
14.6 6.7
33.8 Alcohol abuse 29.3%
Smoking 28.6%
17.6
16.3 14.3
16 Smoking 13%
23
27
7.5
4 10.5 17.4
6 15.4 Cardiomyopathy 8.8%
33 3.7 Alcohol abuse 5%
COPD 7%
5 History of alcohol intake 48%
Smoking 47%
3.3
art failure; IHD: ischemic heart disease; DM: diabetes mellitus; COPD: chronic obstruc-
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Table 4
Treatment of atrial ﬁbrillation in developing countries.
Country Authors and year Number of AF patients Antithrombotic treatment Percentage of
therapeutic INR values
Rate-control or
rhythm-control
East Asia and Paciﬁc
China Chen et al., 2011 [21] 84 AF patients Warfarin 26.1%
Aspirin 41.7%
Gao et al., 2011 [34] 499 stroke patients
with AF
OAC 20%
Guo et al., 2011 [80] 105 AF patients (mean age
85±6 years)
Warfarin 5.7%
Antiplatelets 94.3%
(84.8% on a single drug, 9.5% on
aspirin+clopidogrel)
Healey et al., 2011 [81] 1905 Chinese patients
participating in
Multinational survey of
14,434 AF patients
OAC 19%
Xiao-Bin et al., 2011 [77] 1207 AF patients Warfarin 19.4%
Liu et al., 2010 [67] 372 AF patients >65 years
old
Warfarin 50%
Aspirin 34.1%
Rate control: 55.3%
Yao et al., 2010 [82] 638 AF patients Warfarin 16.3%
Aspirin 55.5%
40%
Liu et al., 2009 [68] 298 AF patients with a his-
tory of hypertension
Warfarin 9.7%
Sun et al., 2009 [78] 3425 AF patients OAC 9.27%
Zhou et al., 2008 [23] 190 AF patients Warfarin 2.7%
Aspirin 39.7%
Zuo et al., 2007 [79] 583 AF patients Warfarin 18.9%
Aspirin 59.3%
39.1%
Han et al., 2006 [83] AF patients>75 years old Warfarin 19%
Aspirin 73.4%
Wen-Hang, 2005 [56] 735 AF patients OAC 6.6%
Antiplatelets 57.9%
(Aspirin>90%)
Rate control: 82.8%
Malaysia Freestone et al., 2003 [63] 40 AF patients Warfarin 16%
Aspirin 8%
Europe and Central Asia
Bosnia and
Herzegovina
Kulo et al., 2009 [87] 117 AF patients 51.77%–53.62%
Kosovo Elezi et al., 2010 [59] 525 AF patients OAC 27%
Aspirin 72%
Both 11%
Moldova Diaconu et al., 2011 [36] 21 AF patients OAC 7.1% 28.5%
Serbia Potpara et al., 2012 [84] 346 patients with lone AF At baseline:
OAC 13%
Antiplatelets 38.1%
During the study:
OAC 53.9%
Antiplatelets 74.6%
Turkey Karacaglar et al., 2012 [58]
Ertas et al., 2009 [85]
432 AF patients
426 AF patients
OAC rate in those with
CHADS2VASC score≥2 was 67.3%, 43.2%
with score 1, 55.6% with score 0
OAC 30.1%
(25.1% warfarin+aspirin
4.9% warfarin alone)
Aspirin 55.6%
83.5%
47.7%
Latin America and the Caribbean
Argentina Fitz Maurice et al. (2011) [69] 872 AF/AFL patients OAC 72.7%
Antiplatelets 63%
Brazil Fornari et al., 2007 [57],
Lavitoba et al., 2009 [88],
Oliveira et al., 2012 [89]
301 AF patients
338 AF patients on warfarin
167 AF patients
OAC 46.7%–57.8%
Antiplatelets 19.9%–21.2%
50.1%
Rate control 79.5%
Mexico Cortes-Ramirez et al., 2011 [86] 19 AF patients OAC 36.8%
Aspirin 63%
South Asia
India Healay et al., 2011 [81] 2450 AF patients from India 32.6%
Pakistan Haq et al., 2009 [66],
Rasool et al., 2009 [71]
Randhawa et al., 1998 [72]
221 patients with AF
218 patients with AF
80 patients with AF
OAC 44%
Warfarin 26% Aspirin 60%
Warfarin 5% Aspirin 10%
Sub-Saharan Africa
Cameroon Ntep-Gweth et al., 2010 [73] 172 AF patients OAC 34.2%
Aspirin 61%
Rate control 83.7%
Senegal Mbaye et al., 2010 [54] 150 AF patients Warfarin 62% Rate control 87.33%
(continued on next page)
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Table 4 (continued)
Country Authors and year Number of AF patients Antithrombotic treatment Percentage of
therapeutic INR values
Rate-control or
rhythm-control
South Africa Sliwa et al., 2010 [53] 246 AF patients Warfarin 33%
Aspirin 23%
Zimbabwe Bhagat et al., 1999 [74] 150 AF patients Warfarin
21.3%
(Urban 26.5%, Rural 11.5%)
Aspirin 10%
(Urban 11.2%, Rural 7.7%)
AF: atrial ﬁbrillation; AFL: atrial ﬂutter; INR: international normalized ratio; OAC: oral anticoagulant.
2418 T.N. Nguyen et al. / International Journal of Cardiology 167 (2013) 2412–2420high risk of stroke. Highly variable use of anticoagulants may be
related to different health care and socioeconomic settings. Large
studies of representative populations are needed to improve under-
standing of the epidemiology and management of AF in developing
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Introduction
The world’s population is ageing, not only in developed 
countries but also in developing countries. In 2010 about two 
third of the world’s population 60 years and older lived in 
less developed countries and it is estimated that the speed of 
aging in middle- and low-income countries will outpace that 
of the high-income countries (1). As the population ages, the 
prevalence and clinical importance of frailty are increasing.
Frailty is a clinical syndrome resulting from multisystem 
impairments and characterized by increased vulnerability 
and disabilities (2). Frailty occurs as a result of impacts 
from multiple physical, social and environmental factors, 
and is a changeable condition. Multiple physiological 
factors are thought to be involved in the development of 
frailty, including the immune, cardiovascular, metabolic 
and nervous systems. Frailty is also consistently associated 
with inflammation and activation of thrombotic pathways. 
Frailty predicts adverse outcomes for older people, such as 
comorbidities, polypharmacy, loss of independence, increasing 
hospitalizations, and mortality. Clinically, frailty may have 
an impact on treatment strategies and responses to therapy 
and prognosis. For hospitalized patients, frailty status prior 
to admission has been shown to predict poor outcomes (3). 
Understanding the etiology, prevalence and outcomes of frailty 
informs research and policy to optimize care for older people 
(2). 
Although the concept of frailty has been emerging in 
geriatric medicine for many years, there is no gold standard 
for the definition of frailty. The two most commonly used 
definitions in research revolve around deficit accumulation 
and around the frailty phenotype (2). Rockwood et al used an 
accumulation of deficits which include physical dysfunction, 
cognitive deficits, comorbidities and socio-economic conditions 
to calculate a Frailty Index (FI) (2). On the other hand, Fried et 
al defined frailty with five criteria: unintentional weight loss 
(more than 10 pounds in prior year), weakness (measured by 
grip strength), self-report exhaustion, slowness (measured by 
walking speed) and low physical activity (measured by energy 
expenditure). Having three or more criteria indicates a frailty 
phenotype, while one or two criteria indicate intermediate 
or prefrail (2). Recently, the Edmonton Frail Scale has been 
applied in many studies. This scale, which was elaborated by 
Rolfson in Cananda, involves 9 frailty domains (cognition, 
general health status, functional independence, social support, 
medication use, nutrition, mood, continence and functional 
performance). With a maximum score of 17, 0 to 4 score 
indicates robust, 5 to 6 scores indicates apparently vulnerable 
status, 7 to 8 mild frailty, 9 to 10 moderate frailty and 11 or 
more indicates severe frailty (4). In terms of feasibility, the 
Edmonton Frail Scale seems to be the quickest, FI requires 
simple measures, while phenotype requires specific equipment. 
The FI can be done retrospectively, others need specific data 
collection or modification of the tools. The frailty phenotype 
seems to be the most affected by acute illness for studies in 
acute setting.
Many studies have reported the prevalence of frailty in 
Western countries. The prevalence of frailty in the community 
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Table 1
Studies of frailty in community-dwelling older adults
Authors and year of publication N Participants Sampling method and time period Prevalence of 
frailty/ Mean FI
Definition of frailty
Brazil
Asmar Alencar et al, 2012 (6) 207 Aged 65 years or older.
Mean age ± SD:
74.5 ± 6.4 (non-frail)
78.3 ± 8.0 (pre-frail)
82.3 ± 7.1 (frail)
Simple random probabilistic sampling, 
response rate not provided in the paper.
Data collected 2009
23.2% Fried’s criteria
Fabricio-Wehbe et al, 2009 (7) 137 Aged 65 years or older
65-79: 67%
≥80: 33%
Representative sample based on a probabi-
listic double-stage sampling process in the 
population. Response rate 80%.
Data collected 2007-2008.
31.4% The Edmonton Frail Scale
The FIBRA Study, 2011 (8) 391 Aged 65 years or older.
65-74: 60%
75-84: 33%
≥85: 7%
Representative sample based on a probabi-
listic multi-stage sampling process in the 
population. Response rate not provided in 
the paper.
Data collected 2007-2008.
17.1% Fried’s criteria
Mexico
Mexican Study on Nutritional and 
Psychosocial Markers of Frailty, 
2012 (9) 
838 Aged 70 years or older.
Mean  age ± SD: 77.9 ± 6.3
Representative sample based on a random 
sampling process in the population, stratified 
by age and gender. Response rate 86.9%.
Data collected 2008-2009.
15% Fried’s criteria
The Mexican Health and Aging 
Study, 2009 (10) 
4082 Aged 65 years or older.
Mean age: 73.0
Representative sample. Response rate 84.2%. 
(Participants and their spouse/partners were 
selected from a nationally representative 
sample of non-institutionalized Mexicans 
who had previously participated in the fourth 
quarter of 2000 in an employment survey).
Data collected 2001.
Mean FI:
0.16 ± 0.11
Frailty Index (34 deficits)
China
Lee et al, 2011 (11) 4000 Aged 65 years or older. 
Mean age ± SD:
72.3 ± 5.0 (men)
72.5 ± 5.3 (women)
Sample may be not representative (recruiting 
by placing recruitment notices in community 
centers for older persons and housing 
estates). Response rate not provided in the 
paper.
Data collected 2001-2003
5.4%
1.8% in people 
from 65-69 years 
old
3% in people70-74 
years old 
11.8% in people 
≥75 years old
Fried’s criteria
The Beijing Longitudinal Study of 
Ageing, 2011 (12) 
3257 Aged 55 years or older.
55-64: 32.0%
65-74:34.0%
75-84: 28.6%
85-94: 5.2%
≥95: 0.2%
Representative sample based on a random 
sampling process in the population. Res-
ponse rate 91.2%. 
Data collected 1992-2000.
Mean FI: 0.11±0.1 
in men and 
0.14±0.11 in 
women.
Prevalence of 
frailty (cut-off 
0.22): 28.9% in 
men and 30.8% in 
women
Frailty Index (35 deficits)
The Chinese Longitudinal Healthy 
Longevity Survey, 2009 (13) 
13717 Aged 65 years or older.
65-79: 30.7%
80-89: 26.8%
90-99: 23.7%
≥100: 18.8%
Representative sample based on a random 
sampling process in the population. Res-
ponse rate 88%.
Data collected 2002 -2005.
Mean FI:
0.19 in men
0.26 in women
Frailty Index
(39 deficits)
Russia
Gurina et al, 2011 (14) 611 Aged 65 years or older.
65-74: 50% (mean±SD: 69.7 ± 2.4 
for male, 70.2 ± 2.3 for female)
≥75: 50% (mean±SD: 78.8 ± 3.2  
for male, 80.5 ± 2.4 for female)
Representative sample based on a random 
sampling process in the population, stratified 
by age.
Response rates:
59.5% in male aged 65-74
70.1% in female aged 65-74
61.3% in male aged ≥75
70.3% in female aged ≥75
Data collected 2009.
21.1% (Fried’s 
criteria)
32.6% (Steve-
rink-Slaets model)
43.9% (Puts 
model)
Fried’s criteria
Steverink-Slaets model
Puts model
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has ranged from 4% to 10% in studies in the United States, 
6.5% in Italy, 7% in France, 8.1% in the United Kingdom 
(using Fried’s phenotype) (3, 5).  In Australia, the prevalence 
of frailty has ranged from 9.4% (using Fried’s phenotype)  to 
15.2% (using FRAIL scale)  in community-dwelling older men 
and up to 64% in older patients admitted to hospital with atrial 
fibrillation (using the Reported Edmonton Frail Scale) (3). 
However, there have been few published studies about frailty 
in the developing world. Therefore, the aim of this paper is to 
systematically review the evidence from developing countries 
on the prevalence of frailty, definitions of frailty and outcomes 
associated with frailty.
Methods
A literature search was conducted via MEDLINE and 
EMBASE (from 1990 to January 2014). Keywords used for 
searching included “frail”, “frailty”, “prevalence”, “criteria”, 
“definition”, “risk factors”, “outcomes”, “developing country”, 
“developing world”, and the names of low and middle 
countries according to the classification of the World Bank . 
The articles attained by this method of searching were screened 
by title and relevant papers were retrieved. Both community 
and hospital/institutional-based studies were included. Studies 
were stratified by study population into those that studied 
prevalence of frailty in the community and those that studied 
prevalence in institutionalized or hospitalized older people. 
In cases where there were many publications based on one 
study, the first publication was chosen and full papers were 
chosen instead of letters to the editor. Language was restricted 
to English. Information extracted from papers included sample 
size, sampling methodology, prevalence of frailty, definition 
of frailty and outcomes. When necessary, percentages were 
calculated from data reported in published studies. 
Results
A total of 110 abstracts was obtained. After further 
screening for prevalence, definition, and outcomes of frailty, 
79 abstracts were rejected. Another 6 abstracts were rejected 
because full texts in English could not be obtained, leaving 
25 papers. Among these 25 papers, there were some studies 
with several reports. In these cases, the first publication was 
chosen and full papers were chosen instead of letters to the 
editor, leaving a total of 14 papers from 14 studies included in 
this review (6-19). There were 6 studies from Brazil, 3 from 
China, 2 from Mexico, and one each from Russia, India, and 
Peru. There were 9 studies from community-based studies 
(3 in Brazil, 3 in China, 2 in Mexico, and one from Russia). 
The remainder were in institutions or hospitals. Most of the 
publications in Brazil, Mexico and China were based on large 
cohort studies about ageing and frailty, such as the study on 
Frailty in Elderly Brazilians (the FIBRA study), the Mexican 
Study on Nutritional and Psychosocial Markers of Frailty, the 
Mexican Health and Aging Study, the Beijing Longitudinal 
Study of Ageing and the Chinese Longitudinal Healthy 
Longevity Survey. 
The 14 reviewed papers were all published between 2009 
and 2014 and, apart from the Beijing Longitudinal Study of 
Ageing (12), the studies were conducted after 2000. All the 
studies of community-dwelling older people used a probability 
sampling methodology except the study from China by Lee et 
al, which involved volunteers recruited via advertisements on 
noticeboards (11).  Response rates were reported in 6 of the 
community studies and were above 80% in all but the study 
from Russia (14). It is difficult to compare age distributions 
between studies because of differences in reporting; however, 
it appears that most subjects in the community studies were in 
their 70s. The exception is the Chinese Longitudinal Healthy 
Longevity Survey, where more than 40% of subjects were aged 
90 years and over.
Prevalence of frailty in community-dwelling older adults, 
outpatients and institutionalized patients varied between 
countries. The prevalence of frailty in older people in the 
community ranged from 17.1% to 31.4% in Brazil (data from 
2 studies), 15% in Mexico (from 1 study), 5.4% to 30.8% in 
China (2 studies), and 21.1% to 43.9% in Russia (from 1 study) 
(Table 1). The low prevalence of 5.4% was from the only study 
involving a convenience sample (11).  Three studies in geriatric 
medicine outpatients found that the prevalence of frailty was 
55.3% to 71.3% in Brazil and 27.8% in Peru. The prevalence 
of frailty in older people in long stay institutions was 49.3% in 
one study in Brazil and the prevalence in older inpatients was 
32.3% in one study in India (Table 2).
Fried’s phenotype was used to define frailty in the majority 
of studies. Only one study (from Brazil) used the Edmonton 
Frail Scale, one from Russia reported the Steverink-Slaets and 
Puts score. The Frailty Index was used in 3  community-based 
studies: the Beijing Longitudinal Study of Ageing (35 deficits, 
mean FI 0.11±0.1 in men and 0.14±0.11 in women), the 
Chinese Longitudinal Healthy Longevity Survey (39 deficits, 
mean FI 0.19 in men and 0.26 in women) and The Mexican 
Health and Aging Study (34 deficits, mean FI 0.16±0.11). 
Outcomes of frailty were inconsistently assessed in 
the reviewed studies (6-19). Cross-sectional approach for 
examining the relationship between frailty and the various 
outcomes was applied in seven out of the fourteen studies 
(7-9, 15-18). In the reviewed studies, frailty was associated 
with increased health care utilization, increased mortality and 
comorbidities such as cardiovascular diseases, depression, falls 
and fractures, incontinence, anemia, increased hospitalizations, 
increased number of medications, increased use of medical and 
dental services, increased physical dependence and decreased 
physical and cognitive function, and poor perception of health. 
One publication from the Mexican Study on Nutritional and 
Psychosocial Markers of Frailty reported that frailty was not 
associated with quality of social networks (9).
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Discussion
A total of 14 articles describing 14 studies about frailty in 
developing countries were included in this review. Most of the 
studies of community-dwelling older adults were conducted 
using probability sampling methods and achieved high response 
rates. The quality of the sampling methods for the studies 
in health care settings was more variable. The prevalence 
of frailty in older people in developing countries was quite 
variable, from 5.4% to 44% in community-dwelling older 
adults, 27.8% to 71.3% in geriatric outpatients and 32.3% to 
49.3% in institutionalized older patients. 
Fried’s phenotype was the most common approach used 
to determine frailty, not only in community setting but also 
in hospital based studies in these developing countries. This 
finding is rather consistent with studies from developed 
countries. The phenotypic approach to frailty is the most widely 
used approach and it has been shown to correlate well with both 
the risk of adverse outcomes and with many important clinical 
parameters (20). In studies using Fried’s frailty phenotype, 
the prevalence of frailty in community-dwelling adults was 
variable, ranging from 5.4% in China, 17.1% to 23.2% in 
Brazil, 15% in Mexico, and 21.1% in Russia. Except for the 
study in China in which the sample may not be representative 
(participants were recruited by placing recruitment notices 
in community centers for the older persons and housing 
estates), the prevalence of frailty in the developing countries 
in this review prevalence was high compared to developed 
countries, in which the prevalence of frailty has ranged from 
4% to 17% in the United States, Australia, Canada, the United 
Kingdom, France and Italy, and other European countries 
(5). Poor nutritional health, high prevalence of physical labor 
during lifetimes and disability may contribute to this result. 
According to the Study on Global Ageing and Adult Health 
(SAGE), which was conducted in six countries - China, Ghana, 
India, Mexico, Russia, and South Africa- approximately 
70% of the population aged 50 and over had some types 
of disability, with up to 90% of older Indians and Russians 
suffering from disabilities (1). In a recent published study 
based on the SAGE study data, average walking speeds were 
slower in SAGE countries than commonly reported in Western 
countries (21). Variations in measurement when applying the 
frailty phenotypes in these countries may also explain why the 
prevalence of frailty in developing countries was more variable 
and generally higher compared to Western countries. 
Only three studies, all in the community, used the Frailty 
Index to define frailty. All Frailty Indices included symptoms, 
diseases and physical function. The Beijing Longitudinal Study 
of Ageing also included cognitive function. The mean Frailty 
Index in these studies is consistent and rather similar to studies 
in  developed countries. In the Survey of Health, Ageing and 
Retirement in 12 European countries (based on 40 deficits), the 
mean FI was 0.08 for those aged 50, 0.10 for those aged 60, 
0.14 for those aged 70, 0.21 for those aged 80, 0.30 for those 
aged 90, and 0.43 for those aged 100 (22). According to the 
National Population Health Survey of Canada, the mean values 
of the Frailty Index were 0.046 for non-frail, 0.156 for pre-frail, 
and 0.310 for frail people (23). 
The number of institution-based and hospital-based studies 
in this review was small and all used Fried’s frailty phenotype. 
There were three studies in geriatric outpatient clinics. One 
study in Peru in participants aged 60 years or older found that 
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Table 2
Studies of frailty in health care settings
Authors and year of 
publication
N Participants Sampling Method Definition of frailty Prevalence of frailty 
Nobrega et al, 2013 (15) 
(Brazil)
69 Older residents of six long stay 
institutions.
Representative sample 
based on a random 
sampling process. 
Response rate 80%. 
Fried’s criteria 49.3%
Batista et al, 2012 (16) 
(Brazil)
150 Older patients aged 80 years or older, 
or patients aged 60 years or older 
with functional impairment at the 
outpatient clinic.
Non-probabilistic 
convenience sampling 
method.
Fried’s criteria 55.3%
Da Silva et al, 2011 (17) 
(Brazil)
100 Older patients aged 80 years or older, 
or patients aged 60 years or older 
with functional impairment at the 
outpatient clinic.
Non-probabilistic 
convenience sampling 
method.
Fried’s criteria 71.3%
Runzer-Colmenares et 
al, 2014 (18) 
(Peru)
311 Older patients aged 60 years or older 
at the outpatient clinic (mostly men 
and retired military personnel).
Random sampling 
method.
Response rate 52.5%. 
Fried’s criteria 27.8%
Khandelwal et al, 2012 
(19) 
(India)
250 Hospitalized patients aged 60 years 
or older.
Consecutive series of 
patients were recruited.
Fried’s criteria 32.3%
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the prevalence of frailty was 27.8% (18) while two separate 
studies in Brazil in older outpatients aged ≥ 80 years or aged 
≥ 60 years with functional impairment found the prevalence of 
55.3% and 71.3% (16, 17). One study in India found that the 
prevalence of frailty in hospitalized older patients was 32.3% 
and one study in Brazil showed that frailty was present in 
49.3% of older residents of long stay institutions (Table 2). 
Frailty has been reported to be associated with many adverse 
outcomes (3). The outcomes for frail people in the studies 
reviewed in this paper are consistent with reports from the 
developed world.
Most of the studies in this review were from Latin America 
and Asia and all were middle income countries. The prevalence 
of frailty was variable among these regions. There was no data 
from low income countries where the prevalence of frailty may 
be higher. A recent study in Europe found that a country’s level 
of frailty and fitness in older adults was strongly correlated 
with national economic indicators, such that lower income 
countries had higher levels of frailty and lower levels of fitness 
when compared with the higher-income countries (24). There 
appear to have been  no studies on frailty from Africa. In the 
United States, studies have found that African Americans have 
a higher prevalence of frailty than Caucasians using Fried’s 
frailty phenotype model (25).
The Fried’s phenotype and the Frailty Index can identify 
older people at high risk of death and correlate well with 
each other, with the deficit accumulation approach predicting 
mortality better (26). Although the Frailty Index has been 
shown to be more applicable for predicting mortality than 
the phenotypic criteria, in this review there were no studies 
in hospital settings using the Frailty Index. These findings 
raise a question regarding the most feasible approaches for 
frailty research in developing countries. The newer deficit 
accumulation scales, The Edmonton Frail Scale (4), and the 
Reported Edmonton Frail Scale that was adapted from the 
Edmonton Frail Scale for use with Australian acute inpatients 
(27), are both based on a questionnaire and seem to be easy to 
apply. This scale is less time-consuming and may be practical 
for both outpatients and inpatients in the developing world 
where there are limited resources for conducting research.
This review has some limitations. First, the articles were 
restricted to English only. We may have missed some papers 
that were not available in English fulltext or in journals that 
were not indexed on MEDLINE and EMBASE. Secondly, there 
may be bias due to inadequate sampling techniques, including 
use of convenience samples. Thirdly, comparison of prevalence 
between studies using different frailty assessment methods is 
complicated by the fact that, even within the same population, 
different frailty assessments classify different participants as 
frail (3). Since within populations the prevalence of frailty 
increases with age (3, 23), another limitation of this study 
was comparing studies that included people of different ages. 
The strength of our study is that it is a systematic review that 
comprehensively addresses the published English language 
literature on prevalence, definition and outcomes of frailty in 
developing countries.
Conclusions
Frailty is an important issue in geriatric medicine. There 
is emerging evidence that frailty can be used clinically to 
individualise treatment plans, predict therapeutic outcomes 
and inform public policy for older people. At the societal level, 
understanding frailty can help to identify groups of people who 
need extra medical care. The limited studies available suggest 
that frailty occurs frequently in the developing world. This 
has implications for policy and health care provision for these 
ageing populations.  
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Dr. Tu Nguyen     Royal North Shore Hospital 
 Study Code: 
Data Collection Sheet 
Patient Demographics 
1. Date of Birth:
2. Gender:     □ Male     □ Female
3. Ward: □ General Medicine □ Cardiology □ Aged Care
4. Date of hospitalization:
5. Date of discharge:
6. Phone number:
7. GP’s name:
Questions to patient 
1. Why are you in hospital?
2. Ethnicity: (1) Caucasian (2) Aboriginal or Torres Strait Islander
(3) Asian (4) Other
3. Residence: Where do you live and with whom?   Is it a:
□Nursing Home   □Hostel   □Residential with family    □Residential Alone   □ Other
4. Education: What level of education did you achieve? □ Did not finish high school
□ Finish high school □ TAFE □ Finished University □ Other
5. How tall are you?
6. How much do you weigh?
7. Do you take any herbal medications, vitamins or other OTC meds?   □ Yes      □ No
If yes:  ▫St John’s Wort      ▫Ginkgo biloba    ▫Ginger    ▫Ginseng   ▫Garlic    ▫Kava
▫Saw palmetto     ▫Echinacea product
8. Have you been educated about antithrombotic medication, e.g. warfarin and aspirin?
□Yes  □No
9. Are you allergic to any medication? □ Yes □ No
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10. How would you describe your diet?         □ Poor       □ Stable       □ Healthy 
11. Do you drink any alcohol?   □ Yes          □ No 
If Yes:  How many drinks per week?         □ ˂ 8               □ ≥ 8                       
How often do you drink  □ Daily       □ Weekly     □ Less frequently than weekly 
12. Frailty assessment: The Reported Edmonton Frail Scale                           
Frailty domain Item 0  1  2  
Cognition 
(Refer to page 
4) 
Please imagine that this pre-drawn circle is a 
clock. I would like you to place the numbers 
in the correct positions then place the hands to 
indicate a time of ‘ten after eleven’ 
No errors  Minor 
spacing 
errors  
Other 
errors 
General Health 
Status 
In the past year, how many times have you 
been admitted to a hospital? 
In general, how would you describe your 
health? 
0 
Excellent/ 
Very good/ 
Good 
1-2 
Fair 
>2 
Poor 
Functional 
Independence 
Do you require help with: 
□ meal preparation 
□shopping 
□transportation 
□telephone 
□housekeeping 
□laundry 
□managing money 
□taking medications) 
0-1 2-4 5-8 
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Social Support When you need help, can you count on 
someone who is willing and able to meet your 
needs? 
Always Sometimes Never 
Medication Use Do you use five or more different prescription 
medications on a regular basis? 
At times, do you forget to take your 
prescription medications? 
No 
 
No 
Yes 
 
Yes 
 
Nutrition Have you recently lost weight such that your 
clothing has become looser? 
No Yes  
Mood  Do you often feel sad or depressed? No Yes  
Continence Do you have a problem with losing control of 
urine when you don’t want to? 
No Yes  
Self Reported 
Performance 
Two weeks ago were you able to: 
(1) Do heavy work around the house like 
washing windows, walls, or floors without 
help? 
(2) Walk up and down stairs to the second 
floor without help?  
(3) Walk a 1 km without help? 
 
Yes 
 
 
Yes 
Yes 
 
No 
 
 
No 
No 
 
 
Scoring the Modified Edmonton Frail Scale:       / 18 
Not Frail 0-5, Apparently Vulnerable 6-7, Mild Frailty 8-9, Moderate Frailty 10-11, Severely Frailty 12+ 
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Please imagine that this pre-drawn circle is a clock.  
I would like you to place the numbers in the correct positions, 
then place the hands to indicate a time of ‘ten after eleven’ 
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Data Obtained From Medical Notes 
1. Presenting symptoms: 
 
2. Blood pressure (mmHg):  on admission: ……………..     
                       
3. Heart rate (per minute): on admission: ……………..     
                  
 
4. Diagnosis: 
 
 
 
 
5. Medical conditions: 
 
 
 
6. Investigations: 
Blood test: 
 Date  Date  Date  Date  Date Date  
INR       
Serum 
Creatinin 
(Clcr)  
eGFR 
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Hemoglobin 
Platelet  
      
AST 
ALT 
ALP 
      
Bilirubin       
Protein 
Albumin 
      
Other 
coagulation 
tests: 
      
 
ECG:    □No           □ Yes                     If Yes:      □ Rate:           □ MI:            Other:   
7. What antithrombotic treatment is patient on admission?     
 □ None          □ Warfarin            □ Aspirin             □ Clopidogrel              □ Dabigatran 
 □ Combination of Warfarin & Aspirin         □ Combination of Warfarin & Clopidogrel     
 □ Combination of Aspirin & Clopidogrel           □ Other 
□ Combination of Warfarin & Aspirin & Clopidogrel 
8. What antithrombotic treatment is patient on upon discharge?   
□ None          □ Warfarin             □ Aspirin             □ Clopidogrel              □ Dabigatran    
□ Combination of Warfarin & Aspirin         □ Combination of Warfarin & Clopidogrel     
□ Combination of Aspirin & Clopidogrel   □ Other 
□ Combination of Warfarin & Aspirin & Clopidogrel 
 
9. Is patient allergic to or has had previous ADR to aspirin?        
 □ Allergic       □ Major hemorrhage      □ Minor hemorrhage           □ Other          □ None   
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10. Is patient allergic to or has had previous ADR to warfarin?    
 □ Allergic       □ Major hemorrhage      □ Minor hemorrhage           □ Other          □ None         
                                                              
11. Dose of antithrombotic treatment prescribed currently? --------------- 
 
12. Events during hospitalisation: 
(1) Stroke          □ Yes     □ No             (If Yes:   □ Ischemic              □Hemorrhage)       
(2) Bleeding      □ Yes     □ No             (If Yes:   □ Minor      □ Major        □ Severe)      
(3) Death             (4) Other 
13. Medication Assessment: 
(1) Does the patient take any medication, daily or almost daily, for at least the past 
month? This include both prescription and non-prescription medication.                     
□ Yes       □ No 
If Yes: 
Prescription 
Name  Dose  Duration 
(months) 
   
   
   
   
   
 
Non-prescription 
Name  Dose  Duration 
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(months) 
   
   
   
 
(2) List of medication on admission: 
Name  Dose  Duration 
 
   
   
   
   
   
   
   
   
   
   
   
(3) List of medication on discharge: 
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Name  Dose  Duration 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 
 
ASSESSMENT OF STROKE RISK, BLEEDING RISK AND CHARLSON COMORBIDITY INDEX (to 
be completed with all the data above) 
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**Bleeding Risk Assessment (HAS-BLED score) 
 
1. HTN (1 point):   □ systolic blood pressure >160 mmHg 
2. Abnormal renal function (1 point):   
□ serum creatinine 200μmol/L          □ chronic dialysis               □ renal transplantation 
Abnormal liver function (1 point):   □ chronic hepatic disease (eg. cirrhosis)    
 □ biochemical evidence of significant hepatic derangement (eg. bilirubin >2x upper limit of normal, in 
association with AST/ALT/ALP >3x upper limit normal 
 
3. Stroke (1 point):    □ Previous history of stroke 
4. Bleeding  (1 point):    
□ Major bleeding history         □ anemia or predisposition to bleeding  
5. Labile INRs (1 point):   □ refers to unstable/high INRs or poor time in therapeutic range, eg <60% 
6. Elderly (1 point):    □ ≥65y 
7. Drug therapy (1 point):    □ concomitant therapy such as antiplatelet agents, NSAID's 
Alcohol Intake (1 point):    □ consuming 8 or more alcoholic drinks per week 
  
Total score:        / 9 
 
**Stroke Risk Assessment (CHA2DS2-VASc Score) 
 
1. Cardiac failure (1 point): 
2. HTN (1 point):    
3. Age ≥ 75 y (2 point):    
4. Diabetes (1 point):    
5. Stroke (2 point):    
6. Vascular disease (1 point):   □ MI      □  PAD     □  aortic atherosclerosis 
7. Age 65-74 (1 point):    
8. Female sex (1 point):    
 
Total score:    
 
 
** Charlson Comorbidity Index: 
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Does the patient have any of the following conditions? 
Group 1 (1 point) 
o Myocardial infarct                  
o Congestive heart failure 
o Peripheral vascular disease 
o Cerebrovascular disease 
o Dementia 
o Chronic pulmonary disease 
o Connective tissue disease 
o Ulcer disease 
o Mild liver disease 
o Diabetes   
 
 
Group 2 (2 points) 
o Hemiplegia  
o Moderate or severe renal disease 
o Diabetes with end organ damage  
o Any tumor 
o Leukemia 
o Lymphoma 
Group 3 (3 points) 
o Moderate or severe liver disease 
Group 4 (6 points) 
o Metastatic solid tumor 
o AIDS 
 
Total score: 
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Data Collection Sheet – Follow up 
Study Code: 
1. Did you have any hemorrhages over the last 6 months?
If yes:  What kind of bleeding and date?
□ Minor (Self Inflicted Cuts, Nose Bleeds, Bruising or any other bleed that did not
require hospitalization)
□ Major (Internal Bleeding or bleeding/bruising requiring hospitalization)
□ Severe (Bleeding in the brain of any type, haemorrhage resulting in death)
2. Did you get any strokes over the last 6 months?
If yes:      □ ischemic stroke               □ embolic stroke
Date: 
3. How many times have you been in the hospital over the last 6 months?
(number, date, main reasons)
4. Death:
If yes: Date: Cause: 
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AURED NEAF REF:  LNR/12/HAWKE/227 
NSLHD REF NO:    1208-239M, 
 
  
 
Research Office 
Kolling Building, Level 13 
Royal North Shore Hospital  
St Leonards NSW 2065 
Tel (02) 9926 4590 Fax (02) 9926 6179 
 
04 October 2012 
 
Dr Tu Nguyen 
Royal North Shore Hospital 
Clinical Pharmacology 
11C Main Building, Pacific Hwy 
St Leonards 2065 
 
Dear Dr Nguyen, 
 
1208-239M :  Anticoagulant Utilization and Outcomes in Frail and Non-frail Older Inpatients with 
Atrial Fibrillation, Dr Tu Nguyen,  
 
I am pleased to inform you that on the 4 October 2012, the delegate of the Chief Executive authorised the 
Site Specific Assessment for the above study on behalf of Northern Sydney Local Health District (NSLHD).  
 
It is noted that the approval covers the following NSW Health site:  
 Royal North Shore Hospital 
 
The documentation included in the approval is as follows: 
 HREC approval letter dated 21 August 2012 
 NSW LNR SSA Submission Code AU/7/732D019 
 Patient Information Sheet and Consent Form version 1 dated 24/02/2012 
 Substitute Patient Information Sheet and Consent Form version 1 dated 24/02/2012 
 Sub Study Patient Information Sheet and Consent Form version 1 dated 24/02/2012 
 Substitute Sub Study Patient Information Sheet and Consent Form version 1 dated 24/02/2012 
 Data Collection Sheet version 1 dated 21/05/2012 
 
At this time, we also remind you that, in order to comply with the Guidelines for Good Clinical Research 
Practice (GCRP) in Australia, and in line with NSLHD HREC policy, the Chief Investigator is responsible to 
ensure that: 
 
1. The HREC is notified of anything that might warrant review of the ethical approval of the project, including unforeseen 
events that might affect the ethical acceptability of the project.  
2. The HREC is notified of all Serious Adverse Events (SAEs) or Serious Unexpected Suspected Adverse Reactions 
(SUSARs) in accordance with the Serious Adverse Event Reporting Guidelines. Please refer to the Research Office 
website. 
3. Proposed amendments to the research protocol or conduct of the research that may affect the ethical acceptability of the 
project are submitted to the HREC on an amendment form (including any relevant attachments). For multi-centre studies, 
the Chief Investigator should submit to the Lead HREC and then send the amendment approval letter to the investigators 
at each of the sites so that they can notify their Research Governance Officer.  
4. Proposed changes to the personnel involved in the study are submitted to the HREC on a Change in Personnel Form 
(accompanied by the investigator’s CV where applicable). 
5. The HREC must be provided with an annual progress report for the study by the 31
st
 October each year. For multi-centre 
studies the Chief Investigator should submit to the Lead HREC on behalf of all sites. The annual report acknowledgment 
from the Lead HREC should be submitted to the Research Governance Officer.  
6. The HREC must be provided with a final report upon completion of the study. For multi-centre studies the Chief 
Investigator should notify the Lead HREC and the investigators at each site should notify the relevant Research 
Governance Officer. 
7. The HREC must be notified, giving reasons if the project is discontinued at a site before the expected date of completion. 
 
Internet: http://www.northernsydneyresearch.com.au 
 
Site Authorisation remains valid until the HREC approval associated with this project expires. It is 
therefore noted that the Ethics approval for this project will expire on 21 August 2017. Should you 
require an extension an amendment form should be submitted to the approving HREC. Once 
approved by the Lead HREC you will need to notify the Research Governance Officer. 
 
 
Yours sincerely, 
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NSLHD REF NO:    1208-239M, 
Research Office 
Kolling Building, Level 13 
Royal North Shore Hospital  
St Leonards NSW 2065 
Tel (02) 9926 4590 Fax (02) 9926 6179 
Kylie Becker 
Ethics & Governance Officer 
RESEARCH OFFICE 
NORTHERN SYDNEY CENTRAL COAST HEALTH 
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Letter of ethics approval for the study: “Frailty and its associated factors in older 
inpatients at the National Geriatric Hospital in Vietnam” (in Vietnamese language). 
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